Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.3.2.13 - protein-glutamine gamma-glutamyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature.
Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature.
Factor XII but not protein C, protein S, antithrombin III, or factor XIII is a predictor of recurrent miscarriage.
Factor XIII deficiency causing mutation, Ser295Arg, in exon 7 of the factor XIIIA gene.
Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis.
Genetic factors in fetal growth restriction and miscarriage.
Management of pregnancy and delivery in women with inherited bleeding disorders.
Premarital Screening Program for Congenital Factor XIII Deficiency in Iran.
Prevalence of coagulation factor XIII and plasminogen activator inhibitor-1 gene polymorphisms among Egyptian women suffering from unexplained primary recurrent miscarriage.
Prevalence of the coagulation factor XIII polymorphism Val34Leu in women with recurrent miscarriage.
The burden and management of FXIII deficiency.
Treatment with Recombinant Factor XIII (Tretten) in a Pregnant Woman with Factor XIII Deficiency.
[Congenital factor XIII deficiency in pregnancy. A case report]
Abortion, Spontaneous
An unusual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy.
Celiac Disease and Gyneco-obstetrics Complications: Can Serum Antibodies Modulate Tissue Transglutaminase Functions and Contribute to Clinical Pattern?
Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature.
Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study.
Factor XII but not protein C, protein S, antithrombin III, or factor XIII is a predictor of recurrent miscarriage.
Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages.
Fibrinolysis and factor XIII in women with spontaneous abortion.
Gynecological and obstetric outcome in the French cohort of women with factor XIII deficiency.
Immunohistochemical detection of factor XIII subunit a in histiocytes of human uterus.
Impact of Rare Bleeding Disorders during Pregnancy on Maternal and Fetal Outcomes: Review of 29 Pregnancies at a Single Center.
Inherited bleeding disorders in pregnancy.
Management of pregnancy, labour and delivery in women with inherited bleeding disorders.
Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell.
Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss.
Polymorphisms of plasminogen activator inhibitor-1, angiotensin converting enzyme and coagulation factor XIII genes in patients with recurrent spontaneous abortion.
Risk for early pregnancy loss by factor XIII Val34Leu: the impact of fibrinogen concentration.
Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
The Val34Leu genetic variation in the A Subunit of Coagulation Factor XIII in recurrent spontaneous abortion.
Treatment with Recombinant Factor XIII (Tretten) in a Pregnant Woman with Factor XIII Deficiency.
Abruptio Placentae
Management of pregnancy, labour and delivery in women with inherited bleeding disorders.
[Role of the fibrin stabilizing factor (factor XIII) in early placental abruption]
Abscess
Effects of transfusion on gastrointestinal anastomotic wound healing and leukocyte function in rats.
Acantholysis
Are acantholysis and transglutaminase inhibition related phenomena?
Acidosis
Cofactors of wheat-dependent exercise-induced anaphylaxis do not increase highly individual gliadin absorption in healthy volunteers.
Acne Vulgaris
Hormonal and dietary factors in acne vulgaris versus controls.
Transglutaminase activity in human and rabbit ear comedogenesis: a histochemical study.
Acquired Immunodeficiency Syndrome
"Tissue" transglutaminase in AIDS.
A novel transglutaminase-catalyzed posttranslational modification of HIV-1 aspartyl protease.
Biomarkers for diagnosis and monitoring of celiac disease.
Evaluating the roles of thrombin and calcium in the activation of coagulation factor XIII using H/D exchange and MALDI-TOF MS.
Identification of the autoantigen of celiac disease.
Role of transglutaminase in keratinization of vaginal epithelial cells in oestrous cycling rats.
The spindle-shaped cells in cutaneous Kaposi's sarcoma. Histologic simulators include factor XIIIa dermal dendrocytes.
Vertebrate keratinization evolved into cornification mainly due to transglutaminase and sulfhydryl oxidase activities on epidermal proteins: An immunohistochemical survey.
Acute Coronary Syndrome
Antitissue transglutaminase antibodies in acute coronary syndrome: an alert signal of myocardial tissue lesion?
Expression of tissue transglutaminase and elafin in human coronary artery: implication for plaque instability.
Myocardial infarctions and other acute coronary syndromes in rare congenital bleeding disorders: a critical analysis of all reported cases.
Acute Kidney Injury
Acute kidney injury is associated with low factor XIII in decompensated cirrhosis.
Early response as shown by enhancement of transglutaminase 1 expression after cisplatin-induced acute kidney injury.
Addison Disease
A rare case of Addison's disease, hepatitis, thyreoiditis, positive IgG anti-tissue transglutaminase antibodies and partial IgA deficiency.
Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups.
Coeliac disease and autoimmune Addison's disease: a clinical pitfall.
One-Third of Patients Have Evidence for an Additional Autoimmune Disease at Type 1 Diabetes Diagnosis.
Prolactin and autoimmunity.
Adenocarcinoma
Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells.
Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions.
Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement.
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma.
Mass spectrum analysis of membrane proteins reveals that CASK, CD36 and EPB42 are differentially expressed in pancreatic adenocarcinoma.
Suppression of macrophage cytostatic activation by serum retinoids: a possible role for transglutaminase.
The expression of "tissue" transglutaminase in two human cancer cell lines is related with the programmed cell death (apoptosis).
Transglutaminase activity of cultured human prostatic epithelium.
Adenocarcinoma of Lung
Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells.
Adenocarcinoma, Bronchiolo-Alveolar
[Bronchiolo-alveolar carcinoma complicating systemic scleroderma under long-term treatment with factor XIII]
Adenoma
Nuclear factor XIIIa staining (clone AC-1A1 mouse monoclonal) is a highly sensitive marker of sebaceous differentiation in normal and neoplastic sebocytes.
Transglutaminase activity in human brain tumors.
Adenoma, Pleomorphic
Immunohistochemical evaluation of transglutaminase C in tumours of salivary glands.
Adrenal Insufficiency
Shared Genetic Basis for Type 1 Diabetes, Islet Autoantibodies, and Autoantibodies Associated With Other Immune-Mediated Diseases in Families With Type 1 Diabetes.
Afibrinogenemia
Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Clinical audit of inherited bleeding disorders in a developing country.
Congenital afibrinogenemia in a new born: a rare cause for bleeding.
Congenital hemorrhagic disorders in Jordan.
Effect of early cryoprecipitate transfusion versus standard care in women who develop severe postpartum haemorrhage (ACROBAT) in the UK: a protocol for a pilot cluster randomised trial.
Hemophiliacs--a picture from a developing country: Karnataka, a south Indian state.
Identification of acquired coagulation disorders and effects of target-controlled coagulation factor substitution on the incidence and severity of spontaneous intracranial bleeding during veno-venous ECMO therapy.
Impaired factor XIII activation in patients with congenital afibrinogenemia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
[Etiology of factor XIII, factor V and fibrinogen deficiency in acute leukemias]
Airway Obstruction
Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients.
Albuminuria
Transglutaminase inhibition ameliorates experimental diabetic nephropathy.
Alopecia
[Studies on enzyme activities in the hair root in male pattern baldness: glycolytic enzyme, acid hydrolase, transglutaminase and ornithine decarboxylase activities of plucked hair roots]
Alzheimer Disease
A nonradioactive dot blot assay for transglutaminase activity.
Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers.
Catalytically active tissue transglutaminase colocalises with A? pathology in Alzheimer's disease mouse models.
Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease.
Cerebrospinal fluid tissue transglutaminase in vascular dementia.
Coagulation factor XIII Val34Leu gene polymorphism and Alzheimer's disease.
Cognitive performance correlates with cortical isopeptide immunoreactivity as well as Alzheimer type pathology.
Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease.
Immunohistochemical demonstration of tissue transglutaminase in amyloid plaques.
In vitro neurotoxicity of amyloid ?-peptide cross-linked by transglutaminase.
Injury-induced "switch" from GTP-regulated to novel GTP-independent isoform of tissue transglutaminase in the rat spinal cord.
Introducing transglutaminase into the study of Alzheimer's disease. A personal look back.
Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease.
Isolation and characterization of brain-specific transglutaminases from rat.
Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease.
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease.
Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases.
Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.
Possible roles of transglutaminases in Alzheimer's disease.
Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.
Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice.
The association of tissue transglutaminase with human recombinant tau results in the formation of insoluble filamentous structures.
The influence of psychotropic drugs on cerebral cell death: female neurovulnerability to antipsychotics.
Tissue Transglutaminase and Its Product Isopeptide Are Increased in Alzheimer's Disease and APPswe/PS1dE9 Double Transgenic Mice Brains.
Tissue transglutaminase in Alzheimer's disease - facts and fiction: a reply to "Tissue transglutaminase is a biochemical marker for Alzheimer's disease".
Tissue Transglutaminase in Alzheimer's Disease: Involvement in Pathogenesis and its Potential as a Therapeutic Target.
Tissue transglutaminase is a biochemical marker for Alzheimer's disease.
Tissue transglutaminase is not a biochemical marker for Alzheimer's disease.
Tissue Transglutaminase, Protein Cross-linking and Alzheimer's Disease: Review and Views.
Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
Tissue transglutaminase: a possible role in neurodegenerative diseases.
Transglutaminase 2 is involved in homocysteine-induced activation of human THP-1 monocytes.
Transglutaminase activation in neurodegenerative diseases.
Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Transglutaminase activity is increased in Alzheimer's disease brain.
Transglutaminase and the neuronal cytoskeleton in Alzheimer's disease.
Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease.
Transglutaminase catalyzes differential crosslinking of small heat shock proteins and amyloid-beta.
Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau.
Transglutaminase cross-linking of the tau protein.
Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide.
Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Transglutaminase is linked to neurodegenerative diseases.
Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Transglutaminases - possible drug targets in human diseases.
Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Amyloidosis
A possible pivotal role for transglutaminase 2 in the pathophysiology of cutaneous amyloidosis.
Amyloidosis, Familial
Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide.
Amyotrophic Lateral Sclerosis
New target against inflammatory diseases: transglutaminase 2.
Transglutaminase 2 accelerates neuroinflammation in amyotrophic lateral sclerosis through interaction with misfolded superoxide dismutase 1.
Transglutaminase 2 is involved in homocysteine-induced activation of human THP-1 monocytes.
Transglutaminase 6 Antibodies in the Serum of Patients With Amyotrophic Lateral Sclerosis.
Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: a possible use as an indicator of extent of the motor neuron loss.
Anaphylaxis
Transglutaminase II interacts with rac1, regulates production of reactive oxygen species, expression of snail, secretion of Th2 cytokines and mediates in vitro and in vivo allergic inflammation.
Wheat allergy.
Anemia
A case of giant expanding cephalhematoma: does the administration of blood coagulation factor XIII reverse symptoms?
A novel mutation in the erythrocyte protein 4.2 gene of Japanese patients with hereditary spherocytosis (protein 4.2 Fukuoka).
Anemia in Pediatric Celiac Disease: Association with Clinical and Histological Features and Response to Gluten-free Diet.
Anti tissue transglutaminase antibody in idiopathic autoimmune haemolytic anemia.
Celiac disease prevalence in patients with iron deficiency anemia of obscure origin.
Diagnosis and treatment of unexplained anemia with iron deficiency without overt bleeding.
Genetic disorders of the red cell membranes.
HLA-DQ2/DQ8 frequency in adult patients with celiac disease, their first-degree relatives, and normal population in Turkey.
Human erythrocyte protein 4.2 deficiency associated with hemolytic anemia and a homozygous 40glutamic acid-->lysine substitution in the cytoplasmic domain of band 3 (band 3Montefiore).
Lonomia genus caterpillar toxins: biochemical aspects.
Patients with celiac disease may have normal weight or may even be overweight.
Pericardial effusion in celiac disease.
Presence of anemia in patients with celiac disease suggests more severe disease.
The use of real-time PCR technique in the detection of novel protein 4.2 gene mutations that coexist with thalassaemia alpha in a single patient.
Ultra-short Celiac Disease Is a Distinct and Milder Phenotype of the Disease in Children.
[Prevalence of polyglandular autoimmune syndrome in patients with diabetes mellitus type 1]
Anemia, Aplastic
Complete hemostasis achieved by factor XIII concentrate administration in a patient with bleeding after teeth extraction as a complication of aplastic anemia and chronic disseminated intravascular coagulation.
[The state of homeostasis system in patients with aplastic anemia in the period of full-fledged clinical manifestation of disease].
Anemia, Hemolytic
A point mutation in the protein 4.2 gene (allele 4.2 Tozeur) associated with hereditary haemolytic anaemia.
An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2NIPPON).
Band 3 Tuscaloosa: Pro327----Arg327 substitution in the cytoplasmic domain of erythrocyte band 3 protein associated with spherocytic hemolytic anemia and partial deficiency of protein 4.2.
Deficiency of protein 4.2 in erythrocytes from a patient with a Coombs negative hemolytic anemia. Evidence for a role of protein 4.2 in stabilizing ankyrin on the membrane.
Erythrocyte membrane protein destabilization versus clinical outcome in 160 Portuguese Hereditary Spherocytosis patients.
Human erythrocyte protein 4.2 deficiency associated with hemolytic anemia and a homozygous 40glutamic acid-->lysine substitution in the cytoplasmic domain of band 3 (band 3Montefiore).
Mapping of a palmitoylatable band 3-binding domain of human erythrocyte membrane protein 4.2.
Mapping of a spectrin-binding domain of human erythrocyte membrane protein 4.2.
Proteomic identification of erythrocyte membrane protein deficiency in hereditary spherocytosis.
Structure of the cytoplasmic domain of erythrocyte band 3 hereditary spherocytosis variant P327R: band 3 Tuscaloosa.
Anemia, Hemolytic, Congenital
A deletional frameshift mutation in protein 4.2 gene (allele 4.2 Lisboa) associated with hereditary hemolytic anemia.
An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2NIPPON).
Genetic disorders of the red cell membranes.
Human erythrocyte protein 4.2 deficiency associated with hemolytic anemia and a homozygous 40glutamic acid-->lysine substitution in the cytoplasmic domain of band 3 (band 3Montefiore).
Anemia, Hypochromic
"Strongyloides stercoralis infestation in a severely malnourished (SAM) celiac disease child:" A rare case report from Western Rajasthan.
Primary infertility as a rare presentation of celiac disease.
Anemia, Iron-Deficiency
Celiac disease prevalence in patients with iron deficiency anemia of obscure origin.
Pericardial effusion in celiac disease.
THE PREVALENCE OF CELIAC DISEASE IN PATIENTS WITH IRON-DEFICIENCY ANEMIA IN CENTER AND SOUTH AREA OF IRAN.
Anemia, Refractory
Cold urticaria and celiac disease.
Aneurysm
Effects of blood coagulation factor XIII on the development of experimental cerebral aneurysms in rats.
Experimentally induced cerebral aneurysms as model for non-surgical treatment.
Histological Investigation of Endothelial Cell Proliferation on the Coil Surface after Endovascular Treatment Using FactorXIII. Preliminary Results in Swine Model.
Morphologic changes in neo-intimal proliferation in an experimental aneurysm after coil embolization: effect of factor XIII administration.
Angiofibroma
Phenotypic characterisation of stellate and giant cells in giant cell fibroma by immunocytochemistry.
Solitary sclerotic fibroma of skin: a possible link with pleomorphic fibroma with immunophenotypic expression for O13 (CD99) and CD34.
Unilateral facial angiofibromas--a segmental form of tuberous sclerosis.
Angiolymphoid Hyperplasia with Eosinophilia
Ultrastructural localization of factor XIIIa.
Angiomyolipoma
Factor XIIIa in the hamartomas of tuberous sclerosis.
Antiphospholipid Syndrome
Factor XIII in primary antiphospholipid syndrome.
Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome.
Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with anti-thrombin antibody from a patient with antiphospholipid syndrome.
[Diagnosis and treatment of coagulation disorders]
[Prognostic value of allelic variants affecting the hemostatic system in the development of antiphospholipid syndrome and kidney lesion in patients with systemic lupus erythematosus].
[Recurrent miscarriage and inherited thrombophilia: diagnostic work-out and therapeutic management]
Aortic Aneurysm
Successful treatment of chronic disseminated intravascular coagulation using recombinant human soluble thrombomodulin in a dialysis patient with dissecting aortic aneurysm.
Aortic Aneurysm, Abdominal
Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation.
Transglutaminase type 2 in human abdominal aortic aneurysm is a potential factor in the stabilization of extracellular matrix.
Aortic Valve Stenosis
Factor XIII and alternatively activated macrophages - new targets in aortic valve stenosis.
Factor XIII expression within aortic valves and its plasma activity in patients with aortic stenosis: association with severity of disease.
Arnold-Chiari Malformation
Karyotype-Phenotype Correlation in Partial Trisomies of the Short Arm of Chromosome 6: A Family Case Report and Review of the Literature.
Arteriosclerosis
[Pathogenesis of arteriosclerosis. Thrombin, factor XIII and fibronectin as regulators of fibroblast proliferation, endothelial cells and smooth muscle cells]
Arteriovenous Malformations
Unusual presentation of factor XIII deficiency.
Arteritis
Differential behavior of coagulation factor XIII in patients with inflammatory bowel disease and in patients with giant cell arteritis.
Arthralgia
Adult Henoch-Schönlein purpura with severe abdominal pain treated with dapsone and factor XIII concentrate.
Arthritis
Evaluation of screening for celiac disease in children with juvenile idiopathic arthritis.
Factor XIII insufficiency in a patient with severe psoriasis vulgaris, arthritis, and infirmity.
Fibrin dissolution in synovial fluid.
IgA transglutaminase levels in children with Juvenile Idiopathic Arthritis.
New target against inflammatory diseases: transglutaminase 2.
Participation of transglutaminase in the activation of latent transforming growth factor beta1 in aging articular cartilage.
Tissue transglutaminase enhances collagen type II-induced arthritis and modifies the immunodominant T-cell epitope CII260-270.
Transglutaminase 2 cross-linking activity is linked to invadopodia formation and cartilage breakdown in arthritis.
Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion.
[Behavior of factor XIII in progressive chronic polyarthritis]
Arthritis, Juvenile
Evaluation of screening for celiac disease in children with juvenile idiopathic arthritis.
IgA transglutaminase levels in children with Juvenile Idiopathic Arthritis.
Arthritis, Psoriatic
Antibodies to human tissue transglutaminase and alterations of vitamin D metabolism in ankylosing spondylitis and psoriatic arthritis.
Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis.
Arthritis, Rheumatoid
Adult variant of self-healing papular mucinosis in a patient with rheumatoid arthritis: Predominant proliferation of dermal dendritic cells expressing CD34 or factor XIIIa in association with dermal deposition of mucin.
Fibrin degradation in the synovial fluid of rheumatoid arthritis patients: a model for extravascular fibrinolysis.
Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis.
Immunohistochemical detection of factor XIIIa and factor XIIIs in synovial membranes of patients with rheumatoid arthritis or osteoarthritis.
Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients.
Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab).
Peptidylarginine deiminases and the pathogenesis of rheumatoid arthritis: a reflection of the involvement of transglutaminase in coeliac disease.
Significance of diminished factor XIII in Crohn's disease.
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis.
Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis.
Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals.
[Desmofibrinogenic activity of factor XIII and thiol group levels of the plasma of patients with rheumatoid arthritis treated with levamisole]
Ascorbic Acid Deficiency
[The significance of changes in the functional properties of blood platelets, factor XIII activity and fibrin clot quality in the pathogenesis of hemorrhagic diathesis secondary to experimental vitamin C deficiency]
Asthma
An initial assessment of the involvement of transglutaminase2 in eosinophilic bronchitis using a disease model developed in C57BL/6 mice.
Anti-inflammatory effects of the R2 peptide, an inhibitor of transglutaminase 2, in a mouse model of allergic asthma, induced by ovalbumin.
Association of TG2 from mast cells and chronic spontaneous urticaria pathogenesis.
Asthma is associated with reduced fibrinolytic activity, abnormal clot architecture, and decreased clot retraction rate.
Atorvastatin has a protective effect in a mouse model of bronchial asthma through regulating tissue transglutaminase and triggering receptor expressed on myeloid cells-1 expression.
Circulating autoantibodies in patients with aspirin-intolerant asthma: an epiphenomenon related to airway inflammation.
Epithelial regulation of eicosanoid production in asthma.
IgE production in CD40/CD40L cross-talk of B and mast cells and mediator release via TGase 2 in mouse allergic asthma.
PLA2G5 regulates transglutaminase activity of human IL-4-activated M2 macrophages through PGE2 generation.
Tranglutaminase 2 contributes to the asthmatic inflammation by modulating activation of alveolar macrophages.
Transglutaminase 2, a novel regulator of eicosanoid production in asthma revealed by genome-wide expression profiling of distinct asthma phenotypes.
Triterpenoid compound betulin attenuates allergic airway inflammation by modulating antioxidants, inflammatory cytokines and tissue transglutaminase in ovalbumin-induced asthma mice model.
Unusual allergen in a butcher with respiratory symptoms.
Asthma, Occupational
Tissue Transglutaminase Can Be Involved in Airway Inflammation of Toluene Diisocyanate-Induced Occupational Asthma.
Astrocytoma
Factor XIIIa in the hamartomas of tuberous sclerosis.
Increased endothelial expression of transglutaminase in glioblastomas.
Ataxia
A case report of late-onset cerebellar ataxia associated with a rare p.R342W TGM6 (SCA35) mutation.
Ablation of polyamine catabolic enzymes provokes Purkinje cell damage, neuroinflammation, and severe ataxia.
Anti transglutaminase antibodies cause ataxia in mice.
Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase.
Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia.
Coeliac disease patients do not produce antibodies to a common cerebellar epitope.
Epilepsy, cerebral calcifications, and gluten-related disorders: Are anti-transglutaminase 6 antibodies the missing link?
Transglutaminase 6 antibodies in the diagnosis of gluten ataxia.
Transglutaminase 6 Antibodies in the Serum of Patients With Amyotrophic Lateral Sclerosis.
Ataxia Telangiectasia
Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor ? light chain enhancer of activated B cells (NF?B) signaling controls basal and DNA damage-induced transglutaminase 2 expression.
Atherosclerosis
Alterations of haemostasis parameters with special reference to fibrin stabilization, factor XIII and fibronectin in patients with obliterative atherosclerosis.
Erythrocyte transglutaminase activity in patients with obliterative atherosclerosis of the lower limbs.
Factor XIII expression within aortic valves and its plasma activity in patients with aortic stenosis: association with severity of disease.
Factor XIIIA (cross)links AT1 receptors to atherosclerosis.
Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis.
Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study.
Increase in transglutaminase and its extracellular products in response to an inflammatory stimulus by lipopolysaccharide.
Increased tissue transglutaminase expression in human atherosclerotic coronary arteries.
Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression.
Nitric oxide regulates non-classical secretion of tissue transglutaminase.
Pathogenic factors in vascular dementia and Alzheimer's disease. Multiple actions of heparin that probably are beneficial.
Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy.
Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases.
Roles of transglutaminases in cardiac and vascular diseases.
Transglutaminase activity regulates atherosclerotic plaque composition at locations exposed to oscillatory shear stress.
[Inhibition of factor XIII as a preventive and therapeutic possibility in atherosclerosis]
Atrial Fibrillation
alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism.
Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation.
Platelet factor XIII gene expression and embolic propensity in atrial fibrillation.
Autoimmune Diseases
A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases.
Autoimmunity to heat shock proteins and vitamin D status in patients with celiac disease without associated dermatitis herpetiformis.
Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): a population control study.
Gluten ataxia: passive transfer in a mouse model.
IFN-gamma induces transglutaminase 2 expression in rat small intestinal cells.
In vitro and in vivo models of celiac disease.
Intestinal Anti-tissue Transglutaminase2 Autoantibodies: Pathogenic and Clinical Implications for Celiac Disease.
Linear ?-(1???6)-d-glucan from Bifidobacterium bifidum BIM ?-733D is low molecular mass biopolymer with unique immunochemical properties.
Microbial transglutaminase should be considered as an environmental inducer of celiac disease.
New target against inflammatory diseases: transglutaminase 2.
NON-CELIAC SPRUE: A CASE OF OLMESARTAN-INDUCED ENTEROPATHY.
Orbital myositis associated with celiac disease.
Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease.
Pathomechanisms in celiac disease.
Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Potential of transglutaminase 2 as a therapeutic target.
Similarities and differences between older and young adult patients with celiac disease.
Synthetic Neoepitopes of the Transglutaminase-Deamidated Gliadin Complex as Biomarkers for Diagnosing and Monitoring Celiac Disease.
Tissue transglutaminase ELISA positivity in autoimmune disease independent of gluten-sensitive disease.
Tracking early autoimmune disease by bioluminescent imaging of NF-kappaB activation reveals pathology in multiple organ systems.
Transglutaminases as targets for pharmacological inhibition.
[Celiac disease as a model for autoimmune disease. Transglutaminase has the key role--stress reaction triggers the vicious circle]
[Celiac sprue (review)]
[Changing clinical image of celiac sprue in childhood]
Avitaminosis
Celiac Disease: Ten Things That Every Gastroenterologist Should Know.
Axial Spondyloarthritis
Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis.
Relation of ?2-Antiplasmin Genotype and Genetic Determinants of Fibrinogen Synthesis and Fibrin Clot Formation with Vascular Endothelial Growth Factor Level in Axial Spondyloarthritis.
Azoospermia
Identification of genes expressed in primate primordial oocytes.
Azotemia
Feline chronic kidney disease is associated with upregulation of transglutaminase 2: a collagen cross-linking enzyme.
Bacteremia
Factor XIII as a modulator of plasma fibronectin alterations during experimental bacteremia.
Bacterial Infections
Cellular and molecular modification of egg envelope hardening in fertilization.
Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis.
Balanitis
Expression of Transglutaminase in Foreskin of Children with Balanitis Xerotica Obliterans.
Balanitis Xerotica Obliterans
Expression of Transglutaminase in Foreskin of Children with Balanitis Xerotica Obliterans.
Basal Ganglia Diseases
Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders.
Battered Child Syndrome
Factor XIII deficiency mistaken for battered child syndrome: case of "correct" test ordering negated by a commonly accepted qualitative test with limited negative predictive value.
Behcet Syndrome
Prevalence of Celiac Disease Among Patients with Behcet's Disease in Iran.
Bell Palsy
Diagnosis and management of idiopathic facial palsy in children.
Bernard-Soulier Syndrome
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
On the retraction of collagen and fibrin induced by normal, defective and modified platelets.
beta-Thalassemia
Erythrocyte membrane skeleton abnormalities in severe beta-thalassemia.
Blister
Dermatitis herpetiformis and vitiligo.
Effects of androgen deprivation and estrogen treatment on the structure and protein expression of the rat coagulating gland.
Hormonally induced changes in apocrine secretion of transglutaminase in the rat dorsal prostate and coagulating gland.
Simultaneous apocrine and merocrine secretion in the rat coagulating gland.
Blood Coagulation Disorders
Phenotype-genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations.
[Blood coagulation disorder in a patient with moderate factor XIII and IX deficiency]
[Characterization of a large deletion that leads to congenital factor XIII deficiency]
Blood Platelet Disorders
[Pre-hospital diagnosis of nosebleed in children]
Bone Marrow Failure Disorders
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Brain Edema
Tissue-type transglutaminase and the effects of cystamine on intracerebral hemorrhage-induced brain edema and neurological deficits.
Brain Infarction
The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction.
The effect of the Val34Leu polymorphism in the factor XIII gene in infants with a birth weight below 1500 g.
Brain Injuries
Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia.
Brain Injuries, Traumatic
Up-regulation of tissue-type transglutaminase after traumatic brain injury.
Brain Ischemia
Excitotoxic and post-ischemic neurodegeneration: Involvement of transglutaminases.
Transglutaminase activity and transglutaminase mRNA transcripts in gerbil brain ischemia.
Transglutaminase activity in reversible cerebral ischemia in the rat.
Brain Neoplasms
An immunohistochemical study of tissue transglutaminase in gliomas with reference to their cell dying processes.
Application of a Global Proteomic Approach to Archival Precursor Lesions: Deleted in Malignant Brain Tumors 1 and Tissue Transglutaminase 2 Are Upregulated in Pancreatic Cancer Precursors.
Transglutaminase activity in human brain tumors.
[Tissue transglutaminase protein expression in human brain tumors]
Breast Neoplasms
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells.
Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells.
Congenital factor XIII deficiency with multiple benign breast tumours and successful pregnancy with substitutive therapy. A case report.
Correlation between immunoreactivity for transglutaminase K and for markers of proliferation and differentiation in normal breast tissue and breast carcinomas.
Correlation of tissue transglutaminase expression on breast cancer tissue with time to relapse, overall survival, and clinical and molecular prognostic factors: a preliminary report.
Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis.
Expression and Activity of Transglutaminase II in Spontaneous Tumours of Dogs and Cats.
Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.
Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.
High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells.
I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway.
IL-1? induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells.
Immunocytochemical demonstration of tissue transglutaminase indicative of programmed cell death (apoptosis) in hormone sensitive mammary tumours.
Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
Implications of tissue transglutaminase expression in malignant melanoma.
In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model.
Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues.
Increased tissue transglutaminase expression in human atherosclerotic coronary arteries.
Increased transglutaminase 2 and GLUT-1 expression in breast tumors not susceptible to chemoprevention with antioxidants.
Inhibition of the lncRNA Coded within Transglutaminase 2 Gene Impacts Several Relevant Networks in MCF-7 Breast Cancer Cells.
Interplay between membrane lipid peroxidation, transglutaminase activity and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.
Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools.
Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma.
Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation.
Role of TG2 and TGF-?1 in the pathogenesis of human breast cancer.
Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors.
Silencing of TGM2 reverses epithelial to mesenchymal transition and modulates the chemosensitivity of breast cancer to docetaxel.
Targeting p70S6K Prevented Lung Metastasis in a Breast Cancer Xenograft Model.
The 55?kDa tissue transglutaminase cross-linking active isoform TG induces cell death.
The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205.
The tissue transglutaminase: a potential target regulating MDR in breast cancer.
The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer.
Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer.
Tissue transglutaminase expression in breast carcinomas.
Tissue transglutaminase expression in human breast cancer.
Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells.
Tissue transglutaminase is an essential participant in the EGF-stimulated signaling pathway leading to cancer cell migration and invasion.
Transglutaminase 2 and NF-?B: an odd couple that shapes breast cancer phenotype.
Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells.
Treatment of postmenopausal osteoporosis in a patient with celiac disease.
Bronchitis
An initial assessment of the involvement of transglutaminase2 in eosinophilic bronchitis using a disease model developed in C57BL/6 mice.
Bronchopulmonary Dysplasia
Targeting transglutaminase 2 partially restores extracellular matrix structure but not alveolar architecture in experimental bronchopulmonary dysplasia.
Bulbo-Spinal Atrophy, X-Linked
Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases.
Candidiasis
Essential role of the Candida albicans transglutaminase substrate, hyphal wall protein 1, in lethal oroesophageal candidiasis in immunodeficient mice.
Carcinogenesis
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Aging process is accompanied by increase of transglutaminase C.
Alteration of Rb binding to HPV 18 E7 modified by transglutaminase 2 with different type of polyamines.
Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.
Apoptosis induction by S-allylcysteine, a garlic constituent, during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis.
Distribution and activity of transglutaminase in rat brain carcinogenesis and in gliomas.
Effects of C-Phycocyanin on the representative genes of tumor development in mouse skin exposed to 12-O-tetradecanoyl-phorbol-13-acetate.
Expression of epidermal growth factor receptor, polyamine levels, ornithine decarboxylase activity, micronuclei, and transglutaminase I in a 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model.
Expression of the cytosolic and particulate forms of transglutaminase during chemically induced rat liver carcinogenesis.
Garlic induces apoptosis during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis.
Inhibition of the lncRNA Coded within Transglutaminase 2 Gene Impacts Several Relevant Networks in MCF-7 Breast Cancer Cells.
Interplay between membrane lipid peroxidation, transglutaminase activity and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.
Ovarian cancer, the coagulation pathway, and inflammation.
Study of tumor transglutaminase 2 expression in gallbladder cancer - Is it a novel predictor of survival?
The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma.
The Role of Tissue Transglutaminase in Cancer Cell Initiation, Survival and Progression.
Tissue transglutaminase is an essential participant in the EGF-stimulated signaling pathway leading to cancer cell migration and invasion.
Transglutaminase 2 expression and its prognostic significance in clear cell renal cell carcinoma.
Transglutaminase in azoxymethane-induced colon cancer in the rat.
[Study on the loss of heterozygosity and expression of transglutaminase 3 gene in laryngeal carcinoma]
[Tissue transglutaminase protein expression in human brain tumors]
Carcinoma
A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2.
A unique role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell migration.
Agminated Clear Cell Tumor: An Impostor of PEComa and Distinctive Dermal Clear Cell Mesenchymal Neoplasm.
Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Alterations in cholesterol sulfate and its biosynthetic enzyme during multistage carcinogenesis in mouse skin.
Annexin I and involucrin are cross-linked by particulate transglutaminase into the cornified cell envelope of squamous cell carcinoma Y1.
Biochemistry of transglutaminases and cross-linking in the skin.
Carcinoma cell lines resistant for growth inhibition and apoptosis to retinoic acid are responsive to 4-hydroxy-phenyl-retinamide: correlation with tissue transglutaminase.
Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells.
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.
Clinical Significance of GPR56, Transglutaminase 2, and NF-κB in Esophageal Squamous Cell Carcinoma.
Comparative immunohistochemistry of malignant fibrous histiocytoma and sarcomatoid carcinoma of the urinary tract.
Control of growth regulatory and differentiation-specific genes in human epidermal keratinocytes by interferon gamma. Antagonism by retinoic acid and transforming growth factor beta 1.
Cross-linked envelope-related markers for squamous differentiation in human lung cancer cell lines.
Differences in transglutaminase mRNA after polyamine depletion in two cell lines.
Differential expression of the keratin-4, -13, -14, -17 and transglutaminase 3 genes during the development of oral squamous cell carcinoma from leukoplakia.
Differentiation capacity of human non-small-cell lung cancer cell lines after exposure to phorbol ester.
Discovery of a novel target for renal cell carcinoma: transglutaminase 2.
E2F suppression and Sp1 overexpression are sufficient to induce the differentiation-specific marker, transglutaminase type 1, in a squamous cell carcinoma cell line.
E3 ligase STUB1 attenuates stemness and tumorigenicity of oral carcinoma cells via transglutaminase 2 regulation.
Expression and Activity of Transglutaminase II in Spontaneous Tumours of Dogs and Cats.
Expression of epidermal growth factor receptor, polyamine levels, ornithine decarboxylase activity, micronuclei, and transglutaminase I in a 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model.
Expression of retinoic acid receptor beta is associated with inhibition of keratinization in human head and neck squamous carcinoma cells.
Expression of tissue transglutaminase in human bladder carcinoma.
Expression of transglutaminase K in normal cervix tissue and cervix carcinomas.
Fibrin stabilizing factor activity of the skin carcinoma.
Functional studies of a novel oncogene TGM3 in human esophageal squamous cell carcinoma.
Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.
Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes.
Immunohistochemical evaluation of transglutaminase C in tumours of salivary glands.
Immunohistochemical markers informing the diagnosis of sebaceous carcinoma and its distinction from its mimics: Adipophilin and factor XIIIa to the rescue?
Immunological characterization and activity of transglutaminases in human normal and malignant prostate and in prostate cancer cell lines.
Increased expression of transglutaminase 2 drives glycolytic metabolism in renal carcinoma cells.
Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro.
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma.
Keratinocyte differentiation markers: involucrin, transglutaminase, and toxicity.
Keratinocyte transglutaminase expression varies in squamous cell carcinomas.
Keratinocyte transglutaminase in human skin and oral mucosa: cytoplasmic localization and uncoupling of differentiation markers.
New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds.
Nuclear factor XIIIa staining (clone AC-1A1 mouse monoclonal) is a highly sensitive marker of sebaceous differentiation in normal and neoplastic sebocytes.
Phenotypic characterization of macrophage subpopulations and localization of factor XIII in the stromal cells of carcinomas.
Prognostic role of tissue transglutaminase 2 in colon carcinoma.
Purification of keratinocyte transglutaminase and its expression during squamous differentiation.
Rapid increases in the transglutaminase activity of A431 cells following treatment with epidermal growth factor.
Regulation of type I and type II transglutaminase in normal human bronchial epithelial and lung carcinoma cells.
Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition.
Retinoid suppression of transglutaminase activity and envelope competence in cultured human epidermal carcinoma cells. Hydrocortisone is a potent antagonist or retinyl acetate but not retinoic acid.
Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression.
Sebaceous Carcinoma in Situ Masquerading Clinically and Histologically as Paget Disease of the Breast.
The expression of transglutaminase 2 (TG-2) in oral squamous cell carcinoma and its clinical significance.
The hamster cheek pouch carcinogenesis model.
The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma.
The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.
Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer.
Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma.
Tissue transglutaminase is an essential participant in the EGF-stimulated signaling pathway leading to cancer cell migration and invasion.
Tissue transglutaminase links TGF-?, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer.
Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma.
Tissue transglutaminase was up-regulated by EGF-retinoid interplay in epithelial carcinoma cells.
TPA induces transglutaminase C and inhibits cell growth in the colon carcinoma cell line SW620.
Transglutaminase 2 expression and its prognostic significance in clear cell renal cell carcinoma.
Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Transglutaminase 2 Promotes Autophagy by LC3 Induction through p53 Depletion in Cancer Cell.
Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1?-p300 Binding in Renal Cell Carcinoma.
Transglutaminase 2: The Maestro of the Oncogenic Mediators in Renal Cell Carcinoma.
Transglutaminase 3 contributes to malignant transformation of oral leukoplakia to cancer.
Transglutaminase 3 is expressed in basal cell carcinoma of the skin.
Transglutaminase Interaction with ?6/?4-Integrin Stimulates YAP1-Dependent ?Np63? Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.
Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Ultrastructural localization of factor XIIIa.
Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma.
[Disseminated intravascular coagulation syndrome (D.I.C.) and carcinoma of the prostate (author's transl)]
[Factor XIII (fibrin stabilizing factor) in cutaneous epitheliomas]
[Is the use of factor XIII for delayed wound healing in patients with head-neck tumors of value?]
[Study on the loss of heterozygosity and expression of transglutaminase 3 gene in laryngeal carcinoma]
Carcinoma in Situ
Sebaceous Carcinoma in Situ Masquerading Clinically and Histologically as Paget Disease of the Breast.
Carcinoma, Acinar Cell
Immunohistochemical evaluation of transglutaminase C in tumours of salivary glands.
Carcinoma, Adenoid Cystic
Immunohistochemical evaluation of transglutaminase C in tumours of salivary glands.
Carcinoma, Basal Cell
Biochemistry of transglutaminases and cross-linking in the skin.
Fibrin stabilizing factor activity of the skin carcinoma.
Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes.
Transglutaminase 3 is expressed in basal cell carcinoma of the skin.
Ultrastructural localization of factor XIIIa.
Carcinoma, Ductal
Interplay between membrane lipid peroxidation, transglutaminase activity and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.
Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.
Carcinoma, Embryonal
Transglutaminase activity and embryonal carcinoma cell differentiation.
Carcinoma, Hepatocellular
Activated hepatic stellate cells promote epithelial-to-mesenchymal transition in hepatocellular carcinoma through transglutaminase 2-induced pseudohypoxia.
Alterations in the distribution and activity of transglutaminase during tumour growth and metastasis.
Biosynthesis of factor XIII B subunit by human hepatoma cell lines.
Biosynthesis of plasma factor XIII: evidence for transcription and translation in hepatoma cells.
Cancer-associated Fibroblasts induce epithelial-mesenchymal transition via the Transglutaminase 2-dependent IL-6/IL6R/STAT3 axis in Hepatocellular Carcinoma.
Characterisation of the cellular substrates for transglutaminase in normal liver and hepatocellular carcinoma.
Construction of a pH/TGase "Dual Key"-Responsive Gold Nano-radiosensitizer with Liver Tumor-Targeting Ability.
Differential regulation of tissue transglutaminase in rat hepatoma cell lines McA-RH7777 and McA-RH8994: relation to growth rate and cell death.
Differential transglutaminase distribution in normal rat liver and rat hepatoma.
Effects of phenyl saligenin phosphate on cell viability and transglutaminase activity in N2a neuroblastoma and HepG2 hepatoma cell lines.
Expression of the cytosolic and particulate forms of transglutaminase during chemically induced rat liver carcinogenesis.
Induction of apoptosis by transforming growth factor-beta 1 in the rat hepatoma cell line McA-RH7777: a possible association with tissue transglutaminase expression.
Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells.
Multifunctional nanocatalyst-based ultrasensitive detection of human tissue transglutaminase 2.
Primary vs metastatic hepatic carcinoma. An immunohistochemical study of 34 cases.
Properties of particulate transglutaminase from Yoshida tumor cells.
Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma.
Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma.
Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles.
Transglutaminase and epsilon-(gamma-glutamyl) lysine isopeptide bonds in eukaryotic cells.
[High expressions of tissue transglutaminase in human hepatocellular carcinomas]
Carcinoma, Intraductal, Noninfiltrating
Interplay between membrane lipid peroxidation, transglutaminase activity and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.
Carcinoma, Mucoepidermoid
Immunohistochemical evaluation of transglutaminase C in tumours of salivary glands.
Carcinoma, Non-Small-Cell Lung
Association between TGM5, PPAP2B and PSMA4 polymorphisms and NSCLC in never-smoking Chinese population.
Clinical value of exogenous factor XIII for prolonged air leak following pulmonary lobectomy: a case control study.
Cross-linked envelope-related markers for squamous differentiation in human lung cancer cell lines.
Dynamics of coagulation factor XIII activity after video-assisted thoracoscopic lobectomy for non-small cell lung cancer.
Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients.
Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer.
Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer.
Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer.
Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor.
Carcinoma, Ovarian Epithelial
Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.
Tissue transglutaminase regulates MMP-2 in ovarian cancer by modulating CREB activity.
Carcinoma, Renal Cell
A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2.
Agminated Clear Cell Tumor: An Impostor of PEComa and Distinctive Dermal Clear Cell Mesenchymal Neoplasm.
Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Discovery of a novel target for renal cell carcinoma: transglutaminase 2.
Increased expression of transglutaminase 2 drives glycolytic metabolism in renal carcinoma cells.
Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma.
New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds.
Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition.
Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression.
The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma.
The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma.
Transglutaminase 2 expression and its prognostic significance in clear cell renal cell carcinoma.
Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Transglutaminase 2 Promotes Autophagy by LC3 Induction through p53 Depletion in Cancer Cell.
Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1?-p300 Binding in Renal Cell Carcinoma.
Transglutaminase 2: The Maestro of the Oncogenic Mediators in Renal Cell Carcinoma.
Carcinoma, Squamous Cell
2,3,7,8-Tetrachlorodibenzo-p-dioxin and polycyclic aromatic hydrocarbons suppress retinoid-induced tissue transglutaminase in SCC-4 cultured human squamous carcinoma cells.
Alterations in cholesterol sulfate and its biosynthetic enzyme during multistage carcinogenesis in mouse skin.
Annexin I and involucrin are cross-linked by particulate transglutaminase into the cornified cell envelope of squamous cell carcinoma Y1.
Control of growth regulatory and differentiation-specific genes in human epidermal keratinocytes by interferon gamma. Antagonism by retinoic acid and transforming growth factor beta 1.
Differential regulation by retinoic acid and calcium of transglutaminases in cultured neoplastic and normal human keratinocytes.
Differentiation of normal and tumoral human keratinocytes cultured on dermis: reconstruction of either normal or tumoral architecture.
E2F suppression and Sp1 overexpression are sufficient to induce the differentiation-specific marker, transglutaminase type 1, in a squamous cell carcinoma cell line.
Expression of epidermal growth factor receptor, polyamine levels, ornithine decarboxylase activity, micronuclei, and transglutaminase I in a 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model.
Expression of retinoic acid receptor beta is associated with inhibition of keratinization in human head and neck squamous carcinoma cells.
Immunohistochemical evaluation of transglutaminase C in tumours of salivary glands.
Keratinocyte transglutaminase expression varies in squamous cell carcinomas.
Keratinocyte transglutaminase in human skin and oral mucosa: cytoplasmic localization and uncoupling of differentiation markers.
Nuclear factor XIIIa staining (clone AC-1A1 mouse monoclonal) is a highly sensitive marker of sebaceous differentiation in normal and neoplastic sebocytes.
Purification of keratinocyte transglutaminase and its expression during squamous differentiation.
Regulation of type I and type II transglutaminase in normal human bronchial epithelial and lung carcinoma cells.
Retinoic acid and IFN inhibition of cell proliferation is associated with apoptosis in squamous carcinoma cell lines: role of IRF-1 and TGase II-dependent pathways.
Retinoid suppression of transglutaminase activity and envelope competence in cultured human epidermal carcinoma cells. Hydrocortisone is a potent antagonist or retinyl acetate but not retinoic acid.
Suppression of keratinocyte differentiation in SSC-9 human squamous carcinoma cells by benzo[a]pyrene, 12-O-tetradecanoylphorbol-13-acetate and hydroxyurea.
TCDD suppression of tissue transglutaminase stimulation by retinoids in malignant human keratinocytes.
Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma.
Transglutaminase Interaction with ?6/?4-Integrin Stimulates YAP1-Dependent ?Np63? Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.
Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Type I keratinocyte transglutaminase: expression in human skin and psoriasis.
Carcinoma, Transitional Cell
Expression of tissue transglutaminase in human bladder carcinoma.
Cardiomegaly
Involvement of tissue transglutaminase in endothelin 1-induced hypertrophy in cultured neonatal rat cardiomyocytes.
Cardiomyopathies
Absence of Thrombospondin-2 Causes Age-Related Dilated Cardiomyopathy.
Cardiomyopathy, Dilated
Damaged myocytes as detected by the colocalization of DNA fragmentation and tissue transglutaminase and their prognostic significance in enterovirus-associated dilated cardiomyopathy.
Cardiovascular Diseases
Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography.
Combined measurement of factor XIII and D-dimer is helpful for differential diagnosis in patients with suspected pulmonary embolism.
Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in Serbian population.
Evaluation of Factor V G1691A, prothrombin G20210A, Factor XIII V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G genotype frequencies of patients subjected to cardiovascular disease (CVD) panel in south-east region of Turkey.
Factor XIII gene V34L mutation in the Lebanese population: another unique feature in this community?
Nitric oxide regulates tissue transglutaminase localization and function in the vasculature.
Pathophysiologic roles of the fibrinogen gamma chain.
Role of inherited thrombophilic profile on survival of patients with sepsis.
The effects of genetic polymorphisms and diabetes mellitus on the development of peripheral artery disease.
The genetics of haemostasis: a twin study.
[Effect of mercurial diuretics on heparin contents fibrinolysis and activity of blood fibrin stabilizing factor in patients with cardiovascular diseases]
Cartilage Diseases
Participation of transglutaminase in the activation of latent transforming growth factor beta1 in aging articular cartilage.
Cataract
Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation: implications of transglutaminase 2 in age-related cataractogenesis.
Cysteamine prevents the development of lens opacity in a rat model of selenite-induced cataract.
Endoplasmic reticulum stress activates transglutaminase 2 leading to protein aggregation.
Enhanced expression of transglutaminase 2 in anterior polar cataracts and its induction by TGF-beta in vitro.
Exposure of beta H-crystallin to hydroxyl radicals enhances the transglutaminase-susceptibility of its existing amine-donor and amine-acceptor sites.
Exposure of beta L-crystallin to oxidizing free radicals enhances its susceptibility to transglutaminase activity.
Expression and rapid purification of highly active hexahistidine-tagged guinea pig liver transglutaminase.
Identification and functional clustering of global gene expression differences between human age-related cataract and clear lenses.
Lamellar ichthyosis associated with pseudoainhum of the toes and eye changes.
Lens transglutaminase and cataract formation.
Localization of transglutaminase in human lenses.
Novel inhibitors against the transglutaminase-catalysed crosslinking of lens proteins.
Polyamine Oxidase Is Involved in Spermidine Reduction of Transglutaminase Type 2-Catalyzed ?H-Crystallins Polymerization in Calcium-Induced Experimental Cataract.
Properties of purified lens transglutaminase and regulation of its transamidase/crosslinking activity by GTP.
Transglutaminase activity in normal human lenses and in senile cataracts.
Transglutaminases as targets for pharmacological inhibition.
Celiac Disease
A Comparison of Antibody Testing, Permeability Testing, and Zonulin Levels with Small-Bowel Biopsy in Celiac Disease Patients on a Gluten-Free Diet.
A Functional Idiotype/Anti-Idiotype Network Is Active in Genetically Gluten-Intolerant Individuals Negative for Both Celiac Disease-Related Intestinal Damage and Serum Autoantibodies.
A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases.
A limp in a pregnant woman as a first presentation of celiac disease.
A modified ELISA for improved detection of IgA, IgG, and IgM anti-tissue transglutaminase antibodies in celiac disease.
A molecular warhead and its target: tissue transglutaminase and Celiac Sprue.
A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease.
A new dot immunoassay for simultaneous detection of celiac specific antibodies and IgA-deficiency.
A new indirect chemiluminescent immunoassay to measure anti-tissue transglutaminase antibodies.
A non-human primate model for gluten sensitivity.
A quantitative analysis of transglutaminase 2-mediated deamidation of gluten peptides: implications for the T-cell response in celiac disease.
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten Challenge.
A report on the International Transglutaminase Autoantibody Workshop for Celiac Disease.
A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects.
A Single Institution's Experience of Primary Headache in Children With Celiac Disease.
A study on early developing celiac disease in children with cerebral palsy.
Accumulation of Heavy Metals in People on a Gluten-Free Diet.
Accuracy of Anti-Tissue Transglutaminase IgA Antibody in the Diagnosis of Paediatric Celiac Disease.
Accuracy of HLA-DQ genotyping in combination with IgA anti-tissue transglutaminase serology and a "scoring system" for the diagnosis of celiac disease in Turkish children.
Accuracy of Screening Tests for Celiac Disease in Asymptomatic Patients With Type 1 Diabetes.
Activity-regulating structural changes and autoantibody epitopes in transglutaminase 2 assessed by hydrogen/deuterium exchange.
Acylideneoxoindoles: A new class of reversible inhibitors of human transglutaminase 2.
Addition of a Short Course of Prednisolone to a Gluten-Free Diet vs. Gluten-Free Diet Alone in Recovery of Celiac Disease: A Pilot Randomized Controlled Trial.
Adherence to a Gluten-Free Diet: Assessment by Dietician Interview and Serology.
Adult celiac disease followed by onset of systemic lupus erythematosus.
AGA Clinical Practice Update on the Evaluation and Management of Seronegative Enteropathies.
AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).
Alpha-enolase involvement in intestinal and extraintestinal manifestations of celiac disease.
Alternative RNA splicing of leukocyte tissue transglutaminase in celiac disease.
An amperometric immunosensor for diagnosis of celiac disease based on covalent immobilization of open conformation tissue transglutaminase for determination of anti-tTG antibodies in human serum.
An explorative study identifies miRNA signatures for the diagnosis of non-celiac wheat sensitivity.
An Unusual "OR" Gate for Allosteric Regulation of Mammalian Transglutaminase 2 in the Extracellular Matrix.
An update on the diagnostics of celiac disease.
Analysis of celiac disease autoreactive gut plasma cells and their corresponding memory compartment in peripheral blood using high-throughput sequencing.
Angiogenesis-related gene expression analysis in celiac disease.
Anthropometric, Serologic, and Laboratory Correlation With Villous Blunting in Pediatric Celiac Disease: Diabetics are Different.
Anti-gliadin antibodies identify celiac patients overlooked by tissue transglutaminase antibodies.
Anti-tissue transglutaminase antibodies activate intracellular tissue transglutaminase by modulating cytosolic Ca(2+) homeostasis.
Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence.
Anti-tissue transglutaminase antibody as the first line screening for celiac disease: good-bye antigliadin tests?
Anti-tissue transglutaminase antibody inhibits apoptotic cell clearance by macrophages in pregnant NOD mice.
Anti-tissue Transglutaminase Normalization Post Diagnosis in Children With Celiac Disease.
Anti-tissue transglutaminase titers are associated with endoscopic findings and severity of mucosal damage in children with celiac disease.
Anti-transglutaminase IgA ELISA: clinical potential and drawbacks in celiac disease diagnosis.
Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.
Antibodies Against Deamidated Gliadin Peptides and Tissue Transglutaminase for Diagnosis of Pediatric Celiac Disease - Diagnostic Performance and Cost in Clinical Practice.
Antibodies Against Deamidated Gliadin Peptides in Early-stage Celiac Disease.
Antibodies against neo-epitope of microbial and human transglutaminase complexes as biomarkers of childhood celiac disease.
Antibodies against neo-epitope tTg complexed to gliadin are different and more reliable then anti-tTg for the diagnosis of pediatric celiac disease.
Antibodies against synthetic deamidated gliadin peptides and tissue transglutaminase for the identification of childhood celiac disease.
Antibodies in celiac disease: implications beyond diagnostics.
Antibodies to Deamidated Gliadin Peptide in Diagnosis of Celiac Disease in Children.
Antibodies to gliadin, endomysium, and tissue transglutaminase for the diagnosis of celiac disease.
Antibodies to human recombinant tissue transglutaminase measured by radioligand assay: evidence for high diagnostic sensitivity for celiac disease.
Antibodies to human tissue transglutaminase for the diagnosis of celiac disease.
Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis.
Antibody Concentrations Decrease 14-Fold in Children With Celiac Disease on a Gluten-Free Diet but Remain High at 3 Months.
Antibody reactivity against human and guinea pig tissue transglutaminase in children with celiac disease.
Antibody testing in Indian children with celiac disease.
Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity.
Antitissue transglutaminase and antithyroid autoantibodies in children with Down syndrome and celiac disease.
Antitissue transglutaminase antibodies outside celiac disease.
Antitissue Transglutaminase IgA for Celiac Disease Testing.
Are Immunoglobulin A anti-gliadin antibodies of any help in the diagnosis of coeliac disease in children below 2 years-old? a French multicenter study.
Assessment of a combination screening assay for celiac disease.
Association between Celiac Disease and Intussusceptions in Children: Two Case Reports and Literature Review.
Association of Anti-tissue Transglutaminase Antibody Titers and Duodenal Biopsy Findings in Pediatric Patients of Celiac Disease.
Association of celiac disease in patients with multiple sclerosis in Tuscany.
Association of Gluten Intake During the First 5 Years of Life With Incidence of Celiac Disease Autoimmunity and Celiac Disease Among Children at Increased Risk.
Association of Tissue Transglutaminase Antibody Titer with Duodenal Histological Changes in Children with Celiac Disease.
Atypical Presentation of Celiac Disease: Recurrent Acute Small Bowel Obstruction.
Autism Spectrum Disorders and Celiac Disease: Is there an Association?
Autoantibodies against soluble and immobilized human recombinant tissue transglutaminase in children with celiac disease.
Autoantibodies and CD: past and future of celiac antibody testing.
Autoantibodies and histogenesis of celiac disease.
Autoantibodies from patients with celiac disease inhibit transglutaminase 2 binding to heparin/heparan sulfate and interfere with intestinal epithelial cell adhesion.
Autoantibodies in celiac disease.
Autoantibodies in the Extraintestinal Manifestations of Celiac Disease.
Autoantibodies to tissue transglutaminase as predictors of celiac disease.
Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups.
Autoantibody screen in inflammatory myopathies high prevalence of antibodies to gliadin.
Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia.
Autoimmunity to heat shock proteins and vitamin D status in patients with celiac disease without associated dermatitis herpetiformis.
B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2.
Beneficial effects of gluten free diet on IgA tissue transglutaminase levels and various growth parameters in celiac disease patients.
Beneficial Effects of Human Anti-Interleukin-15 Antibody in Gluten-Sensitive Rhesus Macaques with Celiac Disease.
Beta-cell autoimmunity in pediatric celiac disease: the case for routine screening?
Beyond the Intestinal Celiac Mucosa: Diagnostic Role of Anti-TG2 Deposits, a Systematic Review.
Blocking Peptides Decrease Tissue Transglutaminase Processing of Gliadin in Vitro.
Bone pain and extremely low bone mineral density due to severe vitamin D deficiency in celiac disease.
Calcium activation of tissue transglutaminase in radioligand binding and enzyme-linked autoantibody immunoassays in childhood celiac disease.
Can head trauma trigger celiac disease? Nation-wide case-control study.
Can tissue transglutaminase antibody titers replace small-bowel biopsy to diagnose celiac disease in select pediatric populations?
Candida albicans in celiac disease: A wolf in sheep's clothing.
Carpal spasm in a girl as initial presentation of celiac disease: a case report.
Celiac anti-tissue transglutaminase antibodies interfere with the uptake of alpha gliadin peptide 31-43 but not of peptide 57-68 by epithelial cells.
Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects.
Celiac disease : risk assessment, diagnosis, and monitoring.
Celiac disease and childhood stroke.
Celiac disease and endocrine autoimmunity - the genetic link.
Celiac Disease and Glandular Autoimmunity.
Celiac Disease and Gyneco-obstetrics Complications: Can Serum Antibodies Modulate Tissue Transglutaminase Functions and Contribute to Clinical Pattern?
Celiac Disease and Liver Disorders: From Putative Pathogenesis to Clinical Implications.
Celiac disease and multiple sclerosis in the northwest of Iran.
Celiac Disease and Nonceliac Gluten Sensitivity: A Review.
Celiac disease and severe vitamin D deficiency: the case for anti-tissue transglutaminase antibody screening.
Celiac disease and the endocrinologist: a diagnostic opportunity.
Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders.
Celiac disease as an autoimmune condition.
Celiac Disease Autoimmunity in Patients with Autoimmune Diabetes and Thyroid Disease among Chinese Population.
Celiac Disease Can be Predicted by High Levels of Anti-Tissue Transglutaminase Antibodies in Population-Based Screening.
Celiac disease can be predicted by high levels of tissue transglutaminase antibodies in children and adolescents with type 1 diabetes.
Celiac disease could be a frequent disease in Mexico: prevalence of tissue transglutaminase antibody in healthy blood donors.
Celiac disease detection using a transglutaminase electrochemical immunosensor fabricated on nanohybrid screen-printed carbon electrodes.
Celiac Disease Diagnosis Without Biopsy: Is a 10× ULN Antitransglutaminase Result Suitable for a Chemiluminescence Method?
Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA.
Celiac Disease in an Adult Presenting as Behavioral Disturbances.
Celiac Disease in an Urban VA Population with Iron Deficiency: The Case Against Routine Duodenal Biopsy.
Celiac Disease in Children with Functional Constipation: A School-Based Multicity Study.
Celiac Disease in Children with Severe Acute Malnutrition (SAM): A Hospital Based Study.
Celiac disease in non-clinical populations of Japan.
Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure.
Celiac disease in patients with type-1 diabetes mellitus screened by tissue transglutaminase antibodies in northwest of Iran.
Celiac disease in Type 1 diabetic children and adults: IgA class transglutaminase autoantibodies as the best screening marker.
Celiac disease in Williams-Beuren syndrome.
Celiac disease is not more prevalent in patients undergoing in vitro fertilization and does not affect reproductive outcomes with or without treatment: a large prospective cohort study.
Celiac Disease Management in the United Kingdom Specialist Pediatric Gastroenterology Centers-A Service Survey.
Celiac disease manifested by polyneuropathy and swollen ankles.
Celiac Disease on FDG PET/CT.
Celiac disease or positive tissue transglutaminase antibodies in patients undergoing renal biopsies.
Celiac disease patient IgA antibodies induce endothelial adhesion and cell polarization defects via extracellular transglutaminase 2.
Celiac disease screening by immunochromatographic visual assays: results of a multicenter study.
Celiac disease with diffuse cutaneous vitamin K-deficiency bleeding.
Celiac disease-associated antibodies in patients with psoriasis and correlation with HLA Cw6.
Celiac disease-associated transglutaminase autoantibody target domains at diagnosis are age and sex dependent.
Celiac Disease-Specific TG2-Targeted Autoantibodies Inhibit Angiogenesis Ex Vivo and In Vivo in Mice by Interfering with Endothelial Cell Dynamics.
Celiac Disease-Type Tissue Transglutaminase Autoantibody Deposits in Kidney Biopsies of Patients with IgA Nephropathy.
Celiac disease.
Celiac disease: a comprehensive current review.
Celiac disease: antibody recognition against native and selectively deamidated gliadin peptides.
Celiac disease: Association with adult-onset Still's disease: Apropos of a clinical case.
Celiac disease: diagnosis and management.
Celiac disease: diagnosis, autoimmune mechanisms and treatment.
Celiac Disease: Ten Things That Every Gastroenterologist Should Know.
Celiac disease: what to do when the tissue transglutaminase is positive.
Central Pontine Myelinolysis Presenting With Tremor in a Child With Celiac Disease.
Cervical esophageal web and celiac disease.
Changing patterns of serological testing for celiac disease in Latvia.
Characterization of the anti-tissue transglutaminase antibody response in nonobese diabetic mice.
Characterization of the heparin binding site of tissue transglutaminase: its importance in the enzyme's cell surface targeting, matrix deposition and cell signalling.
Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
Chronic Diarrhea in Adults: Evaluation and Differential Diagnosis.
Chronic Hepatitis Due to Gluten Enteropathy - a Case Report.
Circulating autoantibodies to tissue transglutaminase differentiate patients with dermatitis herpetiformis from those with linear IgA disease.
Clinical accuracy of anti-tissue transglutaminase as screening test for celiac disease under 2?years.
Clinical and histopathological correlation of duodenal biopsy with IgA anti-tissue transglutaminase titers in children with celiac disease.
Clinical benefit of a gluten-free diet in type 1 diabetic children with screening-detected celiac disease: a population-based screening study with 2 years' follow-up.
Clinical evaluation of the BioPlex 2200 Celiac IgA and IgG Kits - A novel multiplex screen incorporating an integral check for IgA deficiency.
Clinical value of immunoglobulin A antitransglutaminase assay in the diagnosis of celiac disease.
Co-occurrence of IgA antibodies against ethanol metabolites and tissue transglutaminase in alcohol consumers: correlation with proinflammatory cytokines and markers of fibrogenesis.
Co-Silencing of Tissue Transglutaminase-2 and Interleukin-15 Genes in a Celiac Disease Mimetic Mouse Model Using a Nanoparticle-in-Microsphere Oral System.
Combining antibody tests and taking into account antibody levels improves serologic diagnosis of celiac disease.
Community-Based Study of Celiac Disease Autoimmunity Progression in Adults.
Comparative evaluation of serologic tests for celiac disease: a European initiative toward standardization.
Comparison of a novel whole blood transglutaminase-based ELISA with a whole blood rapid antibody test and established conventional serological celiac disease assays.
Comparison of a tissue transglutaminase ELISA with the endomysium antibody test in the diagnosis of gluten-sensitive enteropathy.
Comparison of Commercially Available Serologic Kits for the Detection of Celiac Disease.
Comparison of ELISA for tissue transglutaminase autoantibodies with antiendomysium antibodies in pediatric and adult patients with celiac disease.
Comparison of IgA endomysium antibody and IgA tissue transglutaminase antibody in celiac disease.
Concurrent cerebral arterial and venous sinus thrombosis revealing celiac disease- a case report and literature review.
Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models.
Contribution of celiac disease autoantibodies to the disease process.
Controversies in the laboratory diagnosis of celiac disease in children; new haplotypes discovered.
Correlation analysis of celiac sprue tissue transglutaminase and deamidated gliadin IgG/IgA.
Correlation between antibodies and histology in celiac disease: Incidence of celiac disease is higher than expected in the pediatric population.
Correlation Between Cut-off Level of Tissue Transglutaminase Antibody and Marsh Classification.
Correlation Between IgA Tissue Transglutaminase Antibody Ratio And Histological Finding In Celiac Disease: A Multicentre Study.
Correlation of duodenal histology with tissue transglutaminase and endomysial antibody levels in pediatric celiac disease.
Correlation of tissue transglutaminase antibody with duodenal histologic marsh grading.
Correlation of Tissue Transglutaminase with Modified Marsh Grading in Celiac Disease: A Prospective Cohort Study.
Cosilencing Intestinal Transglutaminase-2 and Interleukin-15 Using Gelatin-Based Nanoparticles in an in Vitro Model of Celiac Disease.
Cow's Milk Protein Allergy Causing Persistent Elevation of Antitissue Transglutaminase Antibodies in a Child With Celiac Disease.
Current Espghan Guidelines for Celiac Disease in Pediatric Age, Tertiary Care Center Experience: A Proposal for Further Simplification.
Current trends and investigative developments in celiac disease.
Daily Intake of Milk Powder and Risk of Celiac Disease in Early Childhood: A Nested Case-Control Study.
Deamidated gliadin peptides form epitopes that transglutaminase antibodies recognize.
Deamidation and cross-linking of gliadin peptides by transglutaminases and the relation to celiac disease.
Decrease by 50% of plasma IgA tissue transglutaminase antibody concentrations within 2 months after start of gluten-free diet in children with celiac disease used as a confirming diagnostic test.
Defining thresholds of antibody levels improves diagnosis of celiac disease.
Dermatitis herpetiformis.
Dermatitis herpetiformis: close to unravelling a disease.
Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
Detection of autoantibodies against tissue transglutaminase in patients with celiac disease and dermatitis herpetiformis.
Determination of Autoantibodies to Transglutaminase by Electrochemiluminescence (ECL) Assay.
Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase.
Diagnosing celiac disease: a comparison of human tissue transglutaminase antibodies with antigliadin and antiendomysium antibodies.
Diagnosis and treatment of unexplained anemia with iron deficiency without overt bleeding.
Diagnosis of celiac disease.
Diagnosis of gluten-related enteropathy in a newborn: how and when?
Diagnostic accuracies for celiac disease of four tissue transglutaminase autoantibody tests using human antigen.
Diagnostic accuracy of IgA anti-tissue transglutaminase antibody assays in celiac disease patients with selective IgA deficiency.
Diagnostic accuracy of ten second-generation (human) tissue transglutaminase antibody assays in celiac disease.
Diagnostic immunology in celiac disease.
Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review.
Diagnostic utility of deamidated gliadin peptide antibody in celiac disease compared to anti-tissue transglutaminase and IgA- endomysium antibodies.
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease.
Diagnostic value of duodenal antitissue transglutaminase antibodies in gluten-sensitive enteropathy.
Diagnostic yield of endoscopic markers for celiac disease.
Diagnostic Yield of Isolated Deamidated Gliadin Peptide Antibody Elevation for Celiac Disease.
Diagnostic Yield of Upper Gastrointestinal Endoscopy in the Evaluation of Iron Deficiency Anemia in Older Children and Adolescents.
Dietary Patterns After the Weaning and Lactation Period Associate with Celiac Disease Autoimmunity in Children.
Distinct and Synergistic Contributions of Epithelial Stress and Adaptive Immunity to Functions of Intraepithelial Killer Cells and Active Celiac Disease.
Does aspirin use reduce cardiovascular risk in diabetes?
Does celiac disease trigger autoimmune thyroiditis?
Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment.
Early diagnosis of celiac disease in IgA deficient children: contribution of a point-of-care test.
Effects of Probiotic Bacteria Lactobacillaceae on the Gut Microbiota in Children With Celiac Disease Autoimmunity: A Placebo-Controlled and Randomized Clinical Trial.
Efficient T cell-B cell collaboration guides autoantibody epitope bias and onset of celiac disease.
Electrochemical detection of celiac disease-related anti-tissue transglutaminase antibodies using thiol based surface chemistry.
ELISA of anti-endomysial antibodies in the diagnosis of celiac disease: comparison with immunofluorescence assay of anti-endomysial antibodies and tissue transglutaminase antibodies.
Endocrinological disorders and celiac disease.
Enhanced B-Cell Receptor Recognition of the Autoantigen Transglutaminase 2 by Efficient Catalytic Self-Multimerization.
Epitope mapping of the N-terminal portion of tissue transglutaminase protein antigen to identify linear epitopes in celiac disease.
Epitope-dependent Functional Effects of Celiac Disease Autoantibodies on Transglutaminase 2.
Erythrocytic transglutaminase inhibition hemolysis at presentation of celiac disease.
Estimating the Impact of Verification Bias on Celiac Disease Testing.
Evaluating diagnostic accuracy of anti-tissue Transglutaminase IgA antibodies as first screening for Celiac Disease in very young children.
Evaluation of BioPlex 2200 tTG-IgA Diagnostic Performance for Serology-Based Diagnosis of Celiac Disease.
Evaluation of screening for celiac disease in children with juvenile idiopathic arthritis.
Evaluation of the Correlation Between tTG-IgA Titer and Duodenal Biopsy Findings in Children With Suspected Celiac Disease.
Evidence That Pathogenic Transglutaminase 2 in Celiac Disease Derives From Enterocytes.
Expression and enzymatic activity of small intestinal tissue transglutaminase in celiac disease.
Expression and rapid purification of highly active hexahistidine-tagged guinea pig liver transglutaminase.
Factors That Increase Risk of Celiac Disease Autoimmunity After a Gastrointestinal Infection in Early Life.
Family recognition of celiac disease.
Fate of five celiac disease-associated antibodies during normal diet in genetically at-risk children observed from birth in a natural history study.
Fertility disorder associated with celiac disease in males and females: fact or fiction?
Fluctuating transglutaminase autoantibodies are related to histologic features of celiac disease.
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis.
Frequency of celiac disease is not increased among multiple sclerosis patients.
Frontiers in Celiac Disease: Where Autoimmunity and Environment Meet.
Fully-automated, chemiluminescence IgA and IgG anti-tissue transglutaminase (tTG) antibodies serum assays for the screening of celiac disease.
Galactosylation of Serum IgA1 O-Glycans in Celiac Disease.
Gamma-gliadin specific celiac disease antibodies recognize p31-43 and p57-68 alpha gliadin peptides in deamidation related manner as a result of cross-reaction.
Genetic and immunological processes in the pathomechanism of gluten-sensitive enteropathy and associated metabolic bone disorders.
Giardiasis mimicking celiac disease in a patient of common variable immunodeficiency.
Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process.
Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis.
Glutamic acid decarboxylase (anti-GAD) & tissue transglutaminase (anti-TTG) antibodies in patients with thyroid autoimmunity.
Gluten ataxia: passive transfer in a mouse model.
Gluten intake interferes with the humoral immune response to recombinant hepatitis B vaccine in patients with celiac disease.
Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia.
Growth trajectories and bone mineral density in anti-tissue transglutaminase antibody-positive children: the Generation R Study.
Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.
Gut microbes and adverse food reactions: Focus on gluten related disorders.
Gut mucosal immunity to tissue transglutaminase in untreated celiac disease and other gastrointestinal disorders.
Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis.
Hearing evaluation with ABR in pediatric patients with celiac disease.
Help Desk: Is an intestinal biopsy necessary when the blood work suggests celiac disease?
Hemolysis and IgA-antibodies against tissue transglutaminase: When are antibody test results no longer reliable?
Hemolysis Interferes with the Detection of Anti-Tissue Transglutaminase Antibodies in Celiac Disease.
Hemolysis may cause false negative results and underdiagnosis of celiac disease when measuring anti-tissue transglutaminase antibodies in serum by immunoassays.
High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions.
High Incidence of Celiac Disease in a Long-term Study of Adolescents With Susceptibility Genotypes.
High Prevalence of Celiac Disease Among Screened First-Degree Relatives.
High prevalence of celiac disease in Brazilian blood donor volunteers based on screening by IgA antitissue transglutaminase antibody.
High prevalence of celiac disease in patients with type 1 diabetes detected by antibodies to endomysium and tissue transglutaminase.
High prevalence of gluten sensitivity in a cohort of patients with undifferentiated connective tissue disease.
High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac sprue.
High-Throughput Single-Cell Analysis of B Cell Receptor Usage among Autoantigen-Specific Plasma Cells in Celiac Disease.
Higher Sensitivity and Earlier Identification of Celiac Disease Autoimmunity by a Nonradioactive Assay for Transglutaminase Autoantibodies.
HLA-DPB1*04:01 Protects Genetically Susceptible Children from Celiac Disease Autoimmunity in the TEDDY Study.
HLA-DQB1*02 dose effect on RIA anti-tissue transglutaminase autoantibody levels and clinicopathological expressivity of celiac disease.
Human recombinant tissue transglutaminase ELISA: an innovative diagnostic assay for celiac disease.
Human tissue transglutaminase antibody screening by immunochromatographic line immunoassay for early diagnosis of celiac disease in Turkish children.
Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease.
Identification of a serum transglutaminase threshold value for the noninvasive diagnosis of symptomatic adult celiac disease patients: a retrospective study.
Identification of Deamidated Peptides in Cytokine-Exposed MIN6 Cells through LC-MS/MS Using a Shortened Digestion Time and Inspection of MS2 Spectra.
Identification of Non-HLA Genes Associated with Celiac Disease and Country-Specific Differences in a Large, International Pediatric Cohort.
Identification of Pediatric Patients With Celiac Disease Based on Serology and a Classification and Regression Tree Analysis.
Identification of the autoantigen of celiac disease.
Identification of tissue transglutaminase as the autoantigen of celiac disease.
Identification of transglutaminase-mediated deamidation sites in a recombinant alpha-gliadin by advanced mass-spectrometric methodologies.
IFN-gamma induces transglutaminase 2 expression in rat small intestinal cells.
IgA anti-Actin antibodies in children with celiac disease: comparison of immunofluorescence with Elisa assay in predicting severe intestinal damage.
IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease.
IgA anti-tissue transglutaminase antibodies and IgG antibodies against deamidated gliadin peptides as predictors of celiac disease.
IgA anti-tissue transglutaminase antibodies, first line in the diagnosis of celiac disease.
IgA anti-tissue transglutaminase as a diagnostic marker of gluten sensitive enteropathy.
IgA antibodies against tissue transglutaminase in the diagnosis of celiac disease: concordance with intestinal biopsy in children and adults.
IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease.
IgA cross-reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease.
IgA-class autoantibodies against neuronal transglutaminase, TG6 in celiac disease: No evidence for gluten dependency.
IgA-tissue transglutaminase (tTG)-antibodies are highly sensitive serum markers for celiac disease.
IgG antibodies against deamidated gliadin peptides for diagnosis of celiac disease in patients with IgA deficiency.
IgG(1) antiendomysium and IgG antitissue transglutaminase (anti-tTG) antibodies in coeliac patients with selective IgA deficiency. Working Groups on Celiac Disease of SIGEP and Club del Tenue.
IgG-F-actin antibodies in celiac disease and dermatitis herpetiformis.
Igs as Substrates for Transglutaminase 2: Implications for Autoantibody Production in Celiac Disease.
Immunoassay for detection of IgA antitissue transglutaminase in patients with celiac disease.
Immunoassays for the detection of IgA antibodies to tissue transglutaminase: significance of multiples of the upper limit of normal and inter-assay correlations.
Immunochromatographic sticks for tissue transglutaminase and antigliadin antibody screening in celiac disease.
Immunogenic peptides can be detected in whole gluten by transamidating highly susceptible glutamine residues: implication in the search for gluten-free cereals.
Immunoglobulin A anti-tissue transglutaminase antibody deposits in the small intestinal mucosa of children with no villous atrophy.
Immunoglobulin G (IgG) anti-tissue transglutaminase antibodies used as markers for IgA-deficient celiac disease patients.
Immunoglobulin G autoantibodies against tissue-transglutaminase. A sensitive, cost-effective assay for the screening of celiac disease.
Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease.
Immunohistologic analysis of the duodenal bulb: a new method for celiac disease diagnosis in children.
Immunoreactivity of antibodies against transglutaminase-deamidated gliadins in adult celiac disease.
Immunoreactivity of Gluten-Sensitized Sera Toward Wheat, Rice, Corn, and Amaranth Flour Proteins Treated With Microbial Transglutaminase.
Impact of celiac autoimmunity on children with type 1 diabetes.
Improved efficacy by using the pTnT-rhtTG plasmid for the detection of celiac disease specific tissue transglutaminase autoantibodies in radioligand binding assays.
In Celiac Disease, a Subset of Autoantibodies against Transglutaminase Binds Toll-Like Receptor 4 and Induces Activation of Monocytes.
In Screening For Celiac Disease, Deamidated Gliadin Rarely Predicts Disease When Tissue Transglutaminase Is Normal.
In Situ Gluten-Chitosan Interlocked Self-Assembled Supramolecular Architecture Reduces T-Cell-Mediated Immune Response to Gluten in Celiac Disease.
In vitro and in vivo models of celiac disease.
Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III.
Increased Prevalence of Antibodies Against Dietary Proteins In Children And Young Adults With Cerebral Palsy.
Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis.
Increased prevalence of celiac disease in girls with Turner syndrome detected using antibodies to endomysium and tissue transglutaminase.
Increased Prevalence of Celiac Disease in School-age Children in Italy.
Increased prevalence of silent celiac disease among Greek epileptic children.
INCREASED TISSUE TRANSGLUTAMINASE LEVELS ARE ASSOCIATED WITH INCREASED EPILEPTIFORM ACTIVITY IN ELECTROENCEPHALOGRAPHY AMONG PATIENTS WITH CELIAC DISEASE.
Increasing prevalence and high incidence of celiac disease in elderly people: a population-based study.
Influence of Age and Type 1 Diabetes Mellitus on Serological Test for Celiac Disease in Children.
Insights in the laboratory diagnosis of celiac disease.
Interferon-? Activates Transglutaminase 2 via a Phosphatidylinositol-3-Kinase-Dependent Pathway: Implications for Celiac Sprue Therapy.
Interplay between Type 2 Transglutaminase (TG2), Gliadin Peptide 31-43 and Anti-TG2 Antibodies in Celiac Disease.
Interpretation of serological tests in the diagnosis of celiac disease: Anti-deamidated gliadin peptide antibodies revisited.
Intestinal Anti-tissue Transglutaminase2 Autoantibodies: Pathogenic and Clinical Implications for Celiac Disease.
Intestinal deposits of anti-tissue transglutaminase IgA in childhood celiac disease.
Intestinal intraepithelial lymphocyte cytometric pattern is more accurate than subepithelial deposits of anti-tissue transglutaminase IgA for the diagnosis of celiac disease in lymphocytic enteritis.
Intestinal Production of Anti-Tissue Transglutaminase 2 Antibodies in Patients with Diagnosis Other Than Celiac Disease.
Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease.
Intraepithelial lymphocytes in celiac disease immunopathology.
Iron deficiency, Helicobacter infection and gastritis.
Is celiac disease an autoimmune disorder?
Is Celiac Disease an Etiological Factor in Children With Migraine?
Is Celiac Disease an Etiological Factor in Children with Nonsyndromic Intellectual Disability?
Is it necessary to use capsular endoscopy to diagnose celiac disease?
Is There a Role of Using a Rapid Finger Prick Antibody Test in Screening for Celiac Disease in Children?
Is tissue transglutaminase autoantibody the best for diagnosing celiac disease in children of developing countries?
Isolated positive anti-gliadin immunoglobin-A antibody in children with gastrointestinal symptoms.
Isolated short stature as a presentation of celiac disease in Saudi children.
Kinetic and functional characterisation of the heparin-binding peptides from human transglutaminase 2.
Lack of Utility of Anti-tTG IgG to Diagnose Celiac Disease When Anti-tTG IgA Is Negative.
Latent and Potential Celiac Disease in Epileptic Turkish Children.
LFRET, a novel rapid assay for anti-tissue transglutaminase antibody detection.
Limitations of anti-guinea pig liver transglutaminase IgA in screening of celiac disease.
Linear ?-(1???6)-d-glucan from Bifidobacterium bifidum BIM ?-733D is low molecular mass biopolymer with unique immunochemical properties.
Longevity, clonal relationship, and transcriptional program of celiac disease-specific plasma cells.
Lower economic status and inferior hygienic environment may protect against celiac disease.
Lower Prevalence of Celiac Disease and Gluten-Related Disorders in Persons Living in Southern vs Northern Latitudes of the United States.
Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia.
Maternal celiac disease autoantibodies bind directly to syncytiotrophoblast and inhibit placental tissue transglutaminase activity.
Metalloelastase (MMP-12) is upregulated in the gut of pediatric patients with potential celiac disease and in type 1 diabetes.
Microbial Transglutaminase Is Immunogenic and Potentially Pathogenic in Pediatric Celiac Disease.
Microbial transglutaminase should be considered as an environmental inducer of celiac disease.
Microbial transglutaminase treatment in pasta-production does not affect the immunoreactivity of gliadin with celiac disease patients' sera.
Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin.
Microbial transglutaminase: A new potential player in celiac disease.
Microbial transglutaminases generate T cell stimulatory epitopes involved in celiac disease
Micropipette Tip-Based Immunoassay with Electrochemical Detection of Antitissue Transglutaminase to Diagnose Celiac Disease Using Staples and a Paper-Based Platform.
MicroRNA profiles in celiac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts.
Molecular dissection of the tissue transglutaminase autoantibody response in celiac disease.
Molecular mechanisms responsible for the involvement of tissue transglutaminase in human diseases: Celiac Disease.
Monitoring of Anti-transglutaminase Autoantibodies in Pediatric Celiac Disease Using a Sensitive Radiobinding Assay.
Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998.
Most Children with Potential Celiac Disease Are Healthy but 1 Third of Them Develop Villous Atrophy at 3-Years Follow-Up.
Mucosal immunity.
Mucosal Molecular Pattern of Tissue Transglutaminase and Interferon Gamma in Suspected Seronegative Celiac Disease at Marsh 1 and 0 Stages.
Mucosal molecular pattern of tissue transglutaminase and interferon gamma in suspected seronegative celiac disease at marsh 1 and 0 stages.
MUCOSAL TISSUE TRANSGLUTAMINASE EXPRESSION IN CELIAC DISEASE.
Nanoparticle-enhanced sensitivity of a nanogap-interdigitated electrode array impedimetric biosensor.
Natural hidden autoantibodies to tissue transglutaminase cross-react with fibrinogen.
Natural history of antibodies to deamidated gliadin peptides and transglutaminase in early childhood celiac disease.
Natural history of transglutaminase autoantibodies and mucosal changes in children carrying HLA-conferred celiac disease susceptibility.
Need for quantitative assessment of transglutaminase autoantibodies for celiac disease in screening-identified children.
Neo-epitope tissue transglutaminase autoantibodies as a biomarker of the gluten sensitive skin disease--dermatitis herpetiformis.
Neurologic Deficits in Patients With Newly Diagnosed Celiac Disease Are Frequent and Linked With Autoimmunity to Transglutaminase 6.
New celiac disease biomarkers.
New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract.
New serology assays can detect gluten sensitivity among enteropathy patients seronegative for anti-tissue transglutaminase.
New target against inflammatory diseases: transglutaminase 2.
No significant difference in antigenicity or tissue transglutaminase substrate specificity of Irish and US wheat gliadins.
NON-CELIAC SPRUE: A CASE OF OLMESARTAN-INDUCED ENTEROPATHY.
Non-Invasive Biomarkers for Celiac Disease.
Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides.
Novel immune response to gluten in individuals with schizophrenia.
Occurrence of Hypothyroidism, Diabetes Mellitus, and Celiac Disease in Emirati Children with Down's Syndrome.
Old and new serological tests for celiac disease screening.
Olmesartan-Induced Enteropathy.
One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease-associated transglutaminase autoantibodies.
One-step cloning of anti tissue transglutaminase scFv from subjects with celiac disease.
One-step immunochromatographic visual assay for anti-transglutaminase detection in organ culture system: An easy and prompt method to simplify the in vitro diagnosis of celiac disease.
One-Third of Patients Have Evidence for an Additional Autoimmune Disease at Type 1 Diabetes Diagnosis.
Pathomechanisms in celiac disease.
Performance of antibodies against tissue transglutaminase for the diagnosis of celiac disease: meta-analysis.
Performance of two commercial ELISAs for detecting IgA anti-human and anti-guinea pig tissue transglutaminase antibodies.
Pericardial effusion in celiac disease.
Pharmacokinetics and Biodistribution Analysis of Small Interference RNA for Silencing Tissue Transglutaminase-2 in Celiac Disease After Oral Administration in Mice Using Gelatin-Based Multicompartmental Delivery Systems.
Pharmacological approaches in celiac disease.
Positive celiac disease serology and reduced bone mineral density in adult women.
Positive predictive value of serological diagnostic measures in celiac disease.
Positive tissue transglutaminase antibodies with negative endomysial antibodies: low rate of celiac disease.
Positive tissue transglutaminase antibodies with negative endomysial antibodies: Unresolved issues in diagnosing celiac disease.
Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis.
Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Potential of transglutaminase 2 as a therapeutic target.
Precision medicine and machine learning towards the prediction of the outcome of potential celiac disease.
Prediction of silent celiac disease at diagnosis of childhood type 1 diabetes by tissue transglutaminase autoantibodies and HLA.
Predictive value of "Marsh 1" type histology in subjects with suspected cealic disease.
Preliminary Notes on Equine Tissue Transglutaminase Serology and A Case of Equine Gluten-Sensitive Enteropathy and Dermatitis in an 11-Year-Old Dutch Warmblood Horse.
Presence of tissue transglutaminase IgA antibody as a celiac disease marker in a sample of patients with irritable bowel syndrome.
Prevalence and clinical significance of IgA anti tissue transglutaminase antibodies in patients with chronic liver disease.
Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases.
Prevalence and Morbidity of Undiagnosed Celiac Disease From a Community-Based Study.
Prevalence and natural history of potential celiac disease in adult patients.
Prevalence of Anti-tissue Transglutaminase (tTG) Antibodies and Celiac Disease in Children with IBD.
Prevalence of antitissue transglutaminase antibodies in different degrees of intestinal damage in celiac disease.
Prevalence of Celiac disease among children in Finland.
Prevalence of celiac disease among first-degree relatives of Indian celiac disease patients.
Prevalence of Celiac Disease Among Patients with Behcet's Disease in Iran.
Prevalence of celiac disease among school children in Punjab, North India.
Prevalence of celiac disease among type 1 diabetic Egyptian patients and the association with autoimmune thyroid disease.
Prevalence of celiac disease in children with Down syndrome screened by anti-tissue transglutaminase antibodies.
Prevalence of celiac disease in children with type 1 diabetes mellitus screened by anti-tissue transglutaminase antibody from Western Saudi Arabia.
Prevalence of celiac disease in collagenous and lymphocytic colitis.
Prevalence of celiac disease in Iranian children with idiopathic short stature.
Prevalence of Celiac disease in Turkish children with type 1 diabetes mellitus and their non-diabetic first-degree relatives.
Prevalence of IgA antitissue transglutaminase antibodies in children with type 1 diabetes mellitus.
Prevalence of Inflammatory Bowel Disease and Celiac Disease in Patients with IgA Nephropathy over Time.
Processed Food Additive Microbial Transglutaminase and Its Cross-Linked Gliadin Complexes Are Potential Public Health Concerns in Celiac Disease.
Progress in the serology-based diagnosis and management of adult celiac disease.
Progression of Celiac Disease in Children With Antibodies Against Tissue Transglutaminase and Normal Duodenal Architecture.
Progression of pediatric celiac disease from potential celiac disease to celiac disease: a retrospective cohort study.
Prolactin and autoimmunity.
Prospective human leukocyte antigen, endomysium immunoglobulin A antibodies, and transglutaminase antibodies testing for celiac disease in children with Down syndrome.
Protein A and protein G ELISA for the detection of IgG autoantibodies against tissue transglutaminase in childhood celiac disease.
Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases.
Proteomics identification of acyl-acceptor and acyl-donor substrates for transglutaminase in a human intestinal epithelial cell line. Implications for celiac disease.
Psychological Manifestations of Celiac Disease Autoimmunity in Young Children.
Raising the Cut-Off Level of Anti-Tissue Transglutaminase Antibodies to Detect Celiac Disease Reduces the Number of Small Bowel Biopsies in Children with Type 1 Diabetes: A Retrospective Study.
Recent advances in biosensors for diagnosis of celiac disease: A review.
Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists.
Recombinant human tissue transglutaminase ELISA for the diagnosis of gluten-sensitive enteropathy.
Recombinant human tissue transglutaminase for diagnosis and follow-up of childhood coeliac disease.
Recurrent Fever and Failure to Thrive in an 11-Year-Old Boy.
Redox signaling in the gastrointestinal tract.
Relationship Between Villous Atrophy and tTGA Levels in Dyspeptic Patients: A Case Series.
Relationships between Clinical Presentation, Serology, Histology, and Duodenal Deposits of Tissue Transglutaminase Antibodies in Pediatric Celiac Disease.
Reliability of Autoantibodies Against a Tissue Transglutaminase Neo-Epitope for the Diagnosis of Pediatric Celiac Disease.
Repeated Screening Can Be Restricted to At-Genetic-Risk Birth Cohorts.
Reproductive changes associated with celiac disease.
Response to: In Screening for Celiac Disease, Deamidated Gliadin Rarely Predicts Disease When Tissue Transglutaminase Is Normal. J Pediatr Gastroenterol Nutr. 2019;68(1):20-25.
Responsive population dynamics and wide seeding into the duodenal lamina propria of transglutaminase-2-specific plasma cells in celiac disease.
Review: dermatitis herpetiformis.
Rising prevalence of celiac disease is not universal and repeated testing is needed for population screening.
Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease.
Risk of pediatric celiac disease according to HLA haplotype and country.
Role of anti-tissue transglutaminase IgA+IgG antibodies in detection of potential celiac disease in patients with type 1 diabetes.
Role of HLA-DQ typing and anti-tissue transglutaminase antibody titers in diagnosing celiac disease without duodenal biopsy in type 1 diabetes: A study of the population-based pediatric type 1 diabetes cohort of Western Australia.
Role of pro-neurotensin as marker of paediatric celiac disease.
Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
Role of tissue transglutaminase in celiac disease.
Role of transglutaminase 2 in celiac disease pathogenesis.
Role of transglutaminase-catalyzed reactions in the post-translational modifications of proteins responsible for immunological disorders.
Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study.
Screening children with severe short stature for celiac disease using tissue transglutaminase.
Screening detects a high proportion of celiac disease in young HLA-genotyped children.
Screening for autoantibodies to tissue transglutaminase reveals a low prevalence of celiac disease in blood donors with cryptogenic hypertransaminasemia.
Screening for Celiac Disease in a North American Population: Sequential Serology and Gastrointestinal Symptoms.
Screening for celiac disease in Down's syndrome patients revealed cases of subtotal villous atrophy without typical for celiac disease HLA-DQ and tissue transglutaminase antibodies.
Screening for celiac disease in short bowel syndrome.
Screening for celiac disease in Tunisian patients with Graves' disease using anti-endomysium and anti-tissue transglutaminase antibodies.
Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Screening of the adult population in Iran for coeliac disease: comparison of the tissue-transglutaminase antibody and anti-endomysial antibody tests.
Screening of tissue transglutaminase antibody in healthy blood donors for celiac disease screening in the Turkish population.
Screening tests using serum tissue transglutaminase IgA may facilitate the identification of undiagnosed celiac disease among Japanese population.
Secretion of celiac disease autoantibodies after in vitro gliadin challenge is dependent on small-bowel mucosal transglutaminase 2-specific IgA deposits.
Sensitization to gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8 mice.
Sequential testing with different tissue transglutaminase antibodies, a new approach for diagnosis of celiac disease.
Sera of patients with celiac disease and neurologic disorders evoke a mitochondrial-dependent apoptosis in vitro.
Serodiagnostic Assays for Celiac Disease Based on the Open or Closed Conformation of the Autoantigen, Transglutaminase 2.
Serologic assay for diagnosis of celiac disease based on a patient-derived monoclonal antigliadin antibody.
Serologic markers of gluten sensitivity in a healthy population from the western region of Saudi Arabia.
Serological responses to microbial antigens in celiac disease patients during a gluten-free diet.
Serological screening for celiac disease in symptomatic 12 to 36 month-old children.
Serological screening for celiac disease using IgA-tissue transglutaminase antibody in patients with recurrent aphthous stomatitis.
Serological testing for celiac disease in women undergoing assisted reproduction techniques.
Serological Tests in Gluten Sensitivity (Nonceliac Gluten Intolerance).
Seronegative celiac disease: where is the specific setting?
Serum and intestinal celiac disease-associated antibodies in children with celiac disease younger than 2 years of age.
Serum anti-endomysial and anti-tissue transglutaminase for screening of celiac disease.
Serum auto-antibodies directed against transglutaminase-2 have a low avidity as compared to allo-antibodies against gliadin in celiac disease.
Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation.
Serum intestinal fatty acid-binding protein in the noninvasive diagnosis of celiac disease.
Serum transglutaminase 3 antibodies correlate with age at celiac disease diagnosis.
Serum transglutaminase antibodies do not always detect the persistent villous atrophy in patients with celiac disease on a gluten-free diet.
Shared Genetic Basis for Type 1 Diabetes, Islet Autoantibodies, and Autoantibodies Associated With Other Immune-Mediated Diseases in Families With Type 1 Diabetes.
Should stored serum of patients previously tested for celiac disease serology be retested for transglutaminase antibodies?
Simultaneous detection of celiac disease-specific IgA antibodies and total IgA.
Simultaneous detection of IgA and IgG antibodies against tissue transglutaminase: The preferred pre-biopsy test in childhood celiac disease.
Slow Decrease of Anti-Tissue Transglutaminase Antibody Positivity In Children With Celiac Disease After Starting the Gluten-Free Diet.
Small intestinal bacterial overgrowth in North Indian patients with celiac disease.
Solid-phase ELISA for tissue transglutaminase, an endomysial target for possible serological diagnosis of celiac disease.
Sourdough fermentation of wheat flour does not prevent the interaction of transglutaminase 2 with ?2-gliadin or gluten.
Specificity of tissue transglutaminase explains cereal toxicity in celiac disease.
Spectrum of gluten-sensitive enteropathy in first-degree relatives of patients with coeliac disease: clinical relevance of lymphocytic enteritis.
Stereotyped antibody responses target posttranslationally modified gluten in celiac disease.
Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography.
Strong Clonal Relatedness between Serum and Gut IgA despite Different Plasma Cell Origins.
Strongly positive tissue transglutaminase antibodies are associated with Marsh 3 histopathology in adult and pediatric celiac disease.
Strongly positive tissue transglutaminase antibody assays without celiac disease.
Structural Basis for Antigen Recognition by Transglutaminase 2-specific Autoantibodies in Celiac Disease.
Structural basis for gluten intolerance in celiac sprue.
Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease.
Structure of natural variant transglutaminase 2 reveals molecular basis of gaining stability and higher activity.
Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2.
Suboptimal Performance of IgG Anti-tissue Transglutaminase in the Diagnosis of Celiac Disease in a Tropical Country.
Symptoms and biomarkers associated with undiagnosed celiac seropositivity.
Synthetic Neoepitopes of the Transglutaminase-Deamidated Gliadin Complex as Biomarkers for Diagnosing and Monitoring Celiac Disease.
Synthetic Peptides Reproducing Tissue Transglutaminase-Gliadin Complex Neo-epitopes as Probes for Antibody Detection in Celiac Disease Patients' Sera.
T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase.
Tailoring the immune response to wheat gliadin by enzymatic transamidation.
Testing for anti-human transglutaminase antibodies in saliva is not useful for diagnosis of celiac disease.
Testing for antireticulin antibodies in patients with celiac disease is obsolete: a review of recommendations for serologic screening and the literature.
Testing for gluten-related disorders in clinical practice: the role of serology in managing the spectrum of gluten sensitivity.
Testing for IgG class antibodies in celiac disease patients with selective IgA deficiency. A comparison of the diagnostic accuracy of 9 IgG anti-tissue transglutaminase, 1 IgG anti-gliadin and 1 IgG anti-deaminated gliadin peptide antibody assays.
Tests for Serum Transglutaminase and Endomysial Antibodies Do Not Detect Most Patients With Celiac Disease and Persistent Villous Atrophy on Gluten-free Diets: a Meta-analysis.
TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy.
The adaptive immune response in celiac disease.
The analysis of the fine specificity of celiac disease antibodies using tissue transglutaminase fragments.
The association between de novo inflammatory bowel disease and celiac disease.
The diagnosis and treatment of celiac disease.
The function of tissue transglutaminase in celiac disease.
The high prevalence of autoantibodies to tissue transglutaminase in first-degree relatives of patients with type 1 diabetes is not associated with islet autoimmunity.
The iceberg of celiac disease: what is below the waterline?
The incidence of celiac disease antibodies in plasma specimens with low hemoglobin levels.
The incidence of HLA-DQ2/DQ8 in Turkish children with celiac disease and a comparison of the geographical distribution of HLA-DQ.
The industrial food additive, microbial transglutaminase, mimics tissue transglutaminase and is immunogenic in celiac disease patients.
The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase.
The Lack of Utility of Anti-tTG IgG in the Diagnosis of Celiac Disease When Anti-tTG IgA Is Negative.
The many-faced gluten sensitivity: Gluten-induced autoimmunity from dermatological point of view
The measurement of IgA and IgG transglutaminase antibodies in celiac disease: a comparison with current diagnostic methods.
The preferred substrates for transglutaminase 2 in a complex wheat gluten digest are Peptide fragments harboring celiac disease T-cell epitopes.
The prevalence of celiac disease among patients with familial mediterranean Fever.
The prevalence of celiac disease in children and adolescents in Germany.
The prevalence of celiac disease in patients fulfilling Rome III criteria for irritable bowel syndrome.
THE PREVALENCE OF CELIAC DISEASE IN PATIENTS WITH IRON-DEFICIENCY ANEMIA IN CENTER AND SOUTH AREA OF IRAN.
The Prevalence of the Celiac Disease in Patients with Dyspepsia: A Systematic Review and Meta-Analysis.
The Role of Capsule Endoscopy in Suspected Celiac Disease Patients with Positive Celiac Serology.
The role of tissue transglutaminase (transglutaminase type II) for the intestinal manifestations of murine semi-allogenic graft-versus-host disease.
The roles of MHC class II genes and post-translational modification in celiac disease.
The tissue transglutaminase gene is not a primary factor predisposing to celiac disease.
The use of a single serological marker underestimates the prevalence of celiac disease in Israel: a study of blood donors.
The use of microbial transglutaminase in a bread system: A study of gluten protein structure, deamidation state and protein digestion.
Thioredoxin is involved in endothelial cell extracellular transglutaminase 2 activation mediated by celiac disease patient IgA.
Thioredoxin-1 Selectively Activates Transglutaminase 2 in the Extracellular Matrix of the Small Intestine: IMPLICATIONS FOR CELIAC DISEASE.
Timing of initial exposure to cereal grains and the risk of wheat allergy.
Tissue transglutaminase and celiac disease.
Tissue transglutaminase and endomysial antibodies-diagnostic markers of gluten-sensitive enteropathy in dermatitis herpetiformis.
Tissue transglutaminase antibodies are a useful serological marker for the diagnosis of celiac disease in patients with Down syndrome.
Tissue transglutaminase antibodies in celiac disease, comparison of an enzyme linked immunosorbent assay and a dot blot assay.
Tissue transglutaminase antibodies in celiac disease.
Tissue transglutaminase antibodies in celiac disease: assessment of a commercial kit.
Tissue transglutaminase antibodies in celiac disease: focus on the pediatric population.
Tissue transglutaminase antibodies in individuals with celiac disease bind to thyroid follicles and extracellular matrix and may contribute to thyroid dysfunction.
Tissue transglutaminase antibodies in patients with end-stage heart failure.
Tissue transglutaminase antibodies in the diagnosis of celiac disease in Indian children.
Tissue Transglutaminase Antibody and Its Association with Duodenal Biopsy in Diagnosis of Pediatric Celiac Disease.
Tissue transglutaminase antibody determination in celiac disease. Analysis of diagnostic specificity of anti-human IgA-type assays.
Tissue transglutaminase auto-antibodies in cord blood from children to become celiacs.
Tissue transglutaminase autoantibodies in patients with non-Hodgkin's lymphoma. Case reports.
Tissue transglutaminase autoantibody detection in human saliva: a powerful method for celiac disease screening.
Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease.
Tissue transglutaminase enzyme-linked immunosorbent assay as a screening test for celiac disease in pediatric patients.
Tissue transglutaminase expression in celiac mucosa: an immunohistochemical study.
Tissue transglutaminase expression in duodenal mucosa of patients with celiac disease and of normal subjects.
Tissue transglutaminase immunoglobulin isotypes in children with untreated and treated celiac disease.
Tissue transglutaminase in celiac disease: role of autoantibodies.
Tissue transglutaminase is the target in both rodent and primate tissues for celiac disease-specific autoantibodies.
Tissue transglutaminase levels above 100 U/mL and celiac disease: A prospective study.
Tissue Transglutaminase Levels Are Not Sufficient to Diagnose Celiac Disease in North America Without Intestinal Biopsies: Don't Throw the Baby Out with the Bathwater.
Tissue Transglutaminase Levels Are Not Sufficient to Diagnose Celiac Disease in North American Practices Without Intestinal Biopsies.
Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease.
Tissue transglutaminase: the Holy Grail for the diagnosis of celiac disease, at last?
Titers of Anti-tissue Transglutaminase Antibody Correlate Well With Severity of Villous Abnormalities in Celiac Disease.
Towards Celiac-safe foods: Decreasing the affinity of transglutaminase 2 for gliadin by addition of ascorbyl palmitate and ZnCl
Transamidation Down-Regulates Intestinal Immunity of Recombinant ?-Gliadin in HLA-DQ8 Transgenic Mice.
Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.
Transglutaminase 2 dysfunctions in the development of autoimmune disorders: celiac disease and TG2-/- mouse.
Transglutaminase 2 in celiac disease: minireview article.
Transglutaminase 2 Inhibition for Prevention of Mucosal Damage in Celiac Disease.
Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies.
Transglutaminase 2 regulates the GTPase-activating activity of Bcr.
Transglutaminase 2 undergoes a large conformational change upon activation.
Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells.
Transglutaminase 2-targeted autoantibodies in celiac disease: Pathogenetic players in addition to diagnostic tools?
Transglutaminase activity along the rat small bowel and cellular location.
Transglutaminase antibodies and celiac disease in children with type 1 diabetes and in their family members.
Transglutaminase antibodies in children with a genetic risk for celiac disease.
Transglutaminase as a therapeutic target for celiac disease.
Transglutaminase autoantibodies in dermatitis herpetiformis and celiac sprue.
Transglutaminase IgA Antibodies in a Celiac Disease Mass Screening and the Role of HLA-DQ Genotyping and Endomysial Antibodies in Sequential Testing.
Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Transglutaminase treatment of wheat and maize prolamins of bread increases the serum IgA reactivity of celiac disease patients.
Transglutaminase, gluten and celiac disease: food for thought. Transglutaminase is identified as the autoantigen of celiac disease.
Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Transglutaminases - possible drug targets in human diseases.
Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Transglutaminases as targets for pharmacological inhibition.
Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver.
Trend of Antitissue Transglutaminase Antibody Normalization in Children With Celiac Disease Started on Gluten-free Diet: A Comparative Study Between Chemiluminescence and ELISA Serum Assays.
Tricks of the trade: How to avoid histological Pitfalls in celiac disease.
Two thymus-related autoimmune disorders: a case report and review of the literature.
Type 1 Diabetes and Celiac Disease: Can (and Should) We Raise the Cut-off of Tissue Transglutaminase Immunoglobulin A to Decide Whether to Biopsy?
Ultrasensitive transglutaminase based nanosensor for early detection of celiac disease in human.
Unexpected role of surface transglutaminase type II in celiac disease.
Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals.
Update on mucosal immunoglobulin A in gastrointestinal disease.
Update on the evaluation and diagnosis of celiac disease.
Use of HLA typing in diagnosing celiac disease in patients with type 1 diabetes.
Use of likelihood ratios improves clinical interpretation of IgA anti-tTG antibody testing for celiac disease.
Use of low concentrations of human IgA anti-tissue transglutaminase to rule out selective IgA deficiency in patients with suspected celiac disease.
Usefulness of antibodies to deamidated gliadin peptides in celiac disease diagnosis and follow-up.
Usefulness of Small-bowel Mucosal Transglutaminase-2 Specific Autoantibody Deposits in the Diagnosis and Follow-up of Celiac Disease.
Utility in clinical practice of immunoglobulin a anti-tissue transglutaminase antibody for the diagnosis of celiac disease.
Value of a screening algorithm for celiac disease using tissue transglutaminase antibodies as first level in a population-based study.
Variability of anti-human transglutaminase testing in celiac disease across Mediterranean countries.
Variant mannose-binding lectin alleles are associated with celiac disease.
Video capsule enteroscopy in the diagnosis of celiac disease: a multicenter study.
Warfarin hypersensitivity due to gluten-sensitive enteropathy: a case study.
Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis.
Zinc is the modulator of the calcium-dependent activation of post-translationally acting thiol-enzymes in autoimmune diseases.
[Anti-deamidated gliadin peptides antibodies and coeliac disease: state of art and analysis of false-positive results from five assays]
[Anti-tissue transglutaminase antibodies in inflammatory and degenerative arthropathies]
[Antibodies against tissue transglutaminase as a serological marker in dermatitis herpetiformis During]
[Atypical celiac disease - diagnostic difficulties.]
[Atypical manifestations of celiac disease in an adult woman]
[Celiac disease and "gluten sensitivity"].
[Celiac disease and fertility disorders in women]
[Celiac disease as a model for autoimmune disease. Transglutaminase has the key role--stress reaction triggers the vicious circle]
[Celiac disease in adults: new aspects]
[Celiac disease--a diagnostic and therapeutic challenge]
[Celiac disease--a severe disease]
[Celiac disease:a case report detailing clinical and pathological improvement with a gluten-free diet].
[Celiac sprue (review)]
[Clinical courses of celiac disease]
[Dermatitis herpetiformis: A review.]
[Dermatitis herpetiformis]
[Dermatitis herpetiformis].
[Determination of subepithelial deposits of IgA antibodies to tissue transglutaminase: practical experience with application for diagnosis of gluten-sensitive celiac disease].
[Diagnostic validity of anti-tissue transglutaminase and anti-endomysium antibodies in children with celiac disease]
[Evidence of intraepithelial lymphocytes through immunocytochemistry stains in children with celiac disease]
[First determination of the prevalence of celiac disease in a Portuguese population]
[Genetic and immunological processes in the pathomechanism of gluten-sensitive enteropathy and associated metabolic bone disorders]
[Immunological screening and follow-up of celiac disease: Experience of the University Hospital of Marseille.]
[Impact of diagnosis of celiac disease on metabolic control of type 1 diabetes]
[Improving the management of celiac disease: An urgent challenge.]
[Prevalence of celiac disease in apparently healthy blood donors in the autonomous community of Madrid]
[Rectal prolapse as an unusual presentation of celiac disease. Report of two cases].
[Serological screening of relatives of celiac disease patients: antiendomysium antibodies, anti-tissue transglutaminase or both?]
[Serological tests for celiac disease in Moroccan patients with type 1 diabetes].
[Seronegative celiac disease: A case report].
[Serum antibodies in celiac disease]
[The role of celiac disease and type 1 diabetes coexistance. Is celiac disease responsible for diabetic status?]
[Tissue transglutaminase as autoantigen in endemic sprue. New aspects in diagnosis and etiopathogenesis]
[Transglutaminase antibody: usefulness in the diagnosis of celiac disease]
Central Nervous System Diseases
Transglutaminase 2: A Novel Autoantigen in Canine Idiopathic Central Nervous System Inflammatory Diseases.
Cerebellar Diseases
A case report of late-onset cerebellar ataxia associated with a rare p.R342W TGM6 (SCA35) mutation.
Cerebral Amyloid Angiopathy
Lobar Hemorrhage Induced by Acquired Factor XIII Deficiency in a Patient with Cerebral Amyloid Angiopathy.
The blood clotting Factor XIIIa forms unique complexes with amyloid-beta (A?) and colocalizes with deposited A? in cerebral amyloid angiopathy.
Tissue transglutaminase colocalizes with extracellular matrix proteins in cerebral amyloid angiopathy.
Tissue Transglutaminase: A Novel Therapeutic Target in Cerebral Amyloid Angiopathy.
Cerebral Hemorrhage
Coagulation factor XIII VaI34Leu polymorphism in patients with small vessel disease or primary intracerebral hemorrhage.
Ethnic heterogeneity of the factor XIII Val34Leu polymorphism.
Factor XIII deficiency related recurrent spontaneous intracerebral hemorrhage: A case and literature review.
Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage.
No association of factor XIII Val34Leu polymorphism with primary intracerebral hemorrhage and healthy controls in Korean population.
Prevention of postoperative intracerebral hemorrhage with topical recombinant factor XIII in the rat.
Red blood cell lysis and brain tissue-type transglutaminase upregulation in a hippocampal model of intracerebral hemorrhage.
The effect of the Val34Leu polymorphism in the factor XIII gene in infants with a birth weight below 1500 g.
Tissue-type transglutaminase and the effects of cystamine on intracerebral hemorrhage-induced brain edema and neurological deficits.
[Intracerebral hemorrhage associated with long-lasting deficiency of factor XIII]
[Two cases of congenital deficiency of coagulation factor XIII causing intracerebral hemorrhage (author's transl)]
Cerebral Infarction
Early fibrinogen degradation coagulopathy: a predictive factor of parenchymal hematomas in cerebral rt-PA thrombolysis.
Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage.
Reduction of coagulation factor XIII concentration in patients with myocardial infarction, cerebral infarction, and other thromboembolic disorders.
Cerebral Palsy
A study on early developing celiac disease in children with cerebral palsy.
Increased Prevalence of Anti-gliadin Antibodies and Anti-tissue Transglutaminase Antibodies in Children With Cerebral Palsy.
Cerebrospinal Fluid Leak
Treatment of spontaneous intracranial hypotension with intravenous Factor XIII administration: initial clinical experience.
Cerebrospinal Fluid Rhinorrhea
A Case of Traumatic Cerebrospinal Fluid Rhinorrhea Successfully Treated Using Intravenous Factor XIII Administration.
Cerebrovascular Disorders
Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women.
Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency.
Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage.
Role of factor XIII Val 34 Leu polymorphism in patients with migraine.
The V34L polymorphism of factor XIII and peripheral arterial disease.
[Role of coagulation factor XIII in cardio- and cerebrovascular diseases]
Cervical Intraepithelial Neoplasia
Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression.
Cholangiocarcinoma
Transglutaminase 2 Mediates the Cytotoxicity of Resveratrol in a Human Cholangiocarcinoma and Gallbladder Cancer Cell Lines.
Cholangitis
Celiac disease in autoimmune cholestatic liver disorders.
Primary biliary cirrhosis and autoimmune cholangitis are not associated with coeliac disease in Crete.
Cholangitis, Sclerosing
Celiac disease in autoimmune cholestatic liver disorders.
Cholestasis
Celiac disease in autoimmune cholestatic liver disorders.
Cholesteatoma
Differentiation characteristics of cholesteatoma epithelium determined by expression of transglutaminase isoenzymes.
Expressions of isopeptide bonds and corneodesmosin in middle ear cholesteatoma.
Keratinization of middle ear cholesteatomas. I. A histochemical study of epidermal transglutaminase.
Keratinization of middle ear cholesteatomas. II. A histochemical study of epidermal transglutaminase substrates.
Cholesteatoma, Middle Ear
Differentiation characteristics of cholesteatoma epithelium determined by expression of transglutaminase isoenzymes.
Keratinization of middle ear cholesteatomas. I. A histochemical study of epidermal transglutaminase.
Keratinization of middle ear cholesteatomas. II. A histochemical study of epidermal transglutaminase substrates.
Chondrocalcinosis
Calcium pyrophosphate dihydrate and hydroxyapatite crystal deposition in the joint: new developments relevant to the clinician.
Chondrosarcoma
Cellular transglutaminase. The particulate-associated transglutaminase from chondrosarcoma and liver: partial purification and characterization.
Choriocarcinoma
Developmental regulation of tissue transglutaminase during human placentation and expression in neoplastic trophoblast.
Chronic Periodontitis
Differential expression of transglutaminase genes in patients with chronic periodontitis.
Chronic Urticaria
Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria.
Chylothorax
Successful factor XIII administration for persistent chylothorax after lung transplantation for lymphangioleiomyomatosis.
Successful factor XIII treatment of refractory chylothorax in tuberous sclerosis complex-associated lymphangioleiomyomatosis, multifocal multinodular pneumocyte hyperplasia and mediastinal lymphadenopathy.
coagulation factor viia deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Clinical audit of inherited bleeding disorders in a developing country.
Genetic diagnosis of haemophilia and other inherited bleeding disorders.
Inherited bleeding disorders in Indian women with menorrhagia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Rare inherited coagulation disorders in India.
coagulation factor xa deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Advances in treatment of bleeding disorders.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Clinical audit of inherited bleeding disorders in a developing country.
Inherited bleeding disorders in Indian women with menorrhagia.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Rare inherited coagulation disorders in India.
coagulation factor xia deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Congenital hemorrhagic disorders in Jordan.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Platelet and coagulation studies in Ehlers-Danlos syndrome.
The rare inherited coagulation disorders.
coagulation factor xiia deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
Occurrence of coagulation factor deficiency in post-tonsillectomy hemorrhage.
Colitis
Apple polyphenols extract (APE) improves colon damage in a rat model of colitis.
Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model.
Butyrate, mesalamine, and factor XIII in experimental colitis in the rat: effects on transglutaminase activity.
Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis.
Factor XIII Transglutaminase Supports the Resolution of Mucosal Damage in Experimental Colitis.
Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The Factor XIII Study Group.
Mucosal capillary thrombi in rectal biopsies.
Myenteric neuronal loss in rats with experimental colitis: Role of tissue transglutaminase-induced apoptosis.
Peptide Hp(2-20) accelerates healing of TNBS-induced colitis in the rat.
Recombinant factor XIII improves established experimental colitis in rats.
Serological differentiation of inflammatory bowel diseases.
Serum and tissue transglutaminase correlates with the severity of inflammation in induced colitis in the rat.
Serum transglutaminase correlates with endoscopic and histopathologic grading in patients with ulcerative colitis.
Significance of diminished factor XIII in Crohn's disease.
Transglutaminase 2 is dispensable but required for the survival of mice in dextran sulfate sodium-induced colitis.
Colitis, Collagenous
Prevalence of celiac disease in collagenous and lymphocytic colitis.
Colitis, Lymphocytic
Prevalence of celiac disease in collagenous and lymphocytic colitis.
Colitis, Microscopic
Predisposing HLA-DQ2 and HLA-DQ8 haplotypes of coeliac disease and associated enteropathy in microscopic colitis.
Colitis, Ulcerative
Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence.
Apple polyphenols extract (APE) improves colon damage in a rat model of colitis.
Butyrate, mesalamine, and factor XIII in experimental colitis in the rat: effects on transglutaminase activity.
Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis.
Dynamics of blood coagulation factor XIII in ulcerative colitis and preliminary study of the factor XIII concentrate.
Factor XIII in chronic inflammatory bowel diseases.
Factor XIII modulates intestinal epithelial wound healing in vitro.
Factor XIII substitution in ulcerative colitis.
Factor XIII subunits in relation to some other hemostatic parameters in ulcerative colitis.
Histological changes in the colonic mucosa following irrigation with short-chain fatty acids.
How autophagy controls the intestinal epithelial barrier.
Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The Factor XIII Study Group.
Mucosal capillary thrombi in rectal biopsies.
New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract.
Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis.
Serological differentiation of inflammatory bowel diseases.
Serum transglutaminase correlates with endoscopic and histopathologic grading in patients with ulcerative colitis.
Significance of diminished factor XIII in Crohn's disease.
Substitution of factor XIII: a therapeutic approach to ulcerative colitis.
Ulcerative colitis and Crohn's disease: factor XIII, inflammation and haemostasis.
[Blood coagulation factors in ulcerative colitis with special reference to factor XIII]
[Substitution of factor XIII concentrate in treatment refractory ulcerative colitis. A prospective pilot study]
Colonic Neoplasms
Acid ceramidase inhibition sensitizes human colon cancer cells to oxaliplatin through downregulation of transglutaminase 2 and ?1 integrin/FAK-mediated signalling.
Identification of transglutaminase substrates in HT29 colon cancer cells: use of 5-(biotinamido)pentylamine as a transglutaminase-specific probe.
Induction of tissue transglutaminase expression by propionate and n-butyrate in colon cancer cell lines.
Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53.
Transglutaminase in azoxymethane-induced colon cancer in the rat.
Colorectal Neoplasms
Activation peptide of the coagulation factor XIII (AP-F13A1) as a new biomarker for the screening of colorectal cancer.
Clotting Factor Gene Polymorphisms and Colorectal Cancer Risk.
Effects of exogenous transglutaminase on spreading of human colorectal carcinoma cells.
How autophagy controls the intestinal epithelial barrier.
MicroRNA?214 suppresses the viability, migration and invasion of human colorectal carcinoma cells via targeting transglutaminase 2.
miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.
Pharmacological alterations of cellular transglutaminase activity and invasiveness in human colorectal carcinoma cells.
Role of tissue transglutaminase and effect of cantharidinate in human colorectal cancer.
Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells.
Transglutaminase 2 maintains a colorectal cancer stem phenotype by regulating epithelial-mesenchymal transition.
Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem Cells.
Transglutaminase activity in human colorectal carcinomas of differing metastatic potential.
Transglutaminase-2 Mediates the Biomechanical Properties of the Colorectal Cancer Tissue Microenvironment that Contribute to Disease Progression.
Coma
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Communicable Diseases
TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy.
Compartment Syndromes
Successful use of recombinant factor VIIa in a child with Schoenlein-Henoch purpura presenting with compartment syndrome and severe factor XIII deficiency.
Congenital Abnormalities
Hypercoagulability as a cause of stroke in adults.
The role of FV 1691G>A, FII 20210G>A mutations and MTHFR 677C>T; 1298A>C and 103G>T FXIII gene polymorphisms in pathogenesis of intraventricular hemorrhage in infants born before 32 weeks of gestation.
[Congenital defect of factor XIII. Report of a case]
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spontaneous Acute Subdural Hematoma and Chronic Epidural Hematoma in a Child with F XIII Deficiency.
Surgery in severe factor XIII deficiency: report of a case of epilepsy neurosurgery and review.
[Congenital factor XIII deficiency in the south of Tunisia]
Conjunctivitis, Allergic
Developments in ocular allergy.
Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.
Connective Tissue Diseases
IgA and IgG tissue transglutaminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis.
Contracture
Transglutaminase levels in Dupuytren's disease.
Coronary Artery Disease
Association of factor XIII Val34Leu polymorphism and coronary artery disease: A meta-analysis.
Association of fibrinogen and plasmin inhibitor, but not coagulation factor XIII gene polymorphisms with coronary artery disease.
Coagulation factor XIII levels in UK Asian subjects with type 2 diabetes mellitus and coronary artery disease.
Coagulation Factor XIII-A Val34Leu Polymorphism and the Risk of Coronary Artery Disease and Myocardial Infarction in a Chinese Han Population.
Correction: Mezei, Z.A., et al; Factor XIII B subunit polymorphisms and the risk of coronary artery disease. Int. J. Mol. Sci. 2015, 16, 1143-1159.
Decreased factor XIII levels in factor XIII A subunit Leu34 homozygous patients with coronary artery disease.
Factor XIII activity and antigen levels in patients with coronary artery disease.
Factor XIII B subunit polymorphisms and the risk of coronary artery disease.
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease.
Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis.
Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study.
Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability.
Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease.
Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.
Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease.
The V34L polymorphism of factor XIII and peripheral arterial disease.
Venous and intracoronary factor XIII A-subunit antigen and activity levels are not associated with extent of coronary artery disease.
Coronary Disease
Associations of tissue transglutaminase antibody seropositivity with coronary heart disease: Findings from a prospective cohort study.
Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study.
Coronary Thrombosis
Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
COVID-19
COVID-19 is Associated with an Acquired Factor XIII Deficiency.
Severe bleeding in a patient with factor XIII deficiency and COVID-19.
Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals.
Craniocerebral Trauma
Factor XIII deficiency and head trauma: management and therapy.
Spontaneous Epidural Hematoma in a Child With Inherited Factor XIII Deficiency.
Crohn Disease
Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence.
Clinical significance of measuring blood coagulation factor XIIIA regularly and continuously in patients with Crohn's disease.
Combined use of factor XIII and endoscopic balloon dilatation in a patient with Crohn's disease, duodenal stenosis, and associated internal fistulas: the efficacy of coagulation factor XIII for the internal fistulas.
Deficiency of blood coagulation factor XIII in Crohn's disease.
Factor XIII and tissue transglutaminase antibodies in coeliac and inflammatory bowel disease.
Factor XIIIA subunit and Crohn's disease.
Hemostasis in Crohn's disease: low factor XIII levels in active disease.
How autophagy controls the intestinal epithelial barrier.
Mucosal capillary thrombi in rectal biopsies.
Screening for celiac disease in short bowel syndrome.
Serological differentiation of inflammatory bowel diseases.
Significance of diminished factor XIII in Crohn's disease.
The characterization of the repertoire of wheat antigens and peptides involved in the humoral immune responses in patients with gluten sensitivity and Crohn's disease.
The usefulness of factor XIII levels in Crohn's disease.
Transglutaminases in Crohn's disease.
Treatment of Crohn's disease fistulas with coagulation factor XIII.
Ulcerative colitis and Crohn's disease: factor XIII, inflammation and haemostasis.
Cystic Fibrosis
A novel regulatory role for tissue transglutaminase in epithelial-mesenchymal transition in cystic fibrosis.
Cystic fibrosis transmembrane conductance regulator (CFTR) and autophagy: hereditary defects in cystic fibrosis versus gluten-mediated inhibition in celiac disease.
Gut-Ex-Vivo system as a model to study gluten response in celiac disease.
How autophagy controls the intestinal epithelial barrier.
Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation.
Transglutaminase 2 and nucleoside diphosphate kinase activity are correlated in epithelial membranes and are abnormal in cystic fibrosis.
Transglutaminase in erythrocytes of cystic fibrosis patients.
Cystitis
Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases.
[The clinical effect of factor XIII on drug-induced hemorrhagic cystitis]
Cysts
Dependence of Giardia lamblia encystation on novel transglutaminase activity.
Darier Disease
Expression of transglutaminase 5 in normal and pathologic human epidermis.
Dehydration
Dehydration leads to a phase transition in monoclinic factor XIII crystals.
Polyamine concentration, transglutaminase activity and changes in protein synthesis during cryopreservation of shoot tips of apple variety Annurca.
Dementia, Vascular
Cerebrospinal fluid tissue transglutaminase in vascular dementia.
Demyelinating Diseases
Astrocyte-derived tissue Transglutaminase affects fibronectin deposition, but not aggregation, during cuprizone-induced demyelination.
Tissue Transglutaminase Promotes Early Differentiation of Oligodendrocyte Progenitor Cells.
Dermatitis
Atypical cells in radiation dermatitis express factor XIIIa.
Increased Prevalence of Transglutaminase 6 Antibodies in Sera From Schizophrenia Patients.
Preliminary Notes on Equine Tissue Transglutaminase Serology and A Case of Equine Gluten-Sensitive Enteropathy and Dermatitis in an 11-Year-Old Dutch Warmblood Horse.
Recognition of epidermal transglutaminase by IgA and tissue transglutaminase 2 antibodies in a rare case of Rhesus dermatitis.
Dermatitis Herpetiformis
A case of dermatitis herpetiformis with IgA endomysial antibodies but negative direct immunofluorescent findings.
A novel quantitative ELISA as accurate and reproducible tool to detect epidermal transglutaminase antibodies in patients with Dermatitis Herpetiformis.
Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis.
Are anti-epidermal transglutaminase (eTG) antibodies titre correlated with dermatitis herpetiformis lesions during the disease follow-up?
Association between levels of IgA antibodies to tissue transglutaminase and gliadin-related nonapeptides in dermatitis herpetiformis.
Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet.
Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia.
Circulating autoantibodies to tissue transglutaminase differentiate patients with dermatitis herpetiformis from those with linear IgA disease.
Clinical, histological and immunpathological findings in 32 patients with dermatitis herpetiformis Duhring.
Co-localization of IgA and TG3 on healthy skin of coeliac patients.
Coeliac disease.
Concomitant bullous pemphigoid and dermatitis herpetiformis.
Cutaneous expressions of interleukin-6 and neutrophil elastase as well as levels of serum IgA antibodies to gliadin nonapeptides, tissue transglutaminase and epidermal transglutaminase: implications for both autoimmunity and autoinflammation involvement in dermatitis herpetiformis.
Dermatitis herpetiformis: close to unravelling a disease.
Dermatitis herpetiformis: pathognomonic transglutaminase IgA deposits in the skin and excellent prognosis on a gluten-free diet.
Detection of antibodies to epidermal transglutaminase but not tissue transglutaminase in Japanese patients with dermatitis herpetiformis.
Detection of autoantibodies against tissue transglutaminase in patients with celiac disease and dermatitis herpetiformis.
Disappearance of epidermal transglutaminase and IgA deposits from the papillary dermis of dermatitis herpetiformis patients after a long-term gluten-free diet.
Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis.
Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis.
Epidermal transglutaminase deposits in perilesional and uninvolved skin in patients with dermatitis herpetiformis.
Evaluation of a Bi-Analyte Immunoblot as a Useful Tool for Diagnosing Dermatitis Herpetiformis.
Evaluation of IgA epidermal transglutaminase ELISA in suspected dermatitis herpetiformis patients.
Ex vivo Culture of Duodenal Biopsies from Patients with Dermatitis Herpetiformis Indicates that Transglutaminase 3 Antibody Production Occurs in the Gut.
Gluten ataxia: passive transfer in a mouse model.
IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease.
IgA anti-epidermal transglutaminase autoantibodies: a sensible and sensitive marker for diagnosis of dermatitis herpetiformis in adult patients.
Iga anti-epidermal transglutaminase autoantibodies: a simple test to improve differential diagnosis between dermatitis herpetiformis and atopic dermatitis.
IgA antiepidermal transglutaminase antibodies in dermatitis herpetiformis: a significant but not complete response to a gluten-free diet treatment.
IgG-F-actin antibodies in celiac disease and dermatitis herpetiformis.
Immunoglobulin, complement and epidermal transglutaminase deposition in the cutaneous vessels in dermatitis herpetiformis.
In patients with dermatitis herpetiformis distribution of transglutaminase in cutaneous tissue does not differ from controls.
In vitro and in vivo models of celiac disease.
Intestinal TG3- and TG2-Specific Plasma Cell Responses in Dermatitis Herpetiformis Patients Undergoing a Gluten Challenge.
Medical pearl: Using tissue transglutaminase antibodies to diagnose dermatitis herpetiformis.
Mutagenesis of the catalytic triad of tissue transglutaminase abrogates coeliac disease serum IgA autoantibody binding.
Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides.
Prediction of Clinical and Mucosal Severity of Coeliac Disease and Dermatitis Herpetiformis by Quantification of IgA/IgG Serum Antibodies to Tissue Transglutaminase.
Recent advances in dermatitis herpetiformis.
Sensitivity of Transglutaminase 3 in the IgA Aggregates in Dermatitis Herpetiformis Skin to Potassium Iodide.
Small Bowel Transglutaminase 2-specific IgA Deposits in Dermatitis Herpetiformis.
T-Cell Response in Dermatitis Herpetiformis: May Epidermal Transglutaminase Play a Role in Predicting Clinical Relapse?
TG6 Auto-Antibodies in Dermatitis Herpetiformis.
The Decreasing Prevalence of Severe Villous Atrophy in Dermatitis Herpetiformis: A 45-Year Experience in 393 Patients.
The many-faced gluten sensitivity: Gluten-induced autoimmunity from dermatological point of view
Tissue transglutaminase and endomysial antibodies-diagnostic markers of gluten-sensitive enteropathy in dermatitis herpetiformis.
Tissue transglutaminase antibodies in dermatitis herpetiformis.
Tissue transglutaminase antibody assessment in dermatitis herpetiformis.
Transglutaminase 3 present in the IgA aggregates in dermatitis herpetiformis skin is enzymatically active and binds soluble fibrinogen.
Transglutaminase autoantibodies in dermatitis herpetiformis and celiac sprue.
Update on mucosal immunoglobulin A in gastrointestinal disease.
[A girl with an itchy skin disease].
[Antibodies against tissue transglutaminase as a serological marker in dermatitis herpetiformis During]
[Dermatitis herpetiformis]
[Dermatitis herpetiformis].
Dermatitis, Atopic
Genetic variation in the epidermal transglutaminase genes is not associated with atopic dermatitis.
Iga anti-epidermal transglutaminase autoantibodies: a simple test to improve differential diagnosis between dermatitis herpetiformis and atopic dermatitis.
Transglutaminase 3 promotes skin inflammation in atopic dermatitis by activating monocyte-derived dendritic cells via DC-SIGN.
Transglutaminase II interacts with rac1, regulates production of reactive oxygen species, expression of snail, secretion of Th2 cytokines and mediates in vitro and in vivo allergic inflammation.
Dermatitis, Contact
Factor XIIIa positive dendritic cells are a major accessory cell population in the elicitation phase of DNCB-induced contact hypersensitivity.
Dermatitis, Exfoliative
Different TGM1 mutation spectra in Italian and Portuguese patients with autosomal recessive congenital ichthyosis: evidence of founder effects in Portugal.
Identification of two novel nonsense mutations in the transglutaminase 1 gene in a Hungarian patient with congenital ichthyosiform erythroderma.
Knocking-in the R142C mutation in transglutaminase 1 disrupts the stratum corneum barrier and postnatal survival of mice.
Novel mutations of TGM1 in a child with congenital ichthyosiform erythroderma.
Strong founder effect for a transglutaminase 1 gene mutation in lamellar ichthyosis and congenital ichthyosiform erythroderma from Norway.
Structural changes in epidermal scale and appendages as indicators of defective TGM1 activity.
The clinical spectrum of congenital ichthyosis in Sweden: a review of 127 cases.
The pathogenesis of severe congenital ichthyosis of the neonate.
Dermatofibrosarcoma
A light microscopic and immunohistochemical evaluation of scars.
A study of factor XIIIa and MAC 387 immunolabeling in normal and pathological skin.
Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans.
CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa.
Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa.
High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
S100A6 expression in fibrohistiocytic lesions.
Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
When Immunohistochemistry Deceives Us: The Pitfalls of CD34 and Factor XIIIa Stains in Dermatofibroma and Dermatofibrosarcoma Protuberans.
Diabetes Complications
Celiac Autoimmunity Is Associated With Lower Blood Pressure and Renal Risk in Type 1 Diabetes.
Diabetes Mellitus
Anthropometric, Serologic, and Laboratory Correlation With Villous Blunting in Pediatric Celiac Disease: Diabetics are Different.
Antibodies to tissue transglutaminase C in newly diagnosed and long-standing type I diabetes mellitus.
Antibodies to tissue transglutaminase C in type I diabetes.
Association of lethal acquired factor XIII deficiency and type 1 diabetes mellitus with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms with high levels of serum thymus and activation-regulated chemokine.
Autoantibodies to GAD65 and IA-2 antibodies are increased, but not tissue transglutaminase (TTG-Ab) in type 2 diabetes mellitus (T2DM) patients from South India.
Autoantibodies to tissue transglutaminase are sensitive serological parameters for detecting silent coeliac disease in patients with Type 1 diabetes mellitus.
Autoantibodies to tissue transglutaminase in patients from eastern India with malnutrition-modulated diabetes mellitus, insulin-dependent diabetes mellitus, and non-insulin-dependent diabetes mellitus.
Celiac antibodies in children with type 1 diabetes - A diagnostic validation study.
Celiac disease in African American children with type 1 diabetes mellitus in inner city Brooklyn.
Celiac disease in patients with type-1 diabetes mellitus screened by tissue transglutaminase antibodies in northwest of Iran.
Celiac Disease: Ten Things That Every Gastroenterologist Should Know.
Coagulation factor XIII levels in UK Asian subjects with type 2 diabetes mellitus and coronary artery disease.
Coeliac disease.
Concomitant autoantibodies in newly diagnosed diabetic children with transient celiac serology or proven celiac disease.
Frequency of HLA-DQB1*0201/02 and DQB1*0302 alleles and tissue transglutaminase antibody seropositivity in children with type 1 diabetes mellitus.
Glutamic acid decarboxylase (anti-GAD) & tissue transglutaminase (anti-TTG) antibodies in patients with thyroid autoimmunity.
Heritability of carotid artery atherosclerotic lesions: an ultrasound study in 154 families.
High rate of spontaneous normalization of celiac serology in a cohort of 446 children with type 1 diabetes: a prospective study.
Influence of Age and Type 1 Diabetes Mellitus on Serological Test for Celiac Disease in Children.
Lymphocyte transglutaminase function may be impaired in type 2 diabetes mellitus.
Prevalence of celiac disease in children with type 1 diabetes mellitus screened by anti-tissue transglutaminase antibody from Western Saudi Arabia.
Prevalence of Celiac disease in Turkish children with type 1 diabetes mellitus and their non-diabetic first-degree relatives.
Prevalence of IgA antitissue transglutaminase antibodies in children with type 1 diabetes mellitus.
Prolactin and autoimmunity.
Raising the Cut-Off Level of Anti-Tissue Transglutaminase Antibodies to Detect Celiac Disease Reduces the Number of Small Bowel Biopsies in Children with Type 1 Diabetes: A Retrospective Study.
Screening for Celiac Disease In Diabetic Children from Iran.
Spontaneous Normalization of Anti-Tissue Transglutaminase Antibody Levels Is Common in Children with Type 1 Diabetes Mellitus.
The effect of hypoglycemic sulfonylureas on human red blood cell transglutaminase activity.
Transglutaminase-dependent lymphocyte transformation in type 2 diabetes mellitus.
[Activity of factor XIII and various lipid components of blood serum in patients with diabetes mellitus]
[Celiac disease in a group of children and adolescents with type 1 diabetes mellitus]
Diabetes Mellitus, Type 1
A diabetes-specific HLA-DR restricted pro-inflammatory T cell response to wheat polypeptides in tissue transglutaminase antibody negative patients with type 1 diabetes.
Anti-tissue transglutaminase antibodies (IgA and IgG) in both Crohn´s disease and autoimmune diabetes.
Association of lethal acquired factor XIII deficiency and type 1 diabetes mellitus with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms with high levels of serum thymus and activation-regulated chemokine.
Associations of breastfeeding with childhood autoimmunity, allergies, and overweight: The Environmental Determinants of Diabetes in the Young (TEDDY) study.
Autoantibodies to tissue transglutaminase are sensitive serological parameters for detecting silent coeliac disease in patients with Type 1 diabetes mellitus.
Autoantibodies to tissue transglutaminase in patients from eastern India with malnutrition-modulated diabetes mellitus, insulin-dependent diabetes mellitus, and non-insulin-dependent diabetes mellitus.
Celiac antibodies in children with type 1 diabetes - A diagnostic validation study.
Celiac autoantibody positivity in relation to clinical characteristics in children with type 1 diabetes.
Celiac Autoimmunity in Children with Type 1 Diabetes: A Two-Year Follow-Up.
Celiac Autoimmunity Is Associated With Lower Blood Pressure and Renal Risk in Type 1 Diabetes.
Celiac disease and endocrine autoimmunity - the genetic link.
Celiac Disease and Glandular Autoimmunity.
Celiac Disease Autoimmunity in Patients with Autoimmune Diabetes and Thyroid Disease among Chinese Population.
Celiac disease can be predicted by high levels of tissue transglutaminase antibodies in children and adolescents with type 1 diabetes.
Celiac Disease: Ten Things That Every Gastroenterologist Should Know.
Coeliac disease in China, a field waiting for exploration.
Coeliac disease.
Concomitant autoantibodies in newly diagnosed diabetic children with transient celiac serology or proven celiac disease.
Development of autoimmunity to transglutaminase C in children of patients with type 1 diabetes: relationship to islet autoantibodies and infant feeding.
Elevated anti-tissue transglutaminase antibodies in children newly diagnosed with type 1 diabetes do not always indicate coeliac disease.
Frequency of HLA-DQB1*0201/02 and DQB1*0302 alleles and tissue transglutaminase antibody seropositivity in children with type 1 diabetes mellitus.
GADA Titer-Related Risk for Organ-Specific Autoimmunity in LADA Subjects Subdivided according to Gender (NIRAD Study 6).
General screening for celiac disease is advisable in children with type 1 diabetes.
Glutamic acid decarboxylase (anti-GAD) & tissue transglutaminase (anti-TTG) antibodies in patients with thyroid autoimmunity.
Gluten ataxia: passive transfer in a mouse model.
High Incidence of Celiac Disease in a Long-term Study of Adolescents With Susceptibility Genotypes.
High prevalence of celiac disease in patients with type 1 diabetes detected by antibodies to endomysium and tissue transglutaminase.
High rate of spontaneous normalization of celiac serology in a cohort of 446 children with type 1 diabetes: a prospective study.
Identification of Deamidated Peptides in Cytokine-Exposed MIN6 Cells through LC-MS/MS Using a Shortened Digestion Time and Inspection of MS2 Spectra.
Impact of celiac autoimmunity on children with type 1 diabetes.
In vitro and in vivo models of celiac disease.
Influence of Age and Type 1 Diabetes Mellitus on Serological Test for Celiac Disease in Children.
Investigating the potential impact of post translational modification of auto-antigens by tissue transglutaminase on humoral islet autoimmunity in type 1 diabetes.
Islet, thyroid and transglutaminase antibodies in adult Bulgarian patients with type 1 diabetes.
Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients.
Nationwide study of childhood celiac disease incidence over a 35-year period in Estonia.
One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease-associated transglutaminase autoantibodies.
One-Third of Patients Have Evidence for an Additional Autoimmune Disease at Type 1 Diabetes Diagnosis.
Prediction of silent celiac disease at diagnosis of childhood type 1 diabetes by tissue transglutaminase autoantibodies and HLA.
Prevalence of celiac disease in children with type 1 diabetes mellitus screened by anti-tissue transglutaminase antibody from Western Saudi Arabia.
Prevalence of Celiac disease in Turkish children with type 1 diabetes mellitus and their non-diabetic first-degree relatives.
Prevalence of IgA antitissue transglutaminase antibodies in children with type 1 diabetes mellitus.
Prolactin and autoimmunity.
Raising the Cut-Off Level of Anti-Tissue Transglutaminase Antibodies to Detect Celiac Disease Reduces the Number of Small Bowel Biopsies in Children with Type 1 Diabetes: A Retrospective Study.
Role of anti-tissue transglutaminase IgA+IgG antibodies in detection of potential celiac disease in patients with type 1 diabetes.
Role of HLA-DQ typing and anti-tissue transglutaminase antibody titers in diagnosing celiac disease without duodenal biopsy in type 1 diabetes: A study of the population-based pediatric type 1 diabetes cohort of Western Australia.
Screening for Celiac Disease In Diabetic Children from Iran.
Sensitization to gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8 mice.
Silent coeliac disease is over-represented in children with type 1 diabetes and their siblings.
Spontaneous Normalization of Anti-Tissue Transglutaminase Antibody Levels Is Common in Children with Type 1 Diabetes Mellitus.
The great majority of children with type 1 diabetes produce and deposit anti-tissue transglutaminase antibodies in the small intestine.
The high prevalence of autoantibodies to tissue transglutaminase in first-degree relatives of patients with type 1 diabetes is not associated with islet autoimmunity.
Tissue transglutaminase autoantibodies in children with newly diagnosed type 1 diabetes are related to human leukocyte antigen but not to islet autoantibodies: A Swedish nationwide prospective population-based cohort study.
Transglutaminase antibodies and celiac disease in children with type 1 diabetes and in their family members.
Type 1 Diabetes and Celiac Disease: Can (and Should) We Raise the Cut-off of Tissue Transglutaminase Immunoglobulin A to Decide Whether to Biopsy?
Type 1 diabetes associated and tissue transglutaminase autoantibodies in patients without type 1 diabetes and coeliac disease with confirmed viral infections.
Young Age at Diagnosis of Type 1 Diabetes Is Associated with the Development of Celiac Disease-Associated Antibodies in Children Living in Newfoundland and Labrador, Canada.
[Serological tests for celiac disease in Moroccan patients with type 1 diabetes].
[Study of celiac disease in adults with type 1 diabetes mellitus.]
Diabetes Mellitus, Type 2
Autoantibodies to GAD65 and IA-2 antibodies are increased, but not tissue transglutaminase (TTG-Ab) in type 2 diabetes mellitus (T2DM) patients from South India.
Autoantibodies to tissue transglutaminase in patients from eastern India with malnutrition-modulated diabetes mellitus, insulin-dependent diabetes mellitus, and non-insulin-dependent diabetes mellitus.
Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives.
Coagulation factor XIII levels in UK Asian subjects with type 2 diabetes mellitus and coronary artery disease.
Endocrine autoimmunity in patients with Latent Autoimmune Diabetes in Adults (LADA) - association with HLA genotype.
Functional Characterization of Naturally Occurring Transglutaminase 2 Mutants Implicated in Early-Onset Type 2 Diabetes.
GADA Titer-Related Risk for Organ-Specific Autoimmunity in LADA Subjects Subdivided according to Gender (NIRAD Study 6).
Glucose homeostasis in mice is transglutaminase 2 independent.
Islet autoantibodies in Latvian subjects with non-insulin-dependent diabetes mellitus: slow-onset type 1 diabetes or polyendocrine autoimmunity?
Lymphocyte transglutaminase function may be impaired in type 2 diabetes mellitus.
Missense mutations in the TGM2 gene encoding transglutaminase 2 are found in patients with early-onset type 2 diabetes. Mutation in brief no. 982. Online.
Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient.
The effect of hypoglycemic sulfonylureas on human red blood cell transglutaminase activity.
Transglutaminase-dependent lymphocyte transformation in type 2 diabetes mellitus.
Diabetic Angiopathies
Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy.
Diabetic Cardiomyopathies
Role of tissue transglutaminase in the pathogenesis of diabetic cardiomyopathy and the intervention effect of rutin.
Diabetic Foot
Factor XIII Val34Leu polymorphism is associated with increased factor XIII activation and decreased transcutaneous oxygen readings in patients with diabetic foot ulcers.
[Factor XIII: experimental and clinical results in diabetic foot ulcer]
Diabetic Ketoacidosis
Islet autoantibody types mark differential clinical characteristics at diagnosis of pediatric type 1 diabetes.
Diabetic Nephropathies
Elevated epsilon-(gamma-glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase.
Ginkgo biloba leaf extract prevents diabetic nephropathy through the suppression of tissue transglutaminase.
Increases in renal epsilon-(gamma-glutamyl)-lysine crosslinks result from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy: pathologic implications.
Inhibition of collagen I accumulation reduces glomerulosclerosis by a Hic-5-dependent mechanism in experimental diabetic nephropathy.
Tissue transglutaminase inhibition as treatment for diabetic glomerular scarring: it's good to be glueless.
Transglutaminase inhibition ameliorates experimental diabetic nephropathy.
Diabetic Retinopathy
[Detection of coagulation factor XIII in the vitreous body and periretinal membranes in proliferative retinal diseases]
Disseminated Intravascular Coagulation
A contribution to the pathology of acquired plasma factor XIII deficiency.
Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
Complete hemostasis achieved by factor XIII concentrate administration in a patient with bleeding after teeth extraction as a complication of aplastic anemia and chronic disseminated intravascular coagulation.
Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.
Disseminated intravascular coagulation with positive D-dimer: a controversial clinical feature in severe congenital factor XIII deficiency in southeast Iran.
Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Failure to measure plasma activated factor XIII during disseminated intravascular coagulation.
Fibrin stabilizing factor (factor XIII) consumption as an indicator of disseminated intravascular coagulation (DIC).
Molecular subunits and transamidase activity of factor XIII during disseminated intravascular coagulation in acute leukaemia.
Plasma factor XIII activity in patients with disseminated intravascular coagulation.
Reduction of coagulation factor XIII concentration in patients with myocardial infarction, cerebral infarction, and other thromboembolic disorders.
[Changes of factor XIII a and b subunit in patients with disseminated intravascular coagulation syndrome]
[Studies on the blood coagulation factor XIII in patients with increased levels of FDP D-dimer]
Diverticulitis
Significance of diminished factor XIII in Crohn's disease.
Diverticulum
Evaluation of spontaneous intracranial hypotension: assessment on ICP monitoring and radiological imaging.
Down Syndrome
Adherence to Symptom-Based Care Guidelines for Down Syndrome.
Antitissue transglutaminase and antithyroid autoantibodies in children with Down syndrome and celiac disease.
Prevalence of celiac disease in children with Down syndrome screened by anti-tissue transglutaminase antibodies.
Prospective human leukocyte antigen, endomysium immunoglobulin A antibodies, and transglutaminase antibodies testing for celiac disease in children with Down syndrome.
Screening for celiac disease in Down's syndrome patients revealed cases of subtotal villous atrophy without typical for celiac disease HLA-DQ and tissue transglutaminase antibodies.
Tissue transglutaminase antibodies are a useful serological marker for the diagnosis of celiac disease in patients with Down syndrome.
Tissue transglutaminase autoantibodies and human leucocyte antigen in Down's syndrome patients with coeliac disease.
Drug-Related Side Effects and Adverse Reactions
Transglutaminase may mediate certain physiological effects of endogenous amines and of amine-containing therapeutical agents.
Dry Eye Syndromes
Lacritin and other autophagy associated proteins in ocular surface health.
Lacritin and the tear proteome as natural replacement therapy for dry eye.
Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease.
Duodenitis
Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease.
[Evidence of intraepithelial lymphocytes through immunocytochemistry stains in children with celiac disease]
Dupuytren Contracture
Dermal dendrocytes in Dupuytren's disease: a link between the skin and pathogenesis?
Transglutaminase levels in Dupuytren's disease.
Dyskinesias
Characterization of Paroxysmal Gluten-Sensitive Dyskinesia in Border Terriers Using Serological Markers.
Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
Eczema
Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease.
Edema, Cardiac
Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease.
Ehlers-Danlos Syndrome
[Anesthesia for a patient with Ehlers-Danlos syndrome and factor XIII deficiency]
Elephantiasis, Filarial
Evaluation of immunoprophylactic efficacy of Brugia malayi transglutaminase (BmTGA) in single and multiple antigen vaccination with BmALT-2 and BmTPX for human lymphatic filariasis.
Immune responses generated by intramuscular DNA immunization of Brugia malayi transglutaminase (BmTGA) in mice.
Elliptocytosis, Hereditary
DNA methylation in promoter regions of red cell membrane protein genes in healthy individuals and patients with hereditary membrane disorders.
Genetic disorders of the red cell membranes.
Hereditary Red Cell Membrane Disorders in Japan: Their Genotypic and Phenotypic Features in 1014 Cases Studied.
Embolic Stroke
Common genetic coagulation variants are not associated with ischemic stroke in a casecontrol study.
Genetic Factors Influencing Coagulation Factor XIII B-Subunit Contribute to Risk of Ischemic Stroke.
Embolism
Elimination of fibrin ?-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi.
Embolism, Air
[Lethal air embolism after spray of tissue adhesive-fibrinogen and factor XIII aerosol during laparoscopic partial nephrectomy]
Encephalitis
The first case report of a patient with acquired factor XIII deficiency in the context of autoimmune encephalitis.
Encephalomyelitis
Monocyte behaviour and tissue transglutaminase expression during experimental autoimmune encephalomyelitis in transgenic CX3CR1(gfp/gfp) mice.
Neuronal and Endothelial Transglutaminase-2 Expression during Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Transglutaminase 2 exacerbates experimental autoimmune encephalomyelitis through positive regulation of encephalitogenic T cell differentiation and inflammation.
Encephalomyelitis, Autoimmune, Experimental
Monocyte behaviour and tissue transglutaminase expression during experimental autoimmune encephalomyelitis in transgenic CX3CR1(gfp/gfp) mice.
Neuronal and Endothelial Transglutaminase-2 Expression during Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Transglutaminase 2 exacerbates experimental autoimmune encephalomyelitis through positive regulation of encephalitogenic T cell differentiation and inflammation.
Transglutaminase and experimental allergic encephalomyelitis.
Transglutaminase and experimental allergic encephalomyelitis. The effects of encephalitogenic components in mice and guinea pigs.
Transglutaminase levels in brain and reticuloendothelial cells during allergic encephalomyelitis determined by a radiochemical method.
Endometrial Hyperplasia
Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement.
Endometrial Neoplasms
Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement.
Endometriosis
Autoantibodies common in patients with gastrointestinal diseases are not found in patients with endometriosis: A cross-sectional study.
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.
Serological testing for celiac disease in women with endometriosis. A pilot study.
Endotoxemia
Effects of coagulation factor XIII on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation in experimental endotoxemia.
Role of antithrombin and factor XIII in leukocyte-independent plasma extravasation during endotoxemia: an intravital-microscopic study in the rat.
The combinations C1 esterase inhibitor with coagulation factor XIII and N-acetylcysteine with tirilazad mesylate reduce the leukocyte adherence in an experimental endotoxemia in rats.
Enteritis
COELIAC DISEASE AND PSORIASIS COMBINATION IN 5-YEAR-OLD CHILD.
Evidence of anti-gliadin and transglutaminase antibodies in sera of dogs affected by lymphoplasmacytic enteritis.
IgA Antibodies Against Gliadin and Tissue Transglutaminase in Dogs With Chronic Enteritis and Intestinal T-Cell Lymphoma.
Intestinal intraepithelial lymphocyte cytometric pattern is more accurate than subepithelial deposits of anti-tissue transglutaminase IgA for the diagnosis of celiac disease in lymphocytic enteritis.
May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis?
Enterocolitis, Necrotizing
Impaired Activity of Blood Coagulant Factor XIII in Patients with Necrotizing Enterocolitis.
Enterocolitis, Pseudomembranous
Factor XIII deficiency in antibiotic-associated pseudomembranous colitis and its treatment with factor XIII concentrate.
Enterovirus Infections
Enterovirus Infections Are Associated With the Development of Celiac Disease in a Birth Cohort Study.
Enthesopathy
The enthesopathy of celiac patients: effects of gluten-free diet.
Eosinophilia
Association of lethal acquired factor XIII deficiency and type 1 diabetes mellitus with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms with high levels of serum thymus and activation-regulated chemokine.
Ultrastructural localization of factor XIIIa.
Eosinophilic Esophagitis
Elevated Serum Tissue Transglutaminase Antibodies in Children With Eosinophilic Esophagitis.
Epidermolysis Bullosa
Research in practice: diagnosis of subepidermal autoimmune bullous disorders.
Epidermolysis Bullosa, Junctional
The genetics of human skin diseases.
Epilepsy
Celiac Disease in Children: An Association With Drug-Resistant Epilepsy.
Celiac disease prevalence in epileptic children from Serbia.
Celiac disease-related antibodies in an epilepsy cohort and matched reference population.
Chronotherapeutic dose schedule of phenytoin and carbamazepine in epileptic patients.
Epilepsy, cerebral calcifications, and gluten-related disorders: Are anti-transglutaminase 6 antibodies the missing link?
Latent and Potential Celiac Disease in Epileptic Turkish Children.
Surgery in severe factor XIII deficiency: report of a case of epilepsy neurosurgery and review.
Epilepsy, Generalized
Is there a genetic relationship between epilepsy and birth defects?
Epiretinal Membrane
[Thrombospondin and its importance in proliferative retinal diseases]
Epistaxis
Glanzmann's thrombasthenia associated with a transient deficiency of factor XIII.
Erythema Infectiosum
Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman--reply.
Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman.
Esophageal and Gastric Varices
Effects of endoscopic variceal sclerotherapy using GT XIII on blood coagulation tests and the renal kallikrein-kinin system.
[Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)]
Esophageal Neoplasms
Impact of perioperative peripheral blood values on postoperative complications after esophageal surgery.
Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics.
Transglutaminase 3 protein modulates human esophageal cancer cell growth by targeting the NF-?B signaling pathway.
Esophageal Squamous Cell Carcinoma
Clinical Significance of GPR56, Transglutaminase 2, and NF-κB in Esophageal Squamous Cell Carcinoma.
Functional studies of a novel oncogene TGM3 in human esophageal squamous cell carcinoma.
Exanthema
Gluten Challenge Induces Skin and Small Bowel Relapse in Long-Term Gluten-Free Diet-Treated Dermatitis Herpetiformis.
Successful treatment with leukocytapheresis in refractory Henoch-Schönlein purpura: case report.
Factor V Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Clinical audit of inherited bleeding disorders in a developing country.
Mining of mortality-related findings in rare bleeding disorders: a retrospective study from two centers.
Rare inherited coagulation disorders in India.
Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection.
Factor VII Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Clinical audit of inherited bleeding disorders in a developing country.
Inherited bleeding disorders in Indian women with menorrhagia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Rare inherited coagulation disorders in India.
Factor X Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Advances in treatment of bleeding disorders.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Clinical audit of inherited bleeding disorders in a developing country.
Inherited bleeding disorders in Indian women with menorrhagia.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Rare inherited coagulation disorders in India.
Factor XI Deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Congenital hemorrhagic disorders in Jordan.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Platelet and coagulation studies in Ehlers-Danlos syndrome.
The rare inherited coagulation disorders.
Factor XII Deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
Factor XIII Deficiency
A case of congenital factor XIII deficiency.
A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide.
A case of factor XIII deficiency in an adult male.
A case of giant expanding cephalhematoma: does the administration of blood coagulation factor XIII reverse symptoms?
A child with acquired factor XIII deficiency: case report and literature review.
A clinical and family study of factor XIII deficiency in a New Zealand family.
A common F13A1 intron 1 variant IVS1+12(A) is associated with mild FXIII deficiency in Caucasian population.
A contribution to the pathology of acquired plasma factor XIII deficiency.
A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin.
A fluorescent spot test for coagulation factor XIII.
A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran.
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A new era of therapy for congenital factor XIII deficiency.
A new family with congenital factor XIII deficiency showing a deficit of both subunit A and B. Type I factor XIII deficiency.
A novel compound heterozygous mutation in the F13A gene causing hereditary factor XIII deficiency in a Chinese family.
A novel Cys328-terminator mutant implicated in severe coagulation factor XIII deficiency: a case report.
A Rare Case of Factor XIII Deficiency in the Setting of Cancer Immunotherapy.
A reversed activity staining procedure for detection of an acquired antibody against factor XIII in a girl with factor XIII deficiency.
A specific, fluorescent activity staining procedure applied to plasma and red blood cells in congenital factor XIII deficiency.
A tentative classification of factor XIII deficiency in two groups.
Acquired coagulation factor XIII deficiency: a case report.
Acquired factor XIII deficiency after desensitization as a potential contributor to postoperative bleeding: more than meets the eye.
Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature.
Acquired factor XIII deficiency in a child with pure erythroid leukemia.
Acquired factor XIII deficiency in patients under therapeutic plasma exchange: A poorly explored etiology.
Acquired factor XIII deficiency in two patients with bleeding events during veno-venous extracorporeal membrane oxygenation treatment.
Acquired Factor XIII Deficiency Inducing Recurrent and Fatal Bleeding, Description of a Case.
Acquired factor XIII deficiency with chronic myelomonocytic leukemia.
Acquired factor XIII deficiency: A review.
Acquired factor XIII deficiency: a therapeutic challenge.
Acquired Factor Xiii Deficiency: An Uncommon But Easily Missed Cause Of Severe Bleeding
Acquired factor XIII deficiency: still a clinical challenge in the era of novel therapy.
Acquired plasma factor XIII deficiencies.
Acute Abdomen in a Young Girl with Factor XIII Deficiency Perianesthetic Issues.
Acute abdomen in a young girl with factor XIII deficiency: Perianesthetic issues.
Acute and diffuse postoperative bleeding after free latissimus dorsi flap--Factor XIII deficiency: a case report and review of the literature.
Acute kidney injury is associated with low factor XIII in decompensated cirrhosis.
Acute promyelocytic leukaemia associated Factor XIII deficiency presenting as retro-bulbar haematoma.
An acquired inhibitor to factor XIII A case report.
An electrophoretic and quantitative analysis of coagulation factor XIII in normal and deficient subjects.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
An unusual case of factor xiii deficiency.
An unusual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy.
An update of the mutation profile of Factor 13 A and B genes.
Analytical and clinical utility of a photometric assay for blood coagulation factor XIII.
Application of HUMF13A01 (AAAG)n STR polymorphism to the genetic diagnosis of coagulation factor XIII deficiency.
Arg260-Cys mutation in severe factor XIII deficiency: conformational change of the A subunit is predicted by molecular modelling and mechanics.
Arthropathy associated with factor XIII deficiency.
As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan.
Association between expression of MMP-2 and MMP-9 genes and pathogenesis of intracranial hemorrhage in severe coagulation factor XIII deficiency.
Association of lethal acquired factor XIII deficiency and type 1 diabetes mellitus with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms with high levels of serum thymus and activation-regulated chemokine.
Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: A summary of 93 patients.
Autoimmune Acquired Factor XIII Deficiency: A Case Report.
Autoimmune factor XIII deficiency with unusual laboratory and clinical phenotype.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
Benefits of thromboelastometry for monitoring replacement therapy in patients with severe inherited factor XIII deficiency: 3 illustrative cases.
Biology of Factor XIII and clinical manifestations of Factor XIII deficiency.
Bleeding disorder with abnormal wound healing, acid-soluble clots and normal factor XIII.
Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature.
Blood coagulation factor XIII and factor XIII deficiency.
Blood factor XIII deficiency: review of literature and report of case.
Case report of an acquired factor XIII inhibitor: diagnosis and management.
Central nervous system bleeding in pediatric patients with factor XIII deficiency: A study on 23 new cases.
Cerebral thrombosis associated with heterozygous factor V Leiden mutation and high lipoprotein(a) level in a girl with factor XIII deficiency.
Challenges in implementation of ISTH diagnostic algorithm for diagnosis and classification of factor XIII deficiency in Iran.
Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder.
Choroid Plexus Papilloma and Factor XIII Deficiency: Case Report.
Claw toes correction and factor XIII deficiency--a case report.
Clinical and laboratory features of congenital factor XIII deficiency.
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease.
Clinical audit of inherited bleeding disorders in a developing country.
Clinical experience with a pasteurised human plasma concentrate in factor XIII deficiency.
Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency.
Clinical pharmacokinetics of a placenta-derived factor XIII concentrate in type I and type II factor XIII deficiency.
Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms.
Coagulation factor XIII in pregnant smokers and non-smokers.
Coagulation management in patients undergoing mechanical circulatory support.
Combined occurrence of von Willebrand's disease and factor XIII deficiency: a case report.
Comparison of 2 Methods of Clot Solubility Testing in Detection of Factor XIII Deficiency.
Concurrent hematoma and venous thrombosis in a patient with autoimmune acquired factor XIII deficiency.
Congenital afibrinogenemia in a new born: a rare cause for bleeding.
Congenital blood coagulation factor XIII deficiency and perinatal management.
Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature.
Congenital deficiency of factor XIII with normal subunit S and lack of subunit A. Report of a new family.
Congenital factor XIII deficiency and increased fibrinolysis. A case report.
Congenital factor XIII deficiency associated with von Willebrand disease.
Congenital factor XIII deficiency caused by two mutations in eight Tunisian families: molecular confirmation of a founder effect.
Congenital factor XIII deficiency in a neonate.
Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations.
Congenital factor XIII deficiency in Switzerland: from the worldwide first case in 1960 to its molecular characterisation in 2005.
Congenital factor XIII deficiency in women: a systematic review of literature.
Congenital factor XIII deficiency with multiple benign breast tumours and successful pregnancy with substitutive therapy. A case report.
Congenital Factor XIII Deficiency With the Presence of Inhibitor: A Case Study.
Congenital factor XIII deficiency with treatment of factor XIII concentrate and normal vaginal delivery.
Congenital factor XIII deficiency.
Congenital factor XIII deficiency. A family report.
Congenital factor XIII deficiency. Report of 2 cases.
Congenital factor XIII deficiency: a case report and review of literature.
Congenital factor XIII deficiency: A commentary on 'Homozygous intronic mutation leading to inefficient transcription combined with a novel frame-shift mutation in F13A1 gene causes FXIII deficiency'.
Congenital factor XIII deficiency: a patient report and review of the literature.
Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort.
Congenital factor XIII deficiency: report of a case and literature review.
Congenital factor XIII deficiency: two case reports.
Congenital factor XIII deficiency: type I and type II disease.
Congenital hemorrhagic disorders in Jordan.
Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study.
Corpus luteal hemorrhage: an unusual manifestation of congenital factor XIII deficiency.
COVID-19 is Associated with an Acquired Factor XIII Deficiency.
Cranial hemophilic pseudotumor associated with factor IX deficiency: case report.
Current understanding in diagnosis and management of factor XIII deficiency.
De Novo Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (MYC/BCL-2) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency.
Defective ?2 antiplasmin cross-linking and thrombus stability in a case of acquired factor XIII deficiency.
Defective fibrin crosslinking in acute leukemia.
Deficiency of factor XIII gene in Chinese: 3 novel mutations.
Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.
Delayed umbilical bleeding--a presenting feature for factor XIII deficiency: clinical features, genetics, and management.
Dental Management of Factor XIII Deficiency Patients: A Case Series.
Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories.
Determination of factor XIII activity and of factor XIII inhibitors using an ammonium-sensitive electrode.
Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.
Development of anti-factor XIII antibodies in a patient with hereditary factor XIII deficiency receiving therapy for chronic hepatitis C.
Diagnosis and management of severe congenital factor XIII deficiency in the Emergency Department: lessons from a "model" family.
Diagnosis of factor XIII deficiency.
Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran.
Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency.
Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders.
Disseminated intravascular coagulation with positive D-dimer: a controversial clinical feature in severe congenital factor XIII deficiency in southeast Iran.
Documentation of the plasma factor XIII deficiency in man.
Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Effect of four missense mutations in the factor XIII A-subunit gene on protein stability: studies with recombinant proteins.
Effect of Social Factors on the Highest Global Incidence of Congenital Factor XIII Deficiency in Southeast of Iran.
Effects of Factor XIII Deficiency on Thromboelastography. Thromboelastography with Calcium and Streptokinase Addition is more Sensitive than Solubility Tests.
Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Establishment of a prenatal diagnosis schedule as part of a prophylaxis program of factor XIII deficiency in the southeast of Iran.
ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group.
Expression and CpG island methylation pattern of MMP-2 and MMP-9 genes in patients with congenital factor XIII deficiency and intracranial hemorrhage.
Factor concentrates for the treatment of factor XIII deficiency.
Factor XIII and its deficiency - review literature and the case report of a Thai boy with congenital factor XIII deficiency.
Factor XIII as a modulator of plasma fibronectin alterations during experimental bacteremia.
Factor XIII Assays and associated problems for laboratory diagnosis of factor XIII deficiency: an analysis of International Proficiency testing results.
Factor XIII deficiency (fibrin stabilizing factor).
Factor XIII deficiency and head trauma: management and therapy.
Factor XIII deficiency and intracranial hemorrhages in infancy.
Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures.
Factor XIII Deficiency and Thrombocytopenia Are Frequent Modulators of Postoperative Clot Firmness in a Surgical Intensive Care Unit.
Factor XIII deficiency as a potential cause of supratentorial haemorrhage after posterior fossa surgery.
Factor XIII deficiency associated with Klippel-Weber disease, platelet dysfunction and cryofibrinogenemia.
Factor XIII Deficiency Associated With Noonan Syndrome.
Factor XIII deficiency associated with valproate treatment.
Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction.
Factor XIII deficiency causing mutation, Ser295Arg, in exon 7 of the factor XIIIA gene.
Factor XIII deficiency diagnosis: Challenges and tools.
Factor XIII deficiency does not prevent FeCl3-induced carotid artery thrombus formation in mice.
Factor XIII deficiency due to a Leu660Pro mutation in the factor XIII subunit-a gene in three unrelated Palestinian Arab families.
Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
Factor XIII deficiency in adult polycystic kidney disease.
Factor XIII deficiency in antibiotic-associated pseudomembranous colitis and its treatment with factor XIII concentrate.
Factor XIII deficiency in BALB/c mice with plasmacytoma.
Factor XIII Deficiency in Children-Clinical Presentation and Outcome.
Factor XIII deficiency in Henoch-Schönlein purpura - report on two cases and literature review.
Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature.
Factor XIII deficiency in Pakistan.
Factor XIII Deficiency in Siblings: Importance of Prophylactic Replacement.
Factor XIII deficiency in south of Tunisia.
Factor XIII deficiency in south-east Iran.
Factor XIII deficiency in two Melanesian families from Papua New Guinea.
Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management.
Factor XIII Deficiency in Western Afghanistan due to a Novel F13A Gene Mutation.
Factor XIII deficiency leading to preseptal haematoma post-strabismus surgery.
Factor XIII deficiency management: a review of the literature.
Factor XIII deficiency mistaken for battered child syndrome: case of "correct" test ordering negated by a commonly accepted qualitative test with limited negative predictive value.
Factor XIII deficiency presenting with intracerebral bleed.
Factor XIII deficiency related recurrent spontaneous intracerebral hemorrhage: A case and literature review.
Factor XIII deficiency revealed by spontaneous intramedullary hemorrhage: confirmation of a severe mutation.
Factor XIII Deficiency with a Novel Nonsense Mutation.
Factor XIII deficiency with intracranial haemorrhage.
Factor XIII deficiency.
Factor XIII Deficiency.
Factor XIII deficiency. A family study by measurement of factor XIII subunits A and S.
Factor XIII deficiency. A rare haemorrhagic disease.
Factor XIII deficiency. Treatment with monthly plasma infusions.
Factor XIII deficiency: a differential diagnosis to be considered in suspected nonaccidental injury presenting with intracranial hemorrhage.
Factor XIII deficiency: a genetic study of two affected kindreds in Finland.
Factor XIII deficiency: a rare cause of repeated abortions.
Factor XIII Deficiency: An Update.
Factor XIII deficiency: complete phenotypic characterization of two cases with novel causative mutations.
Factor XIII deficiency: new nonsense and deletion mutations in the human factor XIIIA gene.
Factor XIII deficiency: pathogenic mechanisms and clinical significance.
Factor XIII deficiency: report of a case complicated by splenic rupture.
Factor XIII deficiency: report of two cases.
Factor XIII levels in five families of patients with inherited factor XIII deficiency: support for an autosomal recessive inheritance.
Factor XIII mutation spectrum in Iranian patients with hereditary factor XIII deficiency: Detection of 3 novel mutations.
Factor XIII.
Factor XIIIA Calgary: a candidate missense mutation (Leu667Pro) in the beta barrel 2 domain of the factor XIIIA subunit.
Fibrin cross-linking in congenital factor XIII deficiency.
Fibrinogen but not factor XIII deficiency is associated with bleeding after craniotomy.
Fibronectin and wound healing.
First cases of severe congenital factor XIII deficiency in Southwestern Afghanistan in the vicinity of southeast of Iran.
Fracture neck of femur in Factor XIII deficiency: Was better outcome possible?
Further evidence of heterogeneity of gene defects in Italian families with factor XIII deficiency.
FXIII deficiency due to base exchange Thr 449 (ACT) --> Ile (ATT) in exon 11 of the factor 13A gene. A cause of bleeding?
Gene defects in congenital factor XIII deficiency.
Genetic aspects of factor XIII deficiency.
Genetic basis of severe factor XIII deficiency in a large cohort of Indian patients: Identification of fourteen novel mutations.
Genetic heterogeneity of factor XIII deficiency: first description of unstable A subunits.
Glanzmann's thrombasthenia in a Melanesian.
Guidelines for laboratory diagnosis of factor XIII deficiency.
Gynecological and obstetric outcome in the French cohort of women with factor XIII deficiency.
Hemophiliacs--a picture from a developing country: Karnataka, a south Indian state.
Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.
Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis.
Hemostasis in Crohn's disease: low factor XIII levels in active disease.
Hereditary factor XIII deficiency.
Hereditary factor XIII deficiency: report of four families and definition of the carrier state.
How to Assess Founder Effect in Patients with Congenital Factor XIII Deficiency.
How to deal with medical and social aspects of bleeding disorders--preparing women and the family in developing countries.
Hyperfibrinolysis and acquired factor XIII deficiency in newly diagnosed pediatric malignancies.
Identification of a new Leu354Pro mutation responsible for factor XIII deficiency.
Identification of a new mutation (Gly420Ser), distal to the active site, that leads to factor XIII deficiency.
Identification of a Novel Mutation Combination in Factor XIII Deficiency: Genetic Update to the First Reported Case in the United States.
Identification of a novel nonsense mutation leading to congenital factor XIII deficiency.
Identification of acquired coagulation disorders and effects of target-controlled coagulation factor substitution on the incidence and severity of spontaneous intracranial bleeding during veno-venous ECMO therapy.
Identification of an inframe deletion and a missense mutation in the factor XIIIA gene in two Turkish patients.
Identification of novel pathogenic F13A1 mutation and novel NBEAL2 gene missense mutation in a pedigree with hereditary congenital factor XIII deficiency.
Identification of two novel missense mutations causing severe factor XIII deficiency.
Immunotolerance approach to refractory CNS bleeding in a patient with congenital factor XIII deficiency and acquired alloantibody.
Impact of Rare Bleeding Disorders during Pregnancy on Maternal and Fetal Outcomes: Review of 29 Pregnancies at a Single Center.
Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII.
Important roles of the human leukocyte antigen class I and II molecules and their associated genes in the autoimmune coagulation factor XIII deficiency via whole-exome sequencing analysis.
In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.
Induction of hemodialysis therapy in a case with factor XIII deficiency.
Inherited bleeding disorders in Indian women with menorrhagia.
Inherited bleeding disorders in pregnancy.
Inherited factor XIII deficiency.
International registry on factor XIII deficiency: a basis formed mostly on European data.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Intracranial hemorrhage in congenital deficiency of factor XIII.
Intracranial hemorrhage pattern in the patients with factor XIII deficiency.
Intracranial Hemorrhage: A Devastating Outcome of Congenital Bleeding Disorders-Prevalence, Diagnosis, and Management, with a Special Focus on Congenital Factor XIII Deficiency.
Intraspinal hemorrhage in a child with factor XIII deficiency.
Investigation of a link between raised levels of pepsinogen in blood as a mediator of in-vitro clot lysis in acid and a cause of abnormal factor XIII screening tests.
Is Embolization an Effective Treatment for Recurrent Hemorrhage After Hip or Knee Arthroplasty?
Is extracorporeal CO2-Removal really "safe" and "less" invasive? Observation of blood injury and coagulation impairment during ECCO2R.
Laboratory Diagnosis of Factor XIII Deficiency in Developing Countries: An Iranian Experience.
Laboratory Diagnosis of Factor XIII Deficiency, Routine Coagulation Tests with Quantitative and Qualitative Methods.
Laboratory testing for bleeding disorders: strategic uses of high and low-yield tests.
Lobar Hemorrhage Induced by Acquired Factor XIII Deficiency in a Patient with Cerebral Amyloid Angiopathy.
Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®.
Long-term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran.
Long-term prophylaxis in patients with severe congenital factor XIII deficiency is not complicated by inhibitor formation.
Low levels of fibrin-stabilizing factor (factor XIII) in human Plasmodium falciparum malaria: correlation with clinical severity.
Low prevalence of antibodies against human immunodeficiency virus in Finnish haemophiliacs.
Male fertility in factor XIII deficiency.
Management of acute myocardial infarction in a patient with factor XIII deficiency using prophylactic factor replacement therapy.
Management of Dilutional Coagulopathy during Pediatric Major Surgery.
Management of Neuraxial Analgesia in a Parturient with Factor XIII Deficiency: A Case Report and Proposed Management Algorithm.
Management of pregnancy and delivery in women with inherited bleeding disorders.
Massive recurrent post-tonsillectomy bleedings revealing a transient factor XIII deficiency in a 10-year-old boy. A case report.
Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell.
Medical and Surgical Management of Postpartum Hemorrhage in a Woman with Factor XIII Deficiency.
Melanoma associated with subacute primitive fibrinolysis.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Mild Acquired Factor XIII Deficiency and Clinical Relevance at the ICU-A Retrospective Analysis.
Mild factor XIII deficiency and concurrent hypofibrinogenemia: effect of pregnancy.
Mining of mortality-related findings in rare bleeding disorders: a retrospective study from two centers.
Molecular and genetic mechanisms of factor XIII A subunit deficiency.
Molecular Basis of Congenital Factor XIII Deficiency in Iran.
Molecular basis of inherited factor XIII deficiency: identification of multiple mutations provides insights into protein function.
Molecular characterization of five Italian families with inherited severe factor XIII deficiency.
Molecular diagnosis of factor XIII deficiency, data from comprehensive coagulation laboratory in Iran.
Molecular genetic analysis of ten unrelated Iranian patients with congenital factor XIII deficiency.
Molecular mechanisms of mutations in factor XIII A-subunit deficiency: in vitro expression in COS-cells demonstrates intracellular degradation of the mutant proteins.
Molecular mechanisms of type II factor XIII deficiency: novel Gly562-Arg mutation and C-terminal truncation of the A subunit cause factor XIII deficiency as characterized in a mammalian expression system.
Molecular modeling predicts structural changes in the A subunit of factor XIII caused by two novel mutations identified in a neonate with severe congenital factor XIII deficiency.
Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency.
Mutations causing coagulation factor XIII subunit A deficiency: characterization of the mutant proteins after expression in yeast.
Mutations in coagulation factor XIII A gene in eight unrelated Indians. Five novel mutations identified by a novel PCR-CSGE approach.
Mutations in coagulation factor XIII subunit A in severe factor XIII deficiency patients: five novel mutations detected.
Neonatal factor XIII deficiency.
Neoplasm-induced bleeding in inherited, heterozygous FXIII-A deficiency.
New developments in the management of congenital Factor XIII deficiency.
New mutations causing the premature termination of translation in the A subunit gene of coagulation factor XIII.
Nonhemophiliac musculoskeletal pseudotumor.
Nonimmune-acquired factor XIII deficiency: a cause of high volume and delayed postoperative hemorrhage.
Novel and recurrent mutations in the F13A1 gene in unrelated Korean patients with congenital factor XIII deficiency.
Novel aspects of factor XIII deficiency.
Novel deep intronic mutation in the coagulation factor XIII a chain gene leading to unexpected RNA splicing in a patient with factor XIII deficiency.
Novel deletion and insertion mutations cause splicing defects, leading to severe reduction in mRNA levels of the A subunit in severe factor XIII deficiency.
Novel Factor XIII variant identified through whole-genome sequencing in a child with intracranial hemorrhage.
Novel human pathological mutations. Gene symbol: F13A1. Disease: Factor XIII Deficiency.
Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.
Novel Y283C mutation of the A subunit for coagulation factor XIII: molecular modelling predicts its impaired protein folding and dimer formation.
Occurrence and recurrence of spontaneous chronic subdural haematoma is associated with a factor XIII deficiency.
Ocular complications of factor XIII deficiency.
On the retraction of collagen and fibrin induced by normal, defective and modified platelets.
Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection.
Optimisation of a new continuous UV assay for the determination of blood coagulation factor XIII activity in human plasma.
Original tandem duplication in FXIIIA gene with splicing site modification and four amino acids insertion causes factor XIII deficiency.
Ovarian haemorrhage: a rare presentation and diagnostic dilemma in factor XIII deficiency.
Pathogenicity analysis of variations and prenatal diagnosis in a hereditary coagulation factor XIII deficiency family.
Pathological coagulation parameters in as many as 54 patients with autoimmune acquired factor XIII deficiency due to anti-factor XIII autoantibodies.
Patient-centered approach to managing factor XIII deficiency.
Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency.
Penile prosthesis implant for primary erectile dysfunction in patient with Klippel-Trenaunay syndrome complicated by consumptive coagulopathy: A case report.
Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Phenotype and genotype of FXIII deficiency in two unrelated probands: identification of a novel F13A1 large deletion mediated by complex rearrangement.
Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency.
Phenotype-genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations.
Physiopathology and regulation of factor XIII.
Platelet aggregation in congenital factor XIII deficiency.
Platelet and coagulation studies in Ehlers-Danlos syndrome.
Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency.
Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman--reply.
Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman.
Postoperative bleeding in a patient with normal screening coagulation tests.
Posttraumatic subgaleal and orbital hematoma due to factor XIII deficiency.
Pregnancy complications and obstetric care in women with inherited bleeding disorders.
Premarital Screening Program for Congenital Factor XIII Deficiency in Iran.
Prenatal diagnosis in factor XIII-A deficiency.
Prenatal diagnosis of factor 13 deficiency and its recurrence.
Prevalence of factor XIII deficiency in patients presenting with a bleeding disorder in Pakistan.
Primary structure of blood coagulation factor XIIIa (fibrinoligase, transglutaminase) from human placenta.
Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study.
Proceedings: Factor XIII concentrate in the long term management of congenital factor XIII deficiency.
Procoagulant platelets form an ?-granule protein-covered 'cap' on their surface that promotes their attachment to aggregates.
Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency.
Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency: reply to a rebuttal.
Prophylaxis in factor XIII deficiency.
Prophylaxis in rare coagulation disorders -- factor XIII deficiency.
Pubertal Menorrhagia - A Rare Presentation of Congenital Factor XIII Deficiency.
Quality of life of people with hereditary factor XIII deficiency treated at a reference centre.
Rare bleeding disorders in children: identification and primary care management.
Rare inherited coagulation disorders in India.
Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.
Recombinant factor XIII A-subunit in a patient with factor XIII deficiency and recurrent pregnancy loss.
Recurrent bleeding following rhinoplasty due to factor XIII deficiency.
Recurrent episodes of severe bleeding caused by congenital factor XIII deficiency in a dog.
Recurrent Hematomas following a Revision Total Hip Arthroplasty in Acquired Coagulation Factor XIII Deficiency.
Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update.
Recurrent Post Tonsillectomy Secondary Hemorrhage in Patients with Factor XIII Deficiency: A Case Series and Review of Literature.
Recurrent Spontaneous Splenic Rupture in a Patient With Congenital Factor XIII Deficiency.
Recurrent ulcerations on both legs since early childhood due to a factor V gene mutation.
Reduced difference of ?(2)-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune hemorrhaphilia due to anti-factor XIII antibodies.
Reduced levels of coagulation factor XIII in patients with advanced tumor disease.
Relevant bleeding diathesis due to acquired factor XIII deficiency.
Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition.
Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with liver cirrhosis.
Rotational Thromboelastometry for Assessing Bleeding Complications and Factor XIII Deficiency in Cardiac Surgery Patients.
Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available.
Segmental uniparental disomy as a rare cause of congenital severe factor XIII deficiency in a girl with only one heterozygous carrier parent.
Seven novel mutations in the factor XIII A-subunit gene causing hereditary factor XIII deficiency in 10 unrelated families.
Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency.
Severe bleeding in a patient with factor XIII deficiency and COVID-19.
Severe congenital factor XIII deficiency caused by novel W187X and G273V mutations in the F13A gene; diagnosis and classification according to the ISTH/SSC guidelines.
Solubility fo fibrin clots in monochloroacetic acid. A reflection of serum pepsinogen levels.
Spectrum of hereditary coagulation factor deficiencies in eastern province, Saudi Arabia.
Spinal anaesthesia and caesarean section in a patient with hypofibrinogenaemia and factor XIII deficiency*
Spontaneous Acute Cerebral Hematoma in a Child with Factor XIII Deficiency.
Spontaneous Epidural Hematoma in a Child With Inherited Factor XIII Deficiency.
Spontaneous intracerebral hematoma in a adolescent with factor XIII deficiency. Case report.
Spontaneous regression of the inhibitor against the coagulation factor XIII A subunit in acquired factor XIII deficiency.
Spontaneous rupture of the spleen in Factor XIII deficiency: A report of two cases.
Spontaneous splenic rupture in a patient with factor XIII deficiency and a novel mutation.
State of the art in factor XIII laboratory assessment.
Studies on factor XIII antigen in congenital factor XIII deficiency. A tentative classification of the disease in two groups.
Subgaleal hematoma presenting as a manifestation of Factor XIII deficiency.
Subunits A and S inheritance in four families with congenital factor XIII deficiency.
Successful completion of transurethral lithotripsy in a patient with factor XIII deficiency: A case report.
Successful long-term replacement therapy with FXIII concentrate (Fibrogammin(®) P) for severe congenital factor XIII deficiency: a prospective multicentre study.
Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy. Report of a second case.
Successful treatment of chronic disseminated intravascular coagulation using recombinant human soluble thrombomodulin in a dialysis patient with dissecting aortic aneurysm.
Successful treatment of severe gastrointestinal manifestations of Henoch-Schonlein Purpura and factor XIII deficiency using cryoprecipitate transfusion.
Successful use of recombinant factor VIIa in a child with Schoenlein-Henoch purpura presenting with compartment syndrome and severe factor XIII deficiency.
Surgery in severe factor XIII deficiency: report of a case of epilepsy neurosurgery and review.
Symptomatic factor XIII deficiency with normal urea solubility test.
The first case report of a patient with acquired factor XIII deficiency in the context of autoimmune encephalitis.
The influence of intrinsic coagulation pathway on blood platelets activation by oxidized cellulose.
The normal and abnormal genes of the a and b subunits in coagulation factor XIII.
The perioperative course of factor XIII and associated chest tube drainage in newborn and infants undergoing cardiac surgery.
The rare inherited coagulation disorders.
The role of fibrin matrices and tissue factor in early-term trophoblast proliferation and spreading.
The subunit composition of factor XIII proteins in normal and factor XIII deficient plasma and serum analysed by line immunoelectrophoresis.
Therapeutic factor XIII preparations and perspectives for recombinant factor XIII.
Thromboelastometric detection of clotting Factor XIII deficiency in cardiac surgery patients.
Thromboelastometry Identified Alteration of Clot Stabilization and Factor XIII Supplementation Need in a Patient with Decompensated Liver Disease Undergoing Liver Biopsy.
Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis.
Tooth extraction in two patients who had a congenital deficiency of factor XIII.
Training Program for Home Therapy of People With Factor XIII Deficiency.
Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection.
Treatment of factor XIII deficiency with cryoprecipitate.
Treatment with Recombinant Factor XIII (Tretten) in a Pregnant Woman with Factor XIII Deficiency.
Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation.
Two novel and one recurrent missense mutation in the factor XIII A gene in two Dutch patients with factor XIII deficiency.
Type I and type II disease in congenital factor XIII deficiency. A further demonstration of the correctness of the classification.
Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain.
Unusual presentation of factor XIII deficiency.
Use of Catridecacog in a patient with severe Factor XIII deficiency undergoing surgery.
Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding.
Valproic Acid-Induced Coagulopathy.
Viral markers and use of factor products among Finnish patients with bleeding disorders.
[2 patients with congenital factor XIII deficiency. Contribution to the problem of factor XIII determination]
[A case of congenital factor XIII deficiency and acquired factor XIII deficiency (author's transl)]
[A clinical study of congenital factor XIII deficiency (author's transl)]
[A novel genetic defect in a Chinese family with inherited coagulation factor XIII deficiency]
[A report of two cases with congenital factor XIII deficiency]
[Acquired coagulation disorders].
[Acquired factor XIII deficiency and chronic myeloid splenomegaly]
[Acquired factor XIII deficiency and clinical surgery]
[Acquired factor XIII deficiency and postoperative aseptic wound healing disorders]
[Acquired von Willebrand syndrome in a patient with immune thrombocytopenic purpura].
[Acute malignant myelofibrosis complicated by factor XIII deficiency, protein C decrease and skin necroses]
[An infant with umbilical cord and intracranial hemorrhage--severe factor XIII deficiency]
[Anesthesia for a patient with Ehlers-Danlos syndrome and factor XIII deficiency]
[Bleeding and coagulation disorders in tonsillectomies.]
[Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]
[Blood coagulation factor XIII and fibrin stabilization (author's transl)]
[Case of factor XIII deficiency]
[Case suspected to be factor XIII deficiency]
[Cephalohemoatoma as the first manifestation of congenital factor XIII deficiency]
[Characterization of a large deletion that leads to congenital factor XIII deficiency]
[Clinical course and management of severe congenital factor XIII deficiency]
[Congenital factor XIII deficiency in pregnancy. A case report]
[Congenital factor XIII deficiency in the south of Tunisia]
[Congenital factor XIII deficiency required high-dose factor XIII concentrate in late pregnancy]
[Congenital factor XIII deficiency. Report of a new family (author's transl)]
[Congenital factor XIII deficiency: studies in an infant and his family]
[Congenital factor XIII deficiency]
[Detection of factor XIII deficiency in acute leukemia with resonance thrombography]
[Factor XIII deficiency as the cause of postoperative hemorrhage]
[Factor XIII deficiency due to lack of both the S and A subunits. (Classification of factor XIII deficiency in 2 groups)]
[Factor XIII deficiency in a newborn]
[Factor XIII deficiency in adults with acute leukemia: results of a substitution therapy with factor XIII (author's transl)]
[Factor XIII deficiency in burns]
[Factor XIII deficiency in various patients with acute leukemia]
[Factor XIII deficiency: blood coagulation defect in pregnancy]
[Factor XIII deficiency]
[Factor XIII-guided treatment algorithm reduces blood transfusion in burn surgery].
[Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)]
[Hereditary coagulation factor XIII deficiency: three cases report and literaure review].
[Identification of a novel mutation of F (13) A gene in a pedigree with factor XIII deficiency]
[Identification of genetic defects in a Chinese pedigree with factor XIII deficiency: case report and literature review].
[Identification of two novel mutation in two Chinese hereditary coagulation factor XIII deficiency families]
[Importance, diagnosis and substitution in acquired factor XIII deficiency in the postoperative course]
[Intracranial hematoma accompanying bleeding tendency: therapeutic practice and analysis of literature]
[Intradural hematoma of the foramen magnum associated with factor XIII deficiency]
[Is the use of factor XIII for delayed wound healing in patients with head-neck tumors of value?]
[Leukocytoclastic vasculitis and factor XIII deficiency]
[Longtime therapy of congenital factor XIII deficiency using factor XIII concentrate]
[Molecular mechanisms of two novel mutations of factor XIII gene resulting in hereditary coagulation deficiency]
[Pathogenesis of tracheal stenosis following long-term intubation of patients with multiple injuries]
[Plasma transglutaminase activity in congenital total and partial factor XIII deficiency (a contribution to the problem of factor XIII determination)]
[Postoperative complications due to acquired factor XIII deficiency]
[Pre-hospital diagnosis of nosebleed in children]
[Presence of a plasma antigen indispensable to the stabilization of fibrin in 2 cases on congenital factor XIII deficiency]
[Primary myelofibrosis with fatal mesenteric arterial thromboembolism caused by antiphospholipid syndrome]
[Recurrent hematomas and normal standard hemostasis tests]
[Role of thrombelastometry for the monitoring of factor XIII. A prospective observational study in neurosurgical patients.]
[Severe factor XIII-deficiency. Studies on subunits and turnover of the fibrin stabilizing factor (author's transl)]
[Simplified radiologic factor XIII determination and its clinical use in congenital factor XIII deficiency (I)]
[Spontaneous splenic rupture in a patient with congenital factor XIII deficiency]
[Stenosing ureteritis and factor XIII deficiency in anaphylactoid purpura]
[Studies on abnormal protein in seven patients with congenital factor XIII deficiency (author's transl)]
[Studies on congenital factor XIII deficiency and detection of the carrier in his family (author's transl)]
[Study on the molecular mechanisms of a novel large deletion of FXIIIA mRNA in a new hereditary factor XIII deficiency].
[Substitution treatment of factor XIII deficiency with a new factor XIII concentrate]
[Surgical treatment of intracranial hematoma with congenital factor XIII deficiency. Case report]
[Thrombelastometric detection of factor XIII deficiency]
[Wound healing disorders and factor XIII deficiency after tumor operations in the floor of the mouth]
Fanconi Anemia
The functional interactome of GSTP: A regulatory biomolecular network at the interface with the Nrf2 adaption response to oxidative stress.
Fasciitis
Proliferative myositis and fasciitis. Report of five cases with an ultrastructural and immunohistochemical study.
Fatty Liver
Lamin aggregation is an early sensor of porphyria-induced liver injury.
Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2.
Searching for coeliac disease in patients with non-alcoholic fatty liver disease.
Fatty Liver, Alcoholic
Recent advances in understanding the roles of transglutaminase 2 in alcoholic steatohepatitis.
Fetal Death
[Activity of plasma fibrin stabilizing factor in intra-uterine fetal death]
Fetal Growth Retardation
Parent-of-origin transmission of thrombophilic alleles to intrauterine growth-restricted newborns and transmission-ratio distortion in unaffected newborns.
Thrombophilic polymorphisms and intrauterine growth restriction.
Undiagnosed coeliac disease does not appear to be associated with unfavourable outcome of pregnancy.
Fibroadenoma
Interplay between membrane lipid peroxidation, transglutaminase activity and cyclooxygenase 2 expression in the tissue adjoining to breast cancer.
Fibroma
Phenotypic characterisation of stellate and giant cells in giant cell fibroma by immunocytochemistry.
Pleomorphic Fibroma: A Clinicopathologic Case Series With the Review of the Literature.
S100A6 expression in fibrohistiocytic lesions.
Fibrosarcoma
Apoptosis: a potential role for cytosolic transglutaminase and its importance in tumour progression.
Cell cycle kinetics, tissue transglutaminase and programmed cell death (apoptosis).
Characterization of the transglutaminase-mediated large molecular weight polymer from rat liver; its relationship to apoptosis.
Factor XIII cross-linking of fibronectin at cellular matrix assembly sites.
Identification of the autoantigen of celiac disease.
Induction of tissue transglutaminase by dexamethasone: its correlation to receptor number and transglutaminase-mediated cell death in a series of malignant hamster fibrosarcomas.
Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion.
The existence of an inactive form of transglutaminase within metastasising tumours.
Tissue transglutaminase is not increased during apoptosis of HT-1080 human fibrosarcoma cells.
Transfection of tissue transglutaminase into a highly malignant hamster fibrosarcoma leads to a reduced incidence of primary tumour growth.
Filariasis
Molecular characterization of a Brugia malayi transglutaminase.
Foot Ulcer
Factor XIII Val34Leu polymorphism is associated with increased factor XIII activation and decreased transcutaneous oxygen readings in patients with diabetic foot ulcers.
[Factor XIII: experimental and clinical results in diabetic foot ulcer]
Foramen Ovale, Patent
Factor XIII Val34Leu polymorphism and ischaemic stroke in patients with patent foramen ovale.
Gallbladder Neoplasms
Study of tumor transglutaminase 2 expression in gallbladder cancer - Is it a novel predictor of survival?
Transglutaminase 2 Mediates the Cytotoxicity of Resveratrol in a Human Cholangiocarcinoma and Gallbladder Cancer Cell Lines.
Gastritis
Erosive hemorrhagic gastroduodenitis with fibrinolysis and low factor XIII.
Iron deficiency, Helicobacter infection and gastritis.
Letter: the coeliac stomach - a significant increase in tissue transglutaminase antibodies is associated with gastritis.
Patients with psoriatic arthritis have an increased number of lymphocytes in the duodenal mucosa in comparison with patients with psoriasis vulgaris.
Shared Genetic Basis for Type 1 Diabetes, Islet Autoantibodies, and Autoantibodies Associated With Other Immune-Mediated Diseases in Families With Type 1 Diabetes.
Gastritis, Atrophic
New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract.
Gastrointestinal Diseases
Autoantibody screen in inflammatory myopathies high prevalence of antibodies to gliadin.
Gut mucosal immunity to tissue transglutaminase in untreated celiac disease and other gastrointestinal disorders.
Serum IgA tissue transglutaminase antibodies in coeliac disease and other gastrointestinal diseases.
The Prevalence of the Celiac Disease in Patients with Dyspepsia: A Systematic Review and Meta-Analysis.
Gastrointestinal Hemorrhage
Factor XIII in chronic inflammatory bowel diseases.
Hemostasis in Crohn's disease: low factor XIII levels in active disease.
Genetic Diseases, Inborn
Factor XIII Deficiency in Children-Clinical Presentation and Outcome.
Ovarian haemorrhage: a rare presentation and diagnostic dilemma in factor XIII deficiency.
Giant Cell Arteritis
Differential behavior of coagulation factor XIII in patients with inflammatory bowel disease and in patients with giant cell arteritis.
Giant Cell Tumor of Bone
Factor XIIIa-immunoreactivity in tumors of the central nervous system.
Giant Cell Tumors
Factor XIIIa-immunoreactivity in tumors of the central nervous system.
Giardiasis
Isolated short stature as a presentation of celiac disease in Saudi children.
Transient elevation of anti-transglutaminase and anti-endomysium antibodies in Giardia infection.
Treatment of giardiasis reverses "active" coeliac disease to "latent" coeliac disease.
Gingival Diseases
Accumulation of cells containing factor XIII subunit a around the foci of intense fibrosis in human epulides.
Gingival Overgrowth
Gingival Crevicular Fluid and Plasma Levels of Transglutaminase-2 and Oxidative Stress Markers in Cylosporin A-Induced Gingival Overgrowth.
Transglutaminase 2 expression is significantly increased in cyclosporine-induced gingival overgrowth.
Transglutaminase 2 May Be Associated with Peri-implant Gingival Overgrowth: Preliminary Assessments.
Glaucoma
Corneal Stiffness and Collagen Cross-Linking Proteins in Glaucoma: Potential for Novel Therapeutic Strategy.
Potential role of tissue transglutaminase in glaucoma filtering surgery.
Glioblastoma
A mechanism for the upregulation of EGF receptor levels in glioblastomas.
Increased endothelial expression of transglutaminase in glioblastomas.
Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas.
The complex role of transglutaminase 2 in glioblastoma proliferation.
Tissue transgluaminase 2 expression in meningiomas.
Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.
Tissue transglutaminase inhibition.
Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Glioma
Activation and de novo synthesis of transglutaminase in cultured glioma cells.
An immunohistochemical study of tissue transglutaminase in gliomas with reference to their cell dying processes.
Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells.
Distribution and activity of transglutaminase in rat brain carcinogenesis and in gliomas.
Effects of chlorpyrifos on transglutaminase activity in differentiating rat C6 glioma cells.
G?(h)/transglutaminase-2 activity is required for maximal activation of adenylylcyclase 8 in human and rat glioma cells.
Intracellular distribution of active and inactive transglutaminase in stimulated cultured C6 glioma cells.
Isolation and characterization of brain-specific transglutaminases from rat.
Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion.
Serotonin--more than a neurotransmitter: transglutaminase-mediated serotonylation of C6 glioma cells and fibronectin.
The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2.
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
The transglutaminase 2 gene is aberrantly hypermethylated in glioma.
Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBP? Signaling.
Glomerulonephritis
Elevated epsilon-(gamma-glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase.
Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease.
Localization of tissue transglutaminase (tTG) in kidney of ICR-derived glomerulonephritis (ICGN) mice.
Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring.
Plasma factor XIII levels in children with renal disease.
Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman--reply.
Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman.
Successful Treatment of IgA Vasculitis Complicated with Bowel Perforation and Crescentic Glomerulonephritis by Combination Therapy of Glucocorticoid, Cyclosporine and Factor XIII Replacement.
The protective role of uteroglobin through the modulation of tissue transglutaminase in the experimental crescentic glomerulonephritis.
Transglutaminase type II is a key element in the regulation of the anti-inflammatory response elicited by apoptotic cell engulfment.
Glomerulonephritis, IGA
Celiac Disease-Type Tissue Transglutaminase Autoantibody Deposits in Kidney Biopsies of Patients with IgA Nephropathy.
Food antigens and Transglutaminase 2 in IgA nephropathy: Molecular links between gut and kidney.
Transglutaminase is essential for IgA nephropathy development acting through IgA receptors.
Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and henoch-Schönlein purpura nephritis.
Glomerulonephritis, Membranous
Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease.
Glomerulosclerosis, Focal Segmental
Increase in extracellular cross-linking by tissue transglutaminase and reduction in expression of MMP-9 contribute differentially to focal segmental glomerulosclerosis in rats.
Glucose Intolerance
Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient.
Gout
Fibrin dissolution in synovial fluid.
Graft vs Host Disease
Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease.
Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut.
Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel: report of an initial experience.
The role of tissue transglutaminase (transglutaminase type II) for the intestinal manifestations of murine semi-allogenic graft-versus-host disease.
Granular Cell Tumor
Granular cell dermatofibroma.
Granuloma
Involvement of IL-13 and tissue transglutaminase in liver granuloma and fibrosis after schistosoma japonicum infection.
Granuloma Annulare
Granuloma annulare: an immunohistochemical study.
Graves Disease
IgA and IgG antigliadin, IgA anti-tissue transglutaminase and antiendomysial antibodies in patients with autoimmune thyroid diseases and their relationship to thyroidal replacement therapy.
Screening for celiac disease in Tunisian patients with Graves' disease using anti-endomysium and anti-tissue transglutaminase antibodies.
[Prevalence of polyglandular autoimmune syndrome in patients with diabetes mellitus type 1]
Hamartoma
Factor XIIIa in the hamartomas of tuberous sclerosis.
Medallion-like dermal dendrocyte hamartoma: a case misdiagnosed as neurofibroma.
Hammer Toe Syndrome
Claw toes correction and factor XIII deficiency--a case report.
Hand-Foot Syndrome
Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Head and Neck Neoplasms
TGM3, a candidate tumor suppressor gene, contributes to human head and neck cancer.
Heart Arrest
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Heart Defects, Congenital
Dynamics of Factor XIII Levels After Open Heart Surgery for Congenital Heart Defects: Do Cyanotic and Acyanotic Patients Differ?
Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease.
Heart Failure
Genes up-regulated in hypertrophied ventricle.
Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2.
Tissue transglutaminase antibodies in patients with end-stage heart failure.
Tissue transglutaminase in the pathogenesis of heart failure.
Heart Rupture
Does FXIII deficiency impair wound healing after myocardial infarction?
Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction.
Heart Valve Diseases
Concentrations of factor VIII-related antigen and factor XIII during open heart surgery.
Hemangioma
Hemangiopericytoma of the liver: immunohistochemical observations, expression of angiogenic factors, and review of the literature.
Hemangioma, Cavernous
[Fibrinolysis and the level of fibrin stabilizing factor in patients with cavernous hemangiomas of the maxillofacial region]
Hemangiopericytoma
Factor XIIIa-immunoreactivity in tumors of the central nervous system.
Hemangiopericytoma of the cerebello-pontine angle. Diagnostic pitfalls and the diagnostic value of the subunit A of factor XIII as a tumor marker.
Surgical resection of sinonasal hemangiopericytoma involving anterior skull base: Case reports and literature review.
Hemarthrosis
Arthropathy associated with factor XIII deficiency.
Knee hemarthrosis after arthroscopic surgery in an athlete with low factor XIII activity.
Minimal Factor XIII Activity Level to Prevent Major Spontaneous Bleeds: comment.
Hematologic Diseases
[Plasma factor XIII in various hematologic diseases]
Hematoma, Subdural
Spontaneous Acute Subdural Hematoma and Chronic Epidural Hematoma in a Child with F XIII Deficiency.
Spontaneous subdural hematomas particularly with a decreased coagulation factor XIII activity require follow-ups of the neuroradiological diagnostic.
Hematoma, Subdural, Chronic
Impact of low coagulation factor XIII activity in patients with chronic subdural hematoma associated with cerebrospinal fluid hypovolemia: A retrospective study.
Spontaneous chronic subdural hematomas in young adults with a deficiency in coagulation factor XIII. Report of three cases.
Hematuria
Acquired glomerular lesions in patients with Down syndrome.
Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction.
Hemochromatosis
Clinical implications of gene polymorphisms in venous leg ulcer: a model in tissue injury and reparative process.
Hemophilia A
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Acquired haemophilia A and concomitant factor XIII consumption.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Arthropathy associated with factor XIII deficiency.
Clinical audit of inherited bleeding disorders in a developing country.
Congenital hemorrhagic disorders in Jordan.
Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.
Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin ?-chain crosslinking.
Factor XIII in the treatment of hemophilia A.
Glanzmann's thrombasthenia in a Melanesian.
Hemophiliacs--a picture from a developing country: Karnataka, a south Indian state.
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia.
Mechanistic rationale for factor XIII cotreatment in haemophilia.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection.
Prophylaxis in rare coagulation disorders -- factor XIII deficiency.
Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection.
Treatment of refractory hemorrhage with factor XIII in a patient with hemophilia A with inhibitor.
Viral markers and use of factor products among Finnish patients with bleeding disorders.
[Intracranial hematoma accompanying bleeding tendency: therapeutic practice and analysis of literature]
Hemophilia B
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Clinical audit of inherited bleeding disorders in a developing country.
Congenital hemorrhagic disorders in Jordan.
Hemophiliacs--a picture from a developing country: Karnataka, a south Indian state.
Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection.
Surgical wound healing in bleeding disorders.
Hemorrhagic Disorders
A case of congenital factor XIII deficiency.
A Unique Factor XIII Mutation in Southeastern Iran with an Unexpectedly High Prevalence: Khash Factor XIII.
Agreement between factor XIII activity and antigen assays in measurement of factor XIII: A French multicenter study of 147 human plasma samples.
Choroid Plexus Papilloma and Factor XIII Deficiency: Case Report.
Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency.
Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature.
Congenital hemorrhagic diathesis with deficiency of factor XIII. A case report and a family study.
ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group.
Factor XIII.
Guidelines for laboratory diagnosis of factor XIII deficiency.
Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenström's macroglobulinemia.
Identification of a Novel Mutation Combination in Factor XIII Deficiency: Genetic Update to the First Reported Case in the United States.
Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®.
Neutralizing autoantibody against factor XIII A subunit resulted in severe bleeding diathesis with a fatal outcome - characterization of the antibody.
Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency.
[3 operated cases of congenital deficiency of Factor XIII associated with intracranial hematomas]
[Congenital factor XIII deficiency in pregnancy. A case report]
[Congenital factor XIII deficiency required high-dose factor XIII concentrate in late pregnancy]
[The significance of changes in the functional properties of blood platelets, factor XIII activity and fibrin clot quality in the pathogenesis of hemorrhagic diathesis secondary to experimental vitamin C deficiency]
Hemorrhagic Stroke
Hematology-neurology connection: Association between Factor XIII and hemorrhagic stroke in young women through genetic polymorphism.
Mass spectrometric phenotyping of Val34Leu polymorphism of blood coagulation factor XIII by differential peptide display.
Novel Factor XIII variant identified through whole-genome sequencing in a child with intracranial hemorrhage.
Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women.
Hemostatic Disorders
[Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)]
Hepatitis
A rare case of Addison's disease, hepatitis, thyreoiditis, positive IgG anti-tissue transglutaminase antibodies and partial IgA deficiency.
Factor XIII Val34Leu mutation and liver fibrosis rate in viral hepatitis.
High levels of immunoglobulin A anti-tissue transglutaminase antibodies at diagnosis are a predictive factor for celiac hepatitis.
Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.
Intracerebral haemorrhage due to acquired factor XIII inhibitor--successful response to factor XIII concentrate.
Hepatitis A
The regulatory actions of retinoic acid on M2 polarization of porcine macrophages.
Hepatitis B
Hepatitis B surface antigen binds to human serum albumin cross-linked by transglutaminase.
Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.
Plasma derivatives and viral hepatitis.
Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma.
[Impact of small molecules on intermolecular interactions underlying the ligand technologies in laboratory diagnosis]
[Inactivation of viruses in Factor XIII concentrate by pasteurization]
Hepatitis B, Chronic
Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C.
Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease.
The prevalence of celiac autoantibodies in hepatitis patients.
Hepatitis C
Celiac sprue: another autoimmune syndrome associated with hepatitis C.
Post-translational modification of the hepatitis C virus core protein by tissue transglutaminase.
[Factor XIII and hepatitis C virus infection]
Hepatitis C, Chronic
Celiac disease and non-organ-specific autoantibodies in patients with chronic hepatitis C virus infection.
Development of anti-factor XIII antibodies in a patient with hereditary factor XIII deficiency receiving therapy for chronic hepatitis C.
Pharmaceutical approval update.
Hepatitis, Autoimmune
High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies.
The prevalence of celiac autoantibodies in hepatitis patients.
Hepatoblastoma
Analysis of catalytic action of transglutaminase induced in human promyelocytic leukemia (HL-60) and human hepatoblastoma (HepG2) cells.
Expression induced by interleukin-6 of tissue-type transglutaminase in human hepatoblastoma HepG2 cells.
Increase caused by interleukin-6 in promoter activity of guinea pig liver transglutaminase gene.
Hepatomegaly
Genetic disorder in carbohydrates metabolism: hereditary fructose intolerance associated with celiac disease.
Hermanski-Pudlak Syndrome
On the retraction of collagen and fibrin induced by normal, defective and modified platelets.
Herpes Simplex
[Inactivation of viruses in Factor XIII concentrate by pasteurization]
Herpes Zoster
Cellular and molecular modification of egg envelope hardening in fertilization.
Herpesviridae Infections
Herpesvirus Infections and Transglutaminase type 2 Antibody Positivity in Childhood: The Generation R Study.
Histiocytoma
A study of factor XIIIa and MAC 387 immunolabeling in normal and pathological skin.
Epithelioid cell histiocytoma of the skin with clonal ALK gene rearrangement resulting in VCL-ALK and SQSTM1-ALK gene fusions.
Epithelioid cell histiocytoma. A report of 10 cases including a new cellular variant.
Histiocytoma cutis: a tumour of dermal dendrocytes (dermal dendrocytoma).
Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi.
Indeterminate cell histiocytosis--a clinicopathological entity with features of both X- and non-X histiocytosis.
Histiocytoma, Benign Fibrous
"Juvenile" xanthogranuloma: an immunophenotypic study with a reappraisal of histogenesis.
A light microscopic and immunohistochemical evaluation of scars.
Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans.
CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Cellular digital fibromas: distinctive CD34-positive lesions that may mimic dermatofibrosarcoma protuberans.
Characterization of factor XIIIa+ dendritic cells in dermatofibroma: Immunohistochemical, electron and immunoelectron microscopical observations.
Cytological alterations in dermal dendrocytes in vitro: evidence for transformation to a non-dendritic phenotype.
D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa.
Dermatofibrosarcoma protuberans--an update.
Dermatofibrosarcoma Protuberans: The Current State of Multidisciplinary Management.
Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Epithelioid cell histiocytoma of the skin with clonal ALK gene rearrangement resulting in VCL-ALK and SQSTM1-ALK gene fusions.
Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa.
Granular cell dermatofibroma.
High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Melanoma associated with a dermatofibroma.
S100A6 expression in fibrohistiocytic lesions.
Small Benign Storiform Fibrous Tumor (Fibrous Histiocytoma) of the Conjunctival Substantia Propria in a Child: Review and Clarification of Biologic Behavior.
Solitary (juvenile) xanthogranuloma: a comprehensive immunohistochemical study emphasizing recently developed markers of histiocytic lineage.
Solitary sclerotic fibroma of skin: a possible link with pleomorphic fibroma with immunophenotypic expression for O13 (CD99) and CD34.
Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Tenosynovial Giant Cell Tumor in the Dermis of the External Auditory Meatus.
Type XVI collagen is expressed in factor XIIIa+ monocyte-derived dermal dendrocytes and constitutes a potential substrate for factor XIIIa.
Ultrastructural localization of factor XIIIa.
Verocay body--prominent cutaneous schwannoma.
When Immunohistochemistry Deceives Us: The Pitfalls of CD34 and Factor XIIIa Stains in Dermatofibroma and Dermatofibrosarcoma Protuberans.
Histiocytoma, Malignant Fibrous
An unusual soft tissue tumor with features of angiomatoid malignant fibrous histiocytoma composed of bimodal CD34 and factor XIIIa positive dendritic cell subsets. CD34 and factor XIIIa in angiomatoid MFH.
Comparative immunohistochemistry of malignant fibrous histiocytoma and sarcomatoid carcinoma of the urinary tract.
Congenital, infiltrating giant-cell angioblastoma. A new entity?
Dermatofibrosarcoma protuberans--an update.
Evaluation of CD68 and other histiocytic antigens in angiomatoid malignant fibrous histiocytoma.
Factor XIIIa and the classic histiocytic markers in malignant fibrous histiocytoma: a comparative immunohistochemical study.
Factor XIIIa-immunoreactivity in tumors of the central nervous system.
High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Histiocyte-like cells expressing factor XIIIa do not belong to the neoplastic cell population in malignant fibrous histiocytoma.
Histiocytosis
Nonlipidized juvenile xanthogranuloma: a histologic and immunohistochemical study.
Histiocytosis, Langerhans-Cell
Histologic and immunohistochemical study comparing xanthoma disseminatum and histiocytosis X.
Nonlipidized juvenile xanthogranuloma: a histologic and immunohistochemical study.
Histiocytosis, Non-Langerhans-Cell
Histologic and immunohistochemical study comparing xanthoma disseminatum and histiocytosis X.
HIV Infections
"Tissue" transglutaminase in AIDS.
Antitissue transglutaminase antibodies in HIV infection and effect of highly active antiretroviral therapy.
Intracerebral haemorrhage due to acquired factor XIII inhibitor--successful response to factor XIII concentrate.
Hodgkin Disease
Characterization of factor XIII containing-macrophages in lymph nodes with Hodgkin's disease.
Factor XIIIa-immunoreactivity in tumors of the central nervous system.
Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease.
Monocyte activation in patients with Hodgkin's disease.
Hookworm Infections
Environmental and lifestyle influences on disorders of the large and small intestine: implications for treatment.
Huntington Disease
'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease.
A nonradioactive dot blot assay for transglutaminase activity.
A Profiling Platform for the Characterization of Transglutaminase 2 (TG2) Inhibitors.
Cell cycle and cell death in disease: past, present and future.
Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease.
Cerebrospinal fluid tissue transglutaminase in vascular dementia.
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.
Déjà vu with a twist: transglutaminases in bioenergetics and transcriptional dysfunction in Huntington's disease.
Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications.
Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.
Impaired mitochondrial function results in increased tissue transglutaminase activity in situ.
Increased levels of gamma-glutamylamines in Huntington disease CSF.
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.
Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain.
N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease.
Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases.
Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.
Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
Protective effects of interrupting the binding of calmodulin to mutant huntingtin.
Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.
TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy.
The end product of transglutaminase crosslinking: simultaneous quantitation of [Nepsilon-(gamma-glutamyl) lysine] and lysine by HPLC-MS3.
The influence of psychotropic drugs on cerebral cell death: female neurovulnerability to antipsychotics.
The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
Therapeutic advances in the management of Huntington's disease.
Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
Tissue transglutaminase is increased in Huntington's disease brain.
Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.
Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
Tissue transglutaminase: a possible role in neurodegenerative diseases.
Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders.
Transglutaminase 6 Is Colocalized and Interacts with Mutant Huntingtin in Huntington Disease Rodent Animal Models.
Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.
Transglutaminase activation in neurodegenerative diseases.
Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease.
Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.
Transglutaminase cross-links in intranuclear inclusions in Huntington disease.
Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation.
Transglutaminase is linked to neurodegenerative diseases.
Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases.
Transglutaminases - possible drug targets in human diseases.
Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential.
Type 2 Transglutaminase, mitochondria and Huntington's disease: menage a trois.
Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
Hydatidiform Mole
Developmental regulation of tissue transglutaminase during human placentation and expression in neoplastic trophoblast.
Hydranencephaly
[Posthemorrhagic hydranencephaly in the fetal period with deficiency of factor XIII (fibrin stabilizing factor)]
Hydrocephalus
[Severe factor XIII-deficiency. Studies on subunits and turnover of the fibrin stabilizing factor (author's transl)]
Hypercholesterolemia
Aspirin resistance.
Hyperglycemia
Celiac crisis presenting with status epilepticus and encephalopathy.
Essential Role of Transglutaminase 2 in Vascular Endothelial Growth Factor-Induced Vascular Leakage in the Retina of Diabetic Mice.
Proinsulin C-peptide prevents hyperglycemia-induced vascular leakage and metastasis of melanoma cells in the lungs of diabetic mice.
Hyperlipidemias
Clinical studies concerning factor XIII; with special reference to hyperlipemia.
Factor XIII, fibronectin and clot lysis in hyperlipidemia.
Genetic variants of the hemostatic system and development of transplant coronary artery disease.
Hyperlipoproteinemia Type II
Clinical studies on plasma fibronectin and factor XIII; with special reference to hyperlipoproteinemia.
Hyperlipoproteinemias
Clinical studies on plasma fibronectin and factor XIII; with special reference to hyperlipoproteinemia.
Hyperpigmentation
Involvement of Transglutaminase-2 in ?-MSH-Induced Melanogenesis in SK-MEL-2 Human Melanoma Cells.
Minocycline hyperpigmentation: model for in situ phagocytic activity of factor XIIIa positive dermal dendrocytes.
Hyperprolactinemia
Prolactin and autoimmunity.
Hypersensitivity
Association of lethal acquired factor XIII deficiency and type 1 diabetes mellitus with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms with high levels of serum thymus and activation-regulated chemokine.
Associations of breastfeeding with childhood autoimmunity, allergies, and overweight: The Environmental Determinants of Diabetes in the Young (TEDDY) study.
Cow's Milk Protein Allergy Causing Persistent Elevation of Antitissue Transglutaminase Antibodies in a Child With Celiac Disease.
Developments in ocular allergy.
Transglutaminase II interacts with rac1, regulates production of reactive oxygen species, expression of snail, secretion of Th2 cytokines and mediates in vitro and in vivo allergic inflammation.
Unusual allergen in a butcher with respiratory symptoms.
Hypersplenism
Splenectomy and partial splenectomy improve hematopoietic stem cell engraftment in hypersplenic mice.
Hypertension
Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Clinical and pathological features of children with Henoch-Schoenlein purpura nephritis: risk factors associated with poor prognosis.
Cystamine slows but not inverses the progression of monocrotaline-induced pulmonary arterial hypertension in rats.
Henoch-Schönlein purpura with intracerebral hemorrhage.
Henoch-Schönlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment.
Heritability of carotid artery atherosclerotic lesions: an ultrasound study in 154 families.
Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase.
Pharmacological treatment for keloids.
Roles of transglutaminases in cardiac and vascular diseases.
Small Artery Remodeling and Erythrocyte Deformability in L-NAME-Induced Hypertension: Role of Transglutaminases.
Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension.
The redox state of transglutaminase 2 controls arterial remodeling.
Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.
Transglutaminase is a Critical Link Between Inflammation and Hypertension.
Hypertension, Pulmonary
Cystamine Treatment Fails to Prevent the Development of Pulmonary Hypertension in Chronic Hypoxic Rats.
Elevated transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice.
Role of hypoxia-induced transglutaminase 2 in pulmonary artery smooth muscle cell proliferation.
Transglutaminase 2 in Pulmonary and Cardiac Tissue Remodeling in Experimental Pulmonary Hypertension.
Transglutaminase 2-mediated serotonylation in pulmonary hypertension.
Hyperthyroidism
Prospective screening for coeliac disease in patients with Graves' hyperthyroidism using anti-gliadin and tissue transglutaminase antibodies.
Hypertriglyceridemia
Clinical studies on plasma fibronectin and factor XIII; with special reference to hyperlipoproteinemia.
Hyperlipoproteinemia, hemostatic variables and thromboatherosclerosis.
Hypertrophy, Right Ventricular
Cystamine Treatment Fails to Prevent the Development of Pulmonary Hypertension in Chronic Hypoxic Rats.
Hypoalbuminemia
"Strongyloides stercoralis infestation in a severely malnourished (SAM) celiac disease child:" A rare case report from Western Rajasthan.
Celiac Disease and Secondary Amyloidosis: A Possible Causal Association?
Celiac Disease as a Rare Cause of Membranous Nephropathy: A Case Report.
Hypocalcemia
Psoriasis in autoimmune polyendocrine syndrome type I: A possible complication or a non-endocrine minor component?
Hypoglycemia
Extrapancreatic action of sulfonylureas: hypoglycemic effects are not dependent on altered insulin binding or inhibition of transglutaminase.
Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient.
Hypogonadism
[Prevalence of polyglandular autoimmune syndrome in patients with diabetes mellitus type 1]
Hypoparathyroidism
Psoriasis in autoimmune polyendocrine syndrome type I: A possible complication or a non-endocrine minor component?
Hypophysitis
[Prevalence of polyglandular autoimmune syndrome in patients with diabetes mellitus type 1]
Hypothyroidism
Frequency of celiac disease in patients with hypothyroidism.
Occurrence of Hypothyroidism, Diabetes Mellitus, and Celiac Disease in Emirati Children with Down's Syndrome.
Polyendocrine syndrome type 3C in a family from Pakistan.
Ichthyosiform Erythroderma, Congenital
Different TGM1 mutation spectra in Italian and Portuguese patients with autosomal recessive congenital ichthyosis: evidence of founder effects in Portugal.
Identification of two novel nonsense mutations in the transglutaminase 1 gene in a Hungarian patient with congenital ichthyosiform erythroderma.
Knocking-in the R142C mutation in transglutaminase 1 disrupts the stratum corneum barrier and postnatal survival of mice.
Novel mutations of TGM1 in a child with congenital ichthyosiform erythroderma.
Strong founder effect for a transglutaminase 1 gene mutation in lamellar ichthyosis and congenital ichthyosiform erythroderma from Norway.
Structural changes in epidermal scale and appendages as indicators of defective TGM1 activity.
The pathogenesis of severe congenital ichthyosis of the neonate.
Ichthyosis
Abnormal transglutaminase 1 expression pattern in a subset of patients with erythrodermic autosomal recessive ichthyosis.
Activation of Molecular Signatures for Antimicrobial and Innate Defense Responses in Skin with Transglutaminase 1 Deficiency.
Autosomal recessive congenital ichthyosis in Sweden and Estonia: clinical, genetic and ultrastructural findings in eighty-three patients.
Bricks and mortar of the epidermal barrier.
Characterization of bovine TGM1 and exclusion as candidate gene for ichthyosis in Chianina.
Clinical and morphological correlations for transglutaminase 1 gene mutations in autosomal recessive congenital ichthyosis.
Comparing histopathology from patients with X-linked recessive ichthyosis and autosomal recessive congenital ichthyosis with transglutaminase 1 mutation: A report from the National Registry for Ichthyosis and Related Skin Disorders.
Development of ichthyosiform skin compensates for defective permeability barrier function in mice lacking transglutaminase 1.
Epidermal transglutaminase in the ichthyoses.
Expression of transglutaminase 5 in normal and pathologic human epidermis.
Human stratum corneum proteomics reveals cross-linking of a broad spectrum of proteins in cornified envelopes.
Identification and functional characterization of a novel transglutaminase 1 gene mutation associated with autosomal recessive congenital ichthyosis.
In vitro and rapid in situ transglutaminase assays for congenital ichthyoses--a comparative study.
Knocking-in the R142C mutation in transglutaminase 1 disrupts the stratum corneum barrier and postnatal survival of mice.
Multiple local and recent founder effects of TGM1 in Spanish families.
Mutations in transglutaminase 1 gene in autosomal recessive congenital ichthyosis in Egyptian families.
Novel mutations of the transglutaminase 1 gene in lamellar ichthyosis.
Novel transglutaminase 1 mutations in patients affected by lamellar ichthyosis.
Proteomic Analysis of Loricrin Knockout Mouse Epidermis.
The clinical spectrum of congenital ichthyosis in Sweden: a review of 127 cases.
Transglutaminase 1 deficiency and corneocyte collapse: an indication for targeted molecular screening in autosomal recessive congenital ichthyosis.
Transglutaminase 1 mutations in autosomal recessive congenital ichthyosis: private and recurrent mutations in an isolated population.
Transglutaminase 1 Replacement Therapy Successfully Mitigates the Autosomal Recessive Congenital Ichthyosis Phenotype in Full-Thickness Skin Disease Equivalents.
Transglutaminase 1-deficient recessive lamellar ichthyosis associated with a LINE-1 insertion in Jack Russell terrier dogs.
Type I transglutaminase accumulation in the endoplasmic reticulum may be an underlying cause of autosomal recessive congenital ichthyosis.
Updated molecular genetics and pathogenesis of ichthiyoses.
Visual detection of single-base mismatches in DNA using hairpin oligonucleotide with double-target DNA binding sequences and gold nanoparticles.
Ichthyosis Vulgaris
Expression of transglutaminase 5 in normal and pathologic human epidermis.
Ichthyosis, Lamellar
A Japanese patient with a mild form of lamellar ichthyosis harbouring two missense mutations in the core domain of the transglutaminase 1 gene.
A longitudinal study of a harlequin infant presenting clinically as non-bullous congenital ichthyosiform erythroderma.
A novel function for transglutaminase 1: attachment of long-chain omega-hydroxyceramides to involucrin by ester bond formation.
A novel homozygous mutation 371delA in TGM1 leads to a classic lamellar ichthyosis phenotype.
A novel in situ method for the detection of deficient transglutaminase activity in the skin.
A three-dimensional model of the human transglutaminase 1: insights into the understanding of lamellar ichthyosis.
Abnormal transglutaminase 1 expression pattern in a subset of patients with erythrodermic autosomal recessive ichthyosis.
Absent transglutaminase TGK expression in two of three patients with lamellar ichthyosis.
al mena: a comprehensive resource of human genetic variants integrating genomes and exomes from Arab, Middle Eastern and North African populations.
Altered expression of immunoreactive involucrin in lamellar ichthyosis.
Analyses of the transglutaminase 1 gene mutation and ultrastructural characteristics in a Japanese patient with lamellar ichthyosis.
Analysis of the cornified cell envelope in lamellar ichthyosis.
Assays for transglutaminases in cell death.
Autosomal recessive lamellar ichthyosis: identification of a new mutation in transglutaminase 1 and evidence for genetic heterogeneity.
Biochemical, structural, and transglutaminase substrate properties of human loricrin, the major epidermal cornified cell envelope protein.
Cholesterol 3-sulfate interferes with cornified envelope assembly by diverting transglutaminase 1 activity from the formation of cross-links and esters to the hydrolysis of glutamine.
Clinical and morphological correlations for transglutaminase 1 gene mutations in autosomal recessive congenital ichthyosis.
Consequences of seven novel mutations on the expression and structure of keratinocyte transglutaminase.
Cross-linked envelopes in nail plate in lamellar ichthyosis.
Cuticle cell defects in lamellar ichthyosis hair and anomalous hair shaft syndromes visualized after detergent extraction.
Defective stratum corneum and early neonatal death in mice lacking the gene for transglutaminase 1 (keratinocyte transglutaminase).
Different TGM1 mutation spectra in Italian and Portuguese patients with autosomal recessive congenital ichthyosis: evidence of founder effects in Portugal.
Direct cutaneous gene delivery in a human genetic skin disease.
Expression of transglutaminase 1 (transglutaminase K) in harlequin ichthyosis.
Expression of transglutaminase 5 in normal and pathologic human epidermis.
Genetic and immunohistochemical detection of mutations inactivating the keratinocyte transglutaminase in patients with lamellar ichthyosis.
Genotype/phenotype correlation in autosomal recessive lamellar ichthyosis.
Haplotype association and mutation analysis of the transglutaminase 1 gene for prenatal exclusion of lamellar ichthyosis.
Identification and clinical consequences of a novel mutation in the gene for transglutaminase 1 in a patient with lamellar ichthyosis.
Identification of mutations in the transglutaminase 1 gene in lamellar ichthyosis.
Immunoelectron microscopy links molecules and morphology in the studies of keratinization.
Inability of keratinocytes lacking their specific transglutaminase to form cross-linked envelopes: absence of envelopes as a simple diagnostic test for lamellar ichthyosis.
Knocking-in the R142C mutation in transglutaminase 1 disrupts the stratum corneum barrier and postnatal survival of mice.
Lamellar ichthyosis associated with pseudoainhum of the toes and eye changes.
Lamellar ichthyosis is genetically heterogeneous--cases with normal keratinocyte transglutaminase.
Lamellar ichthyosis with pseudoexon activation in the transglutaminase 1 gene.
Lamellar ichthyosis: response to etretinate with transglutaminase 1 recovery.
Long-term faithful recapitulation of transglutaminase 1-deficient lamellar ichthyosis in a skin-humanized mouse model, and insights from proteomic studies.
Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis.
Mutations of keratinocyte transglutaminase in lamellar ichthyosis.
New mutations in the transglutaminase 1 gene in three families with lamellar ichthyosis.
Novel mutations of TGM1 in a child with congenital ichthyosiform erythroderma.
Novel mutations of the transglutaminase 1 gene in lamellar ichthyosis.
Novel transglutaminase 1 gene mutations (R348X/Y365D) in a Japanese family with lamellar ichthyosis.
Novel transglutaminase 1 mutations in a Chinese patient with severe lamellar ichthyosis phenotype.
Novel transglutaminase 1 mutations in patients affected by lamellar ichthyosis.
Prenatal diagnosis of lamellar ichthyosis by direct mutational analysis of the keratinocyte transglutaminase gene.
Prenatal exclusion of lamellar ichthyosis based on identification of two new mutations in the transglutaminase 1 gene.
Role of Sp1 response element in transcription of the human transglutaminase 1 gene.
Strong founder effect for a transglutaminase 1 gene mutation in lamellar ichthyosis and congenital ichthyosiform erythroderma from Norway.
Structural changes in epidermal scale and appendages as indicators of defective TGM1 activity.
The clinical spectrum of congenital ichthyosis in Sweden: a review of 127 cases.
The eta isoform of protein kinase C mediates transcriptional activation of the human transglutaminase 1 gene.
The genetics of human skin diseases.
The South African "bathing suit ichthyosis" is a form of lamellar ichthyosis caused by a homozygous missense mutation, p.R315L, in transglutaminase 1.
Three novel point mutations in the keratinocyte transglutaminase (TGK) gene in lamellar ichthyosis: significance for mutant transcript level, TGK immunodetection and activity.
Transglutaminase 1 delivery to lamellar ichthyosis keratinocytes.
Transglutaminase 1 expression in a patient with features of harlequin ichthyosis: case report.
Transglutaminase 1 gene mutations in Italian patients with autosomal recessive lamellar ichthyosis.
Transglutaminase 1 mutations in lamellar ichthyosis. Loss of activity due to failure of activation by proteolytic processing.
Transglutaminase 1-deficient recessive lamellar ichthyosis associated with a LINE-1 insertion in Jack Russell terrier dogs.
Transglutaminase diseases: from biochemistry to the bedside.
Idiopathic Pulmonary Fibrosis
Transglutaminase 2 and its Role in Pulmonary Fibrosis.
Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors.
IgA Deficiency
A rare case of Addison's disease, hepatitis, thyreoiditis, positive IgG anti-tissue transglutaminase antibodies and partial IgA deficiency.
AGA Clinical Practice Update on the Evaluation and Management of Seronegative Enteropathies.
CD69 expression on alpha-gliadin-specific T cells in coeliac disease.
Celiac disease in Tunisian children: a second screening study using a "new generation" rapid test.
Clinical presentation of celiac disease and the diagnostic accuracy of serologic markers in children.
Comparison of tissue transglutaminase-specific antibody assays with established antibody measurements for coeliac disease.
Diagnostic accuracy of IgA anti-tissue transglutaminase antibody assays in celiac disease patients with selective IgA deficiency.
Elevation of IgG antibodies against tissue transglutaminase as a diagnostic tool for coeliac disease in selective IgA deficiency.
High density of intraepithelial gammadelta lymphocytes and deposits of immunoglobulin (Ig)M anti-tissue transglutaminase antibodies in the jejunum of coeliac patients with IgA deficiency.
Human tissue transglutaminase enzyme linked immunosorbent assay outperforms both the guinea pig based tissue transglutaminase assay and anti-endomysium antibodies when screening for coeliac disease.
IgA-antitissue transglutaminase: validation of a commercial assay for diagnosing coeliac disease.
IgG(1) antiendomysium and IgG antitissue transglutaminase (anti-tTG) antibodies in coeliac patients with selective IgA deficiency. Working Groups on Celiac Disease of SIGEP and Club del Tenue.
Prevalence and Natural History of Potential Celiac Disease in At-Family-Risk Infants Prospectively Investigated from Birth.
Prevalence of Celiac disease in Turkish children with type 1 diabetes mellitus and their non-diabetic first-degree relatives.
Serologic and Genetic Markers of Celiac Disease: A Sequential Study in the Screening of First Degree Relatives.
Serologic testing for celiac disease in young people with elevated transaminases.
Testing for IgG class antibodies in celiac disease patients with selective IgA deficiency. A comparison of the diagnostic accuracy of 9 IgG anti-tissue transglutaminase, 1 IgG anti-gliadin and 1 IgG anti-deaminated gliadin peptide antibody assays.
The prevalence of celiac disease in children and adolescents in Germany.
The prevalence of coeliac disease in Libyan children with type 1 diabetes mellitus.
Tissue transglutaminase antibody levels predict IgA deficiency.
Undetectable anti-tissue transglutaminase IgA antibody measured with EliA Celikey indicates selective IgA deficiency.
Use of low concentrations of human IgA anti-tissue transglutaminase to rule out selective IgA deficiency in patients with suspected celiac disease.
IgA Vasculitis
Atypical tumour-like involvement of the colon in Henoch-Schonlein purpura successfully treated with the administration of factor XIII.
Decreased factor XIII activity during severe Henoch-Schoenlein purpura -- does it play a role?
Factor XIII as a potential predictor of severe gastrointestinal involvement in Henoch Schoenlein purpura: A case study research.
Severe gastrointestinal vasculitis in Henoch-Schoenlein purpura: pathophysiologic mechanisms, the diagnostic value of factor XIII, and therapeutic options.
Successful Treatment of IgA Vasculitis Complicated with Bowel Perforation and Crescentic Glomerulonephritis by Combination Therapy of Glucocorticoid, Cyclosporine and Factor XIII Replacement.
Successful treatment of severe gastrointestinal manifestations of Henoch-Schonlein Purpura and factor XIII deficiency using cryoprecipitate transfusion.
Successful use of recombinant factor VIIa in a child with Schoenlein-Henoch purpura presenting with compartment syndrome and severe factor XIII deficiency.
von Willebrand factor and factor XIII in children with Henoch-Schonlein purpura.
[Factor XIII substitution in Henoch-Schoenlein purpura with severe gastro-intestinal symptoms]
[Stenosing ureteritis and factor XIII deficiency in anaphylactoid purpura]
Immune System Diseases
Intraepithelial lymphocytes in celiac disease immunopathology.
Immunoproliferative Small Intestinal Disease
Low serum transglutaminase in patients with intestinal lymphoma and alpha-chain disease.
Infant, Newborn, Diseases
Studies on the ontogeny and significance in neonatal disease of the fibrinolysin system and of fibrin stabilizing factor.
Infarction, Middle Cerebral Artery
Increased expression of tissue-type transglutaminase following middle cerebral artery occlusion in rats.
Infections
A Cell Proliferation and Inflammatory Signature Is Induced by Lawsonia intracellularis Infection in Swine.
A prawn transglutaminase: Molecular characterization and biochemical properties.
Altered growth and differentiation of cultured mouse epidermal cells infected with oncogenic retrovirus: contrasting effects of viruses and chemicals.
Analysis of Litopenaeus vannamei hemocyanin interacting proteins reveals its role in hemolymph clotting.
AP-1/Fos-TGase2 axis mediates wounding-induced Plasmodium falciparum killing in Anopheles gambiae.
CD1a and factor XIIIa immunohistochemistry in leprosy: a possible role of dendritic cells in the pathogenesis of Mycobacterium leprae infection.
cDNA cloning, identification, tissue localisation, and transcription profile of a transglutaminase from white shrimp, Litopenaeus vannamei, after infection by Vibrio alginolyticus.
Contribution of tissue transglutaminase to the severity of hepatic fibrosis resulting from Schistosoma japonicum infection through the regulation of IL-33/ST2 expression.
Ehrlichia chaffeensis and E. sennetsu, but not the human granulocytic ehrlichiosis agent, colocalize with transferrin receptor and up-regulate transferrin receptor mRNA by activating iron-responsive protein 1.
Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis.
Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control.
Factor XIIIa expression in granulomatous lesions due to sarcoidosis or mycobacterial infection.
Fibroblastic reticular cell infection by hemorrhagic fever viruses.
Functional and Structural Characterization of the Antiphagocytic Properties of a Novel Transglutaminase from Streptococcus suis.
Gene expression in the chicken caecum in response to infections with non-typhoid Salmonella.
Gene expression profiling in Salmonella Choleraesuis-infected porcine lung using a long oligonucleotide microarray.
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Identification and cloning of a transglutaminase from giant freshwater prawn, Macrobrachium rosenbergii, and its transcription during pathogen infection and moulting.
Identification and cloning of the second type transglutaminase from Litopenaeus vannamei, and its transcription following pathogen infection and in relation to the haemolymph coagulation.
Identification of genes expressed in response to yellow head virus infection in the black tiger shrimp, Penaeus monodon, by suppression subtractive hybridization.
Increase of a calcium independent transglutaminase activity in the erythrocyte during the infection with Plasmodium falciparum.
Involvement of IL-13 and tissue transglutaminase in liver granuloma and fibrosis after schistosoma japonicum infection.
Local activation of coagulation factor XIII reduces systemic complications and improves the survival of mice after Streptococcus pyogenes M1 skin infection.
Multineuropathy in a patient with HBV infection, polyarteritis nodosa and celiac disease.
Parechovirus Infection in Early Childhood and Association With Subsequent Celiac Disease.
Pharmaceutical approval update.
Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis.
Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman--reply.
Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman.
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Rapid activation of protein tyrosine kinase and phospholipase C-gamma2 and increase in cytosolic free calcium are required by Ehrlichia chaffeensis for internalization and growth in THP-1 cells.
Scientifically advanced solutions for chestnut ink disease.
SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation.
The effect of banana (Musa acuminata) peels hot-water extract on the immunity and resistance of giant freshwater prawn, Macrobrachium rosenbergii via dietary administration for a long term: Activity and gene transcription.
The spindle-shaped cells in cutaneous Kaposi's sarcoma. Histologic simulators include factor XIIIa dermal dendrocytes.
Tissue transglutaminase activity in human gastric mucosa according to Helicobacter pylori infection.
Tissue Transglutaminase Elevates Intraocular Pressure in Mice.
Tissue transglutaminase in HCV infection.
Transglutaminase as a target for novel anti-filarial agents.
Transglutaminase Cross-Linked Gelatin-Alginate-Antibacterial Hydrogel as the Drug Delivery-Coatings for Implant-Related Infections.
Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection.
Treatment of giardiasis reverses "active" coeliac disease to "latent" coeliac disease.
Infertility
Celiac Disease and Gyneco-obstetrics Complications: Can Serum Antibodies Modulate Tissue Transglutaminase Functions and Contribute to Clinical Pattern?
Coeliac disease and reproductive disorders.
Combinations of fibrinolytic gene polymorphisms (plasminogen activator inhibitor type 1 4G/5G, factor XIII Val34Leu and angiotensin-converting enzyme I/D) in women with idiopathic infertility.
Fertility disorder associated with celiac disease in males and females: fact or fiction?
Prevalence of celiac disease in a cohort of women with unexplained infertility.
Requirement for transglutaminase in progesterone-induced decidualization of human endometrial stromal cells.
The role of fibrin matrices and tissue factor in early-term trophoblast proliferation and spreading.
Infertility, Male
The prostate-specific protein, transglutaminase 4 (TG4), is an autoantigen associated with male subfertility.
Transglutaminase 4 as a prostate autoantigen in male subfertility.
Inflammatory Bowel Diseases
Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence.
Anti-tissue transglutaminase in inflammatory bowel diseases: An activity disease-related phenomenon?
Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease.
Beneficial effects of treatment with transglutaminase inhibitor cystamine on the severity of inflammation in a rat model of inflammatory bowel disease.
Celiac Disease: From Pathogenesis to Novel Therapies.
Chronic Diarrhea in Adults: Evaluation and Differential Diagnosis.
Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease.
Differential behavior of coagulation factor XIII in patients with inflammatory bowel disease and in patients with giant cell arteritis.
Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut.
Factor XIII and tissue transglutaminase antibodies in coeliac and inflammatory bowel disease.
Factor XIII in chronic inflammatory bowel diseases.
Factor XIII modulates intestinal epithelial wound healing in vitro.
Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease.
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
How autophagy controls the intestinal epithelial barrier.
Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease.
IgA and IgG tissue transglutaminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis.
Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease.
Mucosal capillary thrombi in rectal biopsies.
Reduced levels of factor XIII in patients with chronic inflammatory bowel disease.
Serum and tissue transglutaminase correlates with the severity of inflammation in induced colitis in the rat.
Serum transglutaminase correlates with endoscopic and histopathologic grading in patients with ulcerative colitis.
Serum transglutaminase in inflammatory bowel diseases.
The association between de novo inflammatory bowel disease and celiac disease.
Transglutaminases in Crohn's disease.
Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease.
[A-subunit, b-subunit and a2b2-complex of coagulation factor XIII in inflammatory bowel disease]
Influenza, Human
[The role of influenza virus hemagglutinin in blood anticoagulation processes]
Insulin Resistance
Coagulation factor XIII and atherothrombosis. A mini-review.
Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography.
Factor XIII-A transglutaminase deficient mice show signs of metabolically healthy obesity on high fat diet.
Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease.
Loss of transglutaminase 2 sensitizes for diet-induced obesity-related inflammation and insulin resistance due to enhanced macrophage c-Src signaling.
Insulinoma
Confirmation and Identification of Biomarkers Implicating Environmental Triggers in the Pathogenesis of Type 1 Diabetes.
Inherent ER stress in pancreatic islet ? cells causes self-recognition by autoreactive T cells in type 1 diabetes.
Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes.
Organ-specific autoimmunity in relation to clinical characteristics in children with long-lasting type 1 diabetes.
Weight gain in early life predicts risk of islet autoimmunity in children with a first-degree relative with type 1 diabetes.
Intellectual Disability
Is Celiac Disease an Etiological Factor in Children with Nonsyndromic Intellectual Disability?
Intestinal Diseases
Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis.
Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects.
Presence of anti-"tissue" transglutaminase antibodies in inflammatory intestinal diseases: an apoptosis-associated event?
[Autoimmune reactions in gastrointestinal diseases]
Intestinal Volvulus
Transglutaminase-catalyzed reaction is important for molting of Onchocerca volvulus third-stage larvae.
Intracranial Aneurysm
Effects of blood coagulation factor XIII on the development of experimental cerebral aneurysms in rats.
Intracranial Hemorrhages
Association between expression of MMP-2 and MMP-9 genes and pathogenesis of intracranial hemorrhage in severe coagulation factor XIII deficiency.
Association of a common polymorphism in the factor XIII gene with venous thrombosis.
Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature.
Blood coagulation findings and the efficacy of factor XIII concentrate in premature infants with intracranial hemorrhages.
Choroid Plexus Papilloma and Factor XIII Deficiency: Case Report.
Congenital factor XIII deficiency caused by two mutations in eight Tunisian families: molecular confirmation of a founder effect.
Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study.
Dental Management of Factor XIII Deficiency Patients: A Case Series.
Expression and CpG island methylation pattern of MMP-2 and MMP-9 genes in patients with congenital factor XIII deficiency and intracranial hemorrhage.
Factor XIII deficiency and intracranial hemorrhages in infancy.
Factor XIII deficiency: a differential diagnosis to be considered in suspected nonaccidental injury presenting with intracranial hemorrhage.
Factor XIII deficiency: report of two cases.
Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.
Intracranial hemorrhage in congenital bleeding disorders.
Intracranial hemorrhage in congenital deficiency of factor XIII.
Intracranial hemorrhage pattern in the patients with factor XIII deficiency.
Intracranial Hemorrhage: A Devastating Outcome of Congenital Bleeding Disorders-Prevalence, Diagnosis, and Management, with a Special Focus on Congenital Factor XIII Deficiency.
New developments in the management of congenital Factor XIII deficiency.
Novel Factor XIII variant identified through whole-genome sequencing in a child with intracranial hemorrhage.
Prevention of postoperative intracerebral hemorrhage with topical recombinant factor XIII in the rat.
Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
Spontaneous Acute Cerebral Hematoma in a Child with Factor XIII Deficiency.
[3 operated cases of congenital deficiency of Factor XIII associated with intracranial hematomas]
[Factor XIII deficiency in a newborn]
Intracranial Hypotension
Evaluation of spontaneous intracranial hypotension: assessment on ICP monitoring and radiological imaging.
Impact of low coagulation factor XIII activity in patients with chronic subdural hematoma associated with cerebrospinal fluid hypovolemia: A retrospective study.
Treatment of spontaneous intracranial hypotension with intravenous Factor XIII administration: initial clinical experience.
Intracranial Thrombosis
Cerebral thrombosis associated with heterozygous factor V Leiden mutation and high lipoprotein(a) level in a girl with factor XIII deficiency.
Iron Deficiencies
Celiac Disease: Ten Things That Every Gastroenterologist Should Know.
Diagnosis and treatment of unexplained anemia with iron deficiency without overt bleeding.
Hemoglobin types, erythrocyte membrane skeleton and plasma iron concentration in calves with poikilocytosis.
Recurrent Fever and Failure to Thrive in an 11-Year-Old Boy.
Iron Overload
DNA-array of gene variants in venous leg ulcers: detection of prognostic indicators.
Irritable Bowel Syndrome
Coeliac disease.
Presence of tissue transglutaminase IgA antibody as a celiac disease marker in a sample of patients with irritable bowel syndrome.
Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis.
The prevalence of celiac disease in patients fulfilling Rome III criteria for irritable bowel syndrome.
Ischemic Stroke
Celiac disease and childhood stroke.
Coagulation factor XIII activation peptide and subunit levels in patients with acute ischaemic stroke: a pilot study.
Coagulation factor XIII B subunit antigen, FXIIIVal34Leu genotype and ischaemic stroke in South Asians.
Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke.
Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women.
Common genetic coagulation variants are not associated with ischemic stroke in a casecontrol study.
Correlation with Platelet Parameters and Genetic Markers of Thrombophilia Panel (Factor II g.20210G>A, Factor V Leiden, MTHFR (C677T, A1298C), PAI-1, ?-Fibrinogen, Factor XIIIA (V34L), Glycoprotein IIIa (L33P)) in Ischemic Strokes.
Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis.
Factor XIII A subunit Val34Leu polymorphism in patients suffering atherothrombotic ischemic stroke.
Factor XIII Val34Leu polymorphism and ischaemic stroke in patients with patent foramen ovale.
Genetic Factors Influencing Coagulation Factor XIII B-Subunit Contribute to Risk of Ischemic Stroke.
Low factor XIII levels after intravenous thrombolysis predict short-term mortality in ischemic stroke patients.
Mass spectrometric phenotyping of Val34Leu polymorphism of blood coagulation factor XIII by differential peptide display.
Predictive value of coagulation factor XIII on bleeding risk in ischemic stroke patients treated with intravenous thrombolysis.
Transglutaminase 2 protects against ischemic stroke.
Joint Diseases
Arthropathy associated with factor XIII deficiency.
[Anti-tissue transglutaminase antibodies in inflammatory and degenerative arthropathies]
Joint Instability
Prevalence of celiac disease in children with joint hypermobility.
Keloid
A study of factor XIIIa and MAC 387 immunolabeling in normal and pathological skin.
Clinical and laboratory features of congenital factor XIII deficiency.
Factor XIIIa-positive dermal dendritic cells in keloids and hypertrophic and mature scars.
Keratosis
An immunohistochemical and histochemical study of cytokeratin, involucrin and transglutaminase in seborrhoeic keratosis.
Keratosis, Actinic
Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin?
Kidney Failure, Chronic
Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis.
Factor XIII and its substrates, fibronectin, fibrinogen, and alpha 2-antiplasmin, in plasma and urine of patients with nephrosis.
Plasma factor XIII levels in children with renal disease.
Kidney Neoplasms
CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer.
Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors.
Leg Ulcer
Factor XIII V34L polymorphism modulates the risk of chronic venous leg ulcer progression and extension.
Factor XIII-mediated inhibition of fibrinolysis and venous leg ulcers.
Possible role of coagulation factor XIII in the pathogenesis of venous leg ulcers.
Prognostic role of factor XIII gene variants in nonhealing venous leg ulcers.
Topical treatment of venous ulcer with fibrin stabilizing factor: experimental investigation of effects on vascular permeability.
Treatment of nonhealing leg ulcers with fibrin-stabilizing factor XIII: a case report.
Leiomyoma
Fibrin stabilizing factor activity of the skin carcinoma.
Roles of plasma proteins in the formation of silicotic nodules in rats.
[Molecular mechanisms of two novel mutations of factor XIII gene resulting in hereditary coagulation deficiency]
Leiomyosarcoma
Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract.
Leishmaniasis, Visceral
Deficiency of fibrin stabilizing factor (FSF) in kala-azar.
Lentigo
Alterations in the epidermal-dermal melanin axis and factor XIIIa melanophages in senile lentigo and ageing skin.
Leprosy
CD1a and factor XIIIa immunohistochemistry in leprosy: a possible role of dendritic cells in the pathogenesis of Mycobacterium leprae infection.
Leukemia
A coagulation factor becomes useful in the study of acute leukemias: studies with blood coagulation factor XIII.
A contribution to the pathology of acquired plasma factor XIII deficiency.
Acquired factor XIII deficiency in a child with pure erythroid leukemia.
Acquired factor XIII deficiency with chronic myelomonocytic leukemia.
Acute megakaryoblastic leukemia with erythrophagocytosis and thrombosis in a dog.
Analysis of catalytic action of transglutaminase induced in human promyelocytic leukemia (HL-60) and human hepatoblastoma (HepG2) cells.
Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2.
Defective fibrin crosslinking in acute leukemia.
Differentiation of U937 myelomonocytic cell line by all-trans retinoic acid and 1,25-dihydroxyvitamin D3: synergistic effects on tissue transglutaminase.
Disturbances of desmofibrinogenesis in pateints suffering from acute myeloblastic leukemia.
Expression of coagulation factor XIII subunit A in acute promyelocytic leukemia.
Expression of tissue transglutaminase in cultured monocytic leukemia (THP-1) cells during differentiation.
Factor XIII Subunit A Immunohistochemical Expression is Associated With Inferior Outcomes in Acute Promyelocytic Leukemia.
Identification of Key mRNAs as Prediction Models for Early Metastasis of Pancreatic Cancer Based on LASSO.
Immunocytochemical detection of factor XIII A--subunit in acute leukemia.
Plasma levels of human granulocytic elastase alpha 1-proteinase inhibitor complex (E-alpha 1-PI) in leukemia.
Regulation of tissue transglutaminase gene expression as a molecular model for retinoid effects on proliferation and differentiation.
Retinoic acid-induced expression of tissue transglutaminase in human promyelocytic leukemia (HL-60) cells.
Retinoic acid-induced gene expression in normal and leukemic myeloid cells.
Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
Tissue transglutaminase contributes to the all-trans retinoic acid induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia.
Tissue transglutaminase, coagulation factor XIII, and the pro-polypeptide of von Willebrand factor are all ligands for the integrins alpha 9beta 1 and alpha 4beta 1.
Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-kB activation.
Transglutaminase II interacts with rac1, regulates production of reactive oxygen species, expression of snail, secretion of Th2 cytokines and mediates in vitro and in vivo allergic inflammation.
[A study of oral mucosal ulcers in leukemia patients (changes in plasma coagulation factor XIII levels]
[Antiplasmin drugs and factor XIII concentrates in the treatment of a patient with acute promyelocytic leukemia (M3)]
[Detection of factor XIII deficiency in acute leukemia with resonance thrombography]
[Etiology of factor XIII, factor V and fibrinogen deficiency in acute leukemias]
[Factor XIII deficiency in adults with acute leukemia: results of a substitution therapy with factor XIII (author's transl)]
[Factor XIII deficiency in various patients with acute leukemia]
[Molecular markers of the oral mucosa damage in patients with leukemia.]
[Substitution with blood coagulation factor XIII concentrates in patients with acute leukemia]
Leukemia, Erythroblastic, Acute
A retinoic acid-inducible mRNA from human erythroleukemia cells encodes a novel tissue transglutaminase homologue.
A third human tissue transglutaminase homologue as a result of alternative gene transcripts.
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
Differential expression of transglutaminase in human erythroleukemia cells in response to retinoic acid.
Dimethyl sulfoxide-induced transglutaminase activity in murine-derived Friend erythroleukemia cells.
Induction and translocation of tissue transglutaminase isoforms increased phosphorylation in retinoic Acid treated erythroleukemia cells.
Induction of erythrocyte protein 4.2 gene expression during differentiation of murine erythroleukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Alterations in ornithine decarboxylase and transglutaminase activities in lymphocytes from untreated patients with chronic lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disialoganglioside GD3 synthase expression recruits membrane transglutaminase 2 during erythroid differentiation of the human chronic myelogenous leukemia K562 cells.
Induction of GD3/?1-adrenergic receptor/transglutaminase 2-mediated erythroid differentiation in chronic myelogenous leukemic K562 cells.
Overexpression of transglutaminase 2 accelerates the erythroid differentiation of human chronic myelogenous leukemia K562 cell line through PI3K/Akt signaling pathway.
Leukemia, Myeloid
Characteristics of cyclic AMP enhancement of retinoic acid induction of increased transglutaminase activity in HL60 cells.
Modulation of transglutaminase activity in mononuclear phagocytes and macrophage-like tumor cell lines by differentiation agents.
Retinoid-regulated expression of BCL-2 and tissue transglutaminase during the differentiation and apoptosis of human myeloid leukemia (HL-60) cells.
Leukemia, Myeloid, Acute
Coagulation factor XIII-A. A flow cytometric intracellular marker in the classification of acute myeloid leukemias.
Disturbances of desmofibrinogenesis in pateints suffering from acute myeloblastic leukemia.
High Expression of AHSP, EPB42, GYPC and HEMGN Predicts Favorable Prognosis in FLT3-ITD-Negative Acute Myeloid Leukemia.
Transglutaminase 2 expression in acute myeloid leukemia: association with adhesion molecule expression and leukemic blast motility.
Leukemia, Myelomonocytic, Chronic
Acquired factor XIII deficiency with chronic myelomonocytic leukemia.
Leukemia, Promyelocytic, Acute
Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2.
Expression of coagulation factor XIII subunit A in acute promyelocytic leukemia.
Factor XIII Subunit A Immunohistochemical Expression is Associated With Inferior Outcomes in Acute Promyelocytic Leukemia.
Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.
Tissue transglutaminase contributes to the all-trans retinoic acid induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia.
Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-kB activation.
[Antiplasmin drugs and factor XIII concentrates in the treatment of a patient with acute promyelocytic leukemia (M3)]
Leukoencephalopathies
The effect of the Val34Leu polymorphism in the factor XIII gene in infants with a birth weight below 1500 g.
Leukoplakia
Differential expression of the keratin-4, -13, -14, -17 and transglutaminase 3 genes during the development of oral squamous cell carcinoma from leukoplakia.
The hamster cheek pouch carcinogenesis model.
Leukoplakia, Oral
Transglutaminase 3 contributes to malignant transformation of oral leukoplakia to cancer.
Lichen Planus
Abnormal Bcl-2 and "tissue" transglutaminase expression in psoriatic skin.
Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease.
Lymphocyte and macrophage subsets in active and inactive lesions of lichen planus.
Reduced expression of programmed cell death 1 and programmed cell death ligand 1 in infiltrating inflammatory cells of lichen planus without administration of immune checkpoint inhibitors.
Lichen Planus, Oral
Ectopic transglutaminase 1 and 3 expression accelerating keratinization in oral lichen planus.
Liver Cirrhosis
A contribution to the pathology of acquired plasma factor XIII deficiency.
Aryl hydrocarbon receptor knockout mice (AHR-/-) exhibit liver retinoid accumulation and reduced retinoic acid metabolism.
Chronic liver injury drives non-traditional intrahepatic fibrin(ogen) crosslinking via tissue transglutaminase.
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease.
Contribution of tissue transglutaminase to the severity of hepatic fibrosis resulting from Schistosoma japonicum infection through the regulation of IL-33/ST2 expression.
Cystamine ameliorates liver fibrosis induced by carbon tetrachloride via inhibition of tissue transglutaminase.
Effects of Fructus Piperis Longi extract on fibrotic liver of gamma-irradiated rats.
Expression of cytosolic and membrane associated tissue transglutaminase in rat hepatic stellate cells and its upregulation during transdifferentiation to myofibroblasts in culture.
Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C.
Factor XIII Val34Leu mutation and liver fibrosis rate in viral hepatitis.
False positive reactions for IgA and IgG anti-tissue transglutaminase antibodies in liver cirrhosis are common and method-dependent.
Fibrin stabilization, factor XIII transamidase activity and subunits "A" and "B" concentration in plasma of patients with liver cirrhosis.
Fibrin stabilizing factor (factor XIII) activity in liver cirrhosis.
Garlic extract attenuating rat liver fibrosis by inhibiting TGF-?1.
Garlic extract prevents CCl(4)-induced liver fibrosis in rats: The role of tissue transglutaminase.
Hepatic encephalopathy is linked to alterations of autophagic flux in astrocytes.
Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells: implications for regulation of liver fibrosis.
Positive Feedback Regulation between Transglutaminase 2 and Toll-Like Receptor 4 Signaling in Hepatic Stellate Cells Correlates with Liver Fibrosis Post
Reversal of liver fibrosis in aryl hydrocarbon receptor null mice by dietary vitamin A depletion.
Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with liver cirrhosis.
Structure of fibrin and fibrinmonomer in renal and hepatic failure.
Targeted delivery of a novel group of site-directed transglutaminase inhibitors to the liver using liposomes: a new approach for the potential treatment of liver fibrosis.
Tissue Transglutaminase Does Not Affect Fibrotic Matrix Stability or Regression of Liver Fibrosis in Mice.
Tissue Transglutaminase-Regulated Transformed Growth Factor-?1 in the Parasite Links Schistosoma japonicum Infection with Liver Fibrosis.
[Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)]
Liver Cirrhosis, Biliary
Celiac disease in autoimmune cholestatic liver disorders.
IgA and IgG tissue transglutaminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis.
Low specificity of anti-tissue transglutaminase antibodies in patients with primary biliary cirrhosis.
Prevalence of IgA antibodies to endomysium and tissue transglutaminase in primary biliary cirrhosis.
Primary biliary cirrhosis and autoimmune cholangitis are not associated with coeliac disease in Crete.
[Autoimmune reactions in gastrointestinal diseases]
Liver Diseases
Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?
Celiac disease and non-organ-specific autoantibodies in patients with chronic hepatitis C virus infection.
Celiac disease autoantibodies in severe autoimmune liver disease and the effect of liver transplantation.
Celiac sprue: another autoimmune syndrome associated with hepatitis C.
Chronic Hepatitis Due to Gluten Enteropathy - a Case Report.
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease.
Co-occurrence of IgA antibodies against ethanol metabolites and tissue transglutaminase in alcohol consumers: correlation with proinflammatory cytokines and markers of fibrogenesis.
Coeliac disease and the liver: spectrum of liver histology, serology and treatment response at a tertiary referral centre.
Discordance Between Serology and Histology for Celiac Disease in a Cohort with Coexisting Liver Disorders.
Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease.
High Rate of Positive Anti-Tissue Transglutaminase Antibodies in Chronic Liver Disease.
High rate of positive anti-tissue transglutaminase antibodies in chronic liver disease. Role of liver decompensation and of the antigen source.
Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease.
Involvement of IL-13 and tissue transglutaminase in liver granuloma and fibrosis after schistosoma japonicum infection.
Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2.
Prevalence and clinical significance of IgA anti tissue transglutaminase antibodies in patients with chronic liver disease.
Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases.
Primary biliary cirrhosis and autoimmune cholangitis are not associated with coeliac disease in Crete.
Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen.
Regulation of transglutaminase-mediated hepatic cell death in alcoholic steatohepatitis and non-alcoholic steatohepatitis.
Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with liver cirrhosis.
Searching for coeliac disease in patients with non-alcoholic fatty liver disease.
Systematic review: the liver in coeliac disease.
The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury.
Thromboelastometry Identified Alteration of Clot Stabilization and Factor XIII Supplementation Need in a Patient with Decompensated Liver Disease Undergoing Liver Biopsy.
Tissue transglutaminase, a key enzyme involved in liver diseases.
Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver.
[BEHAVIOR OF FIBRIN STABILIZING FACTOR IN LIVER DISEASES.]
[Is the use of factor XIII for delayed wound healing in patients with head-neck tumors of value?]
[Summary of work session 1: Blood coagulation in gastroenterology]
Liver Diseases, Alcoholic
Co-occurrence of IgA antibodies against ethanol metabolites and tissue transglutaminase in alcohol consumers: correlation with proinflammatory cytokines and markers of fibrogenesis.
[Immunohistochemical study of the distribution of collagens (type I, III, IV), fibronectin, factor XIIIa and factor VIII related antigen in alcoholic liver disease]
Liver Failure, Acute
Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease.
Liver Neoplasms
Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma.
Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma.
Liver Neoplasms, Experimental
Differential transglutaminase distribution in normal rat liver and rat hepatoma.
Lung Injury
Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice.
Role of crosslinked protein in lung injury following total body irradiation and bone marrow transplantation.
Lung Neoplasms
Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability.
Association between TGM5, PPAP2B and PSMA4 polymorphisms and NSCLC in never-smoking Chinese population.
Clinical value of exogenous factor XIII for prolonged air leak following pulmonary lobectomy: a case control study.
Dynamics of coagulation factor XIII activity after video-assisted thoracoscopic lobectomy for non-small cell lung cancer.
Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells.
Ethacrynic Acid Inhibits Sphingosylphosphorylcholine-Induced Keratin 8 Phosphorylation and Reorganization via Transglutaminase-2 Inhibition.
Hydrogen peroxide mediates doxorubicin-induced transglutaminase 2 expression in PC-14 human lung cancer cell line.
In vivo transglutaminase type 1 expression in normal lung, preinvasive bronchial lesions, and lung cancer.
Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5.
Nuclear Transglutaminase 2 interacts with topoisomerase II? to promote DNA damage repair in lung cancer cells.
Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients.
Ras association domain family 1C protein stimulates human lung cancer cell proliferation.
Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line.
Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer.
Tissue transglutaminase 2 expression is epigenetically regulated in human lung cancer cells and prevents reactive oxygen species-induced apoptosis.
Transglutaminase 2 activity promotes membrane resealing after mechanical damage in the lung cancer cell line A549.
Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer.
Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer.
Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor.
Transglutaminase 2 Promotes Migration and Invasion of Lung Cancer Cells.
Transglutaminase-2 induces N-cadherin expression in TGF-?1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation.
Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells.
Lupus Erythematosus, Systemic
Adult celiac disease followed by onset of systemic lupus erythematosus.
Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus.
IgA and IgG tissue transglutaminase antibodies in systemic lupus erythematosus.
Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients.
TG or not TG: IgG-anti-tissue transglutaminase in systemic lupus erythematosus: new role for an old enzyme.
Treatment of an acquired Factor XIII inhibitor in an adolescent with systemic lupus erythematosus and renal failure.
[Prognostic value of allelic variants affecting the hemostatic system in the development of antiphospholipid syndrome and kidney lesion in patients with systemic lupus erythematosus].
Lymphadenopathy
Successful factor XIII treatment of refractory chylothorax in tuberous sclerosis complex-associated lymphangioleiomyomatosis, multifocal multinodular pneumocyte hyperplasia and mediastinal lymphadenopathy.
Lymphangioleiomyomatosis
Successful factor XIII administration for persistent chylothorax after lung transplantation for lymphangioleiomyomatosis.
Successful factor XIII treatment of refractory chylothorax in tuberous sclerosis complex-associated lymphangioleiomyomatosis, multifocal multinodular pneumocyte hyperplasia and mediastinal lymphadenopathy.
Lymphocytosis
[An analysis of clinical features of celiac disease patients in different ethnic].
Lymphoma
Acquired Factor XIII inhibitor associated with mantle cell lymphoma.
Calcifying fibrous tumor of the adrenal gland.
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
Epithelioid cell histiocytoma of the skin with clonal ALK gene rearrangement resulting in VCL-ALK and SQSTM1-ALK gene fusions.
Localization of collagen modifying enzymes on fibroblastic reticular cells and follicular dendritic cells in non-neoplastic and neoplastic lymphoid tissues.
Low serum transglutaminase in patients with intestinal lymphoma and alpha-chain disease.
Multiple calcifying fibrous tumors of the pleura.
Pulmonary "inflammatory myofibroblastic" tumors: a critical examination of the diagnostic category based on quantitative immunohistochemical analysis.
TG2 and NF-kB signaling coordinates the survival of mantle cell lymphoma cells via IL-6-mediated autophagy.
Lymphoma, Follicular
Localization of collagen modifying enzymes on fibroblastic reticular cells and follicular dendritic cells in non-neoplastic and neoplastic lymphoid tissues.
Lymphoma, Mantle-Cell
Acquired Factor XIII inhibitor associated with mantle cell lymphoma.
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
TG2 and NF-kB signaling coordinates the survival of mantle cell lymphoma cells via IL-6-mediated autophagy.
Lymphoma, Non-Hodgkin
Granulomatous reaction in mediastinal B-cell non-Hodgkin lymphoma and intracardiac thrombosis.
Tissue transglutaminase autoantibodies in patients with non-Hodgkin's lymphoma. Case reports.
Lymphoma, T-Cell
IgA Antibodies Against Gliadin and Tissue Transglutaminase in Dogs With Chronic Enteritis and Intestinal T-Cell Lymphoma.
Lymphoproliferative Disorders
[Activity of fibrin stabilizing factor (FSF; factor XIII) in lymphoproliferative disorders]
Machado-Joseph Disease
Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases.
Macular Degeneration
Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration.
Malabsorption Syndromes
Current Espghan Guidelines for Celiac Disease in Pediatric Age, Tertiary Care Center Experience: A Proposal for Further Simplification.
[Reproductive disorders in women with celiac disease: effect of etiotropic therapy].
Malaria
CpG-containing oligodeoxynucleotides increases resistance of Anopheles mosquitoes to Plasmodium infection.
Low levels of fibrin-stabilizing factor (factor XIII) in human Plasmodium falciparum malaria: correlation with clinical severity.
Transglutaminase in Plasmodium parasites: activity and putative role in oocysts and blood stages.
Malnutrition
Intestinal Pseudo-Obstruction and Total Villous Atrophy of the Terminal Ileum: An Unusual Presentation of Untreated Celiac Disease.
Reliability of anti-tissue transglutaminase antibodies in children with malnutrition.
Mastocytosis
Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis.
Ultrastructural localization of factor XIIIa.
Measles
[Inactivation of viruses in Factor XIII concentrate by pasteurization]
Melanoma
A light microscopic and immunohistochemical evaluation of scars.
Aloin enhances cisplatin antineoplastic activity in B16-F10 melanoma cells by transglutaminase-induced differentiation.
Antineoplastic activity of strawberry (Fragaria × ananassa Duch.) crude extracts on B16-F10 melanoma cells.
Antitumor properties of aloe-emodin and induction of transglutaminase 2 activity in B16-F10 melanoma cells.
Apoptosis: a potential role for cytosolic transglutaminase and its importance in tumour progression.
Computerized analysis of tumor cells flowing in a parallel plate chamber to determine their adhesion stabilization lag time.
Decrease of polyamine levels and enhancement of transglutaminase activity in selective reduction of B16-F10 melanoma cell proliferation induced by atrial natriuretic peptide.
Differences in the post-translational modification of proteins by polyamines between weakly and highly metastatic B16 melanoma cells.
Enhancement of transglutaminase activity and polyamine depletion in B16-F10 melanoma cells by flavonoids naringenin and hesperitin correlate to reduction of the in vivo metastatic potential.
Evaluation of polyamines as marker of melanoma cell proliferation and differentiation by an improved high-performance liquid chromatographic method.
Expression of tissue-type transglutaminase correlates positively with metastatic properties of human melanoma cell lines.
Factor XIIIa in nodular malignant melanoma and Spitz naevi.
Factor XIIIa-positive dermal dendritic cells and HLA-DR expression in radial versus vertical growth-phase melanomas.
GPR56 inhibits melanoma growth by internalizing and degrading its ligand TG2.
GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.
Heparin interacts with the adhesion GPCR GPR56, reduces receptor shedding, and promotes cell adhesion and motility.
Heterogeneity of peritoneal macrophages in hamsters-bearing transplantable melanomas in relation to their transglutaminase.
Heterogeneity of transplantable melanomas differing in the rate of growth and cellular differentiation in relation to their cell transglutaminase activity.
Hyaluronic acid induces transglutaminase II to enhance cell motility; role of Rac1 and FAK in the induction of transglutaminase II.
Impairment of the metastatic activity of melanoma cells by transglutaminase-catalyzed incorporation of polyamines into laminin and Matrigel.
Implications of tissue transglutaminase expression in malignant melanoma.
In vivo evaluation of type 2 transglutaminase contribution to the metastasis formation in melanoma.
Involvement of Transglutaminase-2 in ?-MSH-Induced Melanogenesis in SK-MEL-2 Human Melanoma Cells.
Melanoma associated with a dermatofibroma.
Melanoma cell adhesion to injured arterioles: mechanisms of stabilized tethering.
Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas.
Presence and maturity of dendritic cells in melanoma lymph node metastases.
Reduction of COX-2 through modulating miR-124/SPHK1 axis contributes to the antimetastatic effect of alpinumisoflavone in melanoma.
Retinoic acid metabolites exhibit biological activity in human keratinocytes, mouse melanoma cells and hairless mouse skin in vivo.
Retinoids increase transglutaminase activity and inhibit ornithine decarboxylase activity in Chinese hamster ovary cells and in melanoma cells stimulated to differentiate.
Role of transglutaminase 2 in quercetin-induced differentiation of B16-F10 murine melanoma cells.
Specific and direct modulation of the interaction between adhesion GPCR GPR56/ADGRG1 and tissue transglutaminase 2 using synthetic ligands.
The genetics of human skin diseases.
Tissue transglutaminase activity protects from cutaneous melanoma metastatic dissemination: an in vivo study.
Transglutaminase stabilizes melanoma adhesion under laminar flow.
Transglutaminase-dependent antiproliferative and differentiative properties of nimesulide on B16-F10 mouse melanoma cells.
Transglutaminase-mediated oligomerization of galectin-3 modulates human melanoma cell interactions with laminin.
Melanoma, Amelanotic
Heterogeneity of transplantable melanomas differing in the rate of growth and cellular differentiation in relation to their cell transglutaminase activity.
Meningeal Neoplasms
Factor XIIIa-immunoreactivity in tumors of the central nervous system.
Meningioma
Thioredoxin-Interact ing-Pro t e in [TXNIP] and Transglutaminase 2 [TGM2] Expression in Meningiomas of Different Grades and the Role of Their Expression in Meningioma Recurrence and Prognosis
Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma.
Transglutaminase activity in human brain tumors.
Meningitis
[Intradural hematoma of the foramen magnum associated with factor XIII deficiency]
Menorrhagia
Pubertal Menorrhagia - A Rare Presentation of Congenital Factor XIII Deficiency.
Mesothelioma
Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.
Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation.
Mesothelioma, Malignant
Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.
Microphthalmos
Multiple myxoid cellular neurothekeomas in a patient with systemic lupus erythematosus.
Reticulohistiocytoma (solitary epithelioid histiocytoma): a clinicopathologic and immunohistochemical study of 44 cases.
Microvascular Angina
Factor XIII Val34Leu polymorphism in patients with Cardiac Syndrome X.
Migraine Disorders
Increased risk for coeliac disease in paediatric patients with migraine.
Is Celiac Disease an Etiological Factor in Children With Migraine?
Migraine and genetic polymorphisms: an overview.
Role of factor XIII Val 34 Leu polymorphism in patients with migraine.
Milk Hypersensitivity
Cow's Milk Protein Allergy Causing Persistent Elevation of Antitissue Transglutaminase Antibodies in a Child With Celiac Disease.
Mitochondrial Diseases
Tissue transglutaminase (TG2) and mitochondrial function and dysfunction.
Monoclonal Gammopathy of Undetermined Significance
Acquired factor XIII inhibitor in monoclonal gammopathy of undetermined significance: characterization and cross-linked fibrin ultrastructure.
Mouth Neoplasms
Increased risk for oral cancer is associated with coagulation factor XIII but not with factor XII.
The expression of transglutaminase 2 (TG-2) in oral squamous cell carcinoma and its clinical significance.
Mucolipidoses
Secretion of the lysosomal acid triacylglycerol hydrolase precursor by J774 macrophages.
Multiple Myeloma
Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma.
Incomplete fibrin formation and highly elevated Factor XIII activity in multiple myeloma.
Multiple Sclerosis
Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system.
Appearance of Tissue Transglutaminase in Astrocytes in Multiple Sclerosis Lesions: A Role in Cell Adhesion and Migration?
Association of celiac disease in patients with multiple sclerosis in Tuscany.
Astrocyte loss and astrogliosis in neuroinflammatory disorders.
Celiac disease and multiple sclerosis in the northwest of Iran.
Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
Correction: Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients.
Gluten sensitivity in multiple sclerosis: experimental myth or clinical truth?
Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?
Multiple sclerosis and celiac disease: is there an increased risk?
Neuronal and Endothelial Transglutaminase-2 Expression during Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Pathogenesis of autoimmune diseases: antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease.
Tissue Transglutaminase Appears in Monocytes and Macrophages but Not in Lymphocytes in White Matter Multiple Sclerosis Lesions.
Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration.
Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis.
Tissue transglutaminase in marmoset experimental multiple sclerosis: discrepancy between white and grey matter.
Transglutaminase 2 is involved in homocysteine-induced activation of human THP-1 monocytes.
Multiple Sclerosis, Chronic Progressive
Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients.
Mumps
[Inactivation of viruses in Factor XIII concentrate by pasteurization]
Muscle Weakness
Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy.
Muscular Atrophy
Modulation of transglutaminase expression in rat skeletal muscle by induction of atrophy and endurance training.
Muscular Dystrophies
Serum protein profiling in mice: identification of Factor XIIIa as a potential biomarker for muscular dystrophy.
Myasthenia Gravis
Removal Characteristics of Immunoadsorption with the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis.
Mycoplasma Infections
Idiopathic testicular infarction in a boy initially suspected to have acute epididymo-orchitis associated with mycoplasma infection and Henoch-Schönlein purpura.
Mycosis Fungoides
Cutaneous expression of Thy-1 in mycosis fungoides.
Distinctive dendritic cell subsets expressing factor XIIIa, CD1a, CD1b and CD1c in mycosis fungoides and psoriasis.
Myocardial Infarction
A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction.
An injectable peptide hydrogel with excellent self-healing ability to continuously release salvianolic acid B for myocardial infarction.
Association of a common polymorphism in the factor XIII gene with myocardial infarction.
Association of a common polymorphism in the factor XIII gene with venous thrombosis.
Coagulation factor XIII activity predicts left ventricular remodelling after acute myocardial infarction.
Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography.
Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women.
Coagulation Factor XIII-A Val34Leu Polymorphism and the Risk of Coronary Artery Disease and Myocardial Infarction in a Chinese Han Population.
Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction.
Common polymorphisms and cardiovascular factors in patients with myocardial infarction of Costa Rica.
Decreased factor XIII levels in factor XIII A subunit Leu34 homozygous patients with coronary artery disease.
Does FXIII deficiency impair wound healing after myocardial infarction?
Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.
Effect of factor XIII VAL34LEU polymorphism on thrombolytic therapy in premature myocardial infarction.
Elevated factor XIII level and the risk of myocardial infarction in women.
Epistatic and pleiotropic effects of polymorphisms in the fibrinogen and coagulation factor XIII genes on plasma fibrinogen concentration, fibrin gel structure and risk of myocardial infarction.
F13A1 Gene Variant (V34L) and Residual Circulating FXIIIA Levels Predict Short- and Long-Term Mortality in Acute Myocardial Infarction after Coronary Angioplasty.
Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction.
Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage.
Factor XIII val34leu and the risk of myocardial infarction.
Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis.
Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years.
Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis.
Genetic variants of coagulation factor XIII and the risk of myocardial infarction in young women.
Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction.
Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
Increased coagulation factor XIII activity but not genetic variants of coagulation factors is associated with myocardial infarction in young patients.
Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction.
Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease?
Management of acute myocardial infarction in a patient with factor XIII deficiency using prophylactic factor replacement therapy.
Mass spectrometric phenotyping of Val34Leu polymorphism of blood coagulation factor XIII by differential peptide display.
Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population.
MR in mouse models of cardiac disease.
Myocardial infarctions and other acute coronary syndromes in rare congenital bleeding disorders: a critical analysis of all reported cases.
No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.
Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis.
Reduction of coagulation factor XIII concentration in patients with myocardial infarction, cerebral infarction, and other thromboembolic disorders.
Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction.
Role of factor XIII Val34Leu polymorphism in retinal artery occlusion.
Significance of tissue transglutaminase in myocardial fibrosis after myocardial infarction in rats.
Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction.
The Association Between Factor XIII Val34Leu Polymorphism and Early Myocardial Infarction.
Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P(9) and P(4) positions in factor XIII activation.
Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction.
Two factor XIII gene polymorphisms associated with a structural and functional defect and the risk of myocardial infarction in men.
[Factor XIII Val34Leu polymorphism and premature myocardial infarction]
[Measurement of factor XIII (FSF) as an indicator of thrombosis risk in chronic coronary insufficiency and myocardial infarction]
Myocardial Ischemia
[The effect of quantum hemotherapy on the plasma hemostatic indices and fibrinolysis in patients with unstable angina]
Myocarditis
Celiac disease associated with autoimmune myocarditis.
Myoclonic Epilepsies, Progressive
Selective colocalization of transglutaminase-like activity in ubiquitinated intranuclear inclusions of hereditary dentatorubral-pallidoluysian atrophy.
Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases.
Myositis
Can tissue transglutaminase be a marker of idiopathic inflammatory myopathies?
Celiac disease and antibodies associated with celiac disease in patients with inflammatory myopathy.
Expression of transglutaminase 2 does not differentiate focal myositis from generalized inflammatory myopathies.
Increase in transglutaminase 2 in idiopathic inflammatory myopathies.
Proliferative myositis and fasciitis. Report of five cases with an ultrastructural and immunohistochemical study.
Transglutaminase catalyzes differential crosslinking of small heat shock proteins and amyloid-beta.
Myositis, Inclusion Body
Transglutaminase catalyzes differential crosslinking of small heat shock proteins and amyloid-beta.
Myxoma
Cardiac myxoma immunohistochemistry: value of CD34, CD31, and factor XIIIa staining.
Cardiac myxoma is rich in factor XIIIa positive dendrophages: immunohistochemical study of four cases.
Comparison of angiomyofibroblastoma and aggressive angiomyxoma in both sexes: four cases composed of bimodal CD34 and factor XIIIa positive dendritic cell subsets.
Nasal Polyps
PLA2G5 regulates transglutaminase activity of human IL-4-activated M2 macrophages through PGE2 generation.
Neoplasm Metastasis
A fluorescence anisotropy-based assay for determining the activity of tissue transglutaminase.
Alterations in the distribution and activity of transglutaminase during tumour growth and metastasis.
Coagulation factor XIII in plasma of patients with benign and malignant gynaecological tumours.
Correlation of changes in transglutaminase activity and polyamine content of neoplastic tissue during the metastatic process.
Differences in the post-translational modification of proteins by polyamines between weakly and highly metastatic B16 melanoma cells.
Ethacrynic Acid Inhibits Sphingosylphosphorylcholine-Induced Keratin 8 Phosphorylation and Reorganization via Transglutaminase-2 Inhibition.
Extracellular tissue transglutaminase activates noncanonical NF-?B signaling and promotes metastasis in ovarian cancer.
Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function.
Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking.
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.
In vivo evaluation of type 2 transglutaminase contribution to the metastasis formation in melanoma.
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.
Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas.
Novel participation of transglutaminase-2 through c-Jun N-terminal kinase activation in sphingosylphosphorylcholine-induced keratin reorganization of PANC-1 cells.
Potential role for high and low molecular weight tissue transglutaminases in transforming mammalian cell properties.
Presence and maturity of dendritic cells in melanoma lymph node metastases.
Proinsulin C-peptide prevents hyperglycemia-induced vascular leakage and metastasis of melanoma cells in the lungs of diabetic mice.
Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases.
Reduction in transglutaminase activity associated with tumour metastasis is due to the presence of an inactive form of the enzyme.
Targeting p70S6K Prevented Lung Metastasis in a Breast Cancer Xenograft Model.
The G?h-PLC?1 signaling axis drives metastatic progression in triple-negative breast cancer.
The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205.
The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma.
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer.
Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer.
Tissue transglutaminase expression in human breast cancer.
Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells.
Tissue transglutaminase links TGF-?, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer.
Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells.
Tissue transglutaminase regulates MMP-2 in ovarian cancer by modulating CREB activity.
Tissue transglutaminase-interleukin-6 axis facilitates peritoneal tumor spreading and metastasis of human ovarian cancer cells.
Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells.
Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target.
Transglutaminase II/microRNA-218/-181a loop regulates positive feedback relationship between allergic inflammation and tumor metastasis.
Neoplasms
A case of aortic intimal sarcoma manifested with acutely occurring hypertension and aortic occlusion.
A cooperative polymeric platform for tumor-targeted drug delivery.
A fluorescence anisotropy-based assay for determining the activity of tissue transglutaminase.
A homogeneous fluorescence anisotropy assay for measuring transglutaminase 2 activity.
A new regulatory mechanism of NF-kappaB activation by I-kappaBbeta in cancer cells.
A Novel Chromosomal Translocation Associated With COL1A2-PDGFB Gene Fusion in Dermatofibrosarcoma Protuberans: PDGF Expression as a New Diagnostic Tool.
A novel combined resveratrol/berberine phytochemotheraputic using the HePG2 cell line as a model for the treatment of hepatocarcinoma.
A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival.
A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase.
A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2.
A Rare Case of Atrophic Dermatofibroma Featuring Linear Skin Dimple.
A Rare Case of Factor XIII Deficiency in the Setting of Cancer Immunotherapy.
A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.
A small molecule regulator of tissue transglutaminase conformation inhibits the malignant phenotype of cancer cells.
A study of factor XIIIa and MAC 387 immunolabeling in normal and pathological skin.
A unique role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell migration.
Acitretin treatment in (pre)malignant skin disorders of renal transplant recipients: Histologic and immunohistochemical effects.
Activation of the Ras-ERK pathway inhibits retinoic acid-induced stimulation of tissue transglutaminase expression in NIH3T3 cells.
Acute megakaryoblastic leukemia with erythrophagocytosis and thrombosis in a dog.
Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review).
Acylideneoxoindoles: A new class of reversible inhibitors of human transglutaminase 2.
Advances of Coagulation Factor XIII.
Alterations in epidermal functions resulting from exposure to initiators and promoters of carcinogenesis.
Alterations in the distribution and activity of transglutaminase during tumour growth and metastasis.
An immunohistochemical study of tissue transglutaminase in gliomas with reference to their cell dying processes.
An unusual soft tissue tumor with features of angiomatoid malignant fibrous histiocytoma composed of bimodal CD34 and factor XIIIa positive dendritic cell subsets. CD34 and factor XIIIa in angiomatoid MFH.
Analysis of differential gene expression caused by cervical intraepithelial neoplasia based on GEO database.
Analysis of epidermal-type transglutaminase (TGase 3) expression in mouse tissues and cell lines.
Analysis of the balance between proliferation and apoptosis of cultured vascular smooth muscle cells for tissue-engineering applications.
Analysis of the vitamin D system in cutaneous malignancies.
Aneurysmal fibrous histiocytoma of the skin. A histological, immunohistochemical, and ultrastructural study.
Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.
Anticancer activity of bovine ??lactalbumin treated with microbial transglutaminase
Apoptosis induction by inhibitors of Ser/Thr phosphatases 1 and 2A is associated with transglutaminase activation in two different human epithelial tumour lines.
Apoptosis: a potential role for cytosolic transglutaminase and its importance in tumour progression.
Arguments against the prostatic origin of the R-3327 Dunning H tumor.
Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor ? light chain enhancer of activated B cells (NF?B) signaling controls basal and DNA damage-induced transglutaminase 2 expression.
Atypical fibrous histiocytoma of the scrotum.
Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells.
Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2.
Benign neural tumors of the oral cavity: a comparative immunohistochemical study.
Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer.
Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model.
Calcifying fibrous tumor of the adrenal gland.
Calcifying fibrous tumor of the gastrointestinal tract: A clinicopathologic review and update.
CAN IMMUNOHISTOCHEMISTRY DISTINGUISH BETWEEN PRIMARY AND METASTATIC HEPATIC CARCINOMA?
Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells.
Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking.
Case of primary malignant hemangiopericytoma of the heart expressing basement membrane-degradable enzymes.
CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis.
CD34-reactive myxoid dermal dendrocytoma.
CD68 and factor XIIIa expressions in granular-cell tumor of the skin.
Cells containing factor XIII subunit a in benign and soft tissue tumours.
Cellular neurothekeoma.
Cellular solitary fibrous tumor (hemangiopericytoma) with anaplasia at cerebellopontine angle-A case report.
Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells.
Characterization of the heparin binding site of tissue transglutaminase: its importance in the enzyme's cell surface targeting, matrix deposition and cell signalling.
Characterization of the transglutaminase-mediated large molecular weight polymer from rat liver; its relationship to apoptosis.
Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
Chemopreventive agents modulate the protein expression profile of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumors in A/J mice.
CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer.
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.
Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients.
Coagulation factor XIII in plasma of patients with benign and malignant gynaecological tumours.
Coagulation Factor XIII-A Subunit Missense Mutation in the Pathobiology of Autosomal Dominant Multiple Dermatofibromas.
Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues.
Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins.
Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Congenital atrophic dermatofibrosarcoma protuberans detected by COL1A1-PDGFB rearrangement.
Congenital factor XIII deficiency with multiple benign breast tumours and successful pregnancy with substitutive therapy. A case report.
Congenital, infiltrating giant-cell angioblastoma. A new entity?
Congenital-infantile fibrosarcoma: a clinicopathological study of five patients entered on the Prague children's tumor registry.
Construction of a pH/TGase "Dual Key"-Responsive Gold Nano-radiosensitizer with Liver Tumor-Targeting Ability.
Correction to: Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Correlation between immunoreactivity for transglutaminase K and for markers of proliferation and differentiation in normal breast tissue and breast carcinomas.
Correlation of changes in transglutaminase activity and polyamine content of neoplastic tissue during the metastatic process.
Cross-linked envelope-related markers for squamous differentiation in human lung cancer cell lines.
Cutaneous clear-cell granular cell tumors: the histologic description of an unusual variant.
Cutaneous sarcomatoid B-cell lymphoma.
Cytological alterations in dermal dendrocytes in vitro: evidence for transformation to a non-dendritic phenotype.
Deep juvenile xanthogranuloma presenting as a chest wall mass: a case report.
Deep penetrating dermatofibroma versus dermatofibrosarcoma protuberans. A clinicopathologic comparison.
Depletion of nucleophosmin via transglutaminase 2 cross-linking increases drug resistance in cancer cells.
Dermatofibroma of the Eyelid: Immunohistochemical Diagnosis.
Dermatofibroma-like granular cell tumor.
Dermatomyofibroma (Plaqueförmige Dermale Fibromatose).
Dermo-epidermal stimulation elicited by a beta-lipohydroxyacid: a comparison with salicylic acid and all-trans-retinoic acid.
Desmoplastic fibroblastoma (collagenous fibroma) of the oral cavity.
Detection of factor XIII-A is a valuable tool for distinguishing dendritic cells and tissue macrophages in granuloma annulare and necrobiosis lipoidica.
Development of an 18F-Labeled Irreversible Inhibitor of Transglutaminase 2 as Radiometric Tool for Quantitative Expression Profiling in Cells and Tissues.
Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase.
Development of magnetic resonance imaging contrast material for in vivo mapping of tissue transglutaminase activity.
Differences in the post-translational modification of proteins by polyamines between weakly and highly metastatic B16 melanoma cells.
Different Protein Expressions between Peripheral Ameloblastoma and Oral Basal Cell Carcinoma Occurred at the Same Mandibular Molar Area.
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.
Differential expression of factor XIIIa and CD34 in cutaneous mesenchymal tumors.
Differential growth of N- and S-type human neuroblastoma cells xenografted into scid mice. correlation with apoptosis.
Differentiation capacity of human non-small-cell lung cancer cell lines after exposure to phorbol ester.
Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
DNA-binding proteins in Yoshida ascites tumor fluid.
Down-regulation of transglutaminase II leads to impaired motility of cancer cells by inactivation of the protein kinase, Akt, and decrease of reactive oxygen species.
Effects of diesel exhaust particles on macrophage polarization.
Effects of exogenous transglutaminase on spreading of human colorectal carcinoma cells.
Effects of nicotinamide on mouse skin tumor development and its mode of action.
Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis.
Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia.
Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase.
Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells.
Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.
Epithelioid cell histiocytoma of the skin with clonal ALK gene rearrangement resulting in VCL-ALK and SQSTM1-ALK gene fusions.
Epithelioid cell histiocytoma with SQSTM1-ALK fusion: a case report.
Ethacrynic Acid Inhibits Sphingosylphosphorylcholine-Induced Keratin 8 Phosphorylation and Reorganization via Transglutaminase-2 Inhibition.
Evaluation and comparison of staining patterns of factor XIIIa (AC-1A1), adipophilin and GATA3 in sebaceous neoplasia.
Evaluation of CD68 and other histiocytic antigens in angiomatoid malignant fibrous histiocytoma.
Evaluation of the efficacy of potential antineoplastic drugs on tumour metastasis by a computer-assisted image analysis.
Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
Examination of oral cancer biomarkers by tissue microarray analysis.
Expression and Activity of Transglutaminase II in Spontaneous Tumours of Dogs and Cats.
Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes.
Expression of the cytosolic and particulate forms of transglutaminase during chemically induced rat liver carcinogenesis.
Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma.
Expression of transglutaminase K in normal cervix tissue and cervix carcinomas.
Expression of transglutaminase-2 isoforms in normal human tissues and cancer cell lines: dysregulation of alternative splicing in cancer.
Expression of transglutaminases in human breast cancer and their possible clinical significance.
Extracellular localization of catalase is associated with the transformed state of malignant cells.
Factor XIII deficiency in BALB/c mice with plasmacytoma.
Factor XIII does not stimulate growth of human cultured tumor cells.
Factor XIII expression in the skin: observations and a hypothesis.
Factor XIII of blood coagulation in human monocytes.
Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding.
Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function.
Factor XIIIa and the classic histiocytic markers in malignant fibrous histiocytoma: a comparative immunohistochemical study.
Factor XIIIa immunoreactivity in primary and secondary tumours of the meninges.
Factor XIIIa in fibrovascular tumors.
Factor XIIIa is expressed by fibroblasts in fibrovascular tumors.
Factor XIIIa-immunoreactivity in tumors of the central nervous system.
Factor XIIIa-positive dendrocytes and proliferative activity of cutaneous cancers.
Fibrin deposition in primary and metastatic human brain tumours.
Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx.
Fibrin stabilizing factor activity of the skin carcinoma.
Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.
Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease.
Fibroblast migration in fibrin gel matrices.
Fibronectin in Layer-by-Layer Assembled Films Switches Tumor Cells between 2D and 3D Morphology.
Fibrous papule: a tumor of fibrohistiocytic cells that contain factor XIIIa.
Follicular lymphoma of the skin and superficial soft tissues associated with a prominent follicular dendritic cell proliferation: an unusual pattern which may represent a diagnostic pitfall.
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Genetics of intracerebral hemorrhage: Insights from candidate gene approaches.
Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.
GPR56 in cancer progression: current status and future perspective.
GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis.
Granular cell dermatofibroma.
Growth regulation of vessel wall cells and of tumor cells by thrombin, factor XIII and fibronectin.
Hemangiopericytoma of the cerebello-pontine angle. Diagnostic pitfalls and the diagnostic value of the subunit A of factor XIII as a tumor marker.
Hemangiopericytoma-like dermatofibroma with mast cells.
Hepatic epithelioid hemangioendothelioma: biological questions based on pattern of recurrence in an allograft and tumor immunophenotype.
High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells.
High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
High salinity induced expression profiling of differentially expressed genes in shrimp (Penaeus monodon).
HIV-1 infection and modulation of cytokine and growth factor expression in Kaposi's sarcoma-derived cells in vitro.
How autophagy controls the intestinal epithelial barrier.
Human immunodeficiency virus-associated oral Kaposi's sarcoma. A heterogeneous cell population dominated by spindle-shaped endothelial cells.
Hyalinizing spindle cell tumor with giant rosettes and low-grade fibromyxoid sarcoma: an immunohistochemical and ultrastructural comparative investigation.
Hyalinizing spindle cell tumors with giant rosette-like structures.
Hyperfibrinolysis and acquired factor XIII deficiency in newly diagnosed pediatric malignancies.
Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status.
Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
Immunocytochemical demonstration of tissue transglutaminase indicative of programmed cell death (apoptosis) in hormone sensitive mammary tumours.
Immunohistochemical analysis of 1,25-dihydroxyvitamin D3 receptor in cervical carcinoma.
Immunohistochemical demonstration of factor XIIIa expression in neurofibromas. A practical means of differentiating these tumors from neurotized melanocytic nevi and schwannomas.
Immunohistochemical evaluation of transglutaminase C in tumours of salivary glands.
Immunohistochemistry of dermatofibromas and benign fibrous histiocytomas.
Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis.
Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
Importance of Ca(2+)-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis.
In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model.
In vivo evaluation of type 2 transglutaminase contribution to the metastasis formation in melanoma.
In vivo transglutaminase type 1 expression in normal lung, preinvasive bronchial lesions, and lung cancer.
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
Incidental calcifying fibrous tumor of the stomach presenting as a polyp.
Increased cytotoxic sensitivity of YPC-1 tumor cells from mice treated with nitrosoureas.
Increased endothelial expression of transglutaminase in glioblastomas.
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
Increased factor XIIIa transglutaminase expression in dermal dendrocytes after treatment with alpha-hydroxy acids: potential physiologic significance.
Increased transglutaminase 2 and GLUT-1 expression in breast tumors not susceptible to chemoprevention with antioxidants.
Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro.
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate induction of epidermal transglutaminase activity by protease inhibitors.
Inhibition of the lncRNA Coded within Transglutaminase 2 Gene Impacts Several Relevant Networks in MCF-7 Breast Cancer Cells.
Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa.
Intracranial suprasellar angiolipoma: ultrastructural and immunohistochemical features.
Involvement of non-coding RNAs and transcription factors in the induction of Transglutaminase isoforms by ATRA.
Keratinocyte transglutaminase expression varies in squamous cell carcinomas.
Keratinocyte transglutaminase in human skin and oral mucosa: cytoplasmic localization and uncoupling of differentiation markers.
Lipomatous hemangiopericytoma: a rare variant of hemangiopericytoma that may be confused with liposarcoma.
Local expression of inflammatory cytokines in human atherosclerotic plaques.
Localization of blood coagulation factors in situ in pancreatic carcinoma.
Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma.
Lymph node reticulum cell neoplasm with progression into cytokeratin-positive interstitial reticulum cell (CIRC) sarcoma: a case study.
Macrophages and vascular adhesion molecules in oral Kaposi's sarcoma.
Malignancies in cases with screening-identified evidence of coeliac disease: a long-term population-based cohort study.
Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Mammary fibroadenoma and some phyllodes tumour stroma are composed of CD34+ fibroblasts and factor XIIIa+ dendrophages.
Mapping the minimum domain of the fibronectin binding site on transglutaminase 2 (TG2) and its importance in mediating signaling, adhesion, and migration in TG2-expressing cells.
Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth.
Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion.
Melanoma associated with a dermatofibroma.
Melanoma cell adhesion to injured arterioles: mechanisms of stabilized tethering.
Meningeal solitary fibrous tumor as an unusual cause of expohthalmos: case report and review of the literature.
Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.
Metastasizing fibrous histiocytoma of the skin: a clinicopathologic and immunohistochemical analysis of three cases.
Microarray analysis uncovers retinoid targets in human bronchial epithelial cells.
miR-19-Mediated Inhibition of Transglutaminase-2 Leads to Enhanced Invasion and Metastasis in Colorectal Cancer.
Modulation of tissue and epidermal transglutaminases in mouse epidermal cells after treatment with 12-O-tetradecanoylphorbol-13-acetate and/or retinoic acid in vivo and in culture.
Modulation of transglutaminase activity in mononuclear phagocytes and macrophage-like tumor cell lines by differentiation agents.
Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas.
MTA1 coregulation of transglutaminase 2 expression and function during inflammatory response.
Multifunctional nanocatalyst-based ultrasensitive detection of human tissue transglutaminase 2.
Multinucleated giant stromal tumor of the omentum: report of a case with immunohistochemical and ultrastructural investigation.
Multiple cutaneous myxomas. Report of a case without other elements of Carney's complex.
Myxomas and angiomyxomas of the orbit: a clinicopathologic study of 6 cases.
New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds.
NF-?B addiction and its role in cancer: 'one size does not fit all'.
Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors.
Novel MRI and fluorescent probes responsive to the Factor XIII transglutaminase activity.
Novel participation of transglutaminase-2 through c-Jun N-terminal kinase activation in sphingosylphosphorylcholine-induced keratin reorganization of PANC-1 cells.
Novel suppressive effects of cardamonin on the activity and expression of transglutaminase-2 lead to blocking the migration and invasion of cancer cells.
Nuclear factor XIIIa staining (clone AC-1A1 mouse monoclonal) is a sensitive and specific marker to discriminate sebaceous proliferations from other cutaneous clear cell neoplasms.
Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation.
Orbital hemangiopericytoma and solitary fibrous tumor: a morphologic continuum.
Overexpression of Tissue Transglutaminase Leads to Constitutive Activation of Nuclear Factor-{kappa}B in Cancer Cells: Delineation of a Novel Pathway.
Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes.
Palisading cutaneous fibrous histiocytoma. An immunohistochemical study demonstrating differentiation from dermal dendrocytes.
Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma.
Pharmacological separation of the expression of tissue transglutaminase and apoptosis after chemotherapeutic treatment of HepG2 cells.
Phenotype and proliferation characteristics of cultured spindle-shaped cells obtained from normal human skin and lesions of dermatofibroma, Kaposi's sarcoma, and dermatofibrosarcoma protuberans: a comparison with fibroblast and endothelial cells of the dermis.
Phenotypic characterization of macrophage subpopulations and localization of factor XIII in the stromal cells of carcinomas.
Phorbol ester tumor promoters induce epidermal transglutaminase activity.
Phosphorylation of transglutaminase 2 (TG2) at serine-216 plays a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of PTEN.
Phytochemicals and protein-polyamine conjugates by transglutaminase as chemopreventive and chemotherapeutic tools in cancer.
Pigmented dermatofibrosarcoma protuberans (Bednár tumor) occurring in a Japanese infant.
Plexiform fibrohistiocytic tumor.
Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis.
Potential role for high and low molecular weight tissue transglutaminases in transforming mammalian cell properties.
Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis.
Prevalence of thrombophilic genetic factors among patients with retinitis pigmentosa.
Primary vs metastatic hepatic carcinoma. An immunohistochemical study of 34 cases.
Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients.
Properties of particulate transglutaminase from Yoshida tumor cells.
Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases.
Protein-polyamine conjugates by transglutaminase 2 as potential markers for antineoplastic screening of natural compounds.
Protein-polyamine conjugation by transglutaminase in cancer cell differentiation: review article.
Proteomic analysis of high-molecular-weight protein polymers in a doxorubicin-resistant breast-cancer cell line.
Provocation with stress and electricity of patients with "sensitivity to electricity".
Quantitative proteomics using formalin-fixed paraffin-embedded tissues of oral squamous cell carcinoma.
Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
Reduced levels of coagulation factor XIII in patients with advanced tumor disease.
Reduction in transglutaminase activity associated with tumour metastasis is due to the presence of an inactive form of the enzyme.
Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line.
Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
Regulation of transglutaminase activity by GTP in digitonin permeabilized Yoshida tumor cells.
Relationship of factor XIIIa-positive dermal dendrocytes to Kaposi's sarcoma.
Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer.
Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Response of carcinogen-altered mouse epidermal cells to phorbol ester tumor promoters and calcium.
Restoration of differentiation and suppression of tumorigenicity in somatic cell hybrids of human squamous carcinoma cells and keratinocytes.
Resveratrol inhibits cell growth in a human cholangiocarcinoma cell line.
Retinoic acid-induced transglutaminase in mouse epidermal cells is distinct from epidermal transglutaminase.
Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation.
Role of fibrinogen covalently associated with cell membrane in blood-borne lung tumor colony formation of murine mammary carcinoma cells.
Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.
Role of tissue transglutaminase and effect of cantharidinate in human colorectal cancer.
Role of Transglutaminase 2 in Migration of Tumor Cells and How Mouse Models Fit.
S-100-negative atypical granular cell tumor: report of a case.
Sarcomatous transformation in a cellular angiofibroma: a case report.
Screening ,development of Transglutaminase-2 Inhibitors and its derivative as anti-lung cancer agent by insilico and invitro approach.
Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity.
Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors.
Simultaneous activity assay of two transglutaminase isozymes, blood coagulation factor XIII and transglutaminase 2, by use of fibrinogen arrays.
Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention.
Sinonasal hemangiopericytomas: a clinicopathologic and immunohistochemical study of seven cases.
Sinonasal-type hemangiopericytoma of the nasal cavity and paranasal sinus.
siRNA-based Analysis of the Abrogation of the Protective Function of Membrane-associated Catalase of Tumor Cells.
Small Benign Storiform Fibrous Tumor (Fibrous Histiocytoma) of the Conjunctival Substantia Propria in a Child: Review and Clarification of Biologic Behavior.
Smart Collagen Hydrogels Based on 1-Ethyl-3-methylimidazolium Acetate and Microbial Transglutaminase for Potential Applications in Tissue Engineering and Cancer Therapy.
Solitary fibrous tumor of the oral soft tissues: a clinicopathologic and immunohistochemical study of 16 cases.
Solitary fibrous tumors of the skin: a clinicopathologic study of 10 cases and review of the literature.
Solute removal capacity of high cut-off membrane plasma separators.
Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract.
Sporadic sclerotic fibroma of the oral soft tissues.
Spotlight on the Transglutaminase 2-Heparan Sulfate Interaction.
Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography.
Structure of natural variant transglutaminase 2 reveals molecular basis of gaining stability and higher activity.
Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
Structures of Human Transglutaminase 2: Finding Clues for Interference in Cross-linking Mediated Activity.
Study of tumor transglutaminase 2 expression in gallbladder cancer - Is it a novel predictor of survival?
Subungual pleomorphic fibroma.
Superficial angiomyxoma (cutaneous myxoma): a clinicopathologic study of 17 cases arising in the genital region.
Suppression of keratinocyte differentiation in SSC-9 human squamous carcinoma cells by benzo[a]pyrene, 12-O-tetradecanoylphorbol-13-acetate and hydroxyurea.
Surgical resection of sinonasal hemangiopericytoma involving anterior skull base: Case reports and literature review.
Synaptotagmin I expression in mast cells of normal human tissues, systemic mast cell disease, and a human mast cell leukemia cell line.
Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids.
Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells.
Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase.
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer.
Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy.
TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma.
TGM3 promotes epithelial-mesenchymal transition and hepatocellular carcinogenesis and predicts poor prognosis for patients after curative resection.
TGM4: an immunogenic prostate-restricted antigen.
The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment.
The clinical and histologic spectrum of cutaneous fibrous perineuriomas.
The complex role of transglutaminase 2 in glioblastoma proliferation.
The existence of an inactive form of transglutaminase within metastasising tumours.
The expression of "tissue" transglutaminase in two human cancer cell lines is related with the programmed cell death (apoptosis).
The G?h-PLC?1 signaling axis drives metastatic progression in triple-negative breast cancer.
The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205.
The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma.
The induction of epidermal transglutaminase and terminal differentiation by tumor promoters in cultured epidermal cells.
The mechanism of transglutaminase 2 inhibition with glucosamine: implications of a possible anti-inflammatory effect through transglutaminase inhibition.
The novel IGF-IR/Akt-dependent anticancer activities of glucosamine.
The role of apoptosis in growing and stationary rat ascites hepatoma, Yoshida AH-130.
The role of Lamin A in cytoskeleton organization in colorectal cancer cells: a proteomic investigation.
The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.
The Role of Tissue Transglutaminase in Cancer Cell Initiation, Survival and Progression.
The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
The treatment of collagen fibrils by tissue transglutaminase to promote vascular smooth muscle cell contractile signaling.
Theophylline-induced apoptosis is paralleled by protein kinase A-dependent tissue transglutaminase activation in cancer cells.
Tissue transglutaminase (TG2) in cancer biology.
Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression.
Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma.
Tissue transglutaminase 2 expression is epigenetically regulated in human lung cancer cells and prevents reactive oxygen species-induced apoptosis.
Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.
Tissue transglutaminase 2 regulates tumor cell tensional homeostasis by increasing contractility.
Tissue transglutaminase activity protects from cutaneous melanoma metastatic dissemination: an in vivo study.
Tissue transglutaminase and its role in human cancer progression.
Tissue transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma.
Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor.
Tissue transglutaminase in tumour progression: friend or foe?
Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells.
Tissue transglutaminase inhibition.
Tissue transglutaminase inhibits autophagy in pancreatic cancer cells.
Tissue transglutaminase is an essential participant in the EGF-stimulated signaling pathway leading to cancer cell migration and invasion.
Tissue transglutaminase is expressed as a host response to tumor invasion and inhibits tumor growth.
Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells.
Tissue transglutaminase promotes or suppresses tumors depending on cell context.
Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb.
Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.
Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.
Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche.
Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship?
Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
Tissue transglutaminase-interleukin-6 axis facilitates peritoneal tumor spreading and metastasis of human ovarian cancer cells.
Tissue transglutaminase-mediated chemoresistance in cancer cells.
Tissue transglutaminase: a new target to reverse cancer drug resistance.
Tissue-type transglutaminase expression in the Dunning tumor.
Tissue-type transglutaminase is not a tumor-related marker.
TNF-alpha mediated NF-kappaB activation is constantly extended by transglutaminase 2.
TRAIL-Induced Keratinocyte Differentiation Requires Caspase Activation and p63 Expression.
Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Transfection of tissue transglutaminase into a highly malignant hamster fibrosarcoma leads to a reduced incidence of primary tumour growth.
Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer.
Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation.
Transglutaminase 2 expression is enhanced synergistically by interferon-? and tumour necrosis factor-? in human small intestine.
Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma.
Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis.
Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells.
Transglutaminase 2 in cancer.
Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Transglutaminase 2 maintains a colorectal cancer stem phenotype by regulating epithelial-mesenchymal transition.
Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.
Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-kB activation.
Transglutaminase 2 Promotes Autophagy by LC3 Induction through p53 Depletion in Cancer Cell.
Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53.
Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target.
Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1?-p300 Binding in Renal Cell Carcinoma.
Transglutaminase 2: A multi-tasking protein in the complex circuitry of inflammation and cancer.
Transglutaminase 3 contributes to malignant transformation of oral leukoplakia to cancer.
Transglutaminase 3: The Involvement in Epithelial Differentiation and Cancer.
Transglutaminase activity in Yoshida ascites tumor cells.
Transglutaminase and tumor growth.
Transglutaminase II/microRNA-218/-181a loop regulates positive feedback relationship between allergic inflammation and tumor metastasis.
Transglutaminase in azoxymethane-induced colon cancer in the rat.
Transglutaminase Interaction with ?6/?4-Integrin Stimulates YAP1-Dependent ?Np63? Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation.
Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation.
Transglutaminase is a tumor cell and cancer stem cell survival factor.
Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Transglutaminase Participates in UVB-Induced Cell Death Pathways in Human Corneal Epithelial Cells.
Transglutaminase stabilizes melanoma adhesion under laminar flow.
Transglutaminase-2 Mediates the Biomechanical Properties of the Colorectal Cancer Tissue Microenvironment that Contribute to Disease Progression.
Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity.
Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
Tumor bioengineering using a transglutaminase crosslinked hydrogel.
Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
Up-regulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells.
Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context.
VGLL4 inhibits YAP1/TEAD signaling to suppress the epidermal squamous cell carcinoma cancer phenotype.
Xanthogranulomas with inconspicuous foam cells and giant cells mimicking malignant melanoma: a clinical, histologic, and immunohistochemical study of three cases.
[Dermal nerve sheath myxoma. (Neurothekeoma)]
[Extra-abdominal fibromatosis. An immunohistochemical analysis]
[Fibrin stabilization and factor XIII substitution in malignant tumors (author's transl)]
[Is the use of factor XIII for delayed wound healing in patients with head-neck tumors of value?]
[Kaposi's disease in a female patient with acquired HIV-negative immunodeficiency]
[Thrombin, factor XIII and fibronectin as regulators of the proliferation of tumor cells and vascular wall cells]
[Wound healing disorders and factor XIII deficiency after tumor operations in the floor of the mouth]
Neoplastic Processes
N?-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling.
Nephritis
Plasma factor XIII levels in children with renal disease.
Therapy for children with henoch-schonlein purpura nephritis: a systematic review.
Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and henoch-Schönlein purpura nephritis.
[Prognostic value of allelic variants affecting the hemostatic system in the development of antiphospholipid syndrome and kidney lesion in patients with systemic lupus erythematosus].
Nephrosis
Factor XIII and its substrates, fibronectin, fibrinogen, and alpha 2-antiplasmin, in plasma and urine of patients with nephrosis.
Nephrosis, Lipoid
Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease.
Nephrotic Syndrome
Acquired glomerular lesions in patients with Down syndrome.
Celiac Disease as a Rare Cause of Membranous Nephropathy: A Case Report.
Clinical and pathological features of children with Henoch-Schoenlein purpura nephritis: risk factors associated with poor prognosis.
Clinical studies on plasma fibronectin and factor XIII; with special reference to hyperlipoproteinemia.
Factor XIII and its substrates, fibronectin, fibrinogen, and alpha 2-antiplasmin, in plasma and urine of patients with nephrosis.
Henoch-Schönlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment.
Plasma factor XIII levels in children with renal disease.
Plasma fibronectin and factor XIII in nephrotic syndrome.
Nervous System Diseases
The many-faced gluten sensitivity: Gluten-induced autoimmunity from dermatological point of view
Netherton Syndrome
LEKTI domains 6, 7 and 8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
Neuralgia
Gluten neuropathy: prevalence of neuropathic pain and the role of gluten-free diet.
Neurilemmoma
Immunohistochemical demonstration of factor XIIIa expression in neurofibromas. A practical means of differentiating these tumors from neurotized melanocytic nevi and schwannomas.
Neuroblastoma
Activation of Rac1 by phosphatidylinositol 3-kinase in vivo: role in activation of mitogen-activated protein kinase (MAPK) pathways and retinoic acid-induced neuronal differentiation of SH-SY5Y cells.
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Activation of transglutaminase 2 by nerve growth factor in differentiating neuroblastoma cells: A role in cell survival and neurite outgrowth.
Changes in gene expression with increased transglutaminase 2 in a SH-SY5Y cell line.
Correlation between transglutaminase activity and polyamine levels in human neuroblastoma cells. Effect of retinoic acid and alpha-difluoromethylornithine.
Distinct nuclear localization and activity of tissue transglutaminase.
Effects of phenyl saligenin phosphate on cell viability and transglutaminase activity in N2a neuroblastoma and HepG2 hepatoma cell lines.
Heterogeneity in retinoic acid signaling in neuroblastomas: Role of matrix metalloproteinases in retinoic acid-induced differentiation.
Identification of 'tissue' transglutaminase binding proteins in neural cells committed to apoptosis.
Intracellular transglutaminase-catalyzed polymerization and assembly for bioimaging of hypoxic neuroblastoma cells.
Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation.
Phenotype-specific "tissue" transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: correlation with cell death by apoptosis.
Protective role of tissue transglutaminase in the cell death induced by TNF-alpha in SH-SY5Y neuroblastoma cells.
Retinoic acid receptors alpha and gamma mediate the induction of "tissue" transglutaminase activity and apoptosis in human neuroblastoma cells.
Role of tissue transglutaminase in neuroblastoma cells undergoing apoptosis.
Role of transglutaminase 2 in PAC1 receptor mediated protection against hypoxia-induced cell death and neurite outgrowth in differentiating N2a neuroblastoma cells.
The expression of "tissue" transglutaminase in two human cancer cell lines is related with the programmed cell death (apoptosis).
The role of tissue transglutaminase in 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in differentiated human SH-SY5Y neuroblastoma cells.
Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells.
Tissue transglutaminase differentially modulates apoptosis in a stimuli-dependent manner.
Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells.
Tissue transglutaminase is not involved in the aggregate formation of stably expressed alpha-synuclein in SH-SY5Y human neuroblastoma cells.
Transglutaminase 2 and NF-kappaB interplay during NGF-induced differentiation of neuroblastoma cells.
Transglutaminase 2 interaction with small heat shock proteins mediate cell survival upon excitotoxic stress.
Transglutaminase and neuronal differentiation.
Transglutaminase catalyzed incorporation of putrescine into surface proteins of mouse neuroblastoma cells.
Transglutaminase-2 Is Involved in All-Trans Retinoic Acid-Induced Invasion and Matrix Metalloproteinases Expression of SH-SY5Y Neuroblastoma Cells via NF-?B Pathway.
VIP potentiates retinoic-acid effect on tissue transglutaminase activity in human neuroblastoma, the SK-N-SH cells.
Neurodegenerative Diseases
A fluorescence anisotropy-based assay for determining the activity of tissue transglutaminase.
A homogeneous fluorescence anisotropy assay for measuring transglutaminase 2 activity.
Cause and consequence: Mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases.
Coagulation factor XIII Val34Leu gene polymorphism and Alzheimer's disease.
Cystamine inhibits transglutaminase and caspase-3 cleavage in glutamate-exposed astroglial cells.
Cytokines regulate neuronal gene expression: Differential effects of Th1, Th2 and monocyte/macrophage cytokines.
Development of a mechanism-based assay for tissue transglutaminase--results of a high-throughput screen and discovery of inhibitors.
Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase.
Endoplasmic reticulum stress activates transglutaminase 2 leading to protein aggregation.
Excitotoxic and post-ischemic neurodegeneration: Involvement of transglutaminases.
Human tissue transglutaminase is inhibited by pharmacologic and chemical acetylation.
Identification of brain substrates of transglutaminase by functional proteomics supports its role in neurodegenerative diseases.
Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.
Identification of tissue transglutaminase-reactive lysine residues in glyceraldehyde-3-phosphate dehydrogenase.
Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the epsilon-(gamma-glutamyl)lysine bonds formed by transglutaminase activity.
Importance of Ca(2+)-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis.
Increased expression of tissue-type transglutaminase following middle cerebral artery occlusion in rats.
Isolation and characterization of brain-specific transglutaminases from rat.
Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.
Molecular mechanisms responsible for the involvement of tissue transglutaminase in human diseases: Celiac Disease.
Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.
Mutations in TGM6 induce the unfolded protein response in SCA35.
Neurodegenerative diseases and transglutaminase.
New insight into transglutaminase 2 and link to neurodegenerative diseases.
New target against inflammatory diseases: transglutaminase 2.
NMDA-evoked excitotoxicity increases tissue transglutaminase in cerebellar granule cells.
Polyamine Homeostasis in Snyder-Robinson Syndrome.
Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases.
Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.
Potential of transglutaminase 2 as a therapeutic target.
Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases.
Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration.
Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography.
Structure of natural variant transglutaminase 2 reveals molecular basis of gaining stability and higher activity.
Structures of Human Transglutaminase 2: Finding Clues for Interference in Cross-linking Mediated Activity.
TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy.
The multifaceted role of transglutaminase in neurodegeneration: review article.
The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
Tissue transglutaminase promotes or suppresses tumors depending on cell context.
Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
Tissue transglutaminase: a possible role in neurodegenerative diseases.
Tissue-type transglutaminase and the effects of cystamine on intracerebral hemorrhage-induced brain edema and neurological deficits.
Transglutaminase 2 expression induced by lipopolysaccharide stimulation together with NO synthase induction in cultured astrocytes.
Transglutaminase 2 expression is enhanced synergistically by interferon-? and tumour necrosis factor-? in human small intestine.
Transglutaminase 2 in neurodegenerative disorders.
Transglutaminase 2 interaction with small heat shock proteins mediate cell survival upon excitotoxic stress.
Transglutaminase 2 is involved in homocysteine-induced activation of human THP-1 monocytes.
Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling.
Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
Transglutaminase activation in neurodegenerative diseases.
Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Transglutaminase as the agent of neurodegenerative diseases due to polyglutamine expansion.
Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Transglutaminase is linked to neurodegenerative diseases.
Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Transglutaminases - possible drug targets in human diseases.
Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection.
Up-regulation of tissue-type transglutaminase after traumatic brain injury.
Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
Neurofibroma
Factor-XIIIa-positive cells in normal peripheral nerves and cutaneous neurofibromas of type-1 neurofibromatosis.
Immunohistochemical demonstration of factor XIIIa expression in neurofibromas. A practical means of differentiating these tumors from neurotized melanocytic nevi and schwannomas.
Neuroinflammatory Diseases
Transglutaminase 2 accelerates neuroinflammation in amyotrophic lateral sclerosis through interaction with misfolded superoxide dismutase 1.
Transglutaminase 2 and neuroinflammation.
Transglutaminase 2 is involved in amyloid-beta1-42-induced pro-inflammatory activation via AP1/JNK signalling pathways in THP-1 monocytes.
Neurologic Manifestations
Anti-transglutaminase 6 Antibody Development in Children With Celiac Disease Correlates With Duration of Gluten Exposure.
Can head trauma trigger celiac disease? Nation-wide case-control study.
Neurologic Deficits in Patients With Newly Diagnosed Celiac Disease Are Frequent and Linked With Autoimmunity to Transglutaminase 6.
Neuromyelitis Optica
Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system.
Neurothekeoma
Multiple desmoplastic cellular neurothekeomas localized to the face of a 16-year-old boy.
Nevus
Factor XIIIa-positive dermal dendritic cells and HLA-DR expression in radial versus vertical growth-phase melanomas.
Fibrous papule: a tumor of fibrohistiocytic cells that contain factor XIIIa.
Immunohistochemical demonstration of factor XIIIa expression in neurofibromas. A practical means of differentiating these tumors from neurotized melanocytic nevi and schwannomas.
Immunohistochemical staining for Ber-EP4, p53, proliferating cell nuclear antigen, Ki-67, bcl-2, CD34, and factor XIIIa in nevus sebaceus.
Nevus, Pigmented
Immunohistochemical demonstration of factor XIIIa expression in neurofibromas. A practical means of differentiating these tumors from neurotized melanocytic nevi and schwannomas.
Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi.
Non-alcoholic Fatty Liver Disease
Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study.
Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2.
Searching for coeliac disease in patients with non-alcoholic fatty liver disease.
[Study of celiac disease in patients with non-alcoholic fatty liver and autoimmune hepatic diseases]
Noonan Syndrome
Factor XIII Deficiency Associated With Noonan Syndrome.
Obesity
Associations of the beta-fibrinogen Hae III and factor XIII Val34Leu gene variants with venous thrombosis.
F13A1 transglutaminase expression in human adipose tissue increases in acquired excess weight and associates with inflammatory status of adipocytes.
Factor XIII-A transglutaminase acts as a switch between preadipocyte proliferation and differentiation.
Factor XIII-A transglutaminase deficient mice show signs of metabolically healthy obesity on high fat diet.
Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6?months after obesity surgery.
Obesity, Metabolically Benign
Factor XIII-A transglutaminase deficient mice show signs of metabolically healthy obesity on high fat diet.
Ocular Hypertension
Knockout of tissue transglutaminase ameliorates TGF?2-induced ocular hypertension: A novel therapeutic target for glaucoma?
Optic Nerve Injuries
A novel activation mechanism of cellular Factor XIII in zebrafish retina after optic nerve injury.
Reciprocal Changes in Factor XIII and Retinal Transglutaminase Expressions in the Fish Retina During Optic Nerve Regeneration.
Upregulation of retinal transglutaminase during the axonal elongation stage of goldfish optic nerve regeneration.
Orchitis
Transglutaminase levels during development of allergic orchitis.
Osteoarthritis
Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis.
Fibrin dissolution in synovial fluid.
Immunohistochemical detection of factor XIIIa and factor XIIIs in synovial membranes of patients with rheumatoid arthritis or osteoarthritis.
Regulation of transglutaminase activity in articular chondrocytes through thrombin receptor-mediated factor XIII synthesis.
Role of transglutaminase 2 in apoptosis induced by hydrogen peroxide in human chondrocytes.
The serine protease inhibitor trappin-2 is present in cartilage and synovial fluid in osteoarthritis.
Transglutaminase 2 as a biomarker of osteoarthritis: an update.
Transglutaminase 2 in cartilage homoeostasis: novel links with inflammatory osteoarthritis.
Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA.
Transglutaminase contributes to CPPD crystal formation in osteoarthritis.
Transglutaminase-2 differently regulates cartilage destruction and osteophyte formation in a surgical model of osteoarthritis.
Transglutaminase-2 regulates Wnt and FoxO3a signaling to determine the severity of osteoarthritis.
Osteophyte
Transglutaminase-2 differently regulates cartilage destruction and osteophyte formation in a surgical model of osteoarthritis.
Osteoporosis
Celiac Disease: Ten Things That Every Gastroenterologist Should Know.
Coeliac disease-specific tissue transglutaminase autoantibodies are associated with osteoporosis and related fractures in middle-aged women.
Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis.
HLA-DQ2/DQ8 frequency in adult patients with celiac disease, their first-degree relatives, and normal population in Turkey.
Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis.
Treatment of postmenopausal osteoporosis in a patient with celiac disease.
[Celiac disease--a frequent cause of "idiopathic osteoporosis" in premenopausal and early postmenopausal women]
Osteosarcoma
Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.
Study of the mechanism underlying the inhibitory effects of transglutaminase II on apoptosis in the osteosarcoma MG-63 cell line under hypoxic conditions.
Transglutaminase-2 is Involved in Cell Apoptosis of Osteosarcoma Cell Line U2OS Under Hypoxia Condition.
Transglutaminase-2 Is Involved in Expression of Osteoprotegerin in MG-63 Osteosarcoma Cells.
Transglutaminase-2 promotes metastatic and stem-like phenotypes in osteosarcoma.
Ovarian Neoplasms
Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking.
Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.
Extracellular tissue transglutaminase activates noncanonical NF-?B signaling and promotes metastasis in ovarian cancer.
siRNA Delivery Using Dithiocarbamate-Anchored Oligonucleotides on Gold Nanorods.
Tissue array-based expression of transglutaminase-2 in human breast and ovarian cancer.
Tissue transglutaminase links TGF-?, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer.
Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche.
Tissue transglutaminase regulates MMP-2 in ovarian cancer by modulating CREB activity.
Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer.
Overweight
Fibrinolysis in diabetes mellitus. Role of overweight and hypertriglyceridemia.
Patients with celiac disease may have normal weight or may even be overweight.
Thrombotic tendency in diabetes mellitus. Revisiting and revising a study initiated 30 years ago.
Pancreatic Neoplasms
Application of a Global Proteomic Approach to Archival Precursor Lesions: Deleted in Malignant Brain Tumors 1 and Tissue Transglutaminase 2 Are Upregulated in Pancreatic Cancer Precursors.
Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer.
Ethacrynic Acid Inhibits Sphingosylphosphorylcholine-Induced Keratin 8 Phosphorylation and Reorganization via Transglutaminase-2 Inhibition.
Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling.
PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells.
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer.
Tissue Transglutaminase (TG2)-Induced Inflammation in Initiation, Progression, and Pathogenesis of Pancreatic Cancer.
Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells.
Tissue transglutaminase inhibits autophagy in pancreatic cancer cells.
Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression.
Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.
Pancreatitis, Chronic
There Is No Association between Coeliac Disease and Autoimmune Pancreatitis.
Papilloma
Alterations in cholesterol sulfate and its biosynthetic enzyme during multistage carcinogenesis in mouse skin.
Choroid Plexus Papilloma and Factor XIII Deficiency: Case Report.
Cultivation and characterization of cells derived from mouse skin papillomas induced by an initiation-promotion protocol.
Papilloma, Choroid Plexus
Choroid Plexus Papilloma and Factor XIII Deficiency: Case Report.
Papillomavirus Infections
Role and predictive strength of transglutaminase type 2 expression in premalignant lesions of the cervix.
Parakeratosis
Acute or chronic topical retinoic acid treatment of human skin in vivo alters the expression of epidermal transglutaminase, loricrin, involucrin, filaggrin, and keratins 6 and 13 but not keratins 1, 10, and 14.
Changes in photo-aged human skin following topical application of all-trans retinoic acid.
Transglutaminase inhibitors induce hyperproliferation and parakeratosis in tissue-engineered skin.
Paralysis
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases.
Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.
Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice.
Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.
Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Transglutaminase is linked to neurodegenerative diseases.
Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Transglutaminases - possible drug targets in human diseases.
Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Paraplegia
Intraspinal hemorrhage in a child with factor XIII deficiency.
Paraproteinemias
Acquired factor XIII inhibitor in monoclonal gammopathy of undetermined significance: characterization and cross-linked fibrin ultrastructure.
Determination of factor XIII activity and of factor XIII inhibitors using an ammonium-sensitive electrode.
[Intradural hematoma of the foramen magnum associated with factor XIII deficiency]
Parkinson Disease
Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of ?-synuclein in a cellular model of Parkinson's disease.
Dissecting the Mechanisms of Tissue Transglutaminase-induced Cross-linking of {alpha}-Synuclein: IMPLICATIONS FOR THE PATHOGENESIS OF PARKINSON DISEASE.
Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis.
Identification of brain substrates of transglutaminase by functional proteomics supports its role in neurodegenerative diseases.
Increase in endoplasmic reticulum-associated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease.
Inflammatory mediators resulting from transglutaminase 2 expressed in mast cells contribute to the development of Parkinson's disease in a mouse model.
Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases.
Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.
Presence of Tissue Transglutaminase in Granular Endoplasmic Reticulum is Characteristic of Melanized Neurons in Parkinson's Disease Brain.
Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
TGM6 variants in Parkinson's disease: clinical findings and functional evidence.
The multifaceted role of transglutaminase in neurodegeneration: review article.
Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease.
Tissue transglutaminase cross-links beclin 1 and regulates autophagy in MPP(+)-treated human SH-SY5Y cells.
Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders.
Transglutaminase 2 is involved in homocysteine-induced activation of human THP-1 monocytes.
Transglutaminase activation in neurodegenerative diseases.
Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation.
Transglutaminase is linked to neurodegenerative diseases.
Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Transglutaminases - possible drug targets in human diseases.
Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Pemphigoid Gestationis
A subset of patients with pemphigoid (herpes) gestationis has serological evidence of celiac disease.
Pemphigoid, Bullous
Concomitant bullous pemphigoid and dermatitis herpetiformis.
Differentiation of normal and tumoral human keratinocytes cultured on dermis: reconstruction of either normal or tumoral architecture.
Reconstructed human epidermis: a model to study in vitro the barrier function of the skin.
Selective plasma exchange can reduce auto-antibodies in patients with bullous pemphigoid without affecting factor XIII and fibrinogen.
The genetics of human skin diseases.
Pemphigus
Selective Plasma Exchange for the Removal of Pemphigus Autoantibodies, Fibrinogen, and Factor XIII in Pemphigus Vulgaris.
Peptic Ulcer
Frequency of Celiac Disease in Children with Peptic Ulcers.
[The healing process of peptic ulcer and coagulation factor XIII]
Perinatal Death
Defective stratum corneum and early neonatal death in mice lacking the gene for transglutaminase 1 (keratinocyte transglutaminase).
Periodontal Diseases
Gingival crevicular fluid and plasma oxidative stress markers and TGM-2 levels in chronic periodontitis.
Periodontitis
Inhibition of transglutaminase activity in periodontitis rescues periodontal ligament collagen content and architecture.
[?linicmolecular indicators of inflammatory destructive damage of the oral cavity in periodontitis in persons with various group accessories of blood.]
Peripheral Arterial Disease
Elevated factor XIII level and the risk of peripheral artery disease.
The V34L polymorphism of factor XIII and peripheral arterial disease.
Peripheral Nerve Injuries
Retrograde changes in transglutaminase activity after peripheral nerve injuries.
Peripheral Nervous System Diseases
Anti-tissue transglutaminase IgA antibodies in peripheral neuropathy and motor neuronopathy.
Neuropathy associated with gluten sensitivity.
Quality of Life in Patients with Gluten Neuropathy: A Case-Controlled Study.
Transglutaminase 6 antibodies in gluten neuropathy.
Peripheral Vascular Diseases
Platelet-associated factor XIII as a marker of platelet activation in patients with peripheral vascular disease.
Pheochromocytoma
Isolation and characterization of brain-specific transglutaminases from rat.
Two types of transglutaminase in the PC12 pheochromocytoma cell line. Stimulation by sodium butyrate.
Phyllodes Tumor
Mammary fibroadenoma and some phyllodes tumour stroma are composed of CD34+ fibroblasts and factor XIIIa+ dendrophages.
Pityriasis
Tissue immunostaining for factor XIIIa in dermal dendrocytes of pityriasis alba skin lesions.
Plasmacytoma
Factor XIII deficiency in BALB/c mice with plasmacytoma.
Platelet Storage Pool Deficiency
The gene encoding protein 4.2 is distinct from the mouse platelet storage pool deficiency mutation pallid.
The murine pallid mutation is a platelet storage pool disease associated with the protein 4.2 (pallidin) gene.
Pleural Effusion
Erratum to Recombinant Factor XIII Reduces Severe Pleural Effusion in Children after Open-Heart Surgery.
Management of Aortic Replacement-Induced Chylothorax by Lipiodol Lymphography.
Recombinant Factor XIII Reduces Severe Pleural Effusion in Children after Open-Heart Surgery.
Pneumonia
A Peptide with anti-transglutaminase activity decreases lipopolysaccharide-induced lung inflammation in mice.
Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice.
Impact of perioperative peripheral blood values on postoperative complications after esophageal surgery.
Regulation of allergic lung inflammation by endothelial cell transglutaminase 2.
Pneumothorax
The treatment of refractory pneumothorax in diffuse panbronchiolitis by intravenous administration of coagulation factor XIII concentrate.
Poliomyelitis
[Inactivation of viruses in Factor XIII concentrate by pasteurization]
Polycystic Kidney, Autosomal Dominant
Factor XIII deficiency in adult polycystic kidney disease.
Polycythemia
Coagulation factor XIII in pregnant smokers and non-smokers.
Is Embolization an Effective Treatment for Recurrent Hemorrhage After Hip or Knee Arthroplasty?
Polycythemia Vera
Is Embolization an Effective Treatment for Recurrent Hemorrhage After Hip or Knee Arthroplasty?
Polydactyly
Characterization of polydactyly chondrocytes and their use in cartilage engineering.
Polyneuropathies
IgA antibodies against tissue transglutaminase, endomysium and gliadin in idiopathic polyneuropathy.
Postpartum Hemorrhage
Medical and Surgical Management of Postpartum Hemorrhage in a Woman with Factor XIII Deficiency.
Pre-Eclampsia
Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia.
OS057. Pathophysiological role of elevated tissue transglutaminase in autoantibody-induced features of preeclampsia in pregnant mice.
Preeclampsia and its interaction with common variants in thrombophilia genes.
The G-to-T point mutation in codon 34 of the factor XIII gene and the risk of pre-eclampsia.
The relationship between circulating tissue transglutaminase, soluble fms-like tyrosine kinase-1, soluble endoglin and vascular endothelial growth factor in pre-eclampsia.
Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.
[Coagulation-fibrinolysis and kinin-forming systems in toxemia of pregnancy]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effect of Tissue Transglutaminase on Steroid Resistance in T-Cell Acute Lymphoblastic Leukemia.
Expression of Coagulation Factor XIII Subunit A Correlates with Outcome in Childhood Acute Lymphoblastic Leukemia.
Expression Patterns of Coagulation Factor XIII Subunit A on Leukemic Lymphoblasts Correlate with Clinical Outcome and Genetic Subtypes in Childhood B-cell Progenitor Acute Lymphoblastic Leukemia.
Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro.
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Effect of Tissue Transglutaminase on Steroid Resistance in T-Cell Acute Lymphoblastic Leukemia.
The TTG-2/RBTN2 T cell oncogene encodes two alternative transcripts from two promoters: the distal promoter is removed by most 11p13 translocations in acute T cell leukaemia's (T-ALL).
Pregnancy Complications
The Angiotensin-converting Enzyme Insertion/Deletion Polymorphism as a Common Risk Factor for Major Pregnancy Complications.
Tissue transglutaminase on trophoblast cells as a possible target of autoantibodies contributing to pregnancy complications in celiac patients.
Pregnancy, Ectopic
Proteinase and proteinase inhibitor localization in the human placenta.
Pressure Ulcer
The role of plasma transglutaminase (F XIII) in wound healing of complicated pressure sores after spinal cord injury.
Primary Myelofibrosis
[Acute malignant myelofibrosis complicated by factor XIII deficiency, protein C decrease and skin necroses]
Prostatic Hyperplasia
Immunological characterization and activity of transglutaminases in human normal and malignant prostate and in prostate cancer cell lines.
Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma.
Prostatic Neoplasms
?-Tocopherol inhibits human prostate cancer cell proliferation by up-regulation of transglutaminase 2 and down-regulation of cyclins.
Changes in tissue transglutaminase activity and expression during retinoic acid-induced growth arrest and apoptosis in primary cultures of human epithelial prostate cells.
Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer.
Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer.
Human prostate-specific transglutaminase gene: promoter cloning, tissue-specific expression, and down-regulation in metastatic prostate cancer.
Immunological characterization and activity of transglutaminases in human normal and malignant prostate and in prostate cancer cell lines.
Markers of prostate region-specific epithelial identity define anatomical locations in the mouse prostate that are molecularly similar to human prostate cancers.
Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients.
Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes.
Pan-cadherin as a high level phenotypic biomarker for prostate cancer.
Prostate transglutaminase (TGase-4) antagonizes the anti-tumour action of MDA-7/IL-24 in prostate cancer.
Prostate Transglutaminase (TGase-4) Induces Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells.
Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain.
Prostate transglutaminase: a unique transglutaminase and its role in prostate cancer.
The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway.
The prostate transglutaminase, TGase-4, coordinates with the HGFL/MSP-RON system in stimulating the migration of prostate cancer cells.
The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer.
Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor.
Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer.
Tissue-type transglutaminase expression in the Dunning tumor.
Prostatitis
Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma.
Protein Deficiency
Characteristic features of the genotype and phenotype of hereditary spherocytosis in the Japanese population.
Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency.
Red cell membrane protein deficiencies in Mexican patients with hereditary spherocytosis.
Protein-Energy Malnutrition
Intestinal Pseudo-Obstruction and Total Villous Atrophy of the Terminal Ileum: An Unusual Presentation of Untreated Celiac Disease.
protein-glutamine gamma-glutamyltransferase deficiency
A case of congenital factor XIII deficiency.
A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide.
A case of factor XIII deficiency in an adult male.
A case of giant expanding cephalhematoma: does the administration of blood coagulation factor XIII reverse symptoms?
A child with acquired factor XIII deficiency: case report and literature review.
A clinical and family study of factor XIII deficiency in a New Zealand family.
A common F13A1 intron 1 variant IVS1+12(A) is associated with mild FXIII deficiency in Caucasian population.
A contribution to the pathology of acquired plasma factor XIII deficiency.
A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin.
A fluorescent spot test for coagulation factor XIII.
A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency.
A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran.
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
A new era of therapy for congenital factor XIII deficiency.
A new family with congenital factor XIII deficiency showing a deficit of both subunit A and B. Type I factor XIII deficiency.
A novel compound heterozygous mutation in the F13A gene causing hereditary factor XIII deficiency in a Chinese family.
A novel Cys328-terminator mutant implicated in severe coagulation factor XIII deficiency: a case report.
A novel mutation causing an aberrant splicing in the protein 4.2 gene associated with hereditary spherocytosis (protein 4.2Notame).
A novel mutation in the erythrocyte protein 4.2 gene of Japanese patients with hereditary spherocytosis (protein 4.2 Fukuoka).
A Rare Case of Factor XIII Deficiency in the Setting of Cancer Immunotherapy.
A reversed activity staining procedure for detection of an acquired antibody against factor XIII in a girl with factor XIII deficiency.
A specific, fluorescent activity staining procedure applied to plasma and red blood cells in congenital factor XIII deficiency.
A tentative classification of factor XIII deficiency in two groups.
Abnormalities of erythrocyte membrane proteins in Korean patients with hereditary spherocytosis.
Acquired coagulation factor XIII deficiency: a case report.
Acquired factor XIII deficiency after desensitization as a potential contributor to postoperative bleeding: more than meets the eye.
Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature.
Acquired factor XIII deficiency in a child with pure erythroid leukemia.
Acquired factor XIII deficiency in patients under therapeutic plasma exchange: A poorly explored etiology.
Acquired factor XIII deficiency in two patients with bleeding events during veno-venous extracorporeal membrane oxygenation treatment.
Acquired Factor XIII Deficiency Inducing Recurrent and Fatal Bleeding, Description of a Case.
Acquired factor XIII deficiency with chronic myelomonocytic leukemia.
Acquired factor XIII deficiency: A review.
Acquired factor XIII deficiency: a therapeutic challenge.
Acquired Factor Xiii Deficiency: An Uncommon But Easily Missed Cause Of Severe Bleeding
Acquired factor XIII deficiency: still a clinical challenge in the era of novel therapy.
Acquired plasma factor XIII deficiencies.
Activation of Molecular Signatures for Antimicrobial and Innate Defense Responses in Skin with Transglutaminase 1 Deficiency.
Acute Abdomen in a Young Girl with Factor XIII Deficiency Perianesthetic Issues.
Acute abdomen in a young girl with factor XIII deficiency: Perianesthetic issues.
Acute and diffuse postoperative bleeding after free latissimus dorsi flap--Factor XIII deficiency: a case report and review of the literature.
Acute kidney injury is associated with low factor XIII in decompensated cirrhosis.
Acute promyelocytic leukaemia associated Factor XIII deficiency presenting as retro-bulbar haematoma.
An acquired inhibitor to factor XIII A case report.
An electrophoretic and quantitative analysis of coagulation factor XIII in normal and deficient subjects.
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
An unusual case of factor xiii deficiency.
An unusual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy.
An update of the mutation profile of Factor 13 A and B genes.
Analytical and clinical utility of a photometric assay for blood coagulation factor XIII.
Application of HUMF13A01 (AAAG)n STR polymorphism to the genetic diagnosis of coagulation factor XIII deficiency.
Arg260-Cys mutation in severe factor XIII deficiency: conformational change of the A subunit is predicted by molecular modelling and mechanics.
Arthropathy associated with factor XIII deficiency.
As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan.
Association between expression of MMP-2 and MMP-9 genes and pathogenesis of intracranial hemorrhage in severe coagulation factor XIII deficiency.
Association of lethal acquired factor XIII deficiency and type 1 diabetes mellitus with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms with high levels of serum thymus and activation-regulated chemokine.
Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: A summary of 93 patients.
Autoimmune Acquired Factor XIII Deficiency: A Case Report.
Autoimmune factor XIII deficiency with unusual laboratory and clinical phenotype.
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
Benefits of thromboelastometry for monitoring replacement therapy in patients with severe inherited factor XIII deficiency: 3 illustrative cases.
Biology of Factor XIII and clinical manifestations of Factor XIII deficiency.
Bleeding disorder with abnormal wound healing, acid-soluble clots and normal factor XIII.
Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature.
Blood coagulation factor XIII and factor XIII deficiency.
Blood factor XIII deficiency: review of literature and report of case.
Case report of an acquired factor XIII inhibitor: diagnosis and management.
Central nervous system bleeding in pediatric patients with factor XIII deficiency: A study on 23 new cases.
Cerebral thrombosis associated with heterozygous factor V Leiden mutation and high lipoprotein(a) level in a girl with factor XIII deficiency.
Challenges in implementation of ISTH diagnostic algorithm for diagnosis and classification of factor XIII deficiency in Iran.
Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder.
Characteristic features of the genotype and phenotype of hereditary spherocytosis in the Japanese population.
Choroid Plexus Papilloma and Factor XIII Deficiency: Case Report.
Claw toes correction and factor XIII deficiency--a case report.
Clinical and laboratory features of congenital factor XIII deficiency.
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease.
Clinical audit of inherited bleeding disorders in a developing country.
Clinical experience with a pasteurised human plasma concentrate in factor XIII deficiency.
Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency.
Clinical pharmacokinetics of a placenta-derived factor XIII concentrate in type I and type II factor XIII deficiency.
Co-existence of hereditary spherocytosis and a new red cell pyruvate kinase variant: PK mallorca.
Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms.
Coagulation factor XIII in pregnant smokers and non-smokers.
Coagulation management in patients undergoing mechanical circulatory support.
Combined occurrence of von Willebrand's disease and factor XIII deficiency: a case report.
Comparison of 2 Methods of Clot Solubility Testing in Detection of Factor XIII Deficiency.
Concurrent hematoma and venous thrombosis in a patient with autoimmune acquired factor XIII deficiency.
Congenital afibrinogenemia in a new born: a rare cause for bleeding.
Congenital blood coagulation factor XIII deficiency and perinatal management.
Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature.
Congenital deficiency of factor XIII with normal subunit S and lack of subunit A. Report of a new family.
Congenital factor XIII deficiency and increased fibrinolysis. A case report.
Congenital factor XIII deficiency associated with von Willebrand disease.
Congenital factor XIII deficiency caused by two mutations in eight Tunisian families: molecular confirmation of a founder effect.
Congenital factor XIII deficiency in a neonate.
Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations.
Congenital factor XIII deficiency in Switzerland: from the worldwide first case in 1960 to its molecular characterisation in 2005.
Congenital factor XIII deficiency in women: a systematic review of literature.
Congenital factor XIII deficiency with multiple benign breast tumours and successful pregnancy with substitutive therapy. A case report.
Congenital Factor XIII Deficiency With the Presence of Inhibitor: A Case Study.
Congenital factor XIII deficiency with treatment of factor XIII concentrate and normal vaginal delivery.
Congenital factor XIII deficiency.
Congenital factor XIII deficiency. A family report.
Congenital factor XIII deficiency. Report of 2 cases.
Congenital factor XIII deficiency: a case report and review of literature.
Congenital factor XIII deficiency: A commentary on 'Homozygous intronic mutation leading to inefficient transcription combined with a novel frame-shift mutation in F13A1 gene causes FXIII deficiency'.
Congenital factor XIII deficiency: a patient report and review of the literature.
Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort.
Congenital factor XIII deficiency: report of a case and literature review.
Congenital factor XIII deficiency: two case reports.
Congenital factor XIII deficiency: type I and type II disease.
Congenital hemorrhagic disorders in Jordan.
Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study.
Corpus luteal hemorrhage: an unusual manifestation of congenital factor XIII deficiency.
COVID-19 is Associated with an Acquired Factor XIII Deficiency.
Cranial hemophilic pseudotumor associated with factor IX deficiency: case report.
Current understanding in diagnosis and management of factor XIII deficiency.
De Novo Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (MYC/BCL-2) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency.
Defective ?2 antiplasmin cross-linking and thrombus stability in a case of acquired factor XIII deficiency.
Defective fibrin crosslinking in acute leukemia.
Deficiency of factor XIII gene in Chinese: 3 novel mutations.
Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.
Delayed umbilical bleeding--a presenting feature for factor XIII deficiency: clinical features, genetics, and management.
Dental Management of Factor XIII Deficiency Patients: A Case Series.
Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories.
Determination of factor XIII activity and of factor XIII inhibitors using an ammonium-sensitive electrode.
Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.
Development of anti-factor XIII antibodies in a patient with hereditary factor XIII deficiency receiving therapy for chronic hepatitis C.
Development of ichthyosiform skin compensates for defective permeability barrier function in mice lacking transglutaminase 1.
Diagnosis and management of severe congenital factor XIII deficiency in the Emergency Department: lessons from a "model" family.
Diagnosis of factor XIII deficiency.
Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran.
Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: its significance in hemostatic defect in factor XIII deficiency.
Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders.
Disseminated intravascular coagulation with positive D-dimer: a controversial clinical feature in severe congenital factor XIII deficiency in southeast Iran.
DNA methylation in promoter regions of red cell membrane protein genes in healthy individuals and patients with hereditary membrane disorders.
Documentation of the plasma factor XIII deficiency in man.
Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Effect of four missense mutations in the factor XIII A-subunit gene on protein stability: studies with recombinant proteins.
Effect of Social Factors on the Highest Global Incidence of Congenital Factor XIII Deficiency in Southeast of Iran.
Effects of Factor XIII Deficiency on Thromboelastography. Thromboelastography with Calcium and Streptokinase Addition is more Sensitive than Solubility Tests.
Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Electroimmunoassay of plasma subunits-a and -s in a case of congenital fibrin stabilizing factor deficiency.
Erythropoiesis: Hereditary Spherocytosis in Greece: Collective Data on a Large Number of Patients.
Establishment of a prenatal diagnosis schedule as part of a prophylaxis program of factor XIII deficiency in the southeast of Iran.
ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group.
Evidence that the red cell skeleton protein 4.2 interacts with the Rh membrane complex member CD47.
Expression and CpG island methylation pattern of MMP-2 and MMP-9 genes in patients with congenital factor XIII deficiency and intracranial hemorrhage.
Factor concentrates for the treatment of factor XIII deficiency.
Factor XIII and its deficiency - review literature and the case report of a Thai boy with congenital factor XIII deficiency.
Factor XIII as a modulator of plasma fibronectin alterations during experimental bacteremia.
Factor XIII Assays and associated problems for laboratory diagnosis of factor XIII deficiency: an analysis of International Proficiency testing results.
Factor XIII deficiency (fibrin stabilizing factor).
Factor XIII deficiency and head trauma: management and therapy.
Factor XIII deficiency and intracranial hemorrhages in infancy.
Factor XIII deficiency and postoperative hemorrhage after neurosurgical procedures.
Factor XIII Deficiency and Thrombocytopenia Are Frequent Modulators of Postoperative Clot Firmness in a Surgical Intensive Care Unit.
Factor XIII deficiency as a potential cause of supratentorial haemorrhage after posterior fossa surgery.
Factor XIII deficiency associated with Klippel-Weber disease, platelet dysfunction and cryofibrinogenemia.
Factor XIII Deficiency Associated With Noonan Syndrome.
Factor XIII deficiency associated with valproate treatment.
Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction.
Factor XIII deficiency causing mutation, Ser295Arg, in exon 7 of the factor XIIIA gene.
Factor XIII deficiency diagnosis: Challenges and tools.
Factor XIII deficiency does not prevent FeCl3-induced carotid artery thrombus formation in mice.
Factor XIII deficiency due to a Leu660Pro mutation in the factor XIII subunit-a gene in three unrelated Palestinian Arab families.
Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
Factor XIII deficiency in adult polycystic kidney disease.
Factor XIII deficiency in antibiotic-associated pseudomembranous colitis and its treatment with factor XIII concentrate.
Factor XIII deficiency in BALB/c mice with plasmacytoma.
Factor XIII Deficiency in Children-Clinical Presentation and Outcome.
Factor XIII deficiency in Henoch-Schönlein purpura - report on two cases and literature review.
Factor XIII Deficiency in Iran: A Comprehensive Review of the Literature.
Factor XIII deficiency in Pakistan.
Factor XIII Deficiency in Siblings: Importance of Prophylactic Replacement.
Factor XIII deficiency in south of Tunisia.
Factor XIII deficiency in south-east Iran.
Factor XIII deficiency in two Melanesian families from Papua New Guinea.
Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management.
Factor XIII Deficiency in Western Afghanistan due to a Novel F13A Gene Mutation.
Factor XIII deficiency leading to preseptal haematoma post-strabismus surgery.
Factor XIII deficiency management: a review of the literature.
Factor XIII deficiency mistaken for battered child syndrome: case of "correct" test ordering negated by a commonly accepted qualitative test with limited negative predictive value.
Factor XIII deficiency presenting with intracerebral bleed.
Factor XIII deficiency related recurrent spontaneous intracerebral hemorrhage: A case and literature review.
Factor XIII deficiency revealed by spontaneous intramedullary hemorrhage: confirmation of a severe mutation.
Factor XIII Deficiency with a Novel Nonsense Mutation.
Factor XIII deficiency with intracranial haemorrhage.
Factor XIII deficiency.
Factor XIII Deficiency.
Factor XIII deficiency. A family study by measurement of factor XIII subunits A and S.
Factor XIII deficiency. A rare haemorrhagic disease.
Factor XIII deficiency. Treatment with monthly plasma infusions.
Factor XIII deficiency: a differential diagnosis to be considered in suspected nonaccidental injury presenting with intracranial hemorrhage.
Factor XIII deficiency: a genetic study of two affected kindreds in Finland.
Factor XIII deficiency: a rare cause of repeated abortions.
Factor XIII Deficiency: An Update.
Factor XIII deficiency: complete phenotypic characterization of two cases with novel causative mutations.
Factor XIII deficiency: new nonsense and deletion mutations in the human factor XIIIA gene.
Factor XIII deficiency: pathogenic mechanisms and clinical significance.
Factor XIII deficiency: report of a case complicated by splenic rupture.
Factor XIII deficiency: report of two cases.
Factor XIII levels in five families of patients with inherited factor XIII deficiency: support for an autosomal recessive inheritance.
Factor XIII mutation spectrum in Iranian patients with hereditary factor XIII deficiency: Detection of 3 novel mutations.
Factor XIII.
Factor XIIIA Calgary: a candidate missense mutation (Leu667Pro) in the beta barrel 2 domain of the factor XIIIA subunit.
Fibrin cross-linking in congenital factor XIII deficiency.
Fibrinogen but not factor XIII deficiency is associated with bleeding after craniotomy.
Fibronectin and wound healing.
First cases of severe congenital factor XIII deficiency in Southwestern Afghanistan in the vicinity of southeast of Iran.
Fracture neck of femur in Factor XIII deficiency: Was better outcome possible?
Further evidence of heterogeneity of gene defects in Italian families with factor XIII deficiency.
FXIII deficiency due to base exchange Thr 449 (ACT) --> Ile (ATT) in exon 11 of the factor 13A gene. A cause of bleeding?
Gene defects in congenital factor XIII deficiency.
Genetic aspects of factor XIII deficiency.
Genetic basis of severe factor XIII deficiency in a large cohort of Indian patients: Identification of fourteen novel mutations.
Genetic heterogeneity of factor XIII deficiency: first description of unstable A subunits.
Glanzmann's thrombasthenia in a Melanesian.
Guidelines for laboratory diagnosis of factor XIII deficiency.
Gynecological and obstetric outcome in the French cohort of women with factor XIII deficiency.
Hemophiliacs--a picture from a developing country: Karnataka, a south Indian state.
Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.
Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis.
Hemostasis in Crohn's disease: low factor XIII levels in active disease.
Hereditary factor XIII deficiency.
Hereditary factor XIII deficiency: report of four families and definition of the carrier state.
Hereditary spherocytosis with spectrin deficiency due to an unstable truncated beta spectrin.
Homozygous missense mutation (band 3 Fukuoka: G130R): a mild form of hereditary spherocytosis with near-normal band 3 content and minimal changes of membrane ultrastructure despite moderate protein 4.2 deficiency.
How to Assess Founder Effect in Patients with Congenital Factor XIII Deficiency.
How to deal with medical and social aspects of bleeding disorders--preparing women and the family in developing countries.
Human erythrocyte protein 4.2 deficiency associated with hemolytic anemia and a homozygous 40glutamic acid-->lysine substitution in the cytoplasmic domain of band 3 (band 3Montefiore).
Hyperfibrinolysis and acquired factor XIII deficiency in newly diagnosed pediatric malignancies.
Identification and characterization of two missense mutations causing factor XIIIA deficiency.
Identification of a new Leu354Pro mutation responsible for factor XIII deficiency.
Identification of a new mutation (Gly420Ser), distal to the active site, that leads to factor XIII deficiency.
Identification of a Novel Mutation Combination in Factor XIII Deficiency: Genetic Update to the First Reported Case in the United States.
Identification of a novel nonsense mutation leading to congenital factor XIII deficiency.
Identification of acquired coagulation disorders and effects of target-controlled coagulation factor substitution on the incidence and severity of spontaneous intracranial bleeding during veno-venous ECMO therapy.
Identification of an inframe deletion and a missense mutation in the factor XIIIA gene in two Turkish patients.
Identification of novel pathogenic F13A1 mutation and novel NBEAL2 gene missense mutation in a pedigree with hereditary congenital factor XIII deficiency.
Identification of two novel missense mutations causing severe factor XIII deficiency.
Immunotolerance approach to refractory CNS bleeding in a patient with congenital factor XIII deficiency and acquired alloantibody.
Impact of Rare Bleeding Disorders during Pregnancy on Maternal and Fetal Outcomes: Review of 29 Pregnancies at a Single Center.
Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII.
Important roles of the human leukocyte antigen class I and II molecules and their associated genes in the autoimmune coagulation factor XIII deficiency via whole-exome sequencing analysis.
In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.
Induction of hemodialysis therapy in a case with factor XIII deficiency.
Inherited bleeding disorders in Indian women with menorrhagia.
Inherited bleeding disorders in pregnancy.
Inherited factor XIII deficiency.
International registry on factor XIII deficiency: a basis formed mostly on European data.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Intracranial hemorrhage in congenital deficiency of factor XIII.
Intracranial hemorrhage pattern in the patients with factor XIII deficiency.
Intracranial Hemorrhage: A Devastating Outcome of Congenital Bleeding Disorders-Prevalence, Diagnosis, and Management, with a Special Focus on Congenital Factor XIII Deficiency.
Intraspinal hemorrhage in a child with factor XIII deficiency.
Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2).
Investigation of a link between raised levels of pepsinogen in blood as a mediator of in-vitro clot lysis in acid and a cause of abnormal factor XIII screening tests.
Is Embolization an Effective Treatment for Recurrent Hemorrhage After Hip or Knee Arthroplasty?
Is extracorporeal CO2-Removal really "safe" and "less" invasive? Observation of blood injury and coagulation impairment during ECCO2R.
Laboratory Diagnosis of Factor XIII Deficiency in Developing Countries: An Iranian Experience.
Laboratory Diagnosis of Factor XIII Deficiency, Routine Coagulation Tests with Quantitative and Qualitative Methods.
Laboratory testing for bleeding disorders: strategic uses of high and low-yield tests.
Lobar Hemorrhage Induced by Acquired Factor XIII Deficiency in a Patient with Cerebral Amyloid Angiopathy.
Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®.
Long-term prophylaxis in patients with factor XIII deficiency complicated by intracranial haemorrhage in Iran.
Long-term prophylaxis in patients with severe congenital factor XIII deficiency is not complicated by inhibitor formation.
Low levels of fibrin-stabilizing factor (factor XIII) in human Plasmodium falciparum malaria: correlation with clinical severity.
Low prevalence of antibodies against human immunodeficiency virus in Finnish haemophiliacs.
Male fertility in factor XIII deficiency.
Management of acute myocardial infarction in a patient with factor XIII deficiency using prophylactic factor replacement therapy.
Management of Dilutional Coagulopathy during Pediatric Major Surgery.
Management of Neuraxial Analgesia in a Parturient with Factor XIII Deficiency: A Case Report and Proposed Management Algorithm.
Management of pregnancy and delivery in women with inherited bleeding disorders.
Massive recurrent post-tonsillectomy bleedings revealing a transient factor XIII deficiency in a 10-year-old boy. A case report.
Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell.
Medical and Surgical Management of Postpartum Hemorrhage in a Woman with Factor XIII Deficiency.
Melanoma associated with subacute primitive fibrinolysis.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Mild Acquired Factor XIII Deficiency and Clinical Relevance at the ICU-A Retrospective Analysis.
Mild factor XIII deficiency and concurrent hypofibrinogenemia: effect of pregnancy.
Mining of mortality-related findings in rare bleeding disorders: a retrospective study from two centers.
Molecular analysis in factor XIIIA deficiency.
Molecular and genetic mechanisms of factor XIII A subunit deficiency.
Molecular Basis of Congenital Factor XIII Deficiency in Iran.
Molecular basis of inherited factor XIII deficiency: identification of multiple mutations provides insights into protein function.
Molecular characterization of five Italian families with inherited severe factor XIII deficiency.
Molecular diagnosis of factor XIII deficiency, data from comprehensive coagulation laboratory in Iran.
Molecular genetic analysis of ten unrelated Iranian patients with congenital factor XIII deficiency.
Molecular mechanisms of mutations in factor XIII A-subunit deficiency: in vitro expression in COS-cells demonstrates intracellular degradation of the mutant proteins.
Molecular mechanisms of type II factor XIII deficiency: novel Gly562-Arg mutation and C-terminal truncation of the A subunit cause factor XIII deficiency as characterized in a mammalian expression system.
Molecular modeling predicts structural changes in the A subunit of factor XIII caused by two novel mutations identified in a neonate with severe congenital factor XIII deficiency.
Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency.
Mutations causing coagulation factor XIII subunit A deficiency: characterization of the mutant proteins after expression in yeast.
Mutations in coagulation factor XIII A gene in eight unrelated Indians. Five novel mutations identified by a novel PCR-CSGE approach.
Mutations in coagulation factor XIII subunit A in severe factor XIII deficiency patients: five novel mutations detected.
Neonatal factor XIII deficiency.
Neoplasm-induced bleeding in inherited, heterozygous FXIII-A deficiency.
New developments in the management of congenital Factor XIII deficiency.
New mutations causing the premature termination of translation in the A subunit gene of coagulation factor XIII.
Nonhemophiliac musculoskeletal pseudotumor.
Nonimmune-acquired factor XIII deficiency: a cause of high volume and delayed postoperative hemorrhage.
Nonsyndromic types of ichthyoses - an update.
Novel and recurrent mutations in the F13A1 gene in unrelated Korean patients with congenital factor XIII deficiency.
Novel aspects of factor XIII deficiency.
Novel deep intronic mutation in the coagulation factor XIII a chain gene leading to unexpected RNA splicing in a patient with factor XIII deficiency.
Novel deletion and insertion mutations cause splicing defects, leading to severe reduction in mRNA levels of the A subunit in severe factor XIII deficiency.
Novel Factor XIII variant identified through whole-genome sequencing in a child with intracranial hemorrhage.
Novel human pathological mutations. Gene symbol: F13A1. Disease: Factor XIII Deficiency.
Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.
Novel Y283C mutation of the A subunit for coagulation factor XIII: molecular modelling predicts its impaired protein folding and dimer formation.
Occurrence and recurrence of spontaneous chronic subdural haematoma is associated with a factor XIII deficiency.
Ocular complications of factor XIII deficiency.
On the retraction of collagen and fibrin induced by normal, defective and modified platelets.
Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection.
Optimisation of a new continuous UV assay for the determination of blood coagulation factor XIII activity in human plasma.
Original tandem duplication in FXIIIA gene with splicing site modification and four amino acids insertion causes factor XIII deficiency.
Ovarian haemorrhage: a rare presentation and diagnostic dilemma in factor XIII deficiency.
Pathogenicity analysis of variations and prenatal diagnosis in a hereditary coagulation factor XIII deficiency family.
Pathological coagulation parameters in as many as 54 patients with autoimmune acquired factor XIII deficiency due to anti-factor XIII autoantibodies.
Patient-centered approach to managing factor XIII deficiency.
Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency.
Penile prosthesis implant for primary erectile dysfunction in patient with Klippel-Trenaunay syndrome complicated by consumptive coagulopathy: A case report.
Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Phenotype and genotype of FXIII deficiency in two unrelated probands: identification of a novel F13A1 large deletion mediated by complex rearrangement.
Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency.
Phenotype-genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations.
Physiopathology and regulation of factor XIII.
Platelet aggregation in congenital factor XIII deficiency.
Platelet and coagulation studies in Ehlers-Danlos syndrome.
Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intracranial haemorrhage in factor XIII deficiency.
Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman--reply.
Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman.
Postoperative bleeding in a patient with normal screening coagulation tests.
Posttraumatic subgaleal and orbital hematoma due to factor XIII deficiency.
Pregnancy complications and obstetric care in women with inherited bleeding disorders.
Premarital Screening Program for Congenital Factor XIII Deficiency in Iran.
Prenatal diagnosis in factor XIII-A deficiency.
Prenatal diagnosis of factor 13 deficiency and its recurrence.
Prevalence of factor XIII deficiency in patients presenting with a bleeding disorder in Pakistan.
Primary structure of blood coagulation factor XIIIa (fibrinoligase, transglutaminase) from human placenta.
Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study.
Proceedings: Factor XIII concentrate in the long term management of congenital factor XIII deficiency.
Procoagulant platelets form an ?-granule protein-covered 'cap' on their surface that promotes their attachment to aggregates.
Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency.
Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency: reply to a rebuttal.
Prophylaxis in factor XIII deficiency.
Prophylaxis in rare coagulation disorders -- factor XIII deficiency.
Protein 4.2: a complex linker.
Pubertal Menorrhagia - A Rare Presentation of Congenital Factor XIII Deficiency.
Quality of life of people with hereditary factor XIII deficiency treated at a reference centre.
Rare bleeding disorders in children: identification and primary care management.
Rare inherited coagulation disorders in India.
Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.
Recombinant factor XIII A-subunit in a patient with factor XIII deficiency and recurrent pregnancy loss.
Recurrent bleeding following rhinoplasty due to factor XIII deficiency.
Recurrent episodes of severe bleeding caused by congenital factor XIII deficiency in a dog.
Recurrent Hematomas following a Revision Total Hip Arthroplasty in Acquired Coagulation Factor XIII Deficiency.
Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update.
Recurrent Post Tonsillectomy Secondary Hemorrhage in Patients with Factor XIII Deficiency: A Case Series and Review of Literature.
Recurrent Spontaneous Splenic Rupture in a Patient With Congenital Factor XIII Deficiency.
Recurrent ulcerations on both legs since early childhood due to a factor V gene mutation.
Reduced difference of ?(2)-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune hemorrhaphilia due to anti-factor XIII antibodies.
Reduced levels of coagulation factor XIII in patients with advanced tumor disease.
Reduced transglutaminase-catalyzed cross-linking of exogenous amines to membrane proteins in sickle erythrocytes.
Relevant bleeding diathesis due to acquired factor XIII deficiency.
Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition.
Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with liver cirrhosis.
Rotational Thromboelastometry for Assessing Bleeding Complications and Factor XIII Deficiency in Cardiac Surgery Patients.
Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available.
Segmental uniparental disomy as a rare cause of congenital severe factor XIII deficiency in a girl with only one heterozygous carrier parent.
Seven novel mutations in the factor XIII A-subunit gene causing hereditary factor XIII deficiency in 10 unrelated families.
Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency.
Severe bleeding in a patient with factor XIII deficiency and COVID-19.
Severe congenital factor XIII deficiency caused by novel W187X and G273V mutations in the F13A gene; diagnosis and classification according to the ISTH/SSC guidelines.
Solubility fo fibrin clots in monochloroacetic acid. A reflection of serum pepsinogen levels.
Spectrum of hereditary coagulation factor deficiencies in eastern province, Saudi Arabia.
Spinal anaesthesia and caesarean section in a patient with hypofibrinogenaemia and factor XIII deficiency*
Spontaneous Acute Cerebral Hematoma in a Child with Factor XIII Deficiency.
Spontaneous Epidural Hematoma in a Child With Inherited Factor XIII Deficiency.
Spontaneous intracerebral hematoma in a adolescent with factor XIII deficiency. Case report.
Spontaneous regression of the inhibitor against the coagulation factor XIII A subunit in acquired factor XIII deficiency.
Spontaneous rupture of the spleen in Factor XIII deficiency: A report of two cases.
Spontaneous splenic rupture in a patient with factor XIII deficiency and a novel mutation.
State of the art in factor XIII laboratory assessment.
Studies on factor XIII antigen in congenital factor XIII deficiency. A tentative classification of the disease in two groups.
Subgaleal hematoma presenting as a manifestation of Factor XIII deficiency.
Subunits A and S inheritance in four families with congenital factor XIII deficiency.
Successful completion of transurethral lithotripsy in a patient with factor XIII deficiency: A case report.
Successful long-term replacement therapy with FXIII concentrate (Fibrogammin(®) P) for severe congenital factor XIII deficiency: a prospective multicentre study.
Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy. Report of a second case.
Successful treatment of chronic disseminated intravascular coagulation using recombinant human soluble thrombomodulin in a dialysis patient with dissecting aortic aneurysm.
Successful treatment of severe gastrointestinal manifestations of Henoch-Schonlein Purpura and factor XIII deficiency using cryoprecipitate transfusion.
Successful use of recombinant factor VIIa in a child with Schoenlein-Henoch purpura presenting with compartment syndrome and severe factor XIII deficiency.
Surgery in severe factor XIII deficiency: report of a case of epilepsy neurosurgery and review.
Symptomatic factor XIII deficiency with normal urea solubility test.
The first case report of a patient with acquired factor XIII deficiency in the context of autoimmune encephalitis.
The influence of intrinsic coagulation pathway on blood platelets activation by oxidized cellulose.
The normal and abnormal genes of the a and b subunits in coagulation factor XIII.
The perioperative course of factor XIII and associated chest tube drainage in newborn and infants undergoing cardiac surgery.
The rare inherited coagulation disorders.
The role of fibrin matrices and tissue factor in early-term trophoblast proliferation and spreading.
The subunit composition of factor XIII proteins in normal and factor XIII deficient plasma and serum analysed by line immunoelectrophoresis.
Therapeutic factor XIII preparations and perspectives for recombinant factor XIII.
Thromboelastometric detection of clotting Factor XIII deficiency in cardiac surgery patients.
Thromboelastometry Identified Alteration of Clot Stabilization and Factor XIII Supplementation Need in a Patient with Decompensated Liver Disease Undergoing Liver Biopsy.
Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis.
Tooth extraction in two patients who had a congenital deficiency of factor XIII.
Total absence of protein 4.2 and partial deficiency of band 3 in hereditary spherocytosis.
Training Program for Home Therapy of People With Factor XIII Deficiency.
Transglutaminase 1 deficiency and corneocyte collapse: an indication for targeted molecular screening in autosomal recessive congenital ichthyosis.
Transglutaminase 2 deficiency decreases plaque fibrosis and increases plaque inflammation in apolipoprotein-E-deficient mice.
Transglutaminase cross-linking properties of the small proline-rich 1 family of cornified cell envelope proteins. Integration with loricrin.
Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection.
Treatment of factor XIII deficiency with cryoprecipitate.
Treatment with Recombinant Factor XIII (Tretten) in a Pregnant Woman with Factor XIII Deficiency.
Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation.
Two cases of haemorrhagic disease arising from fibrin stabilizing factor deficiency.
Two novel and one recurrent missense mutation in the factor XIII A gene in two Dutch patients with factor XIII deficiency.
Type I and type II disease in congenital factor XIII deficiency. A further demonstration of the correctness of the classification.
Type I factor XIII deficiency is caused by a genetic defect of its b subunit: insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain.
Unusual presentation of factor XIII deficiency.
Use of Catridecacog in a patient with severe Factor XIII deficiency undergoing surgery.
Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding.
Valproic Acid-Induced Coagulopathy.
Viral markers and use of factor products among Finnish patients with bleeding disorders.
[2 patients with congenital factor XIII deficiency. Contribution to the problem of factor XIII determination]
[A case of congenital factor XIII deficiency and acquired factor XIII deficiency (author's transl)]
[A clinical study of congenital factor XIII deficiency (author's transl)]
[A novel genetic defect in a Chinese family with inherited coagulation factor XIII deficiency]
[A report of two cases with congenital factor XIII deficiency]
[Acquired coagulation disorders].
[Acquired factor XIII deficiency and chronic myeloid splenomegaly]
[Acquired factor XIII deficiency and clinical surgery]
[Acquired factor XIII deficiency and postoperative aseptic wound healing disorders]
[Acquired von Willebrand syndrome in a patient with immune thrombocytopenic purpura].
[Acute malignant myelofibrosis complicated by factor XIII deficiency, protein C decrease and skin necroses]
[An infant with umbilical cord and intracranial hemorrhage--severe factor XIII deficiency]
[Anesthesia for a patient with Ehlers-Danlos syndrome and factor XIII deficiency]
[Bleeding and coagulation disorders in tonsillectomies.]
[Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study]
[Blood coagulation factor XIII and fibrin stabilization (author's transl)]
[Case of factor XIII deficiency]
[Case suspected to be factor XIII deficiency]
[Cephalohemoatoma as the first manifestation of congenital factor XIII deficiency]
[Characteristics of red cell membrane disorders in the Japanese population]
[Characterization of a large deletion that leads to congenital factor XIII deficiency]
[Clinical course and management of severe congenital factor XIII deficiency]
[Congenital factor XIII deficiency in pregnancy. A case report]
[Congenital factor XIII deficiency in the south of Tunisia]
[Congenital factor XIII deficiency required high-dose factor XIII concentrate in late pregnancy]
[Congenital factor XIII deficiency. Report of a new family (author's transl)]
[Congenital factor XIII deficiency: studies in an infant and his family]
[Congenital factor XIII deficiency]
[Cytoskeleton anomalies in disorders of red cell membrane proteins]
[Detection of factor XIII deficiency in acute leukemia with resonance thrombography]
[Factor XIII deficiency as the cause of postoperative hemorrhage]
[Factor XIII deficiency due to lack of both the S and A subunits. (Classification of factor XIII deficiency in 2 groups)]
[Factor XIII deficiency in a newborn]
[Factor XIII deficiency in adults with acute leukemia: results of a substitution therapy with factor XIII (author's transl)]
[Factor XIII deficiency in burns]
[Factor XIII deficiency in various patients with acute leukemia]
[Factor XIII deficiency: blood coagulation defect in pregnancy]
[Factor XIII deficiency]
[Factor XIII-guided treatment algorithm reduces blood transfusion in burn surgery].
[Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)]
[Hereditary coagulation factor XIII deficiency: three cases report and literaure review].
[Identification of a novel mutation of F (13) A gene in a pedigree with factor XIII deficiency]
[Identification of genetic defects in a Chinese pedigree with factor XIII deficiency: case report and literature review].
[Identification of two novel mutation in two Chinese hereditary coagulation factor XIII deficiency families]
[Importance, diagnosis and substitution in acquired factor XIII deficiency in the postoperative course]
[Intracranial hematoma accompanying bleeding tendency: therapeutic practice and analysis of literature]
[Intradural hematoma of the foramen magnum associated with factor XIII deficiency]
[Is the use of factor XIII for delayed wound healing in patients with head-neck tumors of value?]
[Leukocytoclastic vasculitis and factor XIII deficiency]
[Longtime therapy of congenital factor XIII deficiency using factor XIII concentrate]
[Molecular mechanisms of two novel mutations of factor XIII gene resulting in hereditary coagulation deficiency]
[Pathogenesis of tracheal stenosis following long-term intubation of patients with multiple injuries]
[Plasma transglutaminase activity in congenital total and partial factor XIII deficiency (a contribution to the problem of factor XIII determination)]
[Postoperative complications due to acquired factor XIII deficiency]
[Pre-hospital diagnosis of nosebleed in children]
[Presence of a plasma antigen indispensable to the stabilization of fibrin in 2 cases on congenital factor XIII deficiency]
[Primary myelofibrosis with fatal mesenteric arterial thromboembolism caused by antiphospholipid syndrome]
[Recurrent hematomas and normal standard hemostasis tests]
[Role of thrombelastometry for the monitoring of factor XIII. A prospective observational study in neurosurgical patients.]
[Severe factor XIII-deficiency. Studies on subunits and turnover of the fibrin stabilizing factor (author's transl)]
[Simplified radiologic factor XIII determination and its clinical use in congenital factor XIII deficiency (I)]
[Spontaneous splenic rupture in a patient with congenital factor XIII deficiency]
[Stenosing ureteritis and factor XIII deficiency in anaphylactoid purpura]
[Studies on abnormal protein in seven patients with congenital factor XIII deficiency (author's transl)]
[Studies on congenital factor XIII deficiency and detection of the carrier in his family (author's transl)]
[Study on the molecular mechanisms of a novel large deletion of FXIIIA mRNA in a new hereditary factor XIII deficiency].
[Substitution treatment of factor XIII deficiency with a new factor XIII concentrate]
[Surgical treatment of intracranial hematoma with congenital factor XIII deficiency. Case report]
[Thrombelastometric detection of factor XIII deficiency]
[Wound healing disorders and factor XIII deficiency after tumor operations in the floor of the mouth]
Proteinuria
Acquired glomerular lesions in patients with Down syndrome.
Celiac Disease and Secondary Amyloidosis: A Possible Causal Association?
Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression.
Plasma fibronectin and factor XIII in nephrotic syndrome.
Risk factors of renal involvement and significant proteinuria in Henoch-Schönlein purpura.
Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.
Psoriasis
Abnormal Bcl-2 and "tissue" transglutaminase expression in psoriatic skin.
Abnormal epidermal barrier in the pathogenesis of psoriasis.
Biochemistry of transglutaminases and cross-linking in the skin.
Celiac disease-associated antibodies in patients with psoriasis and correlation with HLA Cw6.
Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease.
Distinctive dendritic cell subsets expressing factor XIIIa, CD1a, CD1b and CD1c in mycosis fungoides and psoriasis.
Elevated transglutaminase-2 expression in the epidermis of psoriatic skin and its role in the skin lesion development.
Epidermal differentiation characteristics of the psoriatic plaque during short contact treatment with dithranol cream.
Estimation of (IgA) anti-gliadin, anti-endomysium and tissue transglutaminase in the serum of patients with psoriasis.
Expression of transglutaminase 5 in normal and pathologic human epidermis.
Factor XIII insufficiency in a patient with severe psoriasis vulgaris, arthritis, and infirmity.
Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): a population control study.
Gluten-free diet in psoriasis patients with antibodies to gliadin results in decreased expression of tissue transglutaminase and fewer Ki67+ cells in the dermis.
Human immunodeficiency virus (HIV) transcripts identified in HIV-related psoriasis and Kaposi's sarcoma lesions.
IL-1 beta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up-regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL-1 production.
Increased membrane-associated transglutaminase activity in psoriasis.
Increased nuclear beta-catenin in suprabasal involved psoriatic epidermis.
Influence of calcium on the proteolytic degradation of the calmodulin-like skin protein (calmodulin-like protein 5) in psoriatic epidermis.
Is the search for serum antibodies to gliadin, endomysium and tissue transglutaminase meaningful in psoriatic patients? Relationship between the pathogenesis of psoriasis and coeliac disease.
Keratinocyte transglutaminase expression varies in squamous cell carcinomas.
Levels of proelafin peptides in the sera of the patients with generalized pustular psoriasis and pustulosis palmoplantaris.
Localization of transglutaminase 1 mRNA in normal and psoriatic epidermis by non-radioactive in situ hybridization.
Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation.
Psoriasis in autoimmune polyendocrine syndrome type I: A possible complication or a non-endocrine minor component?
Serologic markers of celiac disease in psoriatic patients.
Transglutaminase 3 Reduces the Severity of Psoriasis in Imiquimod-Treated Mouse Skin.
Triggered psoriasis.
Type I keratinocyte transglutaminase: expression in human skin and psoriasis.
Type XVI collagen is expressed in factor XIIIa+ monocyte-derived dermal dendrocytes and constitutes a potential substrate for factor XIIIa.
Unique keratinization process in psoriasis: late differentiation markers are abolished because of the premature cell death.
[Pre-hospital diagnosis of nosebleed in children]
Pulmonary Arterial Hypertension
Cystamine slows but not inverses the progression of monocrotaline-induced pulmonary arterial hypertension in rats.
Pulmonary Disease, Chronic Obstructive
Lung tissue proteomics identifies elevated transglutaminase 2 levels in stable chronic obstructive pulmonary disease.
Pharmaceutical approval update.
Pulmonary Embolism
Combined measurement of factor XIII and D-dimer is helpful for differential diagnosis in patients with suspected pulmonary embolism.
Frequency of the TAFI -438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism.
Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.
Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness.
The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism.
Pulmonary Fibrosis
Cells containing factor XIIIa and pulmonary fibrosis induced by bleomycin.
Changes in transglutaminase activity in an experimental model of pulmonary fibrosis induced by paraquat.
Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.
Metformin attenuates TGF-?1-induced pulmonary fibrosis through inhibition of transglutaminase 2 and subsequent TGF-? pathways.
Spatially Resolved Identification of Transglutaminase Substrates by Proteomics in Pulmonary Fibrosis.
Transglutaminase 2 and its Role in Pulmonary Fibrosis.
Purpura
A patient with Henoch-Schönlein purpura manifesting unusual symptoms and clinical course.
Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch-Schönlein purpura. Efficacy of factor XIII substitution.
Adult Henoch-Schönlein purpura with severe abdominal pain treated with dapsone and factor XIII concentrate.
Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Schönlein purpura. Japanese Pediatric Group.
Clinical Significance of Blood Coagulation Factor XIII Activity in Adult Henoch-Schönlein Purpura.
Could measurement of factor XIII level detect the vasculitic process of Henoch-Schönlein purpura without skin rash?
Diagnostic value of plasma factor XIII in Henoch-Schönlein purpura.
Factor XIII (fibrin stabilising factor) in Henoch-Schönlein's purpura.
Factor XIII as a potential predictor of severe gastrointestinal involvement in Henoch Schoenlein purpura: A case study research.
Factor XIII deficiency in Henoch-Schönlein purpura - report on two cases and literature review.
Factor XIII in Henoch-Schönlein purpura with isolated gastrointestinal symptoms.
Henoch-Schönlein purpura in a child with Guillain-Barré syndrome.
Idiopathic testicular infarction in a boy initially suspected to have acute epididymo-orchitis associated with mycoplasma infection and Henoch-Schönlein purpura.
Risk factors of renal involvement and significant proteinuria in Henoch-Schönlein purpura.
Severe Large-Intestine Involvement in Adult-Onset Henoch-Schönlein Purpura: Successful Treatment with Factor XIII Concentrate.
Successful treatment of adult Henoch-Schönlein purpura with factor XIII concentrate.
Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and henoch-Schönlein purpura nephritis.
[The prognostic value of factor XIII in Schönlein-Henoch purpura in childhood (author's transl)]
Purpura, Thrombocytopenic, Idiopathic
Prevalence of Autoantibodies Related to Some Autoimmune Disorders in Patients With Chronic Idiopathic Thrombocytopenic Purpura.
Pyoderma Gangrenosum
Treatment of pyoderma gangrenosum with topical factor XIII.
Radicular Cyst
Distribution of factor XIIIa-containing cells and collagenous components in radicular cysts: histochemic and immunohistochemic studies.
Renal Insufficiency
Acquired glomerular lesions in patients with Down syndrome.
Clinical and pathological features of children with Henoch-Schoenlein purpura nephritis: risk factors associated with poor prognosis.
Early response as shown by enhancement of transglutaminase 1 expression after cisplatin-induced acute kidney injury.
Insights on the heparan sulphate-dependent externalisation of transglutaminase-2 (TG2) in glucose-stimulated proximal-like tubular epithelial cells.
Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy.
Structure of fibrin and fibrinmonomer in renal and hepatic failure.
Transglutaminases: the missing link in nephrogenic systemic fibrosis.
Treatment of an acquired Factor XIII inhibitor in an adolescent with systemic lupus erythematosus and renal failure.
Renal Insufficiency, Chronic
Coagulation factor XIII in patients with acute and chronic renal disease.
Feline chronic kidney disease is associated with upregulation of transglutaminase 2: a collagen cross-linking enzyme.
Interplay between transglutaminases and heparan sulphate in progressive renal scarring.
Transglutaminase 2 Accelerates Vascular Calcification in Chronic Kidney Disease.
Transglutaminase 2 as a novel target in chronic kidney disease - Methods, mechanisms and pharmacological inhibition.
Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease.
Reperfusion Injury
Does Recombinant Factor XIII Eliminate Early Manifestations of Multiple-Organ Injury After Experimental Burn Similarly to Gut Ischemia-Reperfusion Injury or Trauma-Hemorrhagic Shock?
Recombinant factor XIII diminishes multiple organ dysfunction in rats caused by gut ischemia-reperfusion injury.
Respiratory Distress Syndrome
Factor XIII Activity Might Already Be Impaired before Veno-Venous ECMO in ARDS Patients: A Prospective, Observational Single-Center Cohort Study.
Retinal Artery Occlusion
Role of factor XIII Val34Leu polymorphism in retinal artery occlusion.
Retinal Detachment
Blood coagulation factor XIII contributes to the development of traction retinal detachment.
Feasibility of using gelatin-microbial transglutaminase complex to repair experimental retinal detachment in rabbit eyes.
Retinal Diseases
[Detection of coagulation factor XIII in the vitreous body and periretinal membranes in proliferative retinal diseases]
Retinal Dystrophies
Tissue transglutaminase in apoptosis of photoreceptor cells in rat retina.
Retinoblastoma
Dermal plexiform spindle cell lipoma.
Induction of retinoblastoma gene expression during terminal growth arrest of a conditionally immortalized fetal rat lung epithelial cell line and during fetal lung maturation.
Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb.
Transglutaminase 2 kinase activity facilitates protein kinase A-induced phosphorylation of retinoblastoma protein.
Rhabdomyosarcoma
Transglutaminase activity and putrescine-binding capacity in cloned cell lines with different metastatic potential.
Transglutaminase-catalyzed cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma cells.
Rheumatic Diseases
Asymptomatic celiac sprue in juvenile rheumatic diseases children.
Autoantibodies to tissue transglutaminase in Sjögren's syndrome and related rheumatic diseases.
Rheumatic Fever
Fibrin dissolution in synovial fluid.
Rubella
Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome.
[Inactivation of viruses in Factor XIII concentrate by pasteurization]
Sarcoidosis
Factor XIIIa expression in granulomatous lesions due to sarcoidosis or mycobacterial infection.
Sarcoma
Alterations in the distribution and activity of transglutaminase during tumour growth and metastasis.
Correlation of changes in transglutaminase activity and polyamine content of neoplastic tissue during the metastatic process.
Factor XIIIa expression in pseudo-Kaposi sarcoma.
Influences of clotting factors (thrombin, factor XIII) and of fibronectin on the growth of tumor cells and leukemic cells in vitro.
Influences of thrombin, factor XIII and fibronectin on the growth of tumor cells and leukemic cells in vitro.
[Thrombin, factor XIII and fibronectin as regulators of the proliferation of tumor cells and vascular wall cells]
Sarcoma, Kaposi
Cultured Kaposi's sarcoma cell lines express factor XIIIa, CD14, and VCAM-1, but not factor VIII or ELAM-1.
Dendrocyte population in cutaneous and extracutaneous Kaposi's sarcoma.
Factor-XIIIa-expressing dermal dendrocytes in Kaposi's sarcoma. A comparison between classical and immunosuppression-associated types.
HIV-1 infection and modulation of cytokine and growth factor expression in Kaposi's sarcoma-derived cells in vitro.
Macrophages and vascular adhesion molecules in oral Kaposi's sarcoma.
The spindle-shaped cells in cutaneous Kaposi's sarcoma. Histologic simulators include factor XIIIa dermal dendrocytes.
Ultrastructural localization of factor XIIIa.
Schistosomiasis japonica
Contribution of tissue transglutaminase to the severity of hepatic fibrosis resulting from Schistosoma japonicum infection through the regulation of IL-33/ST2 expression.
Involvement of IL-13 and tissue transglutaminase in liver granuloma and fibrosis after schistosoma japonicum infection.
Scleredema Adultorum
Scleredema of Buschke: remission with factor XIII treatment.
Scleroderma, Diffuse
Factor XIII in scleroderma: in vitro studies.
Favorable effects of plasma factor XIII on lower esophageal sphincter pressure of progressive systemic sclerosis.
Treatment of progressive systemic sclerosis using factor XIII.
[Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up]
Scleroderma, Localized
CD34 stromal expression is inversely proportional to smooth muscle actin expression and extent of morphea.
Decreased expression of the human progenitor cell antigen (CD34) in morphea.
Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon.
Scleroderma, Systemic
Coagulation factor XIII, endothelial damage and systemic sclerosis.
Dermal Dendritic Cell Population and Blood Vessels Are Diminished in the Skin of Systemic Sclerosis Patients: Relationship With Fibrosis Degree and Disease Duration.
[Bronchiolo-alveolar carcinoma complicating systemic scleroderma under long-term treatment with factor XIII]
[Desmofibrinogenic activity of factor XIII and plasma concentration of thiol groups in the course of systemic scleroderma]
[Long-term treatment of systemic scleroderma with coagulation factor XIII. Developmental monitoring, especially of respiratory function]
[Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up]
Scleromyxedema
Adult variant of self-healing papular mucinosis in a patient with rheumatoid arthritis: Predominant proliferation of dermal dendritic cells expressing CD34 or factor XIIIa in association with dermal deposition of mucin.
Scoliosis
The Effect of Ex Vivo Factor XIII Supplementation on Clot Formation in Blood Samples From Cardiac and Scoliosis Surgery Patients.
Sepsis
Divergent results induced by different types of septic shock in transglutaminase 2 knockout mice.
Effects of coagulation factor XIII on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation in experimental endotoxemia.
Factor XIII in severe sepsis and septic shock.
Imaging of the ex vivo transglutaminase activity in liver macrophages of sepsis mice.
The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients.
Transglutaminase 2 as a Marker for Inflammation and Therapeutic Target in Sepsis.
Shock, Septic
Disturbances of selected plasma proteins in hyperdynamic septic shock.
Divergent results induced by different types of septic shock in transglutaminase 2 knockout mice.
Factor XIII in severe sepsis and septic shock.
Human mononuclear leukocyte transglutaminase activity is enhanced by streptococcal erythrogenic toxin and a staphylococcal mitogenic factor associated with toxic shock syndrome.
The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients.
Treatment for necrotizing enterocolitis perforation in the extremely premature infant (weighing less than 1,000 g).
Shwartzman Phenomenon
Depletion of plasma factor XIII prevents disseminated intravascular coagulation-induced organ damage.
Skin Diseases
Assays for transglutaminases in cell death.
Evaluation of a Bi-Analyte Immunoblot as a Useful Tool for Diagnosing Dermatitis Herpetiformis.
Increased membrane-associated transglutaminase activity in psoriasis.
Influence of calcium on the proteolytic degradation of the calmodulin-like skin protein (calmodulin-like protein 5) in psoriatic epidermis.
Lamellar ichthyosis associated with pseudoainhum of the toes and eye changes.
Novel interactions between dermal dendrocytes and mast cells in human skin. Implications for hemostasis and matrix repair.
Proliferative activity of CD8(+) T cells as an important clue to analyze T cell-mediated inflammatory dermatoses.
The many-faced gluten sensitivity: Gluten-induced autoimmunity from dermatological point of view
Transglutaminase 1 Replacement Therapy Successfully Mitigates the Autosomal Recessive Congenital Ichthyosis Phenotype in Full-Thickness Skin Disease Equivalents.
[Dermatitis herpetiformis].
Skin Diseases, Genetic
Direct cutaneous gene delivery in a human genetic skin disease.
Structural organization of cornified cell envelopes and alterations in inherited skin disorders.
Soft Tissue Infections
Local activation of coagulation factor XIII reduces systemic complications and improves the survival of mice after Streptococcus pyogenes M1 skin infection.
Spinal Cord Compression
De Novo Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (MYC/BCL-2) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency.
Spinal Cord Injuries
Intraspinal hemorrhage in a child with factor XIII deficiency.
The role of plasma transglutaminase (F XIII) in wound healing of complicated pressure sores after spinal cord injury.
Spinocerebellar Ataxias
A case report of late-onset cerebellar ataxia associated with a rare p.R342W TGM6 (SCA35) mutation.
Distribution of transglutaminase 6 in the central nervous system of adult mice.
Hispanic Spinocerebellar Ataxia Type 35 (SCA35) with a Novel Frameshift Mutation.
Mutations in TGM6 induce the unfolded protein response in SCA35.
Spinocerebellar ataxia 35: novel mutations in TGM6 with clinical and genetic characterization.
Spinocerebellar ataxia type 35 (SCA35)-associated transglutaminase 6 mutants sensitize cells to apoptosis.
TGM6 variants in Parkinson's disease: clinical findings and functional evidence.
Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 pathogenesis.
Transglutaminase 6 interacts with polyQ proteins and promotes the formation of polyQ aggregates.
Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases.
Whole exome sequencing identifies a novel mutation in the transglutaminase 6 gene for spinocerebellar ataxia in a Chinese family.
Splenic Rupture
Factor XIII deficiency: report of a case complicated by splenic rupture.
Recurrent Spontaneous Splenic Rupture in a Patient With Congenital Factor XIII Deficiency.
Spontaneous splenic rupture in a patient with factor XIII deficiency and a novel mutation.
[Spontaneous splenic rupture in a patient with congenital factor XIII deficiency]
Spondylitis, Ankylosing
Antibodies to human tissue transglutaminase and alterations of vitamin D metabolism in ankylosing spondylitis and psoriatic arthritis.
Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis.
Sprue, Tropical
Immunohistochemical Expression of Antitissue Transglutaminase 2 in Tissue Injuries: An Interpretation Beyond Celiac Disease.
Squamous Cell Carcinoma of Head and Neck
Differential expression of the keratin-4, -13, -14, -17 and transglutaminase 3 genes during the development of oral squamous cell carcinoma from leukoplakia.
Expression of retinoic acid receptor beta is associated with inhibition of keratinization in human head and neck squamous carcinoma cells.
Inhibition of growth and squamous-cell differentiation markers in cultured human head and neck squamous carcinoma cells by beta-all-trans retinoic acid.
The expression of transglutaminase 2 (TG-2) in oral squamous cell carcinoma and its clinical significance.
Transglutaminase 3 contributes to malignant transformation of oral leukoplakia to cancer.
ST Elevation Myocardial Infarction
The Association of Hereditary Prothrombotic Risk Factors with ST-Elevation Myocardial Infarction.
Staphylococcal Infections
iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function.
Starvation
Modulation of apoptosis by starvation: morphological and biochemical study of rat intestinal mucosa.
Purification and partial characterization of transglutaminase from Physarum polycephalum.
Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Type 2 transglutaminase is involved in the autophagy-dependent clearance of ubiquitinated proteins.
Stevens-Johnson Syndrome
Epithelial hyperproliferation and transglutaminase 1 gene expression in Stevens-Johnson syndrome conjunctiva.
Stomach Neoplasms
Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers.
Novel peptide GX1 inhibits angiogenesis by specifically binding to transglutaminase-2 in the tumorous endothelial cells of gastric cancer.
Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
[Distribution of fibronectin and other plasma proteins in gastric cancer tissues: investigation of mechanisms of desmoplasia of the stroma]
Stomach Ulcer
Factor XIII improves gastric stress lesions in rats.
[Distribution of fibronectin and other plasma proteins in gastric cancer tissues: investigation of mechanisms of desmoplasia of the stroma]
Stomatitis
[Molecular markers of the oral mucosa damage in patients with leukemia.]
Stomatitis, Aphthous
Serological screening for celiac disease using IgA-tissue transglutaminase antibody in patients with recurrent aphthous stomatitis.
Stroke
Common genetic coagulation variants are not associated with ischemic stroke in a casecontrol study.
Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia.
Factor XIII A-subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy, middle-aged men.
Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage.
Gene mutations and stroke in the young adult.
Hypercoagulability as a cause of stroke in adults.
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.
Role of factor XIII Val34Leu polymorphism in retinal artery occlusion.
Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients.
Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling.
Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation.
Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS block.
Subarachnoid Hemorrhage
Association between factor XIII single nucleotide polymorphisms and aneurysmal subarachnoid hemorrhage.
Factor XIII concentrate for prevention of recurrent subarachnoid hemorrhage: results of a multicenter pilot study. The FISAH Study Group.
Fibrinolytic and factor XIII activity in subarachnoid hemorrhage.
Supranuclear Palsy, Progressive
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice.
Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy.
Transglutaminase is linked to neurodegenerative diseases.
Synucleinopathies
Targeting transglutaminase 2 as a potential disease modifying therapeutic strategy for synucleinopathies.
Tauopathies
Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice.
Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies.
Tendinopathy
Gene expression analysis in calcific tendinopathy of the rotator cuff.
Testicular Neoplasms
Evaluation of nuclear NF-?B, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors.
Tetanus
Covalent modification of synapsin I by a tetanus toxin-activated transglutaminase.
Evidence that transglutaminase and synapsin I are involved in the neuroparalytic action of tetanus toxin.
Microtubules and microfilaments participate in the inhibition of synaptosomal noradrenaline release by tetanus toxin.
Role of transglutaminase in [3H]5-HT release from synaptosomes and in the inhibitory effect of tetanus toxin.
Tetanus toxin potently stimulates tissue transglutaminase. A possible mechanism of neurotoxicity.
The role of transglutaminase in the mechanism of action of tetanus toxin.
The transglutaminase hypothesis for the action of tetanus toxin.
Transglutaminase participates in the blockade of neurotransmitter release by tetanus toxin: evidence for a novel biological function.
Thrombasthenia
Congenital hemorrhagic disorders in Jordan.
Correction of coagulopathy in thrombocytopenia and Glanzmann thrombasthenia models by fibrinogen and factor XIII as assessed by thromboelastometry.
Glanzmann's thrombasthenia associated with a transient deficiency of factor XIII.
How to deal with medical and social aspects of bleeding disorders--preparing women and the family in developing countries.
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
On the retraction of collagen and fibrin induced by normal, defective and modified platelets.
The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia.
Thrombocytopenia
A patient with Henoch-Schönlein purpura manifesting unusual symptoms and clinical course.
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Coagulation management in patients undergoing mechanical circulatory support.
Correction of coagulopathy in thrombocytopenia and Glanzmann thrombasthenia models by fibrinogen and factor XIII as assessed by thromboelastometry.
Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma.
Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases.
Factor XIII Deficiency and Thrombocytopenia Are Frequent Modulators of Postoperative Clot Firmness in a Surgical Intensive Care Unit.
Generalized proteolysis in a young woman with Weber-Christian disease (nodular nonsuppurative panniculitis).
Identification of acquired coagulation disorders and effects of target-controlled coagulation factor substitution on the incidence and severity of spontaneous intracranial bleeding during veno-venous ECMO therapy.
In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.
Is extracorporeal CO2-Removal really "safe" and "less" invasive? Observation of blood injury and coagulation impairment during ECCO2R.
Reduction of fibrin stabilizing factor (FSF) in thrombocytopenia in childhood.
Valproate-associated coagulopathies are frequent and variable in children.
[Intracranial hematoma accompanying bleeding tendency: therapeutic practice and analysis of literature]
Thrombocytosis
Coagulation factor XIII concentration in sickle-cell disease.
[Thrombocytosis and reduced levels of factor VIII in rheumatoid purpura in children]
Thromboembolism
Elimination of fibrin ?-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi.
Low levels of fibrin-stabilizing factor (factor XIII) in human Plasmodium falciparum malaria: correlation with clinical severity.
Thrombophilia
"TEG talk": expanding clinical roles for thromboelastography and rotational thromboelastometry.
Correlation with Platelet Parameters and Genetic Markers of Thrombophilia Panel (Factor II g.20210G>A, Factor V Leiden, MTHFR (C677T, A1298C), PAI-1, ?-Fibrinogen, Factor XIIIA (V34L), Glycoprotein IIIa (L33P)) in Ischemic Strokes.
Factor XIII polymorphisms and venous thromboembolism.
Genetic factors in fetal growth restriction and miscarriage.
Investigating Association of Three Polymorphisms of Coagulation Factor XIII and Recurrent Pregnancy Loss.
Preeclampsia and its interaction with common variants in thrombophilia genes.
ROTEM analysis: a significant advance in the field of rotational thrombelastography.
The Association of Hereditary Prothrombotic Risk Factors with ST-Elevation Myocardial Infarction.
Unusual presentation of a sarcoid patient: multiple arterial and venous thrombosis with chest lymphadenopathy.
Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia.
[Diagnosis and treatment of coagulation disorders]
[Possible involvement of factor XIII in forming a trend towards thrombosis in patients with various types of thrombophilia]
Thrombosis
A novel ultrasonic method for evaluation of blood clotting parameters.
Acute megakaryoblastic leukemia with erythrophagocytosis and thrombosis in a dog.
Addition of a sequence from alpha2-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis.
Adhesion of Blood Clots Can Be Enhanced When Copolymerized with a Macromer That Is Crosslinked by Coagulation Factor XIIIa.
Alternative pathways for the activation of factor XIII.
Associations of the beta-fibrinogen Hae III and factor XIII Val34Leu gene variants with venous thrombosis.
Behaviour of fibrinolysis in the nephrotic syndrome.
Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging.
Characterization of cDNA coding for human factor XIIIa.
Coagulation factor XIII and atherothrombosis. A mini-review.
Coagulation factor XIII concentration in sickle-cell disease.
Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women.
Coagulation factor XIIIa cross-links amyloid ? into dimers and oligomers and to blood proteins.
Coagulation factor XIIIa is inactivated by plasmin.
Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli.
Comparative evaluation of the elasticity and flexibility of bioimpregnated knitted grafts.
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Comparison of thrombophilic gene mutations among patients experiencing recurrent miscarriage and deep vein thrombosis.
Contact with the N termini in the central E domain enhances the reactivities of the distal D domains of fibrin to factor XIIIa.
Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix.
Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences.
Crystal structure of a 30 kDa C-terminal fragment from the gamma chain of human fibrinogen.
Defective ?2 antiplasmin cross-linking and thrombus stability in a case of acquired factor XIII deficiency.
Development of magnetic resonance imaging contrast material for in vivo mapping of tissue transglutaminase activity.
Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots.
Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Effect of haematocrit on fibrin-based clot firmness in the FIBTEM test.
Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.
Effects of Val34Leu and Val35Leu polymorphism on the enzyme activity of the coagulation factor XIII-A.
Efficacy of rituximab in acquired factor XIII inhibitor after arterial rFVIIa-induced thrombosis.
Elimination of fibrin ?-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi.
Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit model of femoral artery thrombosis.
Evaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay.
Evaluating the Effects of Fibrinogen ?C Mutations on the Ability of Factor XIII to Crosslink the Reactive ?C Glutamines (Q237, Q328, Q366).
Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis.
Factor XIII activity mediates red blood cell retention in venous thrombi.
Factor XIII deficiency does not prevent FeCl3-induced carotid artery thrombus formation in mice.
Factor XIII in plasma, but not in platelets, mediates red blood cell retention in clots and venous thrombus size in mice.
Factor XIII polymorphisms and venous thromboembolism.
Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.
Factor XIII val34leu and the risk of myocardial infarction.
Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis.
Factor XIII, clot structure, thrombosis.
Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels.
Feasibility of an automated coagulation factor XIIIa test using its isopeptidase activity.
Fibrinogen and factor XIII: newly recognized roles in venous thrombus formation and composition.
Fibrinogen, red blood cells, and factor XIII in venous thrombosis.
Fibrinolysis in Platelet Thrombi.
Fibronectin and wound healing.
Generation and mechanism of action of a potent inhibitor of factor XIII function.
Genetic Variants in the FGB and FGG Genes Mapping in the Beta and Gamma Nodules of the Fibrinogen Molecule in Congenital Quantitative Fibrinogen Disorders Associated with a Thrombotic Phenotype.
Granulomatous reaction in mediastinal B-cell non-Hodgkin lymphoma and intracardiac thrombosis.
Growth regulation of fibroblasts by thrombin, factor XIII and fibronectin.
Human fibrinogen.
In vivo near-infrared imaging of fibrin deposition in thromboembolic stroke in mice.
Increased endothelial expression of transglutaminase in glioblastomas.
Influence of factor XIIIa activity on human whole blood clot lysis in vitro.
Interaction of the factor XIII activation peptide with alpha -thrombin. Crystal structure of its enzyme-substrate analog complex.
Investigation of the anticoagulant and antithrombotic effects of chlorogenic acid.
Joint linkage and association of six single-nucleotide polymorphisms in the factor XIII-A subunit gene point to V34L as the main functional locus.
Molecular Imaging of Factor XIII Activity for the Early Detection of Mouse Coronary Microvascular Disease.
Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi.
Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent.
Molecular subunits and transamidase activity of factor XIII in patients with deep vein thrombosis.
Monocytes Expose Factor XIII-A and Stabilize Thrombi against Fibrinolytic Degradation.
New splicing mutations in the human factor XIIIA gene, each producing multiple mutant transcripts of varying abundance.
Newly-Recognized Roles of Factor XIII in Thrombosis.
Non-invasive in vivo imaging of acute thrombosis: development of a novel factor XIIIa radiotracer.
Nonclinical analysis of the safety, pharmacodynamics, and pharmacokinetics of plasma-derived human FXIII concentrate in animals.
Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.
Patient-centered approach to managing factor XIII deficiency.
Pharmacokinetic studies of a novel 1,2,4-thiadiazole derivative, inhibitor of Factor XIIIa, in the rabbit by a validated HPLC method.
Plasma D-dimer for the diagnosis of thromboembolic disorders in dogs.
Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth.
Poly(2-hydroxyethyl methacrylate) particles for preoperative endovascular occlusion of extensive angiodysplasias.
Prevalence of the Factor XIII Val34Leu Polymorphism in Korean Patients with Deep Vein Thrombosis.
Prevention of postoperative intracerebral hemorrhage with topical recombinant factor XIII in the rat.
Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria.
Prothrombotic gene polymorphisms: possible contributors to hepatic artery thrombosis after orthotopic liver transplantation.
Ranking reactive glutamines in the fibrinogen ?C region that are targeted by blood coagulant Factor XIII.
Residual iliofemoral thrombosis in a 31-year-old woman on oral contraceptives possessing heterozygous factor V Leiden, factor XIII Val34Leu allele and alpha-fibrinogen Thr312Ala allele: case report.
Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms.
Role of factor XIII Val34Leu polymorphism in retinal artery occlusion.
Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study.
Safety of recombinant human factor XIII in a cynomolgus monkey model of extracorporeal blood circulation.
State of the art in factor XIII laboratory assessment.
Structure of the fibrinogen gamma-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization.
The alternatively spliced V region contributes to the differential incorporation of plasma and cellular fibronectins into fibrin clots.
The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism.
The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis.
The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking.
Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics.
Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation.
Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease.
[A micromethod of determining the activity of factor XIII in whole blood]
[Behavior of the fibrin-stabilizing blood coagulation factor XIII in hemorrhages after tooth extractions]
[Besides fibrinogen, are haemostatic, coagulation and/or fibrinolytic parameters predictors or markers of the risk of cardiovascular events?]
[Diagnosis and treatment of coagulation disorders]
[Hemocoagulation - New views on the old cascade].
[Inhibitors of factor XIIIa]
[Measurement of factor XIII (FSF) as an indicator of thrombosis risk in chronic coronary insufficiency and myocardial infarction]
[Possible involvement of factor XIII in forming a trend towards thrombosis in patients with various types of thrombophilia]
[Replacement of the thoracic aorta by sealed dacron prostheses (author's transl)]
[Structure, function and the role of factor XIII in human pathology]
Thrombotic Microangiopathies
The Homozygous Leu Variant of the Factor XIII Val34Leu Polymorphism as a Risk Factor for the Manifestation of Thrombotic Microangiopathies.
Thyroid Diseases
A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases.
Anti-thyroid antibodies, parietal cell antibodies and tissue transglutaminase antibodies in patients with autoimmune thyroid disease.
Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups.
Celiac disease and endocrine autoimmunity - the genetic link.
Celiac Disease and Glandular Autoimmunity.
Celiac Disease Autoimmunity in Patients with Autoimmune Diabetes and Thyroid Disease among Chinese Population.
Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome.
IgA and IgG antigliadin, IgA anti-tissue transglutaminase and antiendomysial antibodies in patients with autoimmune thyroid diseases and their relationship to thyroidal replacement therapy.
Linear ?-(1???6)-d-glucan from Bifidobacterium bifidum BIM ?-733D is low molecular mass biopolymer with unique immunochemical properties.
One-Third of Patients Have Evidence for an Additional Autoimmune Disease at Type 1 Diabetes Diagnosis.
Prevalence of thyroid autoimmunity in first-degree relatives of patients with celiac disease.
Shared Genetic Basis for Type 1 Diabetes, Islet Autoantibodies, and Autoantibodies Associated With Other Immune-Mediated Diseases in Families With Type 1 Diabetes.
Tissue transglutaminase antibodies in individuals with celiac disease bind to thyroid follicles and extracellular matrix and may contribute to thyroid dysfunction.
Thyroid Nodule
Coeliac disease in patients with autoimmune thyroiditis.
Thyroiditis
A rare case of Addison's disease, hepatitis, thyreoiditis, positive IgG anti-tissue transglutaminase antibodies and partial IgA deficiency.
Coeliac disease in Dutch patients with Hashimoto's thyroiditis and vice versa.
Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): a population control study.
Gliadin antibodies in adult insulin-dependent diabetes--autoimmune and immunogenetic correlates.
Gluten ataxia: passive transfer in a mouse model.
IgA and IgG antigliadin, IgA anti-tissue transglutaminase and antiendomysial antibodies in patients with autoimmune thyroid diseases and their relationship to thyroidal replacement therapy.
Prolactin and autoimmunity.
The Effect of Gluten-Free Diet on Thyroid Autoimmunity in Drug-Naïve Women with Hashimoto's Thyroiditis: A Pilot Study.
THE RELATIONSHIP BETWEEN THYROID HORMONES, ANTITHYROID ANTIBODIES, ANTI-TISSUE TRANSGLUTAMINASE AND ANTI-GLIADIN ANTIBODIES IN PATIENTS WITH HASHIMOTO'S THYROIDITIS.
[Prevalence of polyglandular autoimmune syndrome in patients with diabetes mellitus type 1]
Thyroiditis, Autoimmune
Coeliac disease in patients with autoimmune thyroiditis.
Does celiac disease trigger autoimmune thyroiditis?
Glutamic acid decarboxylase (anti-GAD) & tissue transglutaminase (anti-TTG) antibodies in patients with thyroid autoimmunity.
Prevalence of coeliac disease in patients with autoimmune thyroiditis in a Turkish population.
Tonsillitis
Cerebral thrombosis associated with heterozygous factor V Leiden mutation and high lipoprotein(a) level in a girl with factor XIII deficiency.
Tourette Syndrome
Intracerebral haematomas after deep brain stimulation surgery in a patient with Tourette syndrome and low factor XIIIA activity.
Toxemia
Coagulation-fibrinolytic and kinin-forming systems in toxemia of pregnancy.
[Coagulation-fibrinolysis and kinin-forming systems in toxemia of pregnancy]
[Hemocoagulatological changes in toxemia of pregnancy--in reference to birth weight (author's transl)]
Triple Negative Breast Neoplasms
Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
Tuberculosis
Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against Mycobacterium tuberculosis.
Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection.
Tuberculosis, Pulmonary
Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenström's macroglobulinemia.
Tuberous Sclerosis
Factor XIIIa in the hamartomas of tuberous sclerosis.
Successful factor XIII treatment of refractory chylothorax in tuberous sclerosis complex-associated lymphangioleiomyomatosis, multifocal multinodular pneumocyte hyperplasia and mediastinal lymphadenopathy.
Turner Syndrome
Increased prevalence of celiac disease in girls with Turner syndrome detected using antibodies to endomysium and tissue transglutaminase.
Prevalence of autoantibodies associated with thyroid and celiac disease in Ullrich-Turner syndrome in relation to adult height after growth hormone treatment.
Uremia
[Deficiency in fibrin stabilizing factor (factor XIII) in uremia]
Ureteral Obstruction
Transglutaminase 2 gene ablation protects against renal ischemic injury by blocking constant NF-?B activation.
Urticaria
Cold urticaria and celiac disease.
Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria.
Uterine Cervical Neoplasms
Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine.
Uterine Hemorrhage
Activity of plasma (FSF) fibrin stabilizing factor in dysfunctional uterine hemorrhages.
Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages.
Uveitis
A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor.
Vaccinia
[Inactivation of viruses in Factor XIII concentrate by pasteurization]
Varicose Ulcer
Factor XIII in ulcerative leg disease: background and preliminary clinical results.
Topical treatment of venous ulcer with fibrin stabilizing factor: experimental investigation of effects on vascular permeability.
[Factor XIII: experimental and clinical results in diabetic foot ulcer]
Varicose Veins
Polymorphisms of serum proteins in Japanese patients with vascular diseases. I. Factor XIIIB, plasminogen and complement types in primary varicose veins.
Vascular Calcification
Nitric oxide regulates non-classical secretion of tissue transglutaminase.
Regulation of ATPase activity of transglutaminase 2 by MT1-MMP: implications for mineralization of MC3T3-E1 osteoblast cultures.
Transglutaminase 2 Accelerates Vascular Calcification in Chronic Kidney Disease.
Transglutaminase 2-mediated activation of ?-catenin signaling has a critical role in warfarin-induced vascular calcification.
Transglutaminase inhibitors attenuate vascular calcification in a preclinical model.
Vascular Diseases
Factor XIII A-subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy, middle-aged men.
Migraine and genetic polymorphisms: an overview.
Nitric oxide regulates non-classical secretion of tissue transglutaminase.
Role of blood coagulation factor XIII in vascular diseases.
The treatment of collagen fibrils by tissue transglutaminase to promote vascular smooth muscle cell contractile signaling.
Transglutaminases as targets for pharmacological inhibition.
Vascular System Injuries
Factor XIII supports platelet activation and enhances thrombus formation by matrix proteins under flow conditions.
Vasculitis
Autoantibody screen in inflammatory myopathies high prevalence of antibodies to gliadin.
Severe gastrointestinal vasculitis in Henoch-Schoenlein purpura: pathophysiologic mechanisms, the diagnostic value of factor XIII, and therapeutic options.
[Celiac disease and ischemic stroke.]
[Leukocytoclastic vasculitis and factor XIII deficiency]
Vasculitis, Central Nervous System
[Celiac disease and ischemic stroke.]
Venous Thromboembolism
Association of a common polymorphism in the factor XIII gene with venous thrombosis.
Combined measurement of factor XIII and D-dimer is helpful for differential diagnosis in patients with suspected pulmonary embolism.
Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism.
Factor XIII and Venous Thromboembolism.
Factor XIII levels and factor XIII B subunit polymorphisms in patients with venous thromboembolism.
Factor XIII polymorphisms and venous thromboembolism.
Factor XIII Val34Leu and the risk of venous thromboembolism in factor V Leiden carriers.
Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis.
Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.
Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease?
Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.
Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness.
Venous Thrombosis
A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases.
A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis.
Association of a common polymorphism in the factor XIII gene with venous thrombosis.
Associations of the beta-fibrinogen Hae III and factor XIII Val34Leu gene variants with venous thrombosis.
Coagulation Factor XIII in Cerebral Venous Thrombosis.
Comparison of thrombophilic gene mutations among patients experiencing recurrent miscarriage and deep vein thrombosis.
Concurrent hematoma and venous thrombosis in a patient with autoimmune acquired factor XIII deficiency.
Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
Estrogen plus progestin and risk of venous thrombosis.
Ethnic heterogeneity of the factor XIII Val34Leu polymorphism.
Factor XIII deficiency does not prevent FeCl3-induced carotid artery thrombus formation in mice.
Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis.
Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis.
Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis.
Fibrinogen, red blood cells, and factor XIII in venous thrombosis.
Molecular subunits and transamidase activity of factor XIII in patients with deep vein thrombosis.
Mutations in clotting factors and inflammatory bowel disease.
Prevalence of the Factor XIII Val34Leu Polymorphism in Korean Patients with Deep Vein Thrombosis.
Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria.
Role of factor XIII Val34Leu polymorphism in retinal artery occlusion.
Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.
The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level.
The role of fibrinogen plasma levels, the -455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis.
The V34L polymorphism of factor XIII and peripheral arterial disease.
Unusual presentation of factor XIII deficiency.
Ventilator-Induced Lung Injury
Effects of transglutaminase 2 inhibition on ventilator-induced lung injury.
Virus Diseases
"Tissue" transglutaminase in AIDS.
Celiac disease and non-organ-specific autoantibodies in patients with chronic hepatitis C virus infection.
Essential function of transglutaminase and clotting protein in shrimp immunity.
Role of protein modifications mediated by transglutaminase 2 in human viral diseases.
Transglutaminase regulates immune-related genes in shrimp.
Type 1 diabetes associated and tissue transglutaminase autoantibodies in patients without type 1 diabetes and coeliac disease with confirmed viral infections.
[Factor XIII and hepatitis C virus infection]
Vitamin A Deficiency
Expression of retinoic acid nuclear receptors and tissue transglutaminase is altered in various tissues of rats fed a vitamin A-deficient diet.
Vitamin A deficiency causes metaplasia in vocal fold epithelium: a rat study.
Vitamin D Deficiency
Celiac disease and severe vitamin D deficiency: the case for anti-tissue transglutaminase antibody screening.
Hormonal and dietary factors in acne vulgaris versus controls.
Vitamin K Deficiency
[Intracranial hematoma accompanying bleeding tendency: therapeutic practice and analysis of literature]
Vitreoretinopathy, Proliferative
Keratinocyte transglutaminase in proliferative vitreoretinopathy.
[Detection of coagulation factor XIII in the vitreous body and periretinal membranes in proliferative retinal diseases]
von Willebrand Diseases
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Combined occurrence of von Willebrand's disease and factor XIII deficiency: a case report.
Congenital factor XIII deficiency associated with von Willebrand disease.
Congenital hemorrhagic disorders in Jordan.
Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma.
Hemophiliacs--a picture from a developing country: Karnataka, a south Indian state.
How to deal with medical and social aspects of bleeding disorders--preparing women and the family in developing countries.
Intracranial haemorrhage in patients with congenital haemostatic defects.
Low prevalence of antibodies against human immunodeficiency virus in Finnish haemophiliacs.
Management of pregnancy and delivery in women with inherited bleeding disorders.
Occurrence of coagulation factor deficiency in post-tonsillectomy hemorrhage.
On the retraction of collagen and fibrin induced by normal, defective and modified platelets.
Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection.
Spectrum of hereditary coagulation factor deficiencies in eastern province, Saudi Arabia.
Studies on factor XIII antigen in congenital factor XIII deficiency. A tentative classification of the disease in two groups.
Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection.
Valproate-associated coagulopathies are frequent and variable in children.
Vascular type Ehlers-Danlos syndrome is associated with platelet dysfunction and low vitamin D serum concentration.
Viral markers and use of factor products among Finnish patients with bleeding disorders.
Waldenstrom Macroglobulinemia
Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenström's macroglobulinemia.
Whooping Cough
Pertussis toxin inhibits retinoic acid-induced expression of tissue transglutaminase in macrophages.
Retinoic acid-induced gene expression of tissue transglutaminase via protein kinase C-dependent pathway in mouse peritoneal macrophages.
Williams Syndrome
Celiac disease in Williams-Beuren syndrome.
Wilms Tumor
Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
Xanthogranuloma, Juvenile
Factor XIIIa expression in juvenile xanthogranuloma.
Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi.
Systemic form of juvenile xanthogranuloma: report of a case with liver and bone marrow involvement.
Xanthomatosis
[Possibilities and limits of paraffin-embedded cell markers in diagnosis of primary cutaneous histiocytosis]